Clinical trial NCT03410992
Conditions: Chronic Plaque Psoriasis Moderate to Severe Chronic Plaque Psoriasis Psoriatic Arthritis
Keywords: Bimekizumab PSO Psoriasis
Sponsor: UCB Biopharma SRL
Start date: 2018-02-05; Completion date: 2020-01-07
Enrollment: 435 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.

Detailed description:

Arms: arm 1: Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm. arm 2: Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm. arm 3: Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
Interventions: intervention 1: Bimekizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Bimekizumab will be provided at pre-specified time intervals. intervention 2: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Protocol documents:
Prot_000.pdf: 
UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 1 of 209 
PROTOCOL PS0013 AMENDMENT 3 
A PHASE 3, MULTICENTER, DOUBLE-BLIND, 
PLACEBO-CONTROLLED STUDY WITH AN INITIAL 
TREATMENT PERIOD FOLLOWED BY A RANDOMIZED-
WITHDRAWAL PERIOD TO EVALUATE THE EFFICACY AND 
SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH 
MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS 
PHASE 3 
EudraCT Number: 2016-003426-16 
IND Number: 128707 
Sponsor: 
UCB Biopharma SPRL 
Allée de la Recherche 60 
1070 Brussels 
BELGIUM 
Protocol/Amendment number 
Date 
Type of 
amendment 
Final Protocol 
15 Aug 2017 
Not applicable 
Protocol Amendment 1 
15 Oct 2017 
Not applicable 
Protocol Amendment 2 
06 Apr 2018 
Substantial 
Protocol Amendment 3 
21 May 2019 
Nonsubstantial 
Confidential Material 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 2 of 209 
STUDY CONTACT INFORMATION 
Sponsor 
UCB Biopharma SPRL 
Allée de la Recherche 60 
1070 Brussels, BELGIUM 
Sponsor Study Physician 
Name: 
, MD 
Address: 
UCB Biosciences, 8010 Arco Corporate Drive, Raleigh, NC 27617 
Phone: 
 
Fax: 
 
Clinical Project Manager 
Name: 
 
Address: 
UCB Biosciences GmbH, Alfred Nobel Strasse, Monheim am Rhein, 
40789, Germany 
Phone: 
 
Fax: 
 
Clinical Trial Biostatistician 
Name: 
 
Address: 
208 Bath Road, Slough, SL1 3WE, UK 
Phone: 
 
Fax: 
 
Clinical Monitoring Contract Research Organization 
Name: 
PAREXEL International (IRL) Limited-Ireland 
Address: 
Ireland Limited at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland 
Phone: 
+353 (1) 477 3171 
Fax: 
+353 (1) 477 3308 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 3 of 209 
SERIOUS ADVERSE EVENT REPORTING 
Serious adverse event reporting (24h) 
Fax 
Europe and Rest of the World: +32 2 386 24 21 
USA and Canada: +1 800 880 6949 
 
or +1 866 890 3175 
Email 
Global: DS_ICT@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 4 of 209 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS .................................................................................................. 10 
1 
SUMMARY ..................................................................................................................... 14 
2 
INTRODUCTION ........................................................................................................... 15 
2.1 
Psoriasis ....................................................................................................................... 15 
2.1.1 
Global epidemiology of psoriasis ........................................................................ 16 
2.1.2 
Current treatments for psoriasis ........................................................................... 16 
2.2 
Bimekizumab ............................................................................................................... 18 
2.2.1 
Clinical ................................................................................................................. 18 
2.2.1.1 
Completed studies ..................................................................................... 18 
2.2.1.2 
Ongoing studies ......................................................................................... 20 
2.2.2 
Nonclinical ........................................................................................................... 20 
3 
STUDY OBJECTIVE(S) ................................................................................................. 21 
3.1 
Primary objective ......................................................................................................... 21 
3.2 
Secondary objectives ................................................................................................... 21 
3.3 
Other objectives ........................................................................................................... 22 
4 
STUDY VARIABLES ..................................................................................................... 23 
4.1 
Primary efficacy variables ........................................................................................... 23 
4.2 
Secondary variables ..................................................................................................... 23 
4.2.1 
Secondary efficacy variables ............................................................................... 23 
4.2.2 
Secondary safety variables .................................................................................. 23 
4.3 
Other variables ............................................................................................................. 23 
4.3.1 
Other efficacy variable(s) .................................................................................... 23 
4.3.2 
Other safety variables .......................................................................................... 25 
4.3.3 
Pharmacokinetic variable ..................................................................................... 25 
4.3.4 
Pharmacogenomic variables ................................................................................ 25 
4.3.5 
Immunological variable ....................................................................................... 25 
5 
STUDY DESIGN ............................................................................................................. 25 
5.1 
Study description ......................................................................................................... 25 
5.2 
Study periods ............................................................................................................... 26 
5.2.1 
Screening Period .................................................................................................. 26 
5.2.2 
Initial Treatment Period ....................................................................................... 26 
5.2.3 
Randomized-Withdrawal Period ......................................................................... 27 
5.2.4 
Safety Follow-Up ................................................................................................. 27 
5.2.5 
Escape Treatment ................................................................................................. 27 
5.2.6 
Premature End of Treatment ................................................................................ 28 
5.3 
Study duration per subject ........................................................................................... 28 
5.4 
Planned number of subjects and site(s) ........................................................................ 28 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 5 of 209 
5.5 
Anticipated regions and countries ................................................................................ 28 
5.6 
Schedule of study assessments..................................................................................... 29 
5.7 
Schematic diagram ....................................................................................................... 37 
5.8 
Rationale for study design and selection of dose ......................................................... 38 
5.8.1 
Study design ......................................................................................................... 38 
5.8.2 
Selection of dose .................................................................................................. 38 
6 
SELECTION AND WITHDRAWAL OF SUBJECTS ................................................... 38 
6.1 
Inclusion criteria .......................................................................................................... 38 
6.2 
Exclusion criteria ......................................................................................................... 39 
6.3 
Withdrawal criteria ...................................................................................................... 42 
6.3.1 
Potential drug-induced liver injury IMP discontinuation criteria ........................ 44 
7 
STUDY TREATMENT(S) .............................................................................................. 45 
7.1 
Description of investigational medicinal product(s) .................................................... 45 
7.2 
Treatment(s) to be administered .................................................................................. 46 
7.3 
Packaging ..................................................................................................................... 47 
7.4 
Labeling ....................................................................................................................... 47 
7.5 
Handling and storage requirements ............................................................................. 47 
7.6 
Drug accountability ...................................................................................................... 48 
7.7 
Procedures for monitoring subject compliance ............................................................ 48 
7.8 
Concomitant medication(s)/treatment(s) ..................................................................... 48 
7.8.1 
Permitted concomitant treatments (medications and therapies) .......................... 49 
7.8.1.1 
Topical medications .................................................................................. 49 
7.8.1.2 
Other medications ...................................................................................... 49 
7.8.2 
Prohibited concomitant treatments (medications and therapies) ......................... 49 
7.8.2.1 
Vaccines .................................................................................................... 50 
7.9 
Blinding........................................................................................................................ 50 
7.9.1 
Procedures for maintaining and breaking the treatment blind ............................. 51 
7.9.1.1 
Maintenance of IMP blind ......................................................................... 51 
7.9.1.2 
Breaking the treatment blind in an emergency situation ........................... 51 
7.10 
Randomization and numbering of subjects .................................................................. 51 
8 
STUDY PROCEDURES BY VISIT ............................................................................... 52 
8.1 
Screening Visit (2 to 5 weeks) ..................................................................................... 52 
8.2 
Initial Treatment Period ............................................................................................... 54 
8.2.1 
Baseline Visit ....................................................................................................... 54 
8.2.2 
Weeks 1 and 2 (±3 days relative to Baseline) ...................................................... 55 
8.2.3 
Weeks 4 and 8 (±3 days relative to Baseline) ...................................................... 55 
8.2.4 
Week 12 (±3 days relative to Baseline) ............................................................... 56 
8.2.5 
Week 16 (±3 days relative to Baseline) ............................................................... 58 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 6 of 209 
8.3 
Randomized-Withdrawal Period .................................................................................. 59 
8.3.1 
Weeks 20 and 24 (±3 days relative to Baseline) and Weeks 28, 32, 36, 40, 44, 
48, and 52 (±7 days relative to Baseline)............................................................. 59 
8.3.2 
Week 56 (±3 days relative to Baseline) ............................................................... 60 
8.4 
Escape Treatment Period ............................................................................................. 61 
8.4.1 
Escape Baseline Visit .......................................................................................... 61 
8.4.2 
Escape Weeks 4 and 8 (±3 days) ......................................................................... 62 
8.4.3 
Escape Visit-Week 12/Premature End of Treatment (±3 days relative to 
Baseline) .............................................................................................................. 63 
8.5 
Premature End of Treatment Visit ............................................................................... 64 
8.6 
Safety Follow-Up Visit (20 weeks after final dose, ±7 days) ...................................... 64 
8.7 
Unscheduled Visit ........................................................................................................ 65 
9 
ASSESSMENT OF EFFICACY ...................................................................................... 65 
9.1 
Psoriasis Area and Severity Index ............................................................................... 65 
9.2 
Investigator’s Global Assessment ................................................................................ 66 
9.3 
Dermatology Life Quality Index .................................................................................. 67 
9.4 
Patient Health Questionnaire 9 .................................................................................... 67 
9.5 
Scalp IGA..................................................................................................................... 67 
9.6 
mNAPSI ....................................................................................................................... 68 
9.7 
pp-IGA ......................................................................................................................... 68 
9.8 
Euro Quality of Life 5-Dimensions, 3-Level ............................................................... 69 
9.9 
36-Item Short Form Health Survey.............................................................................. 69 
9.10 
Patient Global Assessment of psoriasis ....................................................................... 70 
9.11 
Patient Symptom Diary responses ............................................................................... 70 
9.12 
PASE questionnaire ..................................................................................................... 70 
9.13 
PGADA for arthritis visual analog scale ..................................................................... 71 
10 ASSESSMENT OF PHARMACOKINETIC AND PHARMACOGENOMIC 
VARIABLE(S) ................................................................................................................ 71 
10.1 
Pharmacokinetic variables ........................................................................................... 71 
10.2 
Pharmacogenomic variables ........................................................................................ 71 
11 ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S) ............................................ 72 
12 ASSESSMENT OF SAFETY .......................................................................................... 72 
12.1 
Adverse events ............................................................................................................. 72 
12.1.1 
Definitions ........................................................................................................... 72 
12.1.1.1 
Adverse event ............................................................................................ 72 
12.1.1.2 
Serious adverse event ................................................................................ 73 
12.1.1.3 
Adverse events of special interest ............................................................. 74 
12.1.1.4 
Other safety topics of interest .................................................................... 74 
12.1.2 
Procedures for reporting and recording adverse events ....................................... 74 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 7 of 209 
12.1.2.1 
Description of adverse events .................................................................... 74 
12.1.2.2 
Rule for repetition of an adverse event...................................................... 75 
12.1.2.3 
Additional procedures for reporting serious adverse events ..................... 75 
12.1.3 
Follow up of adverse events ................................................................................ 76 
12.1.4 
Pregnancy ............................................................................................................ 76 
12.1.5 
Suspected transmission of an infectious agent via a medicinal product .............. 77 
12.1.6 
Overdose of investigational medicinal product ................................................... 77 
12.1.7 
Safety signal detection ......................................................................................... 77 
12.2 
Laboratory measurements ............................................................................................ 78 
12.2.1 
Evaluation of PDILI ............................................................................................ 79 
12.2.1.1 
Consultation with Medical Monitor and local hepatologist ...................... 84 
12.2.1.2 
Immediate action: determination of IMP discontinuation ......................... 84 
12.2.1.3 
Testing: identification/exclusion of alternative etiology ........................... 84 
12.2.1.4 
Follow-up evaluation ................................................................................. 86 
12.3 
Other safety measurements .......................................................................................... 87 
12.3.1 
Assessment and management of TB and TB risk factors .................................... 87 
12.3.1.1 
Tuberculosis assessment by IGRA ............................................................ 90 
12.3.1.2 
Chest x-ray for tuberculosis ...................................................................... 90 
12.3.1.3 
Tuberculosis questionnaire ........................................................................ 90 
12.3.1.4 
Tuberculosis management ......................................................................... 90 
12.3.2 
Pregnancy testing ................................................................................................. 91 
12.3.3 
Vital signs ............................................................................................................ 91 
12.3.4 
12-lead electrocardiograms .................................................................................. 91 
12.3.5 
Physical examination ........................................................................................... 91 
12.3.6 
Height and body weight ....................................................................................... 92 
12.3.7 
Assessment of suicidal ideation and behavior ..................................................... 92 
12.4 
Other study measurements ........................................................................................... 92 
12.4.1 
Demographic information .................................................................................... 92 
12.4.2 
Medical history .................................................................................................... 92 
12.4.3 
Psoriasis history ................................................................................................... 92 
12.4.4 
Data Monitoring and Adjudication Committees .................................................. 92 
13 STUDY MANAGEMENT AND ADMINISTRATION ................................................. 93 
13.1 
Adherence to protocol .................................................................................................. 93 
13.2 
Monitoring ................................................................................................................... 93 
13.2.1 
Definition of source data ..................................................................................... 93 
13.2.2 
Source data verification ....................................................................................... 94 
13.3 
Data handling ............................................................................................................... 94 
13.3.1 
Case Report Form completion ............................................................................. 94 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 8 of 209 
13.3.2 
Database entry and reconciliation ........................................................................ 94 
13.3.3 
Subject Screening and Enrollment log/Subject Identification Code list.............. 95 
13.4 
Termination of the study .............................................................................................. 95 
13.5 
Archiving and data retention ........................................................................................ 95 
13.6 
Audit and inspection .................................................................................................... 95 
13.7 
Good Clinical Practice ................................................................................................. 96 
14 STATISTICS ................................................................................................................... 96 
14.1 
Definition of analysis sets ............................................................................................ 96 
14.2 
General statistical considerations ................................................................................. 97 
14.3 
Planned efficacy analyses ............................................................................................ 98 
14.3.1 
Analysis of the primary efficacy variable ............................................................ 98 
14.3.1.1 
Sensitivity analyses ................................................................................... 98 
14.3.2 
Other efficacy analyses ........................................................................................ 99 
14.3.2.1 
Analysis of the secondary efficacy variables ............................................ 99 
14.3.2.2 
Analysis of the other efficacy variables .................................................. 100 
14.4 
Subgroup analyses ..................................................................................................... 101 
14.5 
Planned safety and other analyses.............................................................................. 101 
14.5.1 
Safety analyses ................................................................................................... 101 
14.5.2 
Pharmacokinetic analyses .................................................................................. 102 
14.5.3 
Immunogenicity analyses .................................................................................. 102 
14.6 
Handling of protocol deviations................................................................................. 102 
14.7 
Handling of dropouts or missing data ........................................................................ 102 
14.8 
Planned interim analysis and data monitoring ........................................................... 104 
14.9 
Determination of sample size ..................................................................................... 104 
15 ETHICS AND REGULATORY REQUIREMENTS .................................................... 104 
15.1 
Informed consent ....................................................................................................... 104 
15.2 
Subject identification cards ........................................................................................ 105 
15.3 
Institutional Review Boards and Independent Ethics Committees ............................ 105 
15.4 
Subject privacy........................................................................................................... 106 
15.5 
Protocol amendments ................................................................................................. 106 
16 FINANCE, INSURANCE, AND PUBLICATION ....................................................... 106 
17 REFERENCES .............................................................................................................. 106 
18 APPENDICES ............................................................................................................... 109 
18.1 
Protocol Amendment 1 .............................................................................................. 109 
18.2 
Protocol Amendment 2 .............................................................................................. 162 
18.3 
Protocol Amendment 3 .............................................................................................. 205 
19 DECLARATION AND SIGNATURE OF INVESTIGATOR ..................................... 208 
20 SPONSOR DECLARATION ........................................................................................ 209 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 9 of 209 
 
LIST OF TABLES 
Table 5‒1: 
Schedule of study assessments......................................................................... 30 
Table 5‒2: 
Schedule of study assessments for subjects allocated to escape treatment ...... 35 
Table 7‒1: 
Dosing Scheme ................................................................................................ 47 
Table 7‒2: 
Prohibited PSO medications ............................................................................ 49 
Table 9‒1: 
Body areas for calculation of percent BSA for PASI ...................................... 66 
Table 9‒2: 
Five-point Investigator’s Global Assessment .................................................. 66 
Table 9‒3: 
Scalp IGA......................................................................................................... 68 
Table 9‒4: 
pp-IGA ............................................................................................................. 69 
Table 12‒1: 
Anticipated serious adverse events for the population of subjects with 
moderate to severe chronic plaque psoriasis .................................................... 74 
Table 12‒2: 
Laboratory measurements ................................................................................ 78 
Table 12‒3: 
Required investigations and follow up for PDILI............................................ 80 
Table 12‒4: 
PDILI laboratory measurements ...................................................................... 85 
Table 12‒5: 
PDILI information to be collected ................................................................... 86 
 
LIST OF FIGURES 
Figure 5‒1: 
Schematic diagram ........................................................................................... 37 
Figure 12-1: 
Schematic diagram of TB test results and study eligibility ............................. 89 
Figure 14-1: 
Sequence of testing .......................................................................................... 97 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 10 of 209 
LIST OF ABBREVIATIONS 
AE 
adverse event 
AESI 
adverse event of special interest 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AMS 
Active Medication Set 
ANCOVA 
analysis of covariance 
AST 
aspartate aminotransferase 
axSpA 
axial sponyloarthritis 
BA 
bioavailability 
BP 
blood pressure 
BSA 
body surface area 
cAMP 
cyclic adenosine monophosphate 
CDC 
Centers for Disease Control 
CDMS 
clinical data management system 
CI 
confidence interval 
CMH 
Cochran-Mantel-Haenszel 
CPM 
Clinical Project Manager 
CPMP 
Committee for Proprietary Medicinal Products 
CRO 
contract research organization 
CSR 
Clinical Study Report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
cardiovascular 
DLQI 
Dermatology Life Quality Index 
DMC 
Data Monitoring Committee 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
eC-SSRS 
electronic Columbia Suicide Severity Rating Scale 
EHR 
Electronic Healthcare Record 
ePRO 
electronic Patient-Reported Outcome 
EQ-5D-3L 
Euro-Quality of Life 5-Dimensions, 3 levels 
ESS 
Escape Subject Set 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 11 of 209 
FAS 
Full Analysis Set 
GCP 
Good Clinical Practice 
GI 
gastrointestinal 
GMP 
Good Manufacturing Practice  
HBcAb 
anti-hepatitis B core antibody 
HBsAg 
anti-hepatitis B surface antigen 
HCP 
healthcare practitioner 
HCV 
hepatitis C virus 
HCV Ab 
hepatitis C antibody 
HIV 
human immunodeficiency virus 
HLT 
High Level Term 
IB 
Investigator’s Brochure 
IBD 
inflammatory bowel disease 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
Ig 
immunoglobulin 
IGA 
Investigator’s Global Assessment 
IGRA 
interferon-gamma release assay 
IL 
interleukin 
IMP 
investigational medicinal product 
IRB 
Institutional Review Board 
IRT 
interactive response technology 
iv 
intravenous 
LOCF 
last observation carried forward  
LTB 
latent tuberculosis 
LTBI 
latent tuberculosis infection 
mAb 
monoclonal antibody 
mNAPSI 
Modified Nail Psoriasis Severity Index Score 
MAR 
missing at random 
MCMC 
Markov-Chain Monte Carlo 
MCS 
Mental Component Summary 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 12 of 209 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
multiple imputation 
NRI 
nonresponder imputation 
NSAID 
nonsteroidal anti-inflammatory drugs 
NTMB 
nontuberculous mycobacterium 
PASE 
Psoriatic Arthritis Screening and Evaluation 
PASI 
Psoriasis Area Severity Index 
PCS 
Physical Component Summary 
PD 
pharmacodynamics 
PDE4 
phosphodiesterase 4 
PDILI 
potential drug-induced liver injury 
PEOT 
Premature End of Treatment 
PFS 
prefilled syringe 
PGA 
Physician’s Global Assessment 
PGADA 
Patient’s Global Assessment of Disease Activity 
PHQ-9 
Patient Health Questionnaire 9 
PK 
pharmacokinetics 
PK-PPS 
Pharmacokinetics Per-Protocol Set 
pp-IGA 
palmoplantar Investigator’s Global Assessment 
PPS 
Per-Protocol Set 
PRO 
patient-reported outcome 
PS 
Patient Safety 
PsA 
psoriatic arthritis 
PSO 
psoriasis 
Q4W 
every 4 weeks 
Q8W 
every 8 weeks 
QOL 
quality of life 
RS 
Randomized Set 
SAE 
serious adverse event 
SAP 
Statistical Analysis Plan 
sc 
subcutaneous 
scalp IGA 
scalp-specific IGA 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 13 of 209 
SD 
standard deviation 
SF-36 
Short Form 36-item Health Survey 
SFU 
Safety Follow-Up 
SOP 
Standard Operating Procedure 
SS 
Safety Set 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event 
TNF 
tumor necrosis factor 
ULN 
upper limit of normal 
VAS 
visual analog scale 
WBC 
white blood cell 
WK16ResS 
Week 16 Responder Set 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 14 of 209 
1 
SUMMARY 
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study consisting of 
a 16-week Initial Treatment Period followed by a 40-week Randomized-Withdrawal Period to 
evaluate the efficacy, safety, and pharmacokinetics (PK) of bimekizumab compared with placebo 
in adult subjects with moderate to severe chronic plaque psoriasis (PSO). 
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5-point scale]) who are a candidate for systemic PSO therapy and/or phototherapy. 
Approximately 535 subjects will be screened in order to have 400 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. For each subject, the study will last a maximum of 
77 weeks and will consist of 4 periods: a Screening Period (2 to 5 weeks), a double-blind, 
placebo-controlled Initial Treatment Period (16 weeks), a double-blind,  placebo-controlled 
Randomized-Withdrawal Period (40 weeks) Period, and a Safety Follow-Up (SFU) Period (20 
weeks after the final dose of investigational medicinal product [IMP]). After completing the 
study, eligible subjects will be allowed to enroll in an open-label study. 
Eligible subjects will be randomized 4:1 to receive the following blinded IMP regimens: 
 Bimekizumab 320mg administered sc every 4 weeks (Q4W) 
 Placebo administered sc Q4W 
Investigational medicinal product will be administered in the clinic at Baseline, Week 4, Week 8, 
and Week 12. At the Week 16 study visit, bimekizumab and placebo subjects who have achieved 
a PASI90 response will enter the 40-week Randomized-Withdrawal Period. Dosing will be based 
on treatment group assignment at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg every 8 weeks (Q8W) or placebo 
(ie, treatment withdrawal) 
 Subjects initially randomized to placebo will continue to receive placebo (Q4W) provided the 
subject is a PASI90 responder 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W for 12 weeks. 
Subjects who achieve a PASI50 response at Week 12 of the open-label escape arm will be 
allowed to enroll in the open-label study. 
All subjects who relapse at Week 20 or later during the Randomized-Withdrawal Period (up to 
Week 56) will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W 
for 12 weeks. Relapse is defined as not achieving a PASI75 response. Subjects who achieve a 
PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in the open-
label study.  
Subjects who complete the Randomized Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll in an 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 15 of 209 
open-label study. Placebo-randomized subjects, who receive placebo during the entire Initial and 
Randomized-Withdrawal periods, that complete Week 56 without relapse into the open-label 
escape arm will not be eligible for the open-label study. 
At Week 56, all subjects enrolling in the open-label study will undergo the Week 56 study 
assessments before receiving their first dose of IMP in the open-label study. All subjects not 
enrolling in the open-label study will have their Week 56 study assessments and enter the SFU 
Period. 
Subjects withdrawing early from the study will undergo the Premature End of Treatment (PEOT) 
Visit assessments and will enter the SFU Period. 
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16 weeks versus placebo in the treatment of subjects with moderate to severe chronic plaque 
PSO. The secondary objectives of the study are listed in Section 3.2. 
The co-primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% reduction from Baseline in the PASI score) at Week 16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 category improvement relative to Baseline) at Week 16. 
The secondary efficacy variables are listed in Section 4.2.1. 
Pharmacokinetic variables are listed in Section 4.3.3. Pharmacogenomic variables are listed in 
Section 4.3.4. Immunological variables are listed in Section 4.3.5. 
Pharmacokinetic, genomic, genetic, proteomic, and immunological variables will be evaluated to 
assess their relationship to treatment response. 
Safety variables to be assessed are adverse events (AEs), vital signs, electrocardiograms (ECGs), 
and measurements of laboratory parameters. 
2 
INTRODUCTION 
2.1 
Psoriasis 
Psoriasis is a common, chronic inflammatory disease characterized by a series of linked cellular 
changes in the skin: hyperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and 
infiltration of T lymphocytes, neutrophils, and other types of leukocytes in affected skin. Though 
the pathophysiology of PSO is not fully understood, the importance of T-cells and inflammatory 
cytokines has been demonstrated by the clinical benefit provided by therapies directed at these 
targets (Krueger and Ellis, 2005). 
There are a variety of forms including plaque, guttate, inverse, pustular, and erythrodermic. 
Plaque PSO is the most common, comprising approximately 80% to 90% of all cases. 
Approximately 17% of those with PSO have moderate to severe disease (Kurd et al, 2008). 
In addition to the impact on skin, PSO has a multitude of psychosocial and emotional effects on 
patients, including increased self-consciousness, frustration, fatigue, depression, and suicidal 
ideation. As a result, patients frequently report sleeping problems, difficulties at work, problems 
interacting with family members, disrupted leisure activities, and sexual difficulties 
(Dowlatshahi et al, 2014; Gottlieb, 2005; Mukhtar et al, 2004; Ortonne, 2004; Krueger et al, 
2001). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 16 of 209 
A number of comorbidities have been associated with PSO, especially with more severe PSO. 
Psoriatic arthritis (PsA), cardiovascular (CV) disease, metabolic syndrome, chronic pulmonary 
disease, peptic ulcer disease, renal disease, and diabetes have all been demonstrated to have an 
increased prevalence in PSO patients (Yeung et al, 2013; Christophers et al, 2010; Gisondi et al, 
2007; Gelfand et al, 2006). 
2.1.1 
Global epidemiology of psoriasis 
Psoriasis affects approximately 3% of the US adult population (Rachakonda et al, 2014; Kurd 
and Gelfand, 2009) and its onset can begin at any age (Augustin et al, 2010; Icen et al, 2009). 
The reported worldwide incidence and prevalence of PSO varies greatly depending on age, 
gender, ethnicity, and geography primarily due to genetic and environmental factors. Estimates 
of incidence and prevalence include all types of PSO. Plaque PSO is the most common form of 
the disease therefore reported estimates of the magnitude of this condition are likely weighted 
heavily by this subtype. Both the incidence and prevalence of PSO are higher among Caucasians 
and those living in higher latitudes. Psoriasis affects approximately 2% to 4% of the population 
of western countries. Geographical differences are also influenced by case definition, study 
design, and the definition of prevalence (Parisi et al, 2013; Langley et al, 2005; Raychaudhuri 
and Gross, 2000). 
2.1.2 
Current treatments for psoriasis 
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with phototherapy, methotrexate, 
cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic agents, such 
as tumor necrosis factor (TNF) antagonists, interleukin (IL)-12/23 inhibitors, IL-23p19 inhibitors 
and IL-17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication include the IL-12/23 antagonist ustekinumab, the IL-23p19 antagonist 
guselkumab, the IL-17A inhibitors secukinumab and ixekizumab, and the IL-17 receptor 
antagonist brodalumab.  
Standard therapies for PSO are listed below: 
 Topical steroids (eg, triamcinolone, mometasone, clobetasol, betamethasone, hydrocortisone) 
are generally used as first-line treatment of PSO. High-strength steroids are typically 
reserved for use on the arms and legs. Areas such as the face and skin folds (axillary, 
inguinal regions, etc) are usually treated with a low potency steroid. Chronic use of topical 
steroids can lead to corticosteroid-related side effects and is generally discouraged. 
 Vitamin D analogs (eg, calcipotriol and tacalcitol) are commonly used to treat mild to 
moderate PSO, and work best within the mild patients. They are safe but lack efficacy for 
more severe disease. 
 Phototherapy is a frequent option for moderate to severe patients, but the inconvenience of 
multiple treatment visits and varying efficacy limits its use in the market. 
 Methotrexate is a systemic immunosuppressant and is used in moderate to severe PSO 
patients. Toxicity concerns, particularly in older patients, are a major drawback. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 17 of 209 
 Cyclosporine is a systemic immunosuppressant used in patients with severe, recalcitrant, 
PSO who have failed at least one systemic therapy or in whom other systemic therapies are 
contraindicated. In recommended dosages cyclosporine can cause systemic hypertension and 
nephrotoxicity, therefore, renal function must be monitored during therapy. 
 Apremilast is an oral small-molecule inhibitor of PDE4 that is also approved for treatment of 
adults with moderate to severe plaque PSO. Phosphodiesterase 4 inhibitors work 
intracellularly to modulate a network of proinflammatory and anti-inflammatory mediators. 
Phosphodiesterase 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the 
dominant PDE in inflammatory cells. Phosphodiesterase 4 inhibition elevates intracellular 
cAMP levels, which in turn down-regulates the inflammatory response by modulating the 
expression of TNFα, IL-23, IL-17, and other inflammatory cytokines. 
 Biologics, including TNFα inhibitors (adalimumab, etanercept, and infliximab), 
IL-12/23 inhibitors (ustekinumab), the IL-23p19 antagonist (guselkumab), the IL-17A 
inhibitors (secukinumab and ixekizumab), and the IL-17 receptor antagonist brodalumab are 
the treatment options of choice for patients with moderate to severe plaque PSO who are 
candidates for systemic therapy or phototherapy. These products are injected sc or delivered 
via intravenous (iv) infusion. Different from the traditional systemic drugs that impact the 
entire immune system, biologics target specific parts of the immune system and offer reduced 
multi-organ toxicity and adverse effects associated with traditional treatments. 
 TNFα inhibitors, while effective, come with boxed warnings including the risk of serious 
infections and reports of lymphoma and malignancy in children and adolescent patients. 
The efficacy of TNFα inhibitors in treating PSO is attributed to their inhibition of 
Th17-T cells.  
 Ustekinumab has been approved in the US and the EU for the treatment of patients with 
moderate to severe plaque PSO who are candidates for phototherapy or systemic therapy. 
Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that binds with 
specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines, 
naturally occurring cytokines that are involved in inflammatory and immune responses, 
such as natural killer cell activation and CD4+ T-cell differentiation and activation.  
 Secukinumab and ixekizumab have been approved in the US and the EU for the treatment 
of moderate to severe plaque PSO in adult patients who are candidates for systemic 
therapy or phototherapy. Secukinumab is a human IgG1 monoclonal antibody that 
selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction 
with the IL-17 receptor. Ixekizumab is a humanized IgG4 monoclonal antibody that 
selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction 
with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in 
normal inflammatory and immune responses. Both drugs inhibit the release of 
proinflammatory cytokines and chemokines. 
 Guselkumab has been approved in the US and EU for the treatment of adult patients with 
moderate to severe plaque PSO who are candidates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a 
naturally occurring cytokine that is involved in normal inflammatory and immune 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 18 of 209 
responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines. 
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
PSO in adult patients who are candidates for systemic therapy or phototherapy and have 
failed to respond or have lost response to other systemic therapies. In the EU, brodalumab 
is indicated for the treatment of moderate to severe plaque PSO in adult patients who are 
candidates for systemic therapy. Brodalumab is a human monoclonal IgG2 antibody that 
selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, 
IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. Blocking IL- 17RA inhibits IL-17 
cytokine-induced responses including the release of proinflammatory cytokines and 
chemokines. Brodalumab has a black box warning regarding suicidal ideation and 
behavior. 
2.2 
Bimekizumab 
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody (mAb) 
of immunoglobulin (Ig) G1 sub-class of approximately 150,000 Daltons which is expressed in a 
genetically engineered Chinese Hamster Ovary cell line. Bimekizumab has high affinity for 
human IL-17A and human IL-17F and selectively and potently inhibits the activity of both 
isoforms in vitro. Interleukin-17A and IL-17F are key proinflammatory cytokines believed to 
play important roles in autoimmune and inflammatory diseases. Bimekizumab is being 
developed for the treatment of patients with inflammatory diseases such as PsA, PSO, and axial 
spondyloarthritis (axSpA). 
While anti-IL-17A antibodies have demonstrated efficacy in patients with PSO, PsA, and 
ankylosing spondylitis, as yet, no therapeutic approach selectively and potently inhibits the 
activity of both IL-17A and IL-17F isoforms in vitro. Bimekizumab is an engineered, 
humanized, full-length IgG1 mAb which has been designed to inhibit the activity of IL-17A and 
IL-17F subtypes of IL-17. This property makes bimekizumab distinct from the other IL-17-
targeting agents like secukinumab and ixekizumab (selective anti-IL-17-A mAb), or brodalumab 
(anti-IL-17 receptor mAb). 
Overexpression of IL-17A, IL-17C, and IL-17F in lesion tissue suggests that broader IL-17 
blockade may be more beneficial in the treatment of plaque PSO. However, blocking all IL-17 
isoforms (including the IL 17E isoform, also known as IL-25) may not be the optimal approach. 
The role of IL-25 in PSO and other IL-17 mediated diseases has not been well established, 
however it has been suggested that IL-25 may play a beneficial role in inflammatory conditions 
associated with type 1 T helper (Th-1) mediated immune responses, such as PSO (as opposed to 
type 2 T helper [Th-2] mediated) (Valizadeh et al, 2015). Thus, it can be hypothesized that 
inhibition of both IL-17A and IL-17F is associated with additional benefits in PSO compared to 
the selective IL-17A inhibition or a broader IL-17 blockade. 
2.2.1 
Clinical 
2.2.1.1 
Completed studies 
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
UP0031 in 12 healthy volunteers, and UP0042 in 48 healthy volunteers.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 19 of 209 
UP0008 was a Phase 1, single ascending dose study in adults with mild to moderate PSO 
affecting ≤5% BSA. In this blinded study, single doses of up to 640mg (approximately 8mg/kg 
in an 80kg adult) were evaluated without any safety concerns. A total of 26 subjects with PSO 
with less than 5% of body surface involvement were treated with a range of single iv doses from 
8 to 640mg. There were no clinically relevant safety findings identified at any dose and all doses 
were well tolerated. The pre-specified exploratory assessment of disease activity showed 
clinically relevant and statistically significant improvements at the higher doses studied. 
RA0124 was a Phase 1, open-label, parallel-group, single-dose study in healthy subjects. The 
primary objective of this study was to determine the absolute bioavailability (BA) of single sc 
doses of bimekizumab (80mg and 160mg). The secondary objectives were to evaluate the dose 
proportionality of bimekizumab 80mg and 160mg sc, and to evaluate the safety and tolerability 
of these sc doses and 160mg given by iv infusion. In RA0124, the absolute BA was similar for 
the 2 doses tested (0.656 and 0.631 for the bimekizumab 80mg and 160mg sc doses, 
respectively). The PK of bimekizumab was linear in the tested dose range and the median t1/2 
following sc administration was similar to that following iv administration (27.81 days and 28.25 
days for bimekizumab 160mg sc and 160mg iv, respectively). 
Bimekizumab has also been investigated in a Phase 1b, proof of concept, randomized, placebo 
controlled, multiple dose study (PA0007). The primary objective of PA0007 was to assess the 
safety and PK of multiple dose administration of iv bimekizumab in subjects with PsA. Four 
active doses and a placebo were tested. Drug was administered as a loading dose at Week 0, and 
2 additional doses were administered at Week 3 and Week 6. In each treatment group, subjects 
received a total of 3 doses of bimekizumab, administered every 3 weeks as shown below: 
 80mg loading dose followed by 40mg at Weeks 3 and 6 
 160mg loading dose followed by 80mg at Weeks 3 and 6 
 240mg loading dose followed by 160 mg at Weeks 3 and 6 
 560mg loading dose followed by 320mg at Weeks 3 and 6 
The results of this study demonstrated that all doses of bimekizumab were well tolerated and 
there were no unexpected clinically relevant safety findings. 
Infections (mostly nasopharyngitis) were the most commonly reported events in both the active 
treatment and the placebo group. None of the infections were considered serious or required 
treatment with antibiotics. Two subjects in the active treatment group experienced 1 local 
candida infection each (oropharhyngitis and vulvovaginitis, respectively) that were non-serious 
and resolved with topical therapy. There was a potential reduction in mean neutrophil count in 
the active treatment group, although this drop was not clinically relevant and a clear relationship 
with dose or time was not evident. Some increases in liver function tests were reported, but none 
had a convincing relationship to exposure to IMP. The exploratory analysis showed clinically 
relevant improvement in activity of PsA and in skin involvement in those subjects with 
concomitant active psoriatic lesions. 
UP0031 was a Phase 1, open-label, parallel-group, randomized, single-dose study to evaluate the 
BA, PK, and tolerability of 2 different formulations of bimekizumab in healthy subjects. Subjects 
receiving Formulation A (
) were administered two 1mL injections of 80mg each 
of bimekizumab and subjects receiving Formulation B 
were administered a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 20 of 209 
single injection of bimekizumab 160mg given as a 1mL injection. Six subjects were randomized 
to each bimekizumab formulation. The geometric means (GeoMeans) for area under the curve 
(AUC) were similar between bimekizumab 2x80mg and 1x160mg groups and the relative BA for 
Formulation B vs Formulation A was 96.1% (95% confidence interval [CI]: 72.7%, 127.0%). 
Administration of the 2 formulations of bimekizumab used in this study identified no new safety 
issues. There were no treatment-emergent adverse events (TEAEs) leading to discontinuation, 
and no serious adverse events (SAEs) or fatalities were reported. The only preferred term 
experienced by more than 1 subject in either treatment group was injection site pain (5 subjects 
[83.3%] and 3 subjects [50.0%] in the 2x80mg and 1x160mg groups, respectively). The most 
frequently reported TEAE considered related to the IMP was injection site pain, experienced by 
5 subjects [83.3%] and 3 subjects [50.0%] in the 2x80mg and 1x160mg groups, respectively. 
There were no clinically significant laboratory values reported in the study. 
UP0042 was a randomized double-blind, placebo-controlled, single-dose, parallel-group study to 
evaluate the safety, tolerability, and PK of bimekizumab administered as an sc injection to 
Japanese and Caucasian healthy subjects. This study demonstrated that the PK profiles following 
single administration of 80mg, 160mg, and 320mg with an sc injection were dose proportional 
with a linear elimination in both Japanese and Caucasian subjects and that the PK profiles of 
Japanese and Caucasian subjects were considered to be generally similar. A single dose of 
bimekizumab (80mg, 160mg, or 320mg) administered as an sc injection was generally safe and 
well tolerated in healthy Japanese and Caucasian subjects and no major differences in safety 
findings were observed between Japanese and Caucasian subjects. 
2.2.1.2 
Ongoing studies 
Four additional studies of bimekizumab in the treatment of PSO are ongoing. 
 PS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO. 
 PS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab. 
 PS0016 is a Phase 2a, subject-blind, investigator-blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. 
 PS0018 is a long-term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab. 
Bimekizumab is also being evaluated in the treatment of other indications (eg, PsA, axSpA, 
hidradenitis suppurativa). Additional information on the clinical data for bimekizumab is 
available in the current version of the Investigator’s Brochure (IB). 
2.2.2 
Nonclinical 
Parallel inhibition of IL-17A and IL-17F has been shown to be efficacious in a variety of animal 
models of inflammatory disease. Intravenously administered bimekizumab was well tolerated in 
repeat dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 21 of 209 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat-dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were revealed. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa (Balantidium coli) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli and is considered the 
consequence of a change in local mucosal immunity. To date, similar findings have not been 
seen in studies in humans. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB. 
3 
STUDY OBJECTIVE(S) 
3.1 
Primary objective 
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16 weeks versus placebo in the treatment of subjects with moderate to severe chronic plaque 
PSO. 
3.2 
Secondary objectives 
The secondary objectives of the study are to: 
 Evaluate the efficacy of bimekizumab compared to placebo at achieving complete clearance 
(PASI100) after 16 weeks of treatment 
 Evaluate the efficacy of bimekizumab compared to placebo after 4 weeks of treatment 
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subjects using the Patient Symptom Diary 
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline 
 Evaluate the efficacy of continuous treatment with bimekizumab versus treatment withdrawal 
(placebo) as defined by PASI90 at Week 56 for subjects who responded to bimekizumab 
treatment at Week 16 
 Assess the maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56 
 Assess TEAEs, SAEs, and TEAEs leading to withdrawal adjusted by duration of subject 
exposure to study treatment 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 22 of 209 
3.3 
Other objectives 
The other objectives of the study are to demonstrate the effects of bimekizumab on aspects of the 
disease: 
 Assess the time to relapse among subjects who responded to bimekizumab treatment at 
Week 16 
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab in subjects who 
relapse (defined as not achieving a PASI75 response) during the Randomized-Withdrawal 
Period 
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab for subjects who do 
not achieve a PASI90 response (defined as a subject that does not achieve 90% reduction in 
the PASI score) at Week 16 
 Assess the efficacy of bimekizumab over time 
 Assess the efficacy of bimekizumab dosing Q4W versus Q8W during the Randomized-
Withdrawal Period 
 Assess the change of skin-related quality of life (QOL) 
 Assess the change of general health-related QOL 
 Assess the change in nail PSO over time in subjects with nail PSO at Baseline 
 Assess the change in scalp PSO over time in subjects with scalp PSO at Baseline 
 Assess the change in palmoplantar PSO over time in subjects with palmoplantar PSO at 
Baseline 
 Assess the symptoms of PsA as measured by the Psoriatic Arthritis Screening and Evaluation 
(PASE) questionnaire 
 Assess the change of patient-reported joint symptoms in subjects with PsA at Baseline 
 Assess the change in symptoms of PSO as reported by subjects using the Patient Symptom 
Diary (all items) through Week 16 
 Assess depression  
 Assess the PK of bimekizumab 
 Assess the immunogenicity of bimekizumab 
 Assess the effect of bimekizumab on gene and protein expression, and explore the 
relationship between genomic, genetic, and proteomic biomarkers and disease biology, drug 
treatment and inflammatory and immune responses (from consenting subjects who agree to 
participate in the biomarker substudy) 
 Assess the safety and tolerability of bimekizumab 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 23 of 209 
4 
STUDY VARIABLES 
4.1 
Primary efficacy variables 
The co-primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% reduction from Baseline in the PASI score) at Week 16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 category improvement relative to Baseline) at Week 16. 
4.2 
Secondary variables 
4.2.1 
Secondary efficacy variables 
The secondary efficacy variables are: 
 PASI100 response at Week 16 
 PASI75 response at Week 4 
 Patient Symptom Diary responses for itch, pain, and scaling at Week 16 
 Scalp IGA response (Clear or Almost Clear with at least a 2-category improvement from 
Baseline) at Week 16 for subjects with scalp PSO at Baseline 
 PASI90 response at Week 56 among Week 16 PASI90 responders 
4.2.2 
Secondary safety variables 
 TEAEs adjusted by duration of subject exposure to study treatment 
 SAEs adjusted by duration of subject exposure to study treatment 
 TEAEs leading to withdrawal adjusted by duration of subject exposure to study treatment 
4.3 
Other variables 
The other variables are listed below and will be evaluated according to the planned assessments 
in Table 5‒1. 
4.3.1 
Other efficacy variable(s) 
The other efficacy variables are listed below and will be evaluated at all scheduled visits in 
accordance with the Schedule of Study Assessments in Table 5‒1. This excludes the timepoints 
for the primary and secondary variables specified above in Section 4.1 and Section 4.2.1, 
respectively. 
Change from Baseline variables evaluated during the Initial Treatment Period are relative to the 
Baseline Visit (first dose). For subjects who are re-randomized at the Week 16 Visit, change 
from Baseline variables during the Randomized-Withdrawal Period may be evaluated relative to 
both the Baseline Visit (first dose) and the Week 16 Visit. Similarly, for subjects who initiate 
escape treatment with bimekizumab (either due to lack of response at Week 16 or loss of 
response [relapse] during the Randomized-Withdrawal Period), these variables during the 
12-week escape treatment period may be evaluated relative to both the Baseline Visit (first dose) 
and the visit at which escape treatment was initiated. 
For simplicity, “change from Baseline” is used below for all such variables and applies to all 
scheduled visits where the assessments were performed (whether during the Initial Period, 
Randomized-Withdrawal Period, or Escape Treatment Period). Greater detail on the definition of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 24 of 209 
Baseline for different summaries will be provided in the Statistical Analysis Plan (SAP). Unless 
otherwise stated PASI responder rates will be calculated relative to the Baseline Visit (first 
dose). 
The other efficacy variables are: 
 PASI50, PASI75, PASI90, and PASI100 response 
 Time to PASI50, PASI75, PASI90, and PASI100 response during the Initial Treatment 
Period 
 Time to relapse during the Randomized-Withdrawal Period 
 Percentage of subjects who relapse during the Randomized-Withdrawal Period 
 Absolute and percent change from Baseline in PASI score 
 IGA response (Clear with at least a 2-category improvement from Baseline) 
 IGA response (Clear or Almost Clear with at least 2-category improvement from Baseline) 
 Shift from Baseline in IGA score 
 Absolute and percent change from Baseline in the BSA affected by PSO 
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA) 
 Change from Baseline in Dermatology Life Quality Index (DLQI) 
 Percentage of subjects achieving a DLQI total score of 0 or 1 
 Percentage of subjects achieving a minimal clinically important difference (improvement 
from Baseline of 4 or more) in the DLQI 
 Change from Baseline in the Patient’s Global Assessment of Disease Activity (PGADA) for 
the arthritis visual analog scale (VAS) in the subgroups of subjects with PsA as defined by 
PASE score at Baseline 
 Change from Baseline in Patient Global Assessment (PGA) of PSO score 
 Patient Symptom Diary responses 
 Scalp-specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear with at least a 2-category improvement relative to Baseline) for subjects with scalp 
PSO at Baseline 
 Change from Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) score for 
subjects with nail PSO at Baseline 
 Palmoplantar Investigator’s Global Assessment (pp-IGA) response (Clear or Almost Clear) 
for subjects with palmoplantar PSO at Baseline 
 Change from Baseline in the PASE questionnaire scores (function score, symptom score, and 
total score) 
 Shift from Baseline in PASE score suggestive of PsA (<47 versus ≥47) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 25 of 209 
 Change from Baseline in Short Form 36-item Health Survey (SF-36) Physical Component 
Summary (PCS) score, and Mental Component Summary (MCS) score, and individual 
domains 
 Responses to Euro-Quality of Life 5-Dimensions, 3 levels (EQ-5D-3L), absolute and changes 
from Baseline in EQ-5D-3L VAS scores 
 Change from Baseline in Patient Health Questionnaire (PHQ)-9 scores 
4.3.2 
Other safety variables 
Safety variables to be assessed are: 
 Severity and frequency of AEs 
 Change from Baseline in vital signs 
 ECG results 
 Change from Baseline in clinical laboratory values (chemistry, hematology, and urinalysis) 
Physical examination findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs. 
4.3.3 
Pharmacokinetic variable 
The PK variable is the plasma concentration of bimekizumab. 
4.3.4 
Pharmacogenomic variables 
Additional blood samples will be collected from subjects who consent to participate in the 
substudy at specific time points and stored at -80°C for up to 20 years. 
Genomic, genetic, epigenetic, proteins, and metabolite biomarkers may be measured to evaluate 
the relationship with response to treatment with bimekizumab, PSO disease biology, and 
inflammatory and immune response processes. The nature and format of these tentative substudy 
analyses will be determined when the results of the main study are made available. 
The candidate exploratory variables are the blood or blood derivative (eg, serum) concentrations 
of cytokines and chemokines of relevance to IL-17A/F signaling pathway and PSO biology. 
Additional variables may include but will not be limited to serum complement concentrations. 
4.3.5 
Immunological variable 
The immunological variable is the anti-bimekizumab antibody level prior to and following IMP. 
5 
STUDY DESIGN 
5.1 
Study description 
PS0013 is a Phase 3, multicenter, randomized, double-blind placebo-controlled study consisting 
of a 16-week Initial Treatment Period followed by a 40-week Randomized-Withdrawal Period to 
evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. To be eligible to participate in this study, subjects must be adults with a 
diagnosis of moderate to severe PSO (Baseline PASI ≥12 and BSA affected by PSO ≥10% and 
IGA score ≥3 [on a 5-point scale]) who are a candidate for systemic PSO therapy and/or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 26 of 209 
phototherapy. Subjects may have been previously exposed to a biologic therapy (see Exclusion 
Criterion #23, Section 6.2). 
5.2 
Study periods 
This study will include 4 periods, a Screening Period (2 to 5 weeks), a placebo-controlled Initial 
Treatment Period (16 weeks), a placebo-controlled Randomized-Withdrawal Period (40 weeks), 
and a SFU Period (20 weeks after the final dose of IMP). After completing the study, eligible 
subjects will be allowed to enroll in an open-label study. Subjects enrolling into the open-label 
study will not have the PS0013 SFU Visit. 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 5.2.5). All subjects who relapse at Week 20 or later 
during the Randomized-Withdrawal Period (up to Week 56) will be allocated to escape treatment 
(see Section 5.2.5). Relapse is defined as not achieving a PASI75 response. Subjects who 
achieve a PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in 
the open-label study.  
Subjects who complete the Randomized Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll in an 
open-label study. Placebo-randomized subjects, who receive placebo during the entire Initial and 
Randomized-Withdrawal periods, that complete Week 56 without relapse into the open-label 
escape arm will not be eligible for the open-label study. 
5.2.1 
Screening Period 
The Screening Period will last 2 weeks, but can be extended up to a total of 5 weeks in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications. During this time, eligible subjects will be informed about the study and sign the 
Informed Consent Form (ICF), laboratory data (hematology, urine, and biochemistry tests) will 
be obtained, and the doses of medications used to treat PsA, will be verified as stable. The 
Screening Period will also enable washout of any medications not permitted for use during the 
study. Subjects who require prophylaxis for latent tuberculosis (LTB) infection must be on 
treatment for at least 8 weeks prior to their first dose of IMP. These subjects may be rescreened 
once they have completed the first 8 weeks of prophylaxis treatment. 
One rescreening may be allowed after consultation with the Medical Monitor. 
The assessments to be performed at the Screening Visit are presented in Table 5‒1. 
5.2.2 
Initial Treatment Period 
During the placebo-controlled Initial Treatment Period, approximately 400 subjects will be 
randomized 4:1 to receive the following blinded IMP regimens: 
 Bimekizumab 320mg administered Q4W (320 subjects) 
 Placebo administered Q4W (80 subjects) 
Investigational medicinal product will be administered in the clinic by sc injection at the time 
points specified in the schedule of assessments (Table 5‒1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 27 of 209 
Subjects will be followed in a double-blind fashion. Subjects may receive placebo injections at 
certain visits in order to blind the IMP. The assessments to be performed at each Initial 
Treatment Period visit are presented in Table 5‒1. 
Subjects withdrawing early from the study will undergo the PEOT Visit assessments and will 
enter the SFU Period. Subjects withdrawing early from the study will not be eligible for 
inclusion in the open-label study. 
5.2.3 
Randomized-Withdrawal Period 
At the Week 16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double-blind, placebo-controlled Randomized-Withdrawal Period lasting 40 weeks. 
Subjects who do not achieve a PASI90 response at the Week 16 study visit will be allocated to 
the escape arm (see Section 5.2.5). 
During the Randomized-Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal) 
 All subjects initially randomized to placebo who achieve a PASI90 response at Week 16 will 
continue to receive placebo (Q4W) 
Investigational medicinal product will be administered in the clinic at Week 16 and Q4W 
thereafter through Week 52. The assessments to be performed at each visit of the Randomized-
Withdrawal Period are presented in Table 5‒1. 
All subjects who relapse at Week 20 or later during the Randomized-Withdrawal Period (up to 
Week 56) will be allocated to the escape arm (see Section 5.2.5). Relapse is defined as not 
achieving a PASI75 response. 
At the end of the Randomized-Withdrawal Period, all subjects enrolling in the open-label study 
(after signing a new ICF) will undergo the Week 56 study assessments before receiving their first 
dose of IMP in the open-label study. All subjects not enrolling in the open-label study will have 
the Week 56 study assessments and will enter the SFU Period. 
5.2.4 
Safety Follow-Up 
All subjects not continuing in the open-label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP. 
The assessments for the SFU are presented in Table 5‒1. 
5.2.5 
Escape Treatment 
As described above, subjects who do not achieve a PASI90 response at Week 16 of the Initial 
Treatment Period and all subjects who relapse at Week 20 or later during the Randomized-
Withdrawal Period (up to Week 56) will receive open-label bimekizumab 320mg Q4W for 
12 weeks (ie, escape treatment). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 28 of 209 
For subjects who relapse during the Randomized-Withdrawal Period, the subject should 
complete the 12-week escape treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped). 
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open-label study. The Schedule of Study Assessments for subjects 
receiving escape treatment is provided in Table 5‒2. 
5.2.6 
Premature End of Treatment 
Subjects withdrawing early from the study will undergo PEOT Visit assessments (see 
Section 8.5) and will enter the SFU Period. 
5.3 
Study duration per subject 
For each subject, the study will last a maximum of up to 77 weeks, as follows: 
 Screening Period: 2 to 5 weeks 
 Double-blind, placebo-controlled Initial Treatment Period: 16 weeks 
 Double-blind, placebo-controlled Randomized-Withdrawal Period: 40 weeks 
 Escape treatment (if required): 12 weeks 
 Safety Follow-Up Period: a SFU Visit is planned 20 weeks after the final dose of IMP (for 
subjects not enrolling in the open-label study) 
After the 40-week Randomized-Withdrawal Period, subjects will be allowed to enroll in an open-
label study, in which case subjects will undergo the Week 56 study assessments before receiving 
their first open-label IMP dose. Subjects who achieve a PASI50 response in the open-label 
escape arm will also be allowed to enroll in the open-label study. Subjects who complete the 
Randomized Withdrawal Period (after a Week 16 response [≥PASI90] on bimekizumab during 
the Initial Treatment Period) will be allowed to enroll in an open-label study. Placebo-
randomized subjects, who receive placebo during the entire Initial and Randomized-Withdrawal 
periods, that complete Week 56 without relapse into the open-label escape arm will not be 
eligible for the open-label study.  
The SFU Visit will not be required for subjects who enroll in the open-label study. 
The end of the study is defined as the date of the last visit of the last subject in the study. 
5.4 
Planned number of subjects and site(s) 
Approximately 535 subjects will be screened in order to have 400 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. The planned number of study sites is approximately 100. 
Every eligible subject who signs an ICF will be randomized. 
5.5 
Anticipated regions and countries 
The regions planned for study conduct are North America, Western Europe, Central/Eastern 
Europe, and Asia/Australia, with possible extension to other regions and countries. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 29 of 209 
5.6 
Schedule of study assessments 
The Schedule of Study Assessments for all subjects enrolled in the study is presented in 
Table 5‒1. The Schedule of Study Assessments for subjects allocated to escape treatment is 
presented in Table 5‒2. At each visit, all study assessments should be performed prior to 
administration of IMP. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 30 of 209 
Table 5‒1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEO
T 
SFU
b 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xd 
 
 
Inclusion/exclusion 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant past medical 
history and concomitant 
diseases 
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examf, g 
X 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
X 
X 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
X 
 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and 
biochemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
X 
Urinalysis 
X 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
ECG 
X 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
 
X 
 
X 
 
Pregnancy testingi 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hepatitis B and C testingj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV testingk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 31 of 209 
Table 5‒1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEO
T 
SFU
b 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Chest x-rayl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGRA Tuberculosis test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tuberculosis 
questionnaire 
X 
X 
 
 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
bimekizumab plasma 
concentrationsm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
anti-bimekizumab 
antibodiesm 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m 
 
X 
X 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
Blood sample for 
genetic/ epigenetic 
analysesc,m 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IGA  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
 
X 
 X 
X  
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
PHQ-9 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X  
X 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 32 of 209 
Table 5‒1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEO
T 
SFU
b 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
eC-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Patient Symptom Diary 
(daily) 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
Scalp IGA 
 
X 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
mNAPSI 
 
X 
 
 
Xo 
Xo 
Xo 
Xo 
Xo 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
pp-IGA 
 
X 
 
 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
EQ-5D-3L 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
SF-36 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Patient Global 
Assessment of PSOq 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
PASE 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PGADAr 
 
X 
 
 
X 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IRTs,t 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bimekizumab or placebo 
administrations,t 
 
X 
 
 
X 
X 
X 
Xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 33 of 209 
Table 5‒1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEO
T 
SFU
b 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
BSA=body surface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic 
Columbia-Suicide Severity Rating Scale; EQ-5D-3L= Euro-Quality of Life 5-Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index;; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global Assessment of Disease Activity; PHQ-9=Patient 
Health Questionnaire 9; pp-IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF-36=Short Form 36 item Health 
Survey; SFU=Safety Follow-Up; scalp IGA=scalp-specific Investigator’s Global Assessment; TB=tuberculosis;  
a Visit windows of ±3 days from the first dose to the Week 24 visit. Visit windows of ±7 days from the Week 28 visit to the Week 52 visit. The SFU Visit 
window is ±7 days from final dose. 
b The SFU Visit will occur 20 weeks after the final dose for subjects who do not enroll in the open-label study. 
c All genomic, proteomic, and metabolomics samples will be stored at -80°C at the central biorepository for up to 20 years. 
d A separate ICF will be required to be completed for the open-label study. 
e Ensure no significant changes in medical history. 
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB. 
g The physical examination will be performed as per Section 12.3.5. 
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits 
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) and negative for anti-hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti-hepatitis B surface antibody. 
k The HIV test results will not be recorded in the eCRF. 
l Screening chest x-ray must occur within 3 months prior to the Screening Visit. 
m All blood samples taken prior to dosing. 
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline. 
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 34 of 209 
Table 5‒1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEO
T 
SFU
b 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline. 
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Screening through the Initial 
Treatment Period. During the Randomized-Withdrawal Period this assessment will be completed at the specified clinic visits . 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47). 
s IMP administration is based on randomization. 
t The dosing window is ±3 days relative to the scheduled dosing visit through Week 24. The dosing window is ±7 days from Week 28 through the end of the 
study. 
u At Week 16, subjects initially randomized to BKZ 320mg Q4W who achieve PASI90 response will be re-randomized 1:1:1 to either BKZ 320mg Q4W, BKZ 
320mg Q8W or placebo; subjects initially randomized to placebo who achieve PASI90 response at Week 16 will continue to receive placebo; and subjects who 
do not achieve PASI90 response at Week 16 will be allocated to the escape arm. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 35 of 209 
Table 5‒2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
eC-SSRS 
X 
X 
X 
X 
X 
Urine drug screen 
 
 
 
X 
 
Physical exam 
 
 
 
X 
X 
Body Weight 
X 
 
 
X 
 
Vital signsc 
X 
X 
X 
X 
X 
Hematology and biochemistry 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
X 
X 
ECG 
 
 
 
X 
 
Pregnancy testingd 
X 
X 
X 
X 
X 
IGRA Tuberculosis test 
 
 
 
X 
 
Tuberculosis questionnaire 
 
 
 
X 
X 
Blood sample for bimekizumab plasma concentrationse 
X 
X 
X 
X 
X 
Blood sample for anti-bimekizumab antibodiese 
X 
X 
X 
X 
X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker analysese 
X 
 
 
X 
 
Blood sample for genetic/epigenetic analysese 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
 
PHQ-9 
X 
X 
X 
X 
 
scalp IGAf 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 36 of 209 
Table 5‒2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
mNAPSIg 
X 
X 
X 
X 
 
pp-IGAh 
X 
X 
X 
X 
 
EQ-5D-3L 
X 
 
 
X 
 
SF-36 
X 
 
 
X 
 
Patient Global Assessment of PSOi 
X 
 
 
X 
 
PASE 
X 
 
 
X 
 
PGADAj 
X 
X 
X 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
IRT 
X 
X 
X 
X 
X 
Bimekizumab administrationk 
X 
X 
X 
 
 
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ-5D-3L=Euro-Quality of Life 5-Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; SF-36=Short Form 36-item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis 
a Visit windows of ±7 days from the first dose at all visits except SFU. SFU Visit window is ±7 days from final dose. 
b The SFU Visit will occur 20 weeks after the final dose for subjects who do not enroll in the open-label study. 
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug. 
e All blood samples taken prior to dosing. 
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline. 
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline. 
h The pp-IGA will only be assessed in subjects with palmoplantar involvement at Baseline. 
i During escape treatment, this assessment will be completed at each clinic visit specified. 
j The PGADA is assessed only for subjects with PsA at Baseline. 
k The dosing window is ±7 days relative to the scheduled dosing visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 37 of 209 
5.7 
Schematic diagram 
Figure 5‒1: Schematic diagram 
          Bimekizumab 320mg Q8W
Bimekizumab 
320mg Q4W
Screening
N=320
Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long-term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study
          Bimekizumab 320mg Q4W
Randomized - Withdrawal Period
<PASI90
          Placebo Q4W
  PASI90
Randomize 
1:1:1
relapse
Week
16
Co-Primary 
Endpoint: PASI90 
Response
IGA response
Randomization
56
Baseline
N=400
Relapse: <PASI75 at 
Week 20 or later
Placebo
  PASI90
N=80
12-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20
          Placebo
28
<PASI90
relapse
Relapse: <PASI75 at 
Week 20 or later
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safety Follow-Up 
Note: Subjects who do not achieve a PASI90 response at Week 16 will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W for 
12 weeks. 
Note: Relapse is defined as not achieving a PASI75 response. All subjects who relapse at Week 20 or later will be allocated to an escape arm and receive open-
label bimekizumab 320mg Q4Wfor 12 weeks. 
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to receive placebo Q4W at Week 16 and later visits provided a PASI90 
response was achieved at Week 16.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 38 of 209 
5.8 
Rationale for study design and selection of dose 
5.8.1 
Study design 
A randomized, double-blind, placebo-controlled study design has been selected in order to 
demonstrate efficacy and safety of bimekizumab for regulatory approval. The study population 
will include adults with moderate to severe chronic plaque PSO and allow subjects who have 
received previous biologic treatment as well as those who are biologic treatment naïve. The 
primary efficacy outcome measures (based on PASI and IGA) and other efficacy assessments 
included in this study are consistent with those used for other PSO studies and are considered 
appropriate for establishing efficacy of bimekizumab. An initial treatment period of 16 weeks 
will be used to demonstrate the efficacy of bimekizumab over placebo. The study duration 
extends beyond the initial treatment period (to 56 weeks) to collect information on dosing 
beyond initial treatment, including the impact on efficacy and safety of withdrawing 
bimekizumab treatment from those who responded at Week 16. 
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PASI90). Subjects 
who do not achieve a PASI90 response at Week 16 in PS0013 are allocated to a 12-week escape 
treatment with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a PASI90 on 
placebo to the bimekizumab 320mg Q4W escape arm provides them with the opportunity to 
potentially achieve a higher level of efficacy. Beyond just achieving a higher level of skin 
clearance, there is evidence that PASI90 is associated with higher levels of patient satisfaction 
(as measured by DLQI) compared with a lower PASI75 threshold (Puig et al, 2017). All subjects 
who relapse at Week 20 or later will be allocated to an escape arm and receive open-label 
bimekizumab 320mg Q4W for 12 weeks. Subjects in the placebo treatment arm in the Initial 
Treatment Period who are ≥PASI90 at Week 16 and ≥PASI 75 at Week 20 or later will continue 
to receive placebo Q4W at Week 16 and later visits.  
5.8.2 
Selection of dose 
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptable safety profile, only required 2 injections 
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthermore, data from the Phase 2a multicenter, randomized, subject-blind, 
Investigator-blind study PS0016 and PK/PD modeling in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg (Q4W initial and Q4W or 
Q8W maintenance) was selected for this study. 
6 
SELECTION AND WITHDRAWAL OF SUBJECTS 
6.1 
Inclusion criteria 
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and at the Baseline Visit: 
1. Subject has provided informed consent. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 39 of 209 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, or medication intake according to the judgment of the 
Investigator. 
3. Male or female at least 18 years of age. 
4. Chronic plaque PSO for at least 6 months prior to the Screening Visit. 
5. PASI ≥12 and BSA affected by PSO ≥10% and IGA score ≥3 on a 5-point scale. 
6a. Subject is a candidate for systemic PSO therapy and/or phototherapy. 
7. Criterion deleted. 
8. Female subjects must be: 
 Postmenopausal. Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause. 
 Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) 
 Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation), must be willing to use a highly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of IMP, and 
have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose. 
The following methods are considered highly effective when used consistently and 
correctly: 
◦ 
Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal) 
◦ 
Progestogen-only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable) 
◦ 
Intrauterine device 
◦ 
Intrauterine hormone-releasing system 
◦ 
Vasectomised partner 
◦ 
Abstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in accordance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abstinence is still in accordance with the 
subject’s lifestyle at regular intervals during the study. 
9. Subject agrees not to change their usual sun exposure during the course of the study and to 
use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs. 
6.2 
Exclusion criteria 
Subjects are not permitted to enroll in the study if any of the following criteria are met: 
1. Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study 
or within 20 weeks following the final dose of IMP. 
2. Subject previously participated in a bimekizumab clinical study who received at least 1 dose 
of the IMP (including placebo). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 40 of 209 
3a. Subject is currently participating in another study of a medication (systemic) under 
investigation. Subject must be washed out of the medication for 12 weeks or at least 5 half-
lives prior to the Baseline Visit, whichever is greater. 
4a. Subject is currently participating in another study of a topical medication under investigation. 
Subject must be washed out of the medication for 4 weeks prior to the Baseline Visit. 
5a. Subject is currently, or was within the 4 weeks prior to the Baseline Visit, participating in 
another study of a medical device under investigation. 
6. Subject has a known hypersensitivity to any excipients of bimekizumab. 
7. Subject has a form of PSO other than chronic plaque-type (eg, pustular, erythrodermic and 
guttate PSO, or drug-induced PSO). 
8. Subject has an active infection or history of infection(s) as follows: 
 Any active infection (except common cold) within 14 days prior to Baseline. 
 A serious infection, defined as requiring hospitalization or iv anti-infective(s) within 
2 months prior to the Baseline visit. 
 A history of opportunistic, recurrent, or chronic infections that, in the opinion of the 
Investigator, might cause this study to be detrimental to the subject. Opportunistic 
infections are infections caused by uncommon pathogens (eg, pneumocystis jirovicii, 
cryptococcosis) or unusually severe infections caused by common pathogens (eg, 
cytomegalovirus, herpes zoster) 
9. Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency 
virus (HIV) infection. Subjects who have evidence of, or tested positive for hepatitis B or 
hepatitis C are excluded. A positive test for the hepatitis B virus is defined as: 1) positive for 
hepatitis B surface antigen (HBsAg+) or 2) positive for anti-hepatitis B core antibody 
(HBcAb+). A positive test for the hepatitis C virus (HCV) is defined as: 1) positive for 
hepatitis C antibody (anti-HCV Ab) and 2) positive via a confirmatory test for HCV (for 
example, HCV polymerase chain reaction). 
10. Subject has received any live (includes attenuated) vaccination within the 8 weeks prior to 
the Baseline visit (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal 
influenza vaccination is not permitted). 
11. Subject has received Bacillus Calmette-Guerin vaccinations within 1 year prior to the 
Baseline visit. 
12. Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or 
has current or history of nontuberculous mycobacterium (NTMB) infection. A subject with 
LTB (a positive interferon-gamma release assay [IGRA] and diagnosis confirmed by TB 
specialist) may be rescreened once and enrolled after receiving at least 8 weeks of 
appropriate LTB infection therapy and if no evidence of therapy-related hepatotoxicity has 
occurred prior to the first injection (alanine aminotransferase [ALT]/aspartate 
aminotransferase [AST] remain ≤3 times upper limit of normal [ULN]). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 41 of 209 
Subject has a past history of active TB involving any organ system unless adequately treated 
according to World Health Organization/Centers for Disease Control (CDC) therapeutic 
guidance and proven to be fully recovered upon consult with a TB specialist. 
Refer to Section 12.3.1 for details on determining full TB exclusion criteria. 
13. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease. 
14a.Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer. 
15. Subject has a diagnosis of inflammatory conditions other than PSO or PsA, including but not 
limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a 
diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they have no active 
symptomatic disease at Screening or Baseline. 
16. Subject has had major surgery (including joint surgery) within the 3 months prior to the 
Baseline Visit, or has planned major surgery within 6 months after entering the study. 
17a.Subject has any systemic disease (ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematological, immunological, etc.) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study. 
18. Subject has had myocardial infarction or stroke within the 6 months prior to the Screening 
Visit. 
19. Subject has laboratory abnormalities at Screening, including any of the following: 
a. ≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome) 
b. White blood cell (WBC) count <3.00x103/μL 
c. Absolute neutrophil count <1.5x103/μL 
d. Lymphocyte count <500 cells/μL 
e. Hemoglobin <8.5g/dL 
f. Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent 
the subject from completing the study or will interfere with the interpretation of the study 
results 
Individual screening tests for which the results are in error, borderline, or indeterminate 
for inclusion in the study can be repeated once for confirmation during the Screening 
Period. Upon retesting, subjects whose results remain outside this threshold should not be 
randomized. 
20. Subject has any other condition, including medical or psychiatric, which, in the Investigator's 
judgment, would make the subject unsuitable for inclusion in the study. 
21. Criterion deleted. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 42 of 209 
22. Criterion deleted. 
23. Subject has experienced primary failure (no response within 12 weeks) to 1 or more IL-17 
biologic response modifier (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 
biologic response modifier other than an IL-17. 
24. Subject is taking PsA medications other than stable doses (ie, stable for at least 1 week prior 
to the Screening Visit) of nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics (see 
Section 7.8.1.2). 
25. Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening as 
evaluated by the Investigator based on medical history, site interview, and/or results of the 
specified urine drug screen. 
26. Presence of active suicidal ideation, or positive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS) and with either 
of the following criteria: 
 History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt more than 5 years ago should be evaluated by a mental 
healthcare practitioner (HCP) before enrolling into the study. 
 Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the eC-
SSRS. 
27a.Subject has presence of moderately severe major depression or severe major depression, 
indicated by a score of ≥15using the screening PHQ-9. Medication used to treat depression 
should be stable for 8 weeks prior to Baseline. 
28. Subject is a member of Investigator site personnel directly affiliated with this study and/or 
their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, 
whether biological or legally adopted. 
29. Subject is a UCB employee or employee of third-party organizations involved in the study. 
30. Subject is taking or has taken prohibited psoriasis medications without meeting the 
mandatory washout period relative to the Baseline Visit (Table 7‒2). 
6.3 
Withdrawal criteria 
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care. Subjects who withdraw from the study should complete the PEOT Visit (see Section 8.5). 
Subjects should be withdrawn from the study and will be encouraged to come back for the SFU 
visit 20 weeks after final dose of IMP if the subject withdraws his/her consent or the Sponsor or 
a regulatory agency requests withdrawal of the subject. 
A subject should be withdrawn from IMP and will be asked to come back for the SFU visit 
20 weeks after final dose of IMP if any of the following events occur:  
1. Subject develops an illness that in the opinion of the Investigator would interfere with his/her 
continued participation if the risk of continuing participation outweighs the potential benefit. 
2. Subject develops erythrodermic, guttate, or pustular form of PSO. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 43 of 209 
3. Criterion deleted. 
4. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator. 
5. Subject uses prohibited concomitant medications, with the exception of topicals, as defined 
in this protocol (Section 7.8.2), that may present a risk to the safety of the subject or the 
integrity of the study data, in the opinion of the Investigator and/or the Medical Monitor. 
6. Subject has a clinical laboratory value meeting any of the following criteria: 
a. Hepatotoxicity as described in Section 6.3.1  
b. A laboratory value meeting any of the following criteria: 
◦ 
Absolute neutrophil count <1.0x103/μL 
◦ 
Absolute lymphocyte count <0.2x103/μL 
Subjects may remain in the study if the result is transient. A retest is required within 1 to 
2 weeks at a scheduled or unscheduled visit. If the repeat absolute neutrophil count or 
absolute lymphocyte count is still below the allowable values, the subject must be 
withdrawn. If the repeat absolute neutrophil count or absolute lymphocyte count is above 
the allowable values, the subject may continue in the study. 
7. The subject experiences a severe AE, an SAE, or a clinically significant change in a 
laboratory value that, in the opinion of the Investigator, merits the discontinuation of the 
investigational product and appropriate measures being taken. 
8. Criterion deleted. 
9. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test (see Section 12.1.4 for more information regarding pregnancies). 
10. A subject considered as having either a suspected new LTB infection or who develops active 
TB or NTMB infection during the study (including but not limited to, conversion 
demonstrated by IGRAs or other diagnostic means) must be immediately discontinued from 
IMP and a PEOT Visit must be scheduled as soon as possible, but not later than the next 
regular visit. 
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with latent TB infection (LTBI) with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion of 
the Investigator or Sponsor, is noncompliant with prophylactic TB therapy. 
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow-up reports should be completed as per protocol requirements until such time as the TB 
infection resolves. 
Additional information on TB policies is provided in Section 12.3.1. 
11. Subjects with newly diagnosed IBD or with IBD flares during the study must: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 44 of 209 
 Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist 
 Discontinue IMP and be followed-up until resolution of active IBD symptoms 
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study. 
12. Subjects must be referred immediately to a mental health care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk for: 
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC-SSRS 
 
Moderately severe major depression as indicated by a PHQ-9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit. 
13. Subjects must be referred immediately to a mental healthcare professional and must be 
withdrawn in case of: 
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC-SSRS 
 Any suicidal behavior since last visit. 
 Severe major depression as indicated by a PHQ-9 score ≥20 
The mental health consultation must be recorded in source documentation. 
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow-up, the Investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The electronic Case Report Form (eCRF) must document the primary reason for 
withdrawal or discontinuation. 
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance. 
6.3.1 
Potential drug-induced liver injury IMP discontinuation criteria 
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP for subjects 
with either of the following: 
 ALT or AST ≥ 8xULN 
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 45 of 209 
The PDILI criterion below requires immediate discontinuation of IMP for: 
 Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%). 
If a nondrug-related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section 12.2.1.2.1 are followed. 
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator. 
 Subjects with ALT or AST ≥5xULN and <8xULN, total bilirubin <2xULN, and no 
eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness). 
Evaluation of PDILI must be initiated as described in Section 12.2.1 with repeat tests 
performed in 2 weeks. Upon re-test, if ALT or AST values have reduced to <5xULN, the 
subject can continue with the study. However, if ALT or AST remains ≥5xULN and 
<8xULN after re-test, IMP should be temporarily withheld and subject should undergo a 
repeat test in two weeks. If ALT or AST values remain ≥5xULN even after the second re-
test, then the subject should be permanently withdrawn from the study and should be 
followed for possible drug-induced liver injury. 
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately. 
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation. 
7 
STUDY TREATMENT(S) 
7.1 
Description of investigational medicinal product(s) 
The IMPs used in this study are bimekizumab and placebo. 
 Bimekizumab will be supplied in a 
 
 for sc 
injection. 
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection. 
Further details of the IMPs and their specifications are provided in the IMP Handling Manual. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 46 of 209 
7.2 
Treatment(s) to be administered 
Unblinded study staff will be responsible for preparation of the clinical trial material, including 
recording the administration information on source documents, and administration of the IMP as 
sc injections. The unblinded personnel will not be involved in the study in any way other than 
assuring the medication is taken from the correct kit and administering the drug to the subjects. 
Suitable areas for sc injections are the lateral abdominal wall, upper outer thigh, or upper arm. 
During each dosing visit, each of the injections should be administered at a separate injection 
site. Injection sites should be rotated at each visit and injections should not be given into a PSO 
plaque or areas where the skin is tender, bruised, erythematous, or indurated. The injection 
should last approximately 10 to 15 seconds. 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing. 
Double-blind Initial Treatment Period dosing 
 Subjects randomized to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W. 
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W. 
Randomized-Withdrawal Period dosing 
Investigational medicinal product treatment during the Randomized-Withdrawal Period will be 
based on treatment group assignment at randomization (see Section 5.2.3). 
 Subjects who are re-randomized to receive bimekizumab 320mg Q4W will receive 2 
bimekizumab 160mg injections sc Q4W. 
 Subjects re-randomized to receive bimekizumab 320mg Q8W will alternate between 
receiving bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by 
placebo (2 placebo injections sc). 
 Subjects re-randomized to receive placebo will receive 2 placebo injections Q4W. 
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75 at Week 20 or later will continue to receive placebo Q4W at 
Week 16 and later visits. 
Subjects who do not achieve a PASI90 response at Week 16 and all subjects who relapse at 
Week 20 or later during the Randomized-Withdrawal Period (up to Week 56) will receive open-
label bimekizumab 320mg Q4W for 12 weeks (escape treatment, see Section 5.2.5). 
The dosing scheme is depicted in Table 7‒1.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 47 of 209 
Table 7‒1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
Bimekizumab 320mg 
Q4W/Q4W 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
Bimekizumab 320mg 
Q4W/Q8W 
●● 
●● 
●● 
●● 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
Bimekizumab 320mg 
Q4W/placebo 
●● 
●● 
●● 
●● 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
Placebo 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks 
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week 16 and all subjects who relapse (defined not 
achieving a ≥PASI75 response at Week 20 or later) during the Randomized-Withdrawal Period (up to Week 52) 
will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Period that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits. 
7.3 
Packaging 
Bimekizumab and placebo will be packaged and labeled according to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations. They will be suitably packaged in 
such a way as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
Manual. 
7.4 
Labeling 
Bimekizumab and placebo will be labeled in accordance with the current International Council 
for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include 
any locally required statements. If necessary, labels will be translated into the local language. 
7.5 
Handling and storage requirements 
Refer to the IMP Handling Manual for the storage conditions of the IMP. 
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label. 
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures 
reached over the time interval. 
In case an out of range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual. 
The IMP will be shipped to the study sites in temperature controlled containers. Out-of-range 
shipping or storage conditions must be brought to the attention of the sponsor or designee, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 48 of 209 
immediately. Authorization to use any out-of-range IMP must be documented and received prior 
to dispensing or administering the IMP at the study site. 
7.6 
Drug accountability 
A Drug Accountability Form will be used to record IMP dispensing and return information on a 
by subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (eg, due to breakage or wastage), not used, partially used, disposed of at 
the study site, or returned to the sponsor or designee must also be recorded on the appropriate 
forms. All supplies and pharmacy documentation must be made available throughout the study 
for UCB (or designee) to review. 
In order to maintain the blind, all IMP documentation (eg, shipping receipts, drug accountability 
logs, Interactive Response Technology [IRT] randomization materials) must be maintained and 
accessed by unblinded, trained site personnel only. Designated, unblinded site personnel must be 
appropriately trained and licensed (per country guidelines) to administer injections. 
Blinded study staff may be delegated the responsibility to receive, inventory, and destroy the 
used kits. The packaging identifies each kit by a unique number that does not correlate to the 
contents and therefore, does not unblind study site staff. Unblinded study staff will be 
responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial 
material, including recording the administration information on source document. 
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed. 
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee. 
The Investigator must ensure that the IMP is used only in accordance with the protocol. 
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB Standard Operating 
Procedures (SOPs) or returned to UCB (or designee). Investigational medicinal product intended 
for the study cannot be used for any other purpose than that described in this protocol. 
7.7 
Procedures for monitoring subject compliance 
Investigational medicinal product will be administered in the clinic and compliance will be 
determined at the visit by study personnel. Drug accountability must be recorded on the Drug 
Accountability Form. 
7.8 
Concomitant medication(s)/treatment(s) 
Any treatment administered from the time of informed consent to the final study visit will be 
considered concomitant medication. This includes medications that were started before the study 
and are ongoing during the study. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 49 of 209 
7.8.1 
Permitted concomitant treatments (medications and therapies) 
7.8.1.1 
Topical medications 
Subjects may continue to use topical moisturizers or emollients, bath oils, or oatmeal bath 
preparations for skin conditions during the study, as needed. Over-the-counter shampoos for the 
treatment of PSO of the scalp are also permitted. 
Mild and low potency topical steroids will be permitted for use limited to the face, axilla, and/or 
genitalia, as needed. These topical medications should not be used within approximately 24 
hours prior to study visits requiring IGA and PASI measures. 
7.8.1.2 
Other medications 
Subjects who are already receiving an established NSAID regimen for PsA or symptoms of 
arthritis and have been on a stable dose for at least 1 week prior to the Screening Visit may 
continue their use during the study. However, initiation of, or increase in dosage of NSAIDs 
during the study (especially in subjects with a history of gastrointestinal [GI] intolerance to 
NSAIDs or a history of GI ulceration) should not occur prior to Week 12 and should not happen 
within 2 weeks of the Week 56 Visit. 
Subjects may take mild pain relievers (acetaminophen/paracetamol, mild opiates) as needed for 
arthritis pain but preferably not within 24 hours of the Baseline and Week 56 Visits. 
Intra-articular steroid injections of any joint and hyaluronic acid injections are allowed after 
Week 12. 
Subjects who are receiving an established regimen for depression should remain on stable dosing 
prior to Baseline and throughout the study. 
7.8.2 
Prohibited concomitant treatments (medications and therapies) 
Table 7‒2 presents the list of prohibited PSO medications. 
Table 7‒2: 
Prohibited PSO medications 
Drug 
Washout period relative to Baseline Visit 
Topicals except for those permitted (Section 7.8.1.1) 
2 weeks  
Systemic retinoids 
3 months  
Systemic treatment (non-biological): 
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, 
thioguanine) 
fumaric acid esters specifically used for the treatment 
of PSO 
systemic corticosteroids 
phototherapy  
1 month 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 50 of 209 
Table 7‒2: 
Prohibited PSO medications 
Drug 
Washout period relative to Baseline Visit 
Anti-TNFs: 
etanercept (including biosimilar) 
infliximab (including biosimilar), golimumab, 
certolizumab pegol, adalimumab (including 
biosimilar) 
 
1 month for etanercept 
3 months for everything other than etanercept  
Other biologics and other systemic therapies, eg: 
 
ustekinumab 
Any exposure for ustekinumab 
apremilast, tofacitinib 
2 weeks for apremilast and tofacitinib 
alefacept, efalizumab, guselkumab 
3 months for alefacept, efalizumab, and 
guselkumab 
tildrakizumab, risankizumab 
5 months for tildrakizumab and risankizumab 
briakinumab 
6 months for briakinumab 
rituximab 
12 months for rituximab 
Anti-IL-17 therapy: 
brodalumab 
ixekizumab 
secukinumab 
3 months 
(bimekizumab is excluded per exclusion 
criteria) 
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is approved) 
3 months or 5 half-lives, whichever is greater 
Any other antipsoriatic agent (topical) under investigation 1 month 
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor 
Subjects who take prohibited medications may be withdrawn from IMP but followed until the 
SFU Visit. The decision to withdraw a subject for taking prohibited medications should be made 
in consultation with the Medical Monitor. 
7.8.2.1 
Vaccines 
Administration of live (including attenuated) vaccines is not allowed during the conduct of the 
study and for 20 weeks after the final dose of IMP (see Exclusion Criterion #10, Section 6.2). 
Administration of inactivated vaccines is allowed during the study at the discretion of the 
Investigator. 
7.9 
Blinding 
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP assignment with the following exceptions: 
 Unblinded study staff will be responsible for preparation (breaking tamper proof sticker on 
kit, etc) of the clinical trial material, including recording the administration information on 
source documents, and administration of the IMP as sc injections. The unblinded personnel 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 51 of 209 
will not be involved in the study in any way other than assuring the medication is taken from 
the correct kit and administering the drug to the subjects. 
 Bioanalytical staff analyzing blood samples for bimekizumab and anti-bimekizumab 
antibody determination. 
During the study the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and drug administration and documentation records. Unblinded 
study site personnel need to be available in order to resolve queries. Study monitors and study 
site personnel, blinded to treatment assignment, will not discuss or have access to any drug 
related information. 
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double-blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in 
the site blinding plan. 
Further details are provided in the study manual and site blinding plan. 
7.9.1 
Procedures for maintaining and breaking the treatment blind 
7.9.1.1 
Maintenance of IMP blind 
All subject treatment details (bimekizumab or placebo) will be allocated and maintained by the 
IRT system. 
7.9.1.2 
Breaking the treatment blind in an emergency situation 
The integrity of this clinical study must be maintained by observing the treatment blind. In the 
event of an emergency for which the appropriate treatment for a subject cannot be made without 
knowing the treatment assignment, it will be possible to determine to which treatment arm and 
dose the subject has been allocated by contacting the IRT. All sites will be provided with details 
of how to contact the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible. 
The Clinical Project Manager (CPM) will be informed immediately via the IRT when a code is 
broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source documents and on the Study 
Termination eCRF page. 
7.10 
Randomization and numbering of subjects 
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biologic exposure (yes/no). The 
IRT will generate individual assignments for subject kits of IMP, as appropriate, according to the 
visit schedule.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 52 of 209 
At Screening, each subject will be assigned a 5-digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject. 
At the Baseline Visit, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. The IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the subject 
based on the subject number during the course of the study. The kits are blinded. 
At Week 16, subjects who received bimekizumab Q4W during the Initial Treatment Period may 
be re-randomized to a new treatment group based on their PASI response. 
Subject numbers and kit numbers will be tracked via the IRT. 
8 
STUDY PROCEDURES BY VISIT 
Table 5‒1 (Schedule of Study Assessments) provides a general overview of study assessments. A 
list of procedures to be completed at each visit is described below. 
 From the Week 1 Visit to the Week 24 Visit, visit windows of ±3 days on either side of the 
scheduled dosing are permitted; however, the Investigator should try to keep the subjects on 
the original dosing schedule. From the Week 28 Visit to the Week 52 Visit, visit windows are 
±7 days. Changes to the dosing schedule outside of the visit window must be discussed with 
the Medical Monitor. 
 The dosing window is ±3 days relative to the scheduled dosing visit through Week 24. The 
dosing window is ±7 days relative to the scheduled dosing visit from Week 28 through the 
end of the study. 
 For the SFU Visit (20 weeks after the final dose), the visit window is ±7 days relative to the 
scheduled visit date. 
8.1 
Screening Visit (2 to 5 weeks) 
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by the Sponsor and an Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC), and that complies with regulatory requirements. Subjects will be given 
adequate time to consider any information concerning the study given to them by the Investigator 
or designee. As part of the informed consent procedure, subjects will be given the opportunity to 
ask the Investigator any questions regarding potential risks and benefits of participation in the 
study. 
Where local regulations permit, subjects will also be given the option to participate in the 
genomics, genetics, and proteomics substudy. Subjects agreeing to participate in the substudy 
will be required to complete a separate ICF. The ICF must be signed prior to collecting any 
samples for the substudy. The substudy will only be conducted where ethically accepted and 
authorized by the regulatory agencies. Refusal to participate in the substudy will not affect a 
subject’s ability to participate in the main PS0013 study. 
The following procedures/assessments will be performed at the Screening Visit: 
 Informed consent 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 53 of 209 
 Inclusion/exclusion 
 Urine drug screen 
 Demographic data (age, gender, race and ethnicity [according to local regulations]) 
 Psoriasis history including the date of onset and past treatments 
 Significant past medical history including clinically relevant past or coexisting medical 
conditions and surgeries 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Vital signs (sitting systolic and diastolic blood pressure [BP), pulse rate, and body 
temperature) should be obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests: 
 Hematology and biochemistry 
 Urinalysis 
 Serum pregnancy test 
 Hepatitis B and Hepatitis C 
 HIV 
 IGRA Tuberculosis test 
 Record 12-lead ECG 
 Chest x-ray (not necessary if performed within 3 months prior to Screening Visit and report 
is available) 
 Tuberculosis questionnaire 
 PASI 
 IGA 
 Percentage of BSA 
 PHQ-9 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Concomitant medication 
 AEs 
 Confirm subject eligibility and contact IRT 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 54 of 209 
8.2 
Initial Treatment Period 
8.2.1 
Baseline Visit 
The following procedures/assessments will be performed/recorded prior to administration of 
IMP: 
 Inclusion/exclusion 
 Significant past medical history and concomitant diseases to ensure no significant changes 
since screening 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Height 
 Body weight 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urinalysis 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 Genetic/epigenetic analysis (participating subjects only) 
 Tuberculosis questionnaire 
 PASI 
 IGA 
 Percentage of BSA 
 DLQI 
 PHQ-9 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Scalp IGA 
 mNAPSI 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 55 of 209 
 pp-IGA 
 EQ-5D-3L 
 SF-36 
 PASE 
 PGADA 
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab or placebo 
will occur. 
8.2.2 
Weeks 1 and 2 (±3 days relative to Baseline) 
The following procedures/assessments will be performed/recorded: 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Bimekizumab plasma concentrations 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (Week 1 only) 
(participating subjects only) 
 PASI 
 IGA 
 Percentage of BSA 
 DLQI 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Scalp IGA for subjects with scalp involvement at Baseline  
 Concomitant medication 
 AEs 
 IRT 
8.2.3 
Weeks 4 and 8 (±3 days relative to Baseline) 
The following procedures/assessments will be performed/recorded: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 56 of 209 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (Week 8 only) 
(participating subjects only) 
 PASI 
 IGA 
 Percentage of BSA 
 DLQI 
 PHQ-9 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 EQ-5D-3L 
 SF-36 
 PGADA (Week 4 only) 
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab or placebo 
will occur. 
8.2.4 
Week 12 (±3 days relative to Baseline) 
The following procedures/assessments will be performed/recorded: 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 57 of 209 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 Record 12-lead ECG  
 Tuberculosis questionnaire  
 PASI 
 IGA 
 Percentage of BSA 
 DLQI 
 PHQ-9 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 EQ-5D-3L 
 SF-36 
 PGADA for subjects with PsA at Baseline  
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab or placebo. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 58 of 209 
8.2.5 
Week 16 (±3 days relative to Baseline) 
The following procedures/assessments will be performed/recorded prior to administration of 
IMP: 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 PASI 
 IGA 
 Percentage of BSA 
 DLQI  
 PHQ-9 
 eC-SSRS 
 Patient Symptom Diary (daily) 
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA for subjects with PsA at Baseline  
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, the Randomized-Withdrawal Period will 
begin with administration of bimekizumab or placebo. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 59 of 209 
8.3 
Randomized-Withdrawal Period 
8.3.1 
Weeks 20 and 24 (±3 days relative to Baseline) and Weeks 28, 32, 36, 
40, 44, 48, and 52 (±7 days relative to Baseline) 
The following procedures/assessments will be performed/recorded prior to administration of 
IMP: 
 Informed consent (to be completed for the open-label study, if applicable) (Week 52 only) 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB (Weeks 24, 36, and 48 only) 
 Body weight (Weeks 24, 36, and 48 only) 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry (Weeks 20, 24, 32, 40, and 48 only) 
 Urinalysis (Weeks 24, 32 40, and 48 only) 
 Urine pregnancy test   
 Bimekizumab plasma concentrations (Weeks 20, 24, 36, and 48 only) 
 Anti-bimekizumab antibodies (Weeks 20, 24, 36, and 48 only) 
 Record 12-lead ECG (Weeks 32 and 48 only) 
 IGRA Tuberculosis test (Week 52 only) 
 Tuberculosis questionnaire (Weeks 24, 36, and 48 only) 
 PASI 
 Percentage of BSA 
 IGA 
 DLQI (Weeks 20, 24, 32, 40, and 48 only) 
 PHQ-9 
 eC-SSRS 
 Scalp IGA for subjects with scalp involvement at Baseline (Weeks 20, 24, 32, 40, and 48 
only) 
 mNAPSI for subjects with nail involvement at Baseline (Weeks 20, 24, 32, 40, and 48 only) 
 pp-IGA for subjects with palmoplantar involvement at Baseline (Weeks 20, 24, 32, 40, and 
48 only)  
 EQ-5D-3L (Weeks 24, 32, 40, and 48 only only) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 60 of 209 
 SF-36 (Weeks 24, 32, 40, and 48 only only) 
 Patient Global Assessment of PSO (Weeks 24, 32, 40, and 48 only) 
 PGADA for subjects with PsA at Baseline (Weeks 24, 32, 40, and 48 only) 
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab or placebo 
will occur. 
8.3.2 
Week 56 (±3 days relative to Baseline) 
The following procedures/assessments will be performed/recorded: 
 Urine drug screen 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Body weight 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urinalysis 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 Genetic/epigenetic analysis (participating subjects only) 
 Record 12-lead ECG 
 Tuberculosis questionnaire 
 PASI 
 Percentage of BSA 
 IGA 
 DLQI 
 PHQ-9 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 61 of 209 
 eC-SSRS 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO 
 PASE 
 PGADA for subjects with PsA at Baseline 
 Concomitant medication 
 AEs 
 Contact IRT 
8.4 
Escape Treatment Period 
As described in Section 5.2.3, subjects who do not achieve a PASI90 response at Week 16 and 
all subjects who relapse at Week 20 or later will be allocated to an escape arm and receive 
open-label bimekizumab 320mg Q4W for 12 weeks. (ie, escape treatment). Subjects should 
complete all visit procedures for their scheduled treatment visit and then only complete unique 
procedures for the escape baseline visit. No duplicate assessments should be performed when a 
subject enters the escape arm. 
8.4.1 
Escape Baseline Visit 
The following procedures/assessments will be performed/recorded: 
 Body weight 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urinalysis 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 PASI 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 62 of 209 
 IGA 
 Percentage of BSA 
 DLQI 
 PHQ-9 
 eC-SSRS 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO 
 PASE 
 PGADA for subjects with PsA at Baseline 
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab will occur. 
8.4.2 
Escape Weeks 4 and 8 (±3 days) 
The following procedures or assessments will be performed/recorded prior to administration of 
IMP: 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 PASI 
 IGA 
 Percentage of BSA 
 DLQI 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 63 of 209 
 PHQ-9 
 eC-SSRS 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 PGADA for subjects with PsA at Baseline 
 Concomitant medication 
 AEs 
 Contact IRT 
After completion of the above-mentioned procedures, administration of bimekizumab will occur. 
8.4.3 
Escape Visit-Week 12/Premature End of Treatment (±3 days relative 
to Baseline) 
The following procedures or assessments will be performed/recorded: 
 Urine drug screen 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Body weight 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
 Urinalysis 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 Genetic/epigenetic analysis (participating subjects only) 
 Record 12-lead ECG 
 IGRA Tuberculosis test 
 Tuberculosis questionnaire 
 PASI 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 64 of 209 
 IGA 
 Percentage of BSA 
 DLQI 
 PHQ-9 
 eC-SSRS 
 Scalp IGA for subjects with scalp involvement at Baseline 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline 
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO 
 PASE 
 PGADA for subjects with PsA at Baseline 
 Concomitant medication 
 AEs 
 Contact IRT 
8.5 
Premature End of Treatment Visit 
If a subject is withdrawn from the study: 
 The subject will be withdrawn from IMP, will undergo the same assessments as the 
Week 56 visit (see Section 8.3.2), and will enter the SFU Period. 
 The subject will be encouraged to return for the SFU Visit (20 weeks after the last 
received dose; see Section 8.6). 
8.6 
Safety Follow-Up Visit (20 weeks after final dose, ±7 days) 
All subjects not continuing in the open-label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP. 
The following procedures/assessments will be performed/recorded: 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Hematology and biochemistry 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 65 of 209 
 Urinalysis 
 Urine pregnancy test 
 Bimekizumab plasma concentrations 
 Anti-bimekizumab antibodies 
 Tuberculosis questionnaire 
 PASI 
 IGA 
 Percentage of BSA 
 eC-SSRS 
 Concomitant medication 
 AEs 
 Contact IRT 
8.7 
Unscheduled Visit 
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well-being. 
If an Unscheduled Visit is conducted due to safety or efficacy reasons, an eC-SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen 
due to collection or analysis issues), an eC-SSRS will not be required at these visits. 
At this visit, any assessment may be performed, as needed, depending on the reason for the visit. 
9 
ASSESSMENT OF EFFICACY 
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. The same assessor should evaluate the subject at each assessment. 
9.1 
Psoriasis Area and Severity Index 
The PASI is the most commonly used and validated assessment for grading the severity of PSO 
in clinical studies (Feldman, 2004). The PASI quantifies the severity and extent of the disease 
and weighs these with the percentage of BSA involvement. 
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a 
given region on a scale of 0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 
3=30% to <50% affected, 4=50% to <70% affected, 5=70% to <90% affected, 6=90% to 100% 
affected) (Table 9‒1). 
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5-point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 66 of 209 
The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity. 
Table 9‒1: 
Body areas for calculation of percent BSA for PASI 
Body area 
Details of area 
BSA 
Degree of 
involvement of 
body areaa 
Head 
Face, back of head 
10%  
0 to 6 
Upper extremities  
Left, right, upper lower, flexor 
surface, extensor surface 
20%  
0 to 6 
Trunk 
Front, back, groin 
30%  
0 to 6 
Lower extremities  
Left, right, upper lower, flexor 
surface, extensor surface, including 
buttocks 
40%  
0 to 6 
Total 
 
100%  
 
BSA=body surface area; PASI=Psoriasis Area and Severity Index 
a Where 0=none; 1=1% to <10% affected; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affected; 6=90% to 100% affected 
The PASI50, PASI75, PASI90, and PASI100 responses are based on at least 50%, 75%, 90%, 
and 100% improvement in the PASI score, respectively. 
The total BSA affected by PSO will be entered as a percentage from 0 to 100. 
The PASI will be completed at the visits specified in Table 5‒1 and Table 5‒2. 
9.2 
Investigator’s Global Assessment 
A static IGA for PSO will be used to assess disease severity in all subjects during the study. The 
IGA will be completed at the visits specified in in Table 5‒1 and Table 5‒2. 
The Investigator will assess the overall severity of PSO using the following 5-point scale 
presented in Table 9-2. 
Table 9‒2: 
Five-point Investigator’s Global Assessment 
Score 
Short descriptor 
Detailed descriptor 
0 
Clear 
No signs of psoriasis; post-inflammatory hyperpigmentation may be present 
1 
Almost clear 
No thickening; normal to pink coloration; no to minimal focal scaling 
2 
Mild 
Just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling 
3 
Moderate 
Clearly distinguishable to moderate thickening; dull to bright red; moderate 
scaling 
4 
Severe 
Severe thickening with hard edges; bright to deep dark red coloration; 
severe/coarse scaling covering almost all or all lesions 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 67 of 209 
9.3 
Dermatology Life Quality Index 
The DLQI is a questionnaire designed for use in adult subjects with PSO. The DLQI is a skin 
disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect 
subjects’ health related QOL. This instrument asks subjects about symptoms and feelings, daily 
activities, leisure, work and school, personal relationships and treatment. It has been shown to be 
valid and reproducible in subjects with PSO. The DLQI score ranges from 0 to 30 with higher 
scores indicating lower health related QOL. A 4-point change in the DLQI score (DLQI 
response) has been reported to be meaningful for the subject (within-subject minimal important 
difference); while a DLQI absolute score of 0 or 1 indicates no or small impact of the disease on 
health related QOL. Subjects will be asked to complete the DLQI as outlined in the Schedule of 
Study Assessments in Table 5‒1 and Table 5‒2. 
9.4 
Patient Health Questionnaire 9 
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression (Kroenke et al, 2001). The PHQ-9 scores for depression range from 0 
to 27, with higher scores indicating worse state. A score of 5 to 9 is considered to be minimal 
symptoms of depression. A score of 10 to 14 is considered to be minor depression, dysthymia, or 
mild major depression. A score of 15 to 19 is considered to indicate moderately severe major 
depression, and a score ≥20 is considered to be severe major depression. 
The PHQ-9 will be assessed at the visits specified in Table 5‒1 and Table 5‒2. 
Refer to Section 6.3 for PHQ-9-related withdrawal criteria. 
9.5 
Scalp IGA 
A static IGA for scalp PSO will be used to assess disease severity on the scalp. 
All subjects will complete the scalp IGA at Baseline. Only subjects with scalp involvement at 
Baseline will complete the scalp IGA at the other visits specified in in Table 5‒1 and Table 5‒2. 
Subjects with scalp involvement at Baseline are defined as those with a scalp IGA score >0 at 
Baseline. 
Scalp lesions will be assessed in terms of clinical signs of redness, thickness, and scaliness using 
a 5-point scale Table 9‒3. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 68 of 209 
Table 9‒3: 
Scalp IGA 
Score 
Short Descriptor 
Detailed Descriptor 
0 
Clear 
Scalp has no signs of PSO; post-inflammatory hyperpigmentation may 
be present 
1 
Almost clear 
Scalp has no thickening; normal to pink coloration; no to minimal focal 
scaling 
2 
Mild 
Scalp has just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling 
3 
Moderate 
Scalp has clearly distinguishable to moderate thickening; dull to bright 
red, moderate scaling 
4 
Severe 
Scalp has severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions 
PSO=psoriasis; scalp IGA=scalp-specific Investigator’s Global Assessment 
9.6 
mNAPSI 
Psoriatic nail disease will be evaluated using the mNAPSI. All affected nails will be scored 
(0 to 3) for onycholysis/oil drop dyschromia, nail plate crumbling, and pitting and will be scored 
(0 for “no” or 1 for “yes”) for leukonychia, nail bed hyperkeratosis, splinter hemorrhages and red 
spots in the lunula. The score for an individual nail ranges from 0 to 13 with higher scores 
indicative of more severe nail disease. The total mNAPSI score is the sum of the scores for each 
individual nail. If a nail is unaffected, it will be recorded as such and will not contribute to the 
total mNAPSI score. Subjects with nail disease at Baseline are defined as those with a mNAPSI 
score >0 at Baseline. 
The mNAPSI will be assessed at the visits specified in Table 5‒1 and Table 5‒2. 
9.7 
pp-IGA 
A static IGA for palmoplantar PSO will be used to assess palmoplantar disease severity. 
All subjects will complete the pp-IGA at Baseline. Only subjects with palmoplantar involvement 
at Baseline will complete the pp-IGA at the other visits specified in in Table 5‒1 and Table 5‒2. 
Subjects with palmoplantar involvement at Baseline are defined as those with a pp-IGA score >0 
at Baseline. 
Palmoplantar disease will be assessed in terms of clinical signs of redness, thickness, and 
scaliness using a 5-point scale (Table 9‒4). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 69 of 209 
Table 9‒4: 
pp-IGA 
Score 
Short Descriptor 
Detailed Descriptor 
0 
Clear 
Palmoplantar areas have no signs of PSO; post-inflammatory 
hyperpigmentation may be present 
1 
Almost clear 
Palmoplantar areas have no thickening; normal to pink coloration; no to 
minimal focal scaling 
2 
Mild 
Palmoplantar areas have just detectable to mild thickening; pink to light 
red coloration; predominately fine scaling 
3 
Moderate 
Palmoplantar areas have clearly distinguishable to moderate thickening; 
dull to bright red and clearly distinguishable coloration; moderate 
scaling 
4 
Severe 
Palmoplantar areas have severe thickening with hard edges; bright to 
deep dark red coloration; severe/coarse scaling covering almost all or 
all lesions; numerous fissures 
PSO=psoriasis; pp-IGA=palmoplantar-specific Investigator’s Global Assessment 
9.8 
Euro Quality of Life 5-Dimensions, 3-Level 
The Euro Quality of Life 5-Dimensions 3-Level (EQ-5D-3L) health questionnaire provides a 
descriptive profile and a single index value for health status. The instrument is comprised of a 
5-item health status measure and a VAS. The EQ-5D-3L VAS records the respondent’s self-rated 
health status on a vertical 20cm scale, graduated from 0 to 100 (0=worst imaginable health 
status, 100=best imaginable health status). 
The EQ-5D-3L will be assessed at the visits specified in Table 5‒1 and Table 5‒2. 
9.9 
36-Item Short Form Health Survey 
The SF-36 (Version 2, standard recall) is a 36-item generic health related QOL instrument that 
uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical 
Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), 
Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 
items), and 1 item for perceived stability or change in health (Health Transition) during the last 
year. The concepts represented by these domains contribute to physical, mental, and social 
aspects of health-related QOL. In addition to domain scores, the PCS and MCS scores are 
calculated from the 8 domains (excluding the Health Transition item). Component scores 
appreciate the impact of each domain on physical and mental health status (Maruish, 2011). Each 
of the 8 domain scores and the component summary scores range from 0 to 100, with a higher 
score indicating a better health status. The domains and the 2 component summary scores are 
standardized with a mean of 50 and a standard deviation (SD) of 10 in the general USA 
population. The minimally important differences (MIDs), in terms of T-score points at a group 
level, for SF-36 domains and component summaries are the following: PCS, 2; MCS, 3; Physical 
Functioning, 3; Role Physical, 3; Bodily Pain, 3; General Health, 2; Vitality, 2; Social 
Functioning, 3; Role Emotional, 4; and Mental Health, 3. 
The SF-36 will be completed by the subject at the visits specified in Table 5‒1 and Table 5‒2. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 70 of 209 
9.10 
Patient Global Assessment of psoriasis 
The Patient Global Assessment of PSO is a PSO-specific item in which the patient responds to 
the multiple-choice question, “How severe are your psoriasis-related symptoms right now?” 
Possible responses to the question are “no symptoms,” “mild symptoms,” “moderate symptoms,” 
“severe symptoms,” or “very severe symptoms.” 
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from Screening through the Initial Treatment Period. 
During the Randomized-Withdrawal Period, this assessment will be completed at the visits 
specified in Table 5‒1. 
During escape treatment, this assessment will be completed at the visits specified in Table 5‒2. 
9.11 
Patient Symptom Diary responses 
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
participating subjects on the use of the electronic PRO (ePRO) diary at the Screening Visit, 
following which the device will be dispensed to the subject for home use until the Week 16 Visit. 
The ePRO diary will be administered on a daily basis from Screening to the Week 16 Visit. 
The ePRO diary will also administer the patient global assessment of psoriasis as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diary. The data collected on the ePRO diary will be uploaded to a central server database and 
will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including subject/site training 
and testing) will be performed at the study sites. 
The Patient Symptom Diary responses for itch, pain, and scaling at Week 16 will be computed 
based on the responder definition as well as the absolute and percent change from Baseline. Each 
of the Patient Symptom Diary response scores included in the statistical testing procedure (itch, 
pain, and scaling) will be characterized in terms of the cumulative percent of subjects 
demonstrating a pre-specified point improvement at Week 16. The threshold for the Patient 
Symptom Diary response score of itch, pain, and scaling is 2.39, 1.98, and 2.86, respectively. 
The responder analysis will be limited to the subjects with a Baseline Patient Symptom Diary 
response score at or above the applicable threshold score (ie, at least 2.39, 1.98, and 2.86 for itch, 
pain, and scaling, respectively). 
9.12 
PASE questionnaire 
The PASE questionnaire is a self-administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7-item 
symptoms subscale and an 8-item functions subscale. Standardized responses are based on 5 
categories relating to agreement (strongly agree [5], agree [4], no idea [3], disagree [2], and 
strongly disagree [1]). The total maximum score is 75 points (symptom score: 35 points and 
function score: 40 points). Psoriatic Arthritis Screening and Evaluation questionnaire scores ≥47 
points are indicative of active PsA. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 71 of 209 
If a subject with a PASE score ≥47 points is referred to a rheumatologist, the referral will be 
recorded in the eCRF. Subjects with PsA, defined as a past medical history of PsA or PASE ≥47, 
are required to receive the additional PsA assessments as noted in Section 9.13. 
The PASE questionnaire will be completed at the visits specified in Table 5‒1 and Table 5‒2. 
9.13 
PGADA for arthritis visual analog scale 
The PGADA for the arthritis VAS will be used to provide an overall evaluation of arthritis 
disease symptoms. Subjects will respond to the question, “Considering all the ways your arthritis 
affects you, please mark a vertical line on the scale below to show how you are feeling today,” 
“using a VAS where 0 is “very good, no symptoms” and 100 is “very poor, severe symptoms.” 
All subjects will complete the PGADA at Baseline. Subjects with PsA at Baseline (defined as a 
past medical history of PsA or PASE ≥47) will complete the PGADA at the visits specified in 
Table 5‒1 and Table 5‒2. 
10 
ASSESSMENT OF PHARMACOKINETIC AND 
PHARMACOGENOMIC VARIABLE(S) 
10.1 
Pharmacokinetic variables 
Blood samples for measurement of PK assessments (Section 4.3.3) will be collected at the time 
points specified in the schedule of study assessments (Table 5‒1 and Table 5‒2). 
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report. 
10.2 
Pharmacogenomic variables 
A separate ICF will be required for those subjects who agree to participate in the genomics, 
genetics, and proteomics substudy, and must be signed prior to collection of any samples for the 
substudy. The substudy will only be conducted where ethically accepted and authorized by the 
regulatory agencies. Refusal to participate in the substudy will not affect a subject’s ability to 
participate in the main study. 
These analyses will enable evaluation of biomarkers relative to disease biology and progression, 
drug treatment, and inflammatory and immune response processes. The nature and format of 
these tentative analyses will be determined at a later date. 
For individuals consenting to the genomics, genetics, and proteomics substudy, blood samples 
will be drawn for exploratory genetic/epigenetic, genomic, proteomic, and metabolomics 
analysis and for candidate exploratory biomarker analyses. Candidate exploratory biomarker 
evaluations may include, but are not limited to, IL-17A/IL17-F pathway signaling and PSO 
biology (eg, IL-17A, IL-17F, IL-23, IL-6, tumor necrosis factor, dendritic cell-specific 
transmembrane protein, and circulating osteoclast precursors). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 72 of 209 
Collection of these samples will occur at the time points specified in the schedule of study 
assessments (Table 5‒1 and Table 5‒2). At dosing visits, blood samples will be drawn prior to 
dosing, and will be drawn at the same time of the sampling for clinical laboratory tests. The time 
and date of collection will be recorded in the eCRF. The samples will be stored at -80°C at the 
central biorepository for up to 20 years. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report. 
11 
ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S) 
Blood samples for measurement of antibodies to bimekizumab will be collected at the visits 
specified in Table 5‒1 and Table 5‒2. The threshold for antibody positivity will be defined prior 
to analysis. 
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF. 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. The presence of antibodies to bimekizumab will 
be determined using a validated bioanalytical method. Detailed information on sample analysis 
will be provided in a bioanalytical report. 
12 
ASSESSMENT OF SAFETY 
12.1 
Adverse events 
12.1.1 
Definitions 
12.1.1.1 
Adverse event 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. 
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the ICF), including any pretreatment and posttreatment periods required by the 
protocol, must be reported in the eCRF even if no IMP was taken but specific study procedures 
were conducted. This includes all AEs not present prior to the initial visit and all AEs that 
recurred or worsened after the initial visit. 
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 73 of 209 
12.1.1.2 
Serious adverse event 
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria: 
 Death 
 Life-threatening 
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.) 
 Significant or persistent disability/incapacity 
 Congenital anomaly/birth defect (including that occurring in a fetus) 
 Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious 
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 12.1.1.3], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.) 
 Initial inpatient hospitalization or prolongation of hospitalization 
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event]. 
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.) 
Confirmed active TB must be reported as an SAE. The Investigator is to complete and submit the 
TB Follow-Up Form provided. 
12.1.1.2.1 
Anticipated serious adverse events 
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
This list does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 12.1.2.3. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 74 of 209 
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with moderate to severe chronic plaque psoriasis 
MedDRA® system order class 
MedDRA preferred term 
Skin and subcutaneous tissue disorders 
Any psoriatic condition HLT 
Musculoskeletal and connective tissue disorders 
Psoriatic arthropathy 
HLT=High Level Term; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event 
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they result 
in the death of the study subject. 
12.1.1.3 
Adverse events of special interest 
An AE of special interest (AESI) is any AE that a regulatory authority has mandated be reported 
on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. 
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting for any additional etiologic 
investigations to have been concluded). Follow-up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject. 
12.1.1.4 
Other safety topics of interest 
Pre-specified safety topics of interest for the study are: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major 
cardiovascular events, liver function test changes/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral, as appropriate) . This is based on 
findings from the IMP clinical program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medicines with a related mechanism of action.gs. 
There are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activities, and/or enhanced signal detection activities (within UCB) are 
in place. 
12.1.2 
Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example: 
“Did you notice anything unusual about your health (since your last visit)?” 
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study. 
12.1.2.1 
Description of adverse events 
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be 
clarified in the source documentation. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 75 of 209 
When recording the severity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator may refer to the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) for 
additional guidance as needed. Details for completion of the Adverse Event eCRF (including 
judgment of relationship to IMP) are described in the eCRF Completion Guidelines. 
12.1.2.2 
Rule for repetition of an adverse event 
An increase in the intensity of an AE should lead to the repetition of the AE being reported with: 
 The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening” 
 The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one 
12.1.2.3 
Additional procedures for reporting serious adverse events 
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report Form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database. 
An Investigator SAE Report Form will be provided to the Investigator. The Investigator SAE 
Report Form must be completed in English. 
It is important for the Investigator, when completing the SAE Report Form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner. 
Additional information (eg, autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report Form. 
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study. 
Upon receipt of the SAE Report Form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 76 of 209 
12.1.3 
Follow up of adverse events 
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events is provided in Section 12.2.1.4. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 20 weeks 
after the subject has discontinued his/her IMP. 
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time. 
12.1.4 
Pregnancy 
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s PS department by providing the completed 
Pregnancy Report and Outcome Form (for contact details see Serious Adverse Event reporting 
information at the beginning of this protocol). The subject should be withdrawn from the study 
as soon as pregnancy is known (by positive pregnancy test), and the following should be 
completed: 
 The subject should return for an early discontinuation visit. 
 The subject should immediately stop the intake of the IMP. 
 A SFU Visit should be scheduled 20 weeks after the subject has discontinued her IMP. 
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives. 
The pregnancy will be documented on the Pregnancy Report and Outcome Form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome Form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up. 
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent Form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/contract research organization (CRO) contract monitor for the 
study. The Investigator will complete the Pregnancy Report and Outcome Form and send it to 
UCB’s PS department (for contact details see Serious Adverse Event reporting information at the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 77 of 209 
beginning of this protocol) only after the partner has agreed that additional information can be 
captured and has provided the signed Partner Pregnancy Consent form. UCB’s PS department is 
also the primary contact for any questions related to the data collection for the partner pregnancy, 
eventual birth, and follow up. 
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective abortion 
when medically indicated (e.g. when pregnancy is endangering life or health of woman or when 
fetus will be born with severe abnormalities), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the Investigator SAE Report Form. 
Should a subject become pregnant while participating in the study, the subject may be offered the 
option to enroll in a separate observational pregnancy follow-up study sponsored by UCB and 
conducted independently from study PS0013. If the study is available locally, the PS0013 PI will 
be provided with the locally approved information about the observational pregnancy follow-up 
study to inform the subject at the time the pregnancy is reported. Participation in this separate 
study will be voluntary and will not impact therapeutic management of the subject nor interfere 
with termination and follow-up procedures as described in study protocol PS0013. 
12.1.5 
Suspected transmission of an infectious agent via a medicinal 
product 
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent. 
12.1.6 
Overdose of investigational medicinal product 
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt). 
12.1.7 
Safety signal detection 
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible. 
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the DMC Charter. 
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the Adjudication 
Committee Charters. 
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 78 of 209 
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study. 
12.2 
Laboratory measurements 
Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen. A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all blood and urine samples for hematology, biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion #9, Section 6.2) will be 
performed at Screening in addition to those measurements listed in Table 12‒2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals. 
The following laboratory parameters will be measured: 
Table 12‒2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Basophils 
Calcium 
pH 
Eosinophils 
Chloride 
Albumin (protein) 
Lymphocytes 
Magnesium 
Glucose 
Monocytes 
Potassium 
Blood 
Neutrophils 
Sodium 
Leukocyte esterase 
Hematocrit 
Glucose 
Nitrite 
Hemoglobin 
BUN 
 
MCH 
Creatinine 
Urine dipstick for pregnancy testingb 
MCHC 
ALP 
Urine drug screenc 
MCV 
AST 
 
Platelet count 
ALT 
 
RBC count 
GGT 
 
WBC count 
Total bilirubin 
 
 
Serum pregnancy testingb 
 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular 
hemoglobin concentration; MCV=mean corpuscular volume; PEOT=Premature End of Treatment; RBC=red blood 
cell; WBC=white blood cell 
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 79 of 209 
b Pregnancy testing will consist of serum testing at the Screening Visit. The pregnancy test will be urine at all other 
visits. 
c Urine drug screen will be performed at Screening Visit, and Week 56 or PEOT Visit. 
12.2.1 
Evaluation of PDILI 
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1 with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and Sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 12.1.1.3), and, if applicable, also reported as an 
SAE (see Section 12.1.1.2). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 12‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 12.2.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 12.2.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and Sponsor. 
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result. 
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages. 
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative. 
When IMP is stopped due to PDILI (as described in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section 12.2.1.2.1 are met, rechallenge with IMP may be appropriate. 
Table 12‒3 summarizes the approach to investigate PDILI. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 80 of 209 
Table 12‒3: Required investigations and follow up for PDILI 
Laboratory value 
 
Immediate 
Follow up 
ALT or 
AST 
Total 
bilirubin 
Symptomsa of 
hepatitis of 
hypersensitivity 
Consultation 
requirements 
Actions 
Testing 
Evaluation 
≥3xULN 
≥2xULNb NA 
Hepatology consultc 
Medical Monitor must 
be notified within 
24 hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP. 
Immediate, 
permanent IMP 
discontinuation. 
 
Essential: Must have 
repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.2.1.3); 
recommended to 
occur at the site with 
HCP. 
Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within baseline values.d 
≥3xULN 
NA 
Yes 
≥8xULN 
NA 
NA 
Need for hepatology 
consult to be 
discussed.(required if 
ALT or AST 
≥8xULN) 
Medical Monitor must 
be notified within 
24 hours (eg, by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP. 
Immediate, 
permanent IMP 
discontinuation 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 81 of 209 
Table 12‒3: Required investigations and follow up for PDILI 
Laboratory value 
 
Immediate 
Follow up 
ALT or 
AST 
Total 
bilirubin 
Symptomsa of 
hepatitis of 
hypersensitivity 
Consultation 
requirements 
Actions 
Testing 
Evaluation 
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN 
<2xULN 
No 
Discussion with 
Medical Monitor 
required. 
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see Follow 
up requirements).c 
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.2.1.2). 
 
IMP discontinuation 
required if any of the 
following occur: 
 
Subject cannot 
comply with 
monitoring 
schedule. 
 
Liver chemistry 
values continue 
to increase. 
 
Liver chemistry 
values remain 
≥5xULN (and 
≥2x baseline) 
after 4 weeks of 
monitoring 
without evidence 
of resolution. 
Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section 12.2.1.3). 
Monitoring of liver 
chemistry values at least 
twice per week for 
2 weeks.d 
 
Immediate IMP 
discontinuation 
required if liver 
chemistry values 
continue to increase. 
After 2 weeks of 
monitoring liver 
chemistry values: 
 ALT or AST 
remains ≥5xULN 
<8xULN, IMP 
should be 
temporarily 
withheld and 
subject should 
undergo repeat test 
in 2 weeks. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 82 of 209 
Table 12‒3: Required investigations and follow up for PDILI 
Laboratory value 
 
Immediate 
Follow up 
ALT or 
AST 
Total 
bilirubin 
Symptomsa of 
hepatitis of 
hypersensitivity 
Consultation 
requirements 
Actions 
Testing 
Evaluation 
 
 
 
 
 
 
 Continue IMP if 
ALT or AST values 
<5xULN; continue 
to monitor at least 
twice per week until 
values normalize, 
stabilize, or return 
to within baseline 
values. 
 If ALT or AST 
remains ≥5xULN 
after second re-test, 
immediate, 
permanent IMP 
discontinuation 
required. 
Continue to monitor 
until values normalize, 
stabilize, or return to 
within baseline values.d 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 83 of 209 
Table 12‒3: Required investigations and follow up for PDILI 
Laboratory value 
 
Immediate 
Follow up 
ALT or 
AST 
Total 
bilirubin 
Symptomsa of 
hepatitis of 
hypersensitivity 
Consultation 
requirements 
Actions 
Testing 
Evaluation 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.2.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 84 of 209 
12.2.1.1 
Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 12.2.1.3) and SAE report (if applicable). 
12.2.1.2 
Immediate action: determination of IMP discontinuation 
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 12‒3 for details). 
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
12.2.1.2.1 
IMP restart/rechallenge  
Rechallenge with IMP can occur only if ALL of the following requirements are met: 
 The results of additional testing and monitoring described in Section 12.2.1.3  and 
Section 12.2.1.4  confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP. 
 Subject’s ALT or AST elevations do not exceed ≥5xULN. 
 Subject’s total bilirubin is <2xULN. 
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. 
The hepatologist must be external to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hepatology expert or the hepatologist treating 
the subject. 
 Subject agrees to the Investigator-recommended monitoring plan. 
12.2.1.3 
Testing: identification/exclusion of alternative etiology 
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 12‒4 (laboratory measurements) and Table 12‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the Sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 85 of 209 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable. 
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory. 
The following measurements are to be assessed: 
Table 12‒4: PDILI laboratory measurements 
Virology-related 
Hepatitis A IgM antibody 
HBsAg 
Hepatitis E IgM antibody 
HBcAb-IgM 
Hepatitis C RNA 
Cytomegalovirus IgM antibody 
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing) 
Immunology 
Anti-nuclear antibody (qualitative and quantitative) 
Anti-smooth muscle antibody (qualitative and quantitative) 
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative) 
Hematology 
Eosinophil count 
Urinalysis 
Urine drug screena 
Chemistry 
Amylase 
Sodium, potassium, chloride, glucose, BUN, creatinine 
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin 
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin 
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation 
Additional 
Prothrombin time/INRb 
Serum pregnancy testc 
PK 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CPK=creatine phosphokinase; GGT=gamma glutamyltransferase; HBcAb-IgM=hepatitis B core 
antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic 
acid; ULN=upper limit of normal 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 86 of 209 
Table 12‒4: PDILI laboratory measurements 
a Tests in addition to the specified analytes may be performed based on the Investigator’s medical judgment and 
subject history. 
b Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause). 
c For women of childbearing potential. 
The following additional information is to be collected: 
Table 12‒5: PDILI information to be collected 
New or updated information 
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included. 
Pertinent medical history, including the following: 
 
History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”) 
 
Adverse reactions to drugs 
 
Allergies 
 
Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency) 
 
Recent travel 
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, should not 
be used as an explanation for significant AST and/or ALT elevations.) 
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash) 
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function 
Alcohol and illicit drug use 
Results of liver imaging or liver biopsy, if done 
Results of any specialist or hepatology consult, if done 
Any postmortem/pathology reports 
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury 
12.2.1.4 
Follow-up evaluation 
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 87 of 209 
12.3 
Other safety measurements 
12.3.1 
Assessment and management of TB and TB risk factors 
All subjects will be assessed for tuberculosis (TB) at Screening and at the timepoints specified in 
the Schedule of Assessments (Table 5‒1 and Table 5‒2) through physical examination for signs 
and symptoms of TB, chest x-ray (Section 12.3.1.2), laboratory testing (Section 12.3.1.1), and 
subject questionnaire (Section 12.3.1.3). 
For the purposes of this study, TB definitions are as follows: 
a. Known TB infection: 
 Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra-pulmonary). 
 History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist. 
 Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the subject’s medical history. 
b. High risk of acquiring TB infection: 
 Known close exposure to another person with active TB infection within the 3 months 
prior to Screening 
 Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high. 
c. Latent TB infection (unless appropriate prophylaxis is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis): 
 The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x-ray (or other 
imaging) without evidence of TB infection. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB specialist and discussion with the Study Physician, if LTB 
infection is identified. The retest must be done during the protocol-defined Screening 
window. 
Note: If available, respiratory or other specimens must also be smear and culture negative 
for TB (CDC diagnosis of LTB infection) http://www.cdc.gov/TB/topic 
/testing/default.htm). 
d. NTMB infection is defined as a clinical infection caused by mycobacterial species other than 
those belonging to the Mycobacterium tuberculosis complex. 
e. Tuberculosis test conversion: 
 A positive IGRA result for the current test when previous IGRA test results were 
negative. All subjects with TB test conversion must immediately stop IMP administration 
and be referred to a TB specialist for further evaluation. Confirmed TB test conversions 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 88 of 209 
should be classified as due to LTBI, active TB infection, or NTMB, and reported to the 
UCB PS function. 
Subject eligibility, retesting requirements, and treatment requirements are depicted in 
Figure 12-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 89 of 209 
Figure 12-1: Schematic diagram of TB test results and study eligibility 
IGRA TB test
IGRA TB test 
negative
IGRA TB test 
indeterminate 
IGRA TB test 
positive
Repeat IGRA TB 
testa
IGRA TB test 
negative
IGRA TB test 
indeterminate 
IGRA TB test 
positive
Subject eligible for 
study
Subject eligible for 
study
Evaluation by TB 
specialist
Latent or active 
TB negative
Latent TB 
positive
Active TB 
positive
Subject eligible for 
study
TB treatment 
initiated
No TB treatment 
initiated
Subject eligible for 
studyb
Subject NOT 
eligible for study
Subject NOT 
eligible for study
IGRA=interferon-gamma release assay; TB=tuberculosis
a IGRA retest must be done during the protocol-defined Screening window
b Subjects with LTBI may enter the study only after they have completed at least 8 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 90 of 209 
12.3.1.1 
Tuberculosis assessment by IGRA 
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed as described Table 5‒1 and Table 5‒2 for all subjects. The test 
results will be reported as positive, negative, or indeterminate. Positive and indeterminate TB test 
results must be reported as an AE and appropriately updated once the final diagnosis is known 
(eg, active TB, latent TB, or false positive TB test). UCB also recommends that a TB specialist 
be consulted where TB (latent or active) is suspected or if there are doubts regarding test results. 
If latent or active TB is identified, subject must undergo appropriate study-specified withdrawal 
procedures. The retest during Screening must be done during the protocol-defined Screening 
window. 
12.3.1.2 
Chest x-ray for tuberculosis 
A plain posteroanterior chest x-ray must be performed in the Screening Period unless one has 
been performed within 3 months prior to the Screening Visit. The chest x-ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or 
current) before first IMP administration. All chest imaging (particularly x-rays) should be 
available for review by the Investigator before randomization of the subject. The chest x-ray 
reading should be repeated if the TB test was confirmed positive. If the second read of the 
pretreatment chest x-ray is confirmed to be clear, the subject may be included in the study 8 
weeks after the start of the TB prophylactic treatment. If the pretreatment chest x-ray is not 
available for a re-read, it should be repeated after notification to the radiologist that this subject 
is IGRA positive, and confirmed to be clear for signs of TB. 
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest x-ray must be documented in the source documents and the eCRF as an AE. 
12.3.1.3 
Tuberculosis questionnaire 
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed as described in specified in Table 5‒1 and 
Table 5‒2. The questionnaire will assist with the identification of subjects who may require 
therapy for TB. A subject who answers “Yes” to the question 
 
 
 at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion #12, Section 6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments to determine if the subject has 
either LTB or active TB infection. 
12.3.1.4 
Tuberculosis management 
LTB infection and active TB identified during study 
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 91 of 209 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB should be withdrawn from the study and receive appropriate TB or 
prophylaxis therapy. 
If a TB specialist excludes an active TB infection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an appropriate prophylactic therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB Follow-Up 
Form provided. 
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the PEOT Visit as soon as possible but no 
later than the next scheduled study visit and complete all PEOT Visit assessments. 
The subject should be encouraged to complete a SFU Visit (20 weeks after the final dose of 
IMP). 
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed. 
12.3.2 
Pregnancy testing 
Pregnancy testing will consist of serum testing at the Screening Visit. The pregnancy test will be 
urine at all other visits. 
The Screening Visit serum pregnancy testing results must be negative and received and reviewed 
prior to randomization. A negative urine pregnancy test result should be obtained immediately 
prior to each administration of IMP at the visits specified in Table 5‒1. Pregnancy tests should 
be administered to all female subjects of childbearing potential, regardless of their use of birth 
control. 
12.3.3 
Vital signs 
Vital signs will be collected at every visit and will include systolic and diastolic BP, pulse rate, 
and body temperature (oral, axillary, or otic). Subjects should be sitting for 5 minutes before and 
during vital signs assessments. 
Vital signs are to be measured prior to blood sampling, and prior to dosing, where applicable. 
12.3.4 
12-lead electrocardiograms 
Twelve-lead standard ECGs will be recorded at the visits specified in the Schedule of Study 
Assessments (Table 5‒1 and Table 5‒2) and read by a central ECG reader. 
Full details of ECG recording will be provided in the ECG Manual. 
12.3.5 
Physical examination 
A physical examination will be performed at the visits specified Table 5‒1 and Table 5‒2. The 
physical examination will include general appearance; ear, nose, and throat; eyes, hair, and skin; 
respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 92 of 209 
status. All physical examinations will also include evaluation of signs and symptoms of active 
TB and risk for exposure to TB. Findings considered clinically significant changes since the 
physical examination at the Screening Visit will be recorded as AEs. 
For subjects on Escape treatment a physical examination will be performed at Escape 
Week 12/PEOT and the SFU Visit. 
12.3.6 
Height and body weight 
Height will be measured at Baseline, only. 
Body weight will be measured at the visits specified in the Schedule of Study Assessments 
(Table 5‒1 and Table 5‒2). 
12.3.7 
Assessment of suicidal ideation and behavior 
Suicidal ideation and behavior will be assessed by using the eC-SSRS; the questionnaire will be 
self-administered by the subject and assessed by trained study personnel. This scale will be used 
to assess suicidal ideation and behavior that may occur during the study. The visits at which the 
eC-SSRS assessments will be performed are specified in the Schedule of Study Assessments 
(Table 5‒1 and Table 5‒2). 
The eC-SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Mundt et al, 2010; Posner et al, 2011). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
eC-SSRS defines 5 subtypes of suicidal ideation and behavior in addition to self-injurious 
behavior with no suicidal intent. The eC-SSRS takes approximately 3 to 10 minutes to complete. 
Refer to Section 6.3 for eC-SSRS-related withdrawal criteria. 
12.4 
Other study measurements 
12.4.1 
Demographic information 
Demographic information will be collected in all subjects and include age, gender, race and 
ethnicity. Information on demographics will be collected according to local rules and regulations. 
Demographic information will be recorded in the eCRF. 
12.4.2 
Medical history 
A complete medical history will be collected as part of the Screening assessment and include all 
clinically relevant past or coexisting medical conditions and surgeries. Findings will be recorded 
in the eCRF. 
12.4.3 
Psoriasis history 
A detailed history of each subject’s PSO history will be collected and include the date of onset 
and past treatments for PSO. 
12.4.4 
Data Monitoring and Adjudication Committees 
The DMC membership includes experienced clinicians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular and Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the committees will be inclusive of planned 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 93 of 209 
analyses for PS0013. Detailed role, scope, responsibilities, and complete procedures, as well as 
the identity of members, are described in the separate committee charters. 
13 
STUDY MANAGEMENT AND ADMINISTRATION 
13.1 
Adherence to protocol 
The Investigator should not deviate from the protocol. However, the Investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
Sponsor. 
After implementation of such measure, the Investigator must notify the CPM of the Sponsor 
within 24 hours and follow any local regulatory requirements. 
13.2 
Monitoring 
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring SOPs, ICH-GCP 
guideline, and applicable regulatory requirements, and to ensure that study initiation, conduct, 
and closure are adequate. Monitoring of the study may be delegated by UCB to a CRO or a 
contract monitor. 
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s). 
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each subject). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities’ regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records. 
13.2.1 
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies and/or printouts of eCRFs are not considered 
acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, or QOL 
questionnaires, for example. Source documents should be kept in a secure, limited access area. 
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 94 of 209 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent. 
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee). 
Patient-reported outcome measures (eg, DLQI, EQ-5D-3L, SF-36, Patient Global Assessment of 
PSO, and PGADA) and ePRO diary data will be entered electronically by the subject. 
The ePRO diary data will be entered into an electronic diary by the subject. The data collection 
and database management system will be supplied by a vendor and will be compliant with the 
US Food and Drug Administration Part 11. The data collected on the ePRO diary will be 
uploaded to a central server database and will be sent electronically to UCB (or a designated 
CRO). 
13.2.2 
Source data verification 
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section 13.2.1. 
13.3 
Data handling 
13.3.1 
Case Report Form completion 
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
eCRFs and in all required reports. 
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change. 
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator. 
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. 
Detailed instructions will be provided in the eCRF Completion Guidelines. 
13.3.2 
Database entry and reconciliation 
Case Report Forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. This study is performed using Electronic Data Capture: the data are entered into the 
eCRFs once and are subsequently verified. 
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 95 of 209 
13.3.3 
Subject Screening and Enrollment log/Subject Identification Code list 
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject. 
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation. 
13.4 
Termination of the study 
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity. 
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the Sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study. 
13.5 
Archiving and data retention 
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data. 
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (Committee for Proprietary Medicinal Products [CPMP]/ICH/135/95, 2002 
[Section 4.9.5]). The Investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study-related files to a 
location other than that specified in the Sponsor’s trial master file. 
13.6 
Audit and inspection 
The Investigator will permit study-related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities. 
The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 96 of 209 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements. 
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee). 
13.7 
Good Clinical Practice 
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the Sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study. 
14 
STATISTICS 
A description of statistical methods follows and will be described in more detail in the SAP. 
14.1 
Definition of analysis sets 
The Enrolled Set will consist of all subjects who have given informed consent. 
The Randomized Set (RS) will consist of all randomized subjects. 
The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP. 
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each of the co-primary efficacy variables at 
Baseline. 
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week 16 or 
experiencing a relapse after entering the Randomized-Withdrawal Period. Summaries based on 
the ESS will be split between subjects who enter the escape arm: 1) due to PASI90 non-response 
at Week 16 or 2) due to relapse during the Randomized-Withdrawal Period (after achieving 
PASI90 response at Week 16). 
The Week 16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week 16and receive at least 1 dose of the IMP during the Randomized-Withdrawal 
Period at Week 16 or later. 
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab). The AMS will be used for summaries of safety that include all 
data from the Initial Treatment Period and/or Randomized-Withdrawal Period . 
The Per-Protocol Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the co-primary efficacy variables. Important protocol deviations will be 
pre-defined and subjects with important protocol deviations will be evaluated during ongoing 
data cleaning meetings prior to unblinding of the data. 
The Pharmacokinetics Per-Protocol Set (PK-PPS) consists of all randomized subjects who 
received at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration 
post-dose without important protocol deviations that would affect the concentration. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 97 of 209 
14.2 
General statistical considerations 
Summary statistics will consist of frequency tables for categorical variables. For continuous 
variables, summary statistics will consist of the number of available observations, arithmetic 
mean, SD, median, minimum, and maximum unless stated otherwise. 
All statistical tests will be performed based on a 2-sided significance level of 5% unless stated 
otherwise. 
The statistical analysis of the co-primary efficacy variables and selected secondary efficacy 
variables will account for multiplicity and control the familywise Type I error rate at a 2-sided 
alpha level of 0.05 by using a fixed sequence testing procedure. 
The first 2 hypotheses (H1 and H2) test whether bimekizumab is superior to placebo for PASI90 
response and IGA response at Week 16. These are the hypothesis tests corresponding to the co-
primary endpoints. If both are rejected at a 2-sided alpha level of 0.05, that alpha will be passed 
to the next test in the sequence, allowing the testing procedure to proceed. 
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo. See Figure 14-1 for details on this procedure. 
Figure 14-1: Sequence of testing 
 
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom diary; 
PSO=psoriasis; Q4W=every 4 weeks; Q8W=every 8 weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 98 of 209 
14.3 
Planned efficacy analyses 
14.3.1 
Analysis of the primary efficacy variable 
The co-primary efficacy variables for this study will be PASI90 response and IGA response at 
Week 16, and the corresponding analyses will be based on the RS. A subject will be classified as 
a PASI90 responder if the PASI score at Week 16 has improved at least 90% from Baseline, and 
an IGA responder will be any subject with a score of 0 or 1 (Clear or Almost Clear) with at least 
a 2-category improvement from Baseline in the IGA score. The primary analyses will be based 
on the stratified Cochran-Mantel-Haenszel (CMH) test where region and prior biologic exposure 
(yes/no) will be used as stratification variables. Region and prior biologic exposure have been 
selected as stratification variables in the analysis because they are stratification variables in the 
randomization and because they may have an impact on efficacy. Pairwise treatment 
comparisons will be made based on the CMH test using the p-value for the general association. 
Nonresponder imputation (NRI) will be used to account for missing data in the primary analysis. 
Specifically, any subject who withdraws from IMP prior to Week 16 or who has missing data for 
the co-primary efficacy variables at the Week 16 time point will be considered a nonresponder. 
Based on previous studies of biologics in subjects with moderate to severe chronic plaque PSO, 
it is expected that the number of subjects who discontinue prior to Week 16 will be low. For the 
small percentage of subjects for whom primary endpoint data are unavailable at Week 16, this 
lack of data is suggestive of an ineffective IMP, thereby supporting the imputation of 
nonresponse. Therefore, NRI is considered an appropriate method for handling missing data 
since achieving the clinical response and making it through 16 weeks of IMP treatment are both 
critical components of the primary outcome. 
14.3.1.1 
Sensitivity analyses 
The primary efficacy analysis described in Section 14.3.1 will be repeated based on the FAS and 
the PPS. 
As a sensitivity analysis to the primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week 16 will be estimated and tested between 
treatment groups using a logistic regression model with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated CI, and p-value based on the Wald 
test will be presented. If the logistic regression model is unable to converge, then prior biologic 
exposure may be dropped from the model to facilitate convergence. If the model is still unable to 
converge, then region may be removed from the model as well. As with the primary analysis, 
missing data will be handled using NRI. 
The center-by-treatment interaction will be tested by replacing region with center in the logistic 
regression model described above and adding a center center-by-treatment interaction term. In 
the model, center will be based on the original centers prior to pooling. However, if the model is 
unable to converge due to a low number of subjects at a given center, a pooling algorithm (to be 
described in the SAP) will be applied in order to allow the model to converge. 
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 15 subjects will be considered acceptable for a center to be included in the model 
without pooling. Given the 4:1 randomization allocation scheme, this should provide a minimum 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 99 of 209 
of about 12 subjects in the bimekizumab arm and 3 subjects in the placebo arm. Centers with 
fewer than 15 subjects will be eligible for pooling. 
The following center pooling algorithm will be used for each geographic region: 
 If a center has 15 or more subjects, then no pooling will be done for that center. 
 Centers with fewer than 15 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner: 
 Two or more centers will be combined until the cumulative subject total is at least 15. 
 Once a pooled center has at least 15 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 15 subjects has been reached in the previous pool. 
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 15 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration. 
This procedure is only to be performed within a geographic region – there will be no pooling of 
centers across regions. 
If the center-by-treatment interaction is not found to be significant (α=0.10), then no further 
analyses will be performed. On the other hand, if the interaction is significant, further analyses 
will be conducted to determine which center or centers may be the source of the interaction. This 
will be done by running the logistic regression model (including the interaction term) where each 
center will be systematically removed from the model. The impact of a given center will be 
based on the change in the interaction p-value when that center is removed. The center or centers 
that appear to be driving the significant interaction effect will then be removed from the model to 
verify that conclusions remain the same with or without the influential center(s). 
Additional sensitivity analyses to evaluate varying assumptions related to the handling of 
missing data will also be performed and are described in greater detail in Section 14.7. 
14.3.2 
Other efficacy analyses 
14.3.2.1 
Analysis of the secondary efficacy variables 
14.3.2.1.1 
Initial Treatment Period 
The secondary efficacy variables for the Initial Treatment Period will be analyzed for all subjects 
in the RS. 
For the binary secondary efficacy variables assessing the superiority of bimekizumab versus 
placebo, the stratified CMH test as specified for the primary analysis will be implemented. As in 
the primary analysis, NRI will be used to account for missing data 
For continuous change from Baseline efficacy variables (Patient Symptom Diary item scores for 
pain, itch, and scaling), an analysis of covariance (ANCOVA) model will be used with fixed 
effects of treatment, region, and prior biologic exposure and Baseline value as covariates. 
Missing data for these variables will be imputed using multiple imputation (MI) and is further 
described in Section 14.7. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 100 of 209 
Sensitivity analyses for the handling of missing data will be performed for the secondary 
variables during the Initial Treatment Period that are part of the fixed sequence testing 
procedures. These analyses will be described in Section 14.7. 
14.3.2.1.2 
Randomized-Withdrawal Period 
PASI90 response at Week 56 for subjects in the WK16ResS will be evaluated using a stratified 
CMH test where region and prior biologic exposure will be used as stratification variables, 
similar to the approach specified for the primary analysis. In this analysis, both dose regimens 
(Q4W and Q8W) within a given bimekizumab dose will be pooled such that each bimekizumab 
dose (regardless of regimen) will be compared to placebo. Missing data will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has met the criterion for relapse during the Randomized-Withdrawal Period, they will be treated 
as a non-responder at Week 56 for this analysis. 
While not part of the fixed sequence testing procedure, it is a secondary objective to assess the 
maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56. While multiple 
variables and analyses will be used to assess this objective, the secondary efficacy variable that 
will be used for this assessment is also PASI90 response at Week 56 for subjects in the 
Wk16ResS. This analysis will be based on simple percentages of PASI90 responders at Week 56 
for each dosing regimen (Q4W and Q8W). Subjects with missing data at Week 56 or who meet 
the criterion for relapse will be counted as non-responders. 
14.3.2.1.3 
Testing Procedure 
The testing of secondary efficacy variables as outlined in the fixed sequence testing procedure 
(see Section 14.3.2) will account for missing data based on the approaches described above (NRI 
for binary variables, and MI for continuous variables). In addition to this, sensitivity analyses for 
the handling of missing data will be performed for the binary and continuous secondary efficacy 
variables that are part of the fixed sequence testing procedures. These analyses are described in 
Section 14.7. 
14.3.2.2 
Analysis of the other efficacy variables 
The other efficacy variables in the Initial Treatment Period will be analyzed for all subjects in the 
RS. For the Randomized-Withdrawal Period, summaries will be based on the WK16ResS and 
the ESS, as appropriate. 
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit. 
Continuous variables will be summarized using descriptive statistics by treatment group for each 
visit. 
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented using the Kaplan-Meier product-limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achieving a response 
will be censored at the date of IMP discontinuation. Subjects who reach the Week 16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week 16 Visit. The median time to response, including the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 101 of 209 
2-sided 95% CI, will be calculated for each treatment. Between-group differences will be 
analyzed with the log-rank statistic. 
Time to relapse (defined as not achieving a PASI75 response) for subjects in the WK16ResS will 
be estimated and presented using the Kaplan-Meier product-limit method for each treatment. 
Time to relapse will be defined as the length in days from date of first re-randomized IMP 
treatment in the Randomized-Withdrawal Period until the date when relapse is confirmed via the 
PASI assessment. Subjects who discontinue IMP prior to a recorded relapse will be considered 
as having relapsed on the date of early discontinuation. This is considered reasonable as early 
discontinuation is indicative of ineffective IMP treatment. Subjects who reach the Week 56 Visit 
without relapsing will be censored at the date of the Week 56 Visit. The median time to 
response, including the 2-sided 95% CI, will be calculated for each treatment. Between-group 
differences will be analyzed with the log-rank statistic. These between-group differences will 
compare each bimekizumab dose (separately for each regimen as well as pooled regimen) to 
placebo based on the re-randomized treatment groups (ie, independent of the initial 
randomization). 
All other efficacy variables will be summarized based on imputed data (NRI and multiple 
imputation for binary and continuous variables, respectively), unless otherwise specified in the 
SAP. In some cases, variables may also be summarized based on observed case data (ie, subjects 
with missing data or who have prematurely discontinued IMP are treated as missing). There may 
be cases where the multiple imputation model fails to converge. In such situations, the last 
observation carried forward (LOCF) approach will instead be used to impute the missing data. If 
LOCF is used instead of multiple imputation for this reason, this will be clearly specified in the 
corresponding table summary. Should there be no missing data for a study variable, then only 
observed case data will be produced. Note that for LOCF imputation, any missing data or data 
collected following discontinuation of IMP will be imputed with the most recent previous value. 
See Section 14.7 for further details. 
14.4 
Subgroup analyses 
Subgroup analyses will be performed on the co-primary and secondary efficacy variables for the 
Initial Treatment Period that are part of the fixed sequence testing procedure described in 
Section 14.3.1. The following variables for subgroup analyses will be defined: age, gender, 
disease duration, region, weight, body mass index, prior systemic chemotherapy or phototherapy, 
prior biologic exposure, prior systemic therapy of any kind, Baseline disease severity, and 
antibody positivity. These summaries will be based on imputed data (NRI or MI) and will 
include descriptive statistics only. Note that the approach for deriving descriptive statistics using 
MI is outlined in Section 14.7. 
14.5 
Planned safety and other analyses 
14.5.1 
Safety analyses 
Safety variables will be analyzed for all subjects in the SS. The AMS will be used for summaries 
of safety that include data from the Initial Treatment Period and/or Randomized-Withdrawal 
Period. Additional summaries focusing on safety during the Randomized-Withdrawal Period will 
also be prepared and will be based on the WK16ResS. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 102 of 209 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events will be summarized descriptively by treatment group, primary 
system organ class, High Level Term (HLT), and preferred term. Additional tables will 
summarize adverse events by intensity and relationship to study drug, adverse events leading to 
withdrawal from the study, SAEs, and deaths. 
For subjects who switch treatment, AEs will be allocated to the treatment the subject was on the 
day the event occurred. If the event occurs on the day of the switch, it will be attributed to the 
initial treatment, unless the event has a HLT of “Injection Site Reactions”, in which case it will 
be attributed to the new treatment. 
Laboratory values (including markedly abnormal labs), urinary values, vital signs and extent of 
exposure will be presented descriptively by treatment group. Definitions for markedly abnormal 
laboratory values will be provided in the SAP. 
14.5.2 
Pharmacokinetic analyses 
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit. 
14.5.3 
Immunogenicity analyses 
Anti-bimekizumab antibody detection (including positivity) will be summarized by treatment at 
each scheduled visit. 
14.6 
Handling of protocol deviations 
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK outcomes for 
an individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document at study start. Important protocol deviations 
will be reviewed as part of the ongoing data cleaning process and all important deviations will be 
identified and documented prior to unblinding to confirm exclusion from analysis sets. 
14.7 
Handling of dropouts or missing data 
Study variables with multiple components may have rules to account for partial missing data of 1 
or more components. Such rules will be defined in the SAP. The following rules are outlined for 
cases where variables are completely missing, including partial missing data where the data 
handling rules conclude that the variable should be treated as completely missing. 
The analysis of the co-primary efficacy variables will use NRI for handling of missing data. That 
is, subjects with missing data or who have discontinued IMP prior to Week 16 will be considered 
as nonresponders for the primary analysis. The following sensitivity analyses for the co-primary 
efficacy variables will be performed: 
1. Missing data will be addressed by using MI (Markov-Chain Monte Carlo [MCMC] method 
for intermittent missing data, followed by monotone regression for monotone missing data) 
to evaluate the effect of the method for handling missing data on the analysis. The actual 
PASI/IGA scores will be imputed and then dichotomized to obtain the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test with region and prior biologic exposure as stratification variables as used 
in the primary analysis. The results from each of the imputed data sets will be combined for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 103 of 209 
overall inference using Rubin’s rules, which account for the uncertainty associated with the 
imputed values (Rubin, 1987). This will be done using SAS PROC MIANALYZE.This 
procedure assumes a missing at random (MAR) pattern of missingness and corresponds to an 
estimand of what has been called the difference in outcome improvement if all subjects 
tolerated or adhered to treatment (Mallinckrodt et al, 2012). This is an estimand of efficacy to 
evaluate the de jure hypothesis. 
1. Deviations from the MAR pattern assumed above will be evaluated. A sensitivity analysis 
will be performed in which, as with the above analysis, intermittent missing data will be 
imputed using MI based on the MCMC method. However, the remaining monotone missing 
data will be assumed to follow a missing not at random pattern. These data will be imputed 
using reference-based imputation in which the imputation model is based on data from the 
placebo group, thereby assuming that monotone missing data follow a trajectory similar to 
the placebo group (Mallinckrodt et al, 2012). As specified in the previous procedure, actual 
PASI/IGA scores will be imputed and then dichotomized to get the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test as used in the primary analysis. The estimand in this procedure is the 
difference in outcome improvement in all randomized subjects at the planned endpoint of the 
study attributable to the initially randomized medication (Mallinckrodt et al, 2012). This is an 
estimand of effectiveness to evaluate the de facto hypothesis. 
2. A final sensitivity analysis will be based on observed data at Week 16. Subjects with missing 
data or who have prematurely discontinued IMP will be treated as missing. The same 
stratified CMH test as in the primary efficacy analysis will be used. 
Further details on the MI procedures will be provided in the SAP. 
Missing data for binary secondary efficacy variables during the Initial Period will be imputed 
using NRI. 
Missing data for the binary secondary efficacy variable during the Randomized-Withdrawal 
Period (PASI90 at Week 56 among Week 16 PASI90 responders) will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has met the criterion for relapse during the Randomized-Withdrawal Period, they will be treated 
as a non-responder at Week 56 for this analysis. 
Missing data for continuous secondary efficacy variables will be imputed using MI. The MI 
procedure for continuous variables will be similar to sensitivity analysis #1 described above for 
the co-primary efficacy endpoints with the following differences: 1) the imputation model will 
use the change from Baseline (instead of actual) values by visit and no dichotomization will be 
necessary; and 2) the analysis model will be based on ANCOVA as opposed to the stratified 
CMH test. 
For other continuous efficacy variables, MI will be used to impute missing data when possible. If 
the imputation model cannot converge, LOCF will be used. The MI procedure will be similar to 
sensitivity analysis #1 described above with the following differences: 1) the imputation model 
will use the change from Baseline (instead of actual) values by visit and no dichotomization will 
be necessary; 2) instead of using the stratified CMH test, the imputed data sets will be combined 
and simple means and standard errors will be calculated using Rubin’s rules (via SAS PROC 
MIANALYZE). For calculation of other descriptive statistics such as the median, min and max, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 104 of 209 
Rubin's rules do not apply. Multiple imputation estimates will be computed by simply averaging 
the estimates from the multiple repetitions of the imputation algorithm. This is the same 
approach that will be used when summarizing continuous secondary efficacy variables by 
subgroup. 
14.8 
Planned interim analysis and data monitoring 
After the final Week 56 visit, an interim analysis will be performed and a corresponding interim 
CSR may be written. A final analysis and updated final CSR will be prepared once all data 
(through the SFU visit) have been collected. 
14.9 
Determination of sample size 
A total of 400 subjects will be randomly assigned in a 4:1 ratio to the following treatment 
groups: 
 Bimekizumab 320mg (320 subjects) 
 Placebo (80 subjects) 
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co-
primary efficacy variables of PASI90 response and IGA response at Week 16. The assumed 
responder rates for PASI90 at Week 16 are 75% and 2% for bimekizumab and placebo, 
respectively. Additionally, the assumed responder rates for IGA are 85% and 5% for 
bimekizumab and placebo, respectively. The assumed responder rates for bimekizumab are 
based on the Phase 2b PS0010 data. The power to show statistical superiority of bimekizumab 
relative to placebo under these assumptions is >99% for the co-primary endpoints. 
15 
ETHICS AND REGULATORY REQUIREMENTS 
15.1 
Informed consent 
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki. 
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator. 
Prior to participation in the study, the ICF should be signed and personally dated by the subject 
and by the person who conducted the informed consent discussion (Investigator or designee). 
The subject must receive a copy of the signed and dated ICF. As part of the consent process, 
each subject must consent to direct access to his/her medical records for study-related 
monitoring, auditing, IRB/IEC review, and regulatory inspection. 
If the ICF is amended during the study, the Investigator (or the sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form. 
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 105 of 209 
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the ICF. A eCRF must not be started, 
nor may any study specific procedure be performed for a given subject, without having obtained 
his/her written consent to participate in the study. 
15.2 
Subject identification cards 
Upon signing the Informed Consent and Assent Form (as applicable), the subject will be 
provided with a subject identification card in the language of the subject. The Investigator will 
fill in the subject identifying information and medical emergency contact information. The 
Investigator will instruct the subject to keep the card with him/her at all times. 
15.3 
Institutional Review Boards and Independent Ethics 
Committees 
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki. 
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
subject-related documents to be used for the study to the IRB/IEC for its review and approval. 
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol. 
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects. 
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed. 
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion. 
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the Investigator or the Sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notification. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 106 of 209 
15.4 
Subject privacy 
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening. 
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study). 
15.5 
Protocol amendments 
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective. 
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented. 
16 
FINANCE, INSURANCE, AND PUBLICATION 
Insurance coverage will be handled according to local requirements. 
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable. 
17 
REFERENCES 
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and 
comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633-6. 
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of 
psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in 
European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548-54. 
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Institutes of 
Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis. 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Updated 03 Mar 
2016. 
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002. 
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive 
symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. 
J Invest Dermatol. 2014;134:1542-51. 
Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog 
Treat. 2004;15(1):27-9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 107 of 209 
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial 
infarction in patients with psoriasis. JAMA. 2006;296:1735-41. 
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of 
metabolic syndrome in patients with psoriasis: a hospital-based case-control study. 
Br J Dermatol. 2007;157:68-73. 
Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19-34. 
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improvement with anti-TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90-5. 
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in 
incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad 
Dermatol. 2009;60:394-401. 
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity 
measure. J Gen Intern Med. 2001;16:606–13. 
Krueger G, Ellis CN. Psoriasis–recent advances in understanding its pathogenesis and treatment. 
J Am Acad Dermatol. 2005;53(1 Suppl 1):S94-100. 
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on 
quality of Life. Results of a 1998 National Psoriasis Foundation patient-membership survey. 
Arch Dermatol. 2001;137:280-4. 
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin 
in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad 
Dermatol. 2008;58:625-31. 
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-24. 
Langley RG, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis. 2005;64(Suppl II):ii18–ii23. 
Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm Stat. 2012;11:456-61. 
Maruish, ME (Ed.). User’s manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Incorporated. 2011. 
Mukhtar R, Choi J, Koo JY. Quality of life issues in psoriasis. Dermatol Clin. 2004;22:389-95. 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer-Automated Columbia-Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8. 
Ortonne JP. Redefining clinical response in psoriasis: targeting the pathological basis of disease. 
J Drugs Dermatol. 2004;3:13-20. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 108 of 209 
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis 
and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A 
systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77. 
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the 
quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-
analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213-220. 
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United 
States. J Am Acad Dermatol. 2014;70:512-6. 
Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset 
psoriasis. Pediatric Dermatology. 2000; 17(3):174–178. 
Rubin DB. 1987. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley and 
Sons. 
Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG. Role of IL-25 in Immunity. J Clin Diagn Res. 
2015;9(4):OE01–OE04. 
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity 
and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 
2013;149:1173-9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 109 of 209 
18 
APPENDICES 
18.1 
Protocol Amendment 1 
Rationale for the amendment 
The purpose of this amendment was the following:   
 Update the study design to remove the ustekinumab arm 
 Remove the mandatory withdrawal at Week 28 or later 
 Clarify the number of subjects to be screened 
 Add assessment of the Patient Symptom Diary (daily) to the Screening and Week 16 Visits 
 Clarify the dosing window 
 Add percentage of BSA as an assessment at all visits 
 Clarify the PGADA will be performed on all subjects at Baseline 
 Remove the WPAI-SHP V2.0 
 Remove the criterion that excluded subjects exposed to more than 3 biologic response 
modifiers (including no more than 1 IL-17) 
 Clarify that subjects who experienced primary failure (no response within 12 weeks) to 1 or 
more IL-17 biologic response modifiers or more than 1 biologic response modifiers other 
than an IL-17 should be excluded from the study 
 Remove the withdrawal criterion that subjects who do not achieve a PASI50 response by 
Week 28 or later be withdrawn from the study 
 Correct discrepancies between Section 8 Study procedures by visit and Table 5-1 Schedule of 
study assessments 
 Clarify that the same assessor should evaluate the subject at each efficacy assessment 
 Clarify in footnote c of Table 12-2 Laboratory measurements the visits in which the urine 
drug screen will be performed 
 Update the assessment and management of TB and TB risk factors 
 Update the sequence testing and definition of the Escape Subject Set (ESS) and Active 
Medication Set (AMS) 
In addition, minor spelling, editorial, and formatting changes were made, and the List of 
Abbreviations was updated. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 110 of 209 
Modifications and changes 
Specific changes 
Change #1  
A PHASE 3, MULTICENTER, DOUBLE-BLIND, ACTIVE COMPARATOR-  AND 
PLACEBO-CONTROLLED STUDY WITH A 16-WEEK INITIAL TREATMENT PERIOD 
FOLLOWED BY A 40-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE 
THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH 
MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS 
Has been changed to: 
A PHASE 3, MULTICENTER, DOUBLE-BLIND, ACTIVE COMPARATOR-  AND 
PLACEBO-CONTROLLED STUDY WITH AN 16-WEEK INITIAL TREATMENT PERIOD 
FOLLOWED BY A 40-WEEK RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE 
THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH 
MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS 
 
Change #2 
Section 1 Summary 
This is a Phase 3, multicenter, randomized, double-blind, active comparator- and placebo-
controlled study consisting of a 16-week Initial Treatment Period followed by a 40-week 
Randomized-Withdrawal Period to evaluate the efficacy and safety, pharmacokinetics (PK) of 
bimekizumab compared with ustekinumab and placebo in adult subjects with moderate to severe 
chronic plaque psoriasis (PSO). 
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5-point scale]) who are a candidate for ustekinumab, or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy. 
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. There will be approximately 240 subjects in the bimekizumab treatment arm, 240 subjects 
in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. For each 
subject, the study will last a maximum of 76 weeks and will consist of 4 periods, a Screening 
Period (2 to 4 weeks), a double-blind, active comparator- and placebo-controlled Initial 
Treatment Period (16 weeks), a double-blind, active comparator- and placebo-controlled 
Randomized-Withdrawal Period (40 weeks) Period, and a Safety Follow-Up (SFU) Period (20 
weeks after the last dose of investigational medicinal product [IMP]). After completing the 
study, eligible subjects will be allowed to enroll in an open-label study. 
During the Initial Treatment Period eligible subjects will be randomized 3:3:1 to receive the 
following blinded IMP regimens: 
 Bimekizumab 320mg administered sc Q4W 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 111 of 209 
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at Baseline and 
4 weeks later, followed by ustekinumab sc every 12 weeks 
 Placebo administered sc Q4W 
Investigational medicinal product will be administered in the clinic at Baseline, Week 4, Week 8, 
and Week 12. At the Week 16 study visit, bimekizumab subjects who have achieved a PASI90 
response will enter the 40-week Randomized-Withdrawal Period. Dosing will be based on 
treatment group assignment at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal) 
 Subjects in the ustekinumab treatment arm will be re-randomized 1:1 to either bimekizumab 
320mg Q4W or bimekizumab 320mg Q8W 
 Subjects initially randomized to placebo will continue to receive placebo (Q4W) 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W for 12 weeks. 
Subjects who achieve a PASI50 response at Week 12 of the open-label escape arm will be 
allowed to enroll in the open-label study. 
Subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treatment 
Period and who relapse at Week 20 or later during the Randomized-Withdrawal Period (up to 
Week 56) will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W 
for 12 weeks. Relapse is defined as not achieving a PASI75 response. Subjects who achieve a 
PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in the open-
label study. 
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment Period 
and do not achieve a PASI50 response at Week 28 or later will be withdrawn from the study. 
Has been changed to: 
This is a Phase 3, multicenter, randomized, double-blind, active comparator- and placebo-
controlled study consisting of a 16-week Initial Treatment Period followed by a 40-week 
Randomized-Withdrawal Period to evaluate the efficacy, and safety, and pharmacokinetics (PK) 
of bimekizumab compared with ustekinumab and placebo in adult subjects with moderate to 
severe chronic plaque psoriasis (PSO). 
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5-point scale]) who are a candidate for ustekinumab, or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy. 
Approximately 535750 subjects will be screened in order to have 400560 subjects randomized in 
the study. There will be approximately 320240 subjects in the bimekizumab treatment arm, 240 
subjects in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. For 
each subject, the study will last a maximum of 76 weeks and will consist of 4 periods, a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 112 of 209 
Screening Period (2 to 4 weeks), a double-blind, active comparator- and placebo-controlled 
Initial Treatment Period (16 weeks), a double-blind, active comparator- and placebo-controlled 
Randomized-Withdrawal Period (40 weeks) Period, and a Safety Follow-Up (SFU) Period (20 
weeks after the last dose of investigational medicinal product [IMP]). After completing the 
study, eligible subjects will be allowed to enroll in an open-label study. 
During the Initial Treatment Period,eEligible subjects will be randomized 43:3:1 to receive 
the following blinded IMP regimens: 
 Bimekizumab 320mg administered sc Q4W 
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at Baseline 
and 4 weeks later, followed by ustekinumab sc every 12 weeks 
 Placebo administered sc Q4W 
Investigational medicinal product will be administered in the clinic at Baseline, Week 4, Week 8, 
and Week 12. At the Week 16 study visit, bimekizumab and placebo subjects who have 
achieved a PASI90 response will enter the 40-week Randomized-Withdrawal Period. Dosing 
will be based on treatment group assignment at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal) 
 Subjects in the ustekinumab treatment arm will be re-randomized 1:1 to either 
bimekizumab 320mg Q4W or bimekizumab 320mg Q8W 
 Subjects initially randomized to placebo will continue to receive placebo (Q4W) provided 
the subject is a PASI90 responder 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W for 12 weeks. 
Subjects who achieve a PASI50 response at Week 12 of the open-label escape arm will be 
allowed to enroll in the open-label study. 
All sSubjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial 
Treatment Period and who relapse at Week 20 or later during the Randomized-Withdrawal 
Period (up to Week 56) will be allocated to an escape arm and receive open-label bimekizumab 
320mg Q4W for 12 weeks. Relapse is defined as not achieving a PASI75 response. Subjects who 
achieve a PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in 
the open-label study. 
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment 
Period and do not achieve a PASI50 response at Week 28 or later will be withdrawn from 
the study. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 113 of 209 
Change #3  
Section 2.1.2 Current treatments for psoriasis 
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. Brodalumab is a 
human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits 
its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. 
Blocking IL 17RA inhibits IL-17 cytokine-induced responses including the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box warning 
regarding suicidal ideation and behavior. 
Has been changed to: 
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. In the EU, 
brodalumab is indicated for the treatment of moderate to severe plaque PSO in 
adult patients who are candidates for systemic therapy. Brodalumab is a human 
monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its 
interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. 
Blocking IL 17RA inhibits IL-17 cytokine-induced responses including the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box warning 
regarding suicidal ideation and behavior. 
 
Change #4  
Section 2.2.1.1 
Completed studies 
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and PS0016) are ongoing in 
subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with moderate to 
severe PSO (PS0010 and PS0016). 
Has been changed to: 
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and PS0016) are ongoing 
in subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with 
moderate to severe PSO (PS0010 and PS0016). 
 
Change #5  
Section 2.2.1.2 Ongoing studies 
Five additional studies of bimekizumab in the treatment of PSO are ongoing. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 114 of 209 
Has been changed to: 
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing. Five additional studies of bimekizumab in the treatment of PSO 
are ongoing. 
 
Change #6  
Section 3.2 Secondary objectives 
The following bullet has been deleted: 
 Evaluate the efficacy of bimekizumab compared to ustekinumab after 12, and 16 weeks of 
treatment 
 
Change #7  
Section 3.3 Other objectives 
The following bullet has been deleted: 
 Assess work productivity 
 
Change #8 
Section 4.2.1 Secondary efficacy variables 
The following bullets have been deleted: 
 PASI90 response at Week 12 
 IGA response at Week 12 
 
Change #9  
Section 4.3.1 Other efficacy variable(s) 
The following bullet has been added: 
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA) 
 
Change #10  
Section 4.3.1 Other efficacy variable(s) 
The following bullet has been deleted: 
 Change from Baseline in Work Productivity and Activity Impairment Questionnaire-specific 
health problem (WPAI-SHP) V2.0 adapted to PSO scores 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 115 of 209 
Change #11  
Section 5.1 Study description 
PS0013 is a Phase 3, multicenter, randomized, double-blind, active comparator- and placebo-
controlled study consisting of a 16-week Initial Treatment Period followed by a 40-week 
Randomized-Withdrawal Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5-point scale]) who are a candidate for 
ustekinumab, or for systemic PSO therapy and/or phototherapy and/or photochemotherapy. 
Subjects may have been previously exposed to a biologic therapy (see Exclusion Criterion #21 
and #22, Section 6.2). 
Has been changed to: 
PS0013 is a Phase 3, multicenter, randomized, double-blind, active comparator- and placebo-
controlled study consisting of a 16-week Initial Treatment Period followed by a 40-week 
Randomized-Withdrawal Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5-point scale]) who are a candidate for 
ustekinumab, or for systemic PSO therapy and/or phototherapy and/or photochemotherapy. 
Subjects may have been previously exposed to a biologic therapy (see Exclusion Criterion #21 
and #23, Section 6.2). 
 
Change #12 
Section 5.2 Study periods 
This study will include 4 periods, a Screening Period (2 to 4 weeks), an active comparator- and 
placebo-controlled, Initial Treatment Period (16 weeks), an active comparator- and placebo-
controlled Randomized-Withdrawal Period (40 weeks), and a SFU Period (20 weeks after the 
last dose of IMP). After completing the study, eligible subjects will be allowed to enroll in an 
open-label study. Subjects enrolling into the open-label study will not have the PS0013 SFU 
Visit. 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 5.2.5). Subjects who were in the biekizumab 320mg 
Q4W treatment arm in the Initial Treatment Period and who relapse at Week 20 or later during 
the Randomized-Withdrawal Period (up to Week 56) will be allocated to escape treatment (see 
Section 5.2.5). Relapse is defined as not achieving a PASI75 response. Subjects who achieve a 
PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in the open-
label study. 
Has been changed to: 
This study will include 4 periods: a Screening Period (2 to 4 weeks), an active comparator- and 
placebo-controlled Initial Treatment Period (16 weeks), an active comparator- and placebo-
controlled Randomized-Withdrawal Period (40 weeks), and a SFU Period (20 weeks after the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 116 of 209 
last dose of IMP). After completing the study, eligible subjects will be allowed to enroll in an 
open-label study. Subjects enrolling into the open-label study will not have the PS0013 SFU 
Visit. 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 5.2.5). All sSubjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse 
at Week 20 or later during the Randomized-Withdrawal Period (up to Week 56) will be allocated 
to escape treatment (see Section 5.2.5). Relapse is defined as not achieving a PASI75 response. 
Subjects who achieve a PASI50 response at Week 12 of the open-label escape arm will be 
allowed to enroll in the open-label study. 
 
Change #13 
Section 5.2.2 Initial Treatment Period 
During the active comparator- and placebo-controlled Initial Treatment Period, approximately 
560 subjects will be randomized 3:3:1 to receive the following blinded IMP regimens: 
 Bimekizumab 320mg administered Q4W (240 subjects) 
 Ustekinumab (240 subjects): 
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and 4 weeks later 
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later 
 Placebo administered Q4W (80 subjects) 
Has been changed to: 
During the active comparator- and placebo-controlled Initial Treatment Period, approximately 
400560 subjects will be randomized 3:34:1 to receive the following blinded IMP regimens: 
 Bimekizumab 320mg administered Q4W (320240 subjects) 
 Ustekinumab (240 subjects): 
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and 4 weeks later 
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later 
 Placebo administered Q4W (80 subjects) 
 
Change #14 
Section 5.2.3 Randomized-Withdrawal Period 
At the Week 16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double-blind, active comparator- and placebo-controlled, Randomized-Withdrawal 
Period lasting 40 weeks. Subjects who do not achieve a PASI90 response at the Week 16 study 
visit will be allocated to the escape arm (see Section 5.2.5). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 117 of 209 
During the Randomized-Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal) 
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week 16 will 
be re-randomized 1:1 to either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W 
 Subjects initially randomized to placebo who achieve a PASI90 response at Week 16 will 
continue to receive placebo (Q4W) 
Investigational medicinal product will be administered in the clinic at Week 16 and Q4W 
thereafter through Week 52. The assessments to be performed at each visit of the Randomized-
Withdrawal Period are presented in Table 5-1. 
Subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treatment 
Period and who relapse at Week 20 or later during the Randomized-Withdrawal Period (up to 
Week 56) will be allocated to the escape arm (see Section 5.2.5). Relapse is defined as not 
achieving a PASI75 response. 
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment Period 
and do not achieve a PASI50 response at Week 28 or later will be withdrawn from the study at 
the time point when the PASI50 response is not achieved. 
Has been changed to: 
At the Week 16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double-blind, active comparator- and placebo-controlled, Randomized-Withdrawal 
Period lasting 40 weeks. Subjects who do not achieve a PASI90 response at the Week 16 study 
visit will be allocated to the escape arm (see Section 5.2.5). 
During the Randomized-Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows: 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal) 
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week 16 
will be re-randomized 1:1 to either bimekizumab 320mg Q4W or bimekizumab 320mg 
Q8W 
 All Ssubjects initially randomized to placebo who achieve a PASI90 response at Week 16 
will continue to receive placebo (Q4W) 
Investigational medicinal product will be administered in the clinic at Week 16 and Q4W 
thereafter through Week 52. The assessments to be performed at each visit of the Randomized-
Withdrawal Period are presented in Table 5-1. 
All subjects who were in the bimekizumab 320mg Q4W or ustekinumab treatment arms in 
the Initial Treatment Period and who relapse at Week 20 or later during the Randomized-
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 118 of 209 
Withdrawal Period (up to Week 56) will be allocated to the escape arm (see Section 5.2.5). 
Relapse is defined as not achieving a PASI75 response. 
Subjects who were in the placebo treatment arm in the Initial Treatment Period and do not 
achieve a PASI50 response at Week 28 or later will be withdrawn from the study at the 
time point when the PASI50 response is not achieved. 
 
Change #15 
Section 5.2.5 Escape Treatment 
As described above, subjects who do not achieve a PASI90 response at Week 16 of the Initial 
Treatment Period and subjects who were in the bimekizumab 320mg Q4W treatment arm in the 
Initial Treatment Period and who relapse at Week 20 or later during the Randomized-Withdrawal 
Period (up to Week 56) will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, 
escape treatment). 
For subjects who relapse during the Randomized-Withdrawal Period, the subject should 
complete the 12-week escape treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped). 
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open-label study. The Schedule of Study Assessments for subjects 
receiving escape treatment is provided in Table 5‒2. 
Subjects who do not achieve a PASI50 response after 12 weeks of escape treatment should be 
withdrawn (see Section 6.3), and will have a SFU Visit 20 weeks after their last dose of IMP. 
Has been changed to: 
As described above, subjects who do not achieve a PASI90 response at Week 16 of the Initial 
Treatment Period and all subjects who were in the bimekizumab 320mg Q4W treatment arm 
in the Initial Treatment Period and who relapse at Week 20 or later during the Randomized-
Withdrawal Period (up to Week 56) will receive open-label bimekizumab 320mg Q4W for 
12 weeks (ie, escape treatment). 
For subjects who relapse during the Randomized-Withdrawal Period, the subject should 
complete the 12-week escape treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped). 
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open-label study. The Schedule of Study Assessments for subjects 
receiving escape treatment is provided in Table 5‒2. 
Subjects who do not achieve a PASI50 response after 12 weeks of escape treatment should 
be withdrawn (see Section 6.3), and will have a SFU Visit 20 weeks after their last dose of 
IMP. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 119 of 209 
Change #16 
Section 5.3 
Study duration per subject 
For each subject, the study will last a maximum of up to 76 weeks, as follows: 
 Screening Period: 2 to 4 weeks 
 Double-blind, active comparator- and placebo-controlled Initial Treatment Period: 16 weeks 
 Double-blind, active comparator- and placebo-controlled Randomized-Withdrawal Period: 
40 weeks 
 Escape treatment (if required): 12 weeks 
 Safety Follow-Up Period: a SFU Visit is planned 20 weeks after the last dose of IMP (for 
subjects not enrolling in the open-label study) 
Has been changed to: 
For each subject, the study will last a maximum of up to 76 weeks, as follows: 
 Screening Period: 2 to 4 weeks 
 Double-blind, active comparator- and placebo-controlled Initial Treatment Period: 16 
weeks 
 Double-blind, active comparator- and placebo-controlled Randomized-Withdrawal Period: 
40 weeks 
 Escape treatment (if required): 12 weeks 
 Safety Follow-Up Period: a SFU Visit is planned 20 weeks after the last dose of IMP (for 
subjects not enrolling in the open-label study) 
 
Change #17 
Section 5.4 
Planned number of subjects and site(s) 
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. There will be approximately 240 subjects in the bimekizumab treatment arm, 240 subjects 
in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. The planned 
number of study sites is approximately 100. Every eligible subject who signs an ICF will be 
randomized. 
Has been changed to: 
Approximately 535750 subjects will be screened in order to have 400560 subjects randomized in 
the study. There will be approximately 320240 subjects in the bimekizumab treatment arm, 240 
subjects in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. The 
planned number of study sites is approximately 100. Every eligible subject who signs an ICF will 
be randomized. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 120 of 209 
Change #18 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xd 
 
 
Inclusion/exclusion 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant past medical 
history and concomitant 
diseases 
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examf,g 
X 
 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
X 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and 
biochemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
X 
Urinalysis 
X 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
ECG 
X 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
Pregnancy testingi 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hepatitis B and C testingj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV testingk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 121 of 209 
Change #18 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Chest x-rayl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGRA Tuberculosis test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tuberculosis 
questionnaire 
X 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
X 
X 
Blood sample for 
bimekizumab plasma 
concentrationsm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
anti-bimekizumab 
antibodiesm 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m 
 
X 
X 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
Blood sample for 
genetic/ epigenetic 
analysesc,m 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IGA  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
 
X 
 X 
X  
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
X 
 
X 
 
PHQ-9 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X  
X 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 122 of 209 
Change #18 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
eC-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Patient Symptom Diary 
(daily) 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Scalp IGA 
 
X 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
mNAPSI 
 
X 
 
 
Xo 
Xo 
Xo 
Xo 
Xo 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
pp-IGA 
 
X 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
EQ-5D-3L 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
SF-36 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Patient Global 
Assessment of PSOq 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
PASE 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PGADAr 
 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
WPAI-SHP V2.0 
 
X 
 
 
 
 
 
X 
 
X 
 
 
 
X 
 
 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IRTs,t 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bimekizumab, 
ustekinumab, or placebo 
administrations,t 
 
X 
 
 
X 
X 
X 
Xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 123 of 209 
Change #18 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic Columbia-Suicide Severity 
Rating Scale; EQ-5D-3L= Euro-Quality of Life 5-Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=human immunodeficiency virus; 
IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IMP=investigational medicinal product; IRT=interactive response 
technologyPASE=Psoriatic Arthritis Screening and Evaluation; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; 
PGADA=Patient’s Global Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; PsA=psoriatic arthritis; PSO=psoriasis; SF-36=Short Form 36 
item Health Survey; SFU=Safety Follow-Up; scalp IGA=scalp-specific Investigator’s Global Assessment; TB=tuberculosis; WPAI-SHP=Work Productivity and 
Activity Impairment Questionnaire-specific health problem 
a Visit windows of ± 3 days from the first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose. 
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The Informed 
Consent Form must be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up to 20 
years. 
e Ensure no significant changes in medical history. 
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB. 
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI. 
h Vital signs (blood pressure, pulse rate, and temperature) are to be measured prior to blood sampling, and prior to dosing, where applicable. 
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits 
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) and negative for anti-hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti-hepatitis B surface antibody. 
k The HIV test results will not be recorded in the eCRF. 
l Screening chest x-ray must occur within 3 months prior to the Screening Visit. 
m All blood samples taken prior to dosing. 
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline. 
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 124 of 209 
Change #18 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline. 
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from baseline through the initial treatment 
period with a +3 day completion window. During the maintenance period this assessment will be completed at each clinic visit specified with a ±3 day 
completion window. 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47). 
s IMP administration is based on randomization. 
t For bimekizumab, the minimum time between doses should be no less than 24 days and no more than 32 days. 
u At Week 16 subjects will be re-allocated based on original treatment and response to treatment and will receive their first Maintenance Treatment Period dose. 
 
Has been changed to: 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xd 
 
 
Inclusion/exclusion 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 125 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant past medical 
history and concomitant 
diseases 
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examf,g 
X 
 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
X 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and 
biochemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
X 
Urinalysis 
X 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
ECG 
X 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
Pregnancy testingi 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hepatitis B and C testingj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV testingk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest x-rayl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGRA Tuberculosis test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tuberculosis 
questionnaire 
X 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
X 
X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 126 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Blood sample for 
bimekizumab plasma 
concentrationsm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
anti-bimekizumab 
antibodiesm 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m 
 
X 
X 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
Blood sample for 
genetic/ epigenetic 
analysesc,m 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IGA  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
 
X 
 X 
X  
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
PHQ-9 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X  
X 
X 
X 
X 
X 
 
eC-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Patient Symptom Diary 
(daily) 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
 
 
 
 
 
 
 
Scalp IGA 
 
X 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
mNAPSI 
 
X 
 
 
Xo 
Xo 
Xo 
Xo 
Xo 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 127 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
pp-IGA 
 
X 
 
 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
EQ-5D-3L 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
SF-36 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Patient Global 
Assessment of PSOq 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
PASE 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PGADAr 
 
X 
 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
WPAI-SHP V2.0 
 
X 
 
 
 
 
 
X 
 
X 
 
 
 
X 
 
 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IRTs,t 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bimekizumab, 
ustekinumab, or placebo 
administrations,t 
 
X 
 
 
X 
X 
X 
Xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic Columbia-Suicide Severity 
Rating Scale; EQ-5D-3L= Euro-Quality of Life 5-Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=human immunodeficiency virus; 
IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IMP=investigational medicinal product; IRT=interactive response 
technologyPASE=Psoriatic Arthritis Screening and Evaluation; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; 
PGADA=Patient’s Global Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; PsA=psoriatic arthritis; PSO=psoriasis; SF-36=Short Form 36 
item Health Survey; SFU=Safety Follow-Up; scalp IGA=scalp-specific Investigator’s Global Assessment; TB=tuberculosis; WPAI-SHP=Work Productivity 
and Activity Impairment Questionnaire-specific health problem 
a Visit windows of ± 3 days from the first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open-label study. 
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The Informed 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 128 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Consent Form must be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up to 20 
years. 
e Ensure no significant changes in medical history. 
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB. 
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI. 
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits 
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) and negative for anti-hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti-hepatitis B surface antibody. 
k The HIV test results will not be recorded in the eCRF. 
l Screening chest x-ray must occur within 3 months prior to the Screening Visit. 
m All blood samples taken prior to dosing. 
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline. 
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline. 
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline. 
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from baselineScreening through the 
Initial Treatment Period with a +3 day completion window. During the Randomized-Withdrawal Period this assessment will be completed at each clinic visit 
specified with a ±3 day completion window. 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47). 
s IMP administration is based on randomization. 
t The dosing window is ±7 days relative to the scheduled dosing visit.For bimekizumab, the minimum time between doses should be no less than 24 days 
and no more than 32 days. 
u At Week 16 subjects will be re-allocated based on original treatment and response to treatment and will receive their first Randomized-Withdrawal Period 
dose. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 129 of 209 
 
Change #19 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
eC-SSRS 
X 
X 
X 
X 
X 
Urine drug screen 
 
 
 
X 
 
Physical exam 
 
 
 
X 
X 
Body Weight 
X 
 
 
X 
 
Vital signsc 
X 
X 
X 
X 
X 
Hematology and biochemistry 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
X 
X 
ECG 
 
 
 
X 
 
Pregnancy testingd 
X 
X 
X 
X 
X 
IGRA Tuberculosis test 
 
 
 
X 
 
Tuberculosis questionnaire 
 
 
 
X 
X 
Blood sample for bimekizumab plasma concentrationse 
X 
X 
X 
X 
X 
Blood sample for anti-bimekizumab antibodiese 
X 
X 
X 
X 
X 
Blood sample for genomic, proteomic, metabolomics, and , candidate 
biomarker analysese 
X 
 
 
X 
 
Blood sample for genetic/epigenetic analysese 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
DLQI 
X 
X 
 
X 
 
PHQ-9 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 130 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
scalp IGAf 
X 
X 
 
X 
 
mNAPSIg 
X 
 
 
X 
 
pp-IGAh 
X 
X 
 
X 
 
EQ-5D-3L 
X 
 
 
X 
 
SF-36 
X 
 
 
X 
 
Patient Global Assessment of PSOi 
X 
 
 
X 
 
PASE 
X 
 
 
X 
 
PGADAj 
X 
 
 
X 
 
WPAI-SHP V2.0 
X 
 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
IRT 
X 
X 
X 
X 
X 
Bimekizumab administrationk 
X 
X 
X 
 
 
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ-5D-3L=Euro-Quality of Life 5-Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; SF-36=Short Form 36-item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis; 
WPAI-SHP=Work Productivity and Activity Impairment Questionnaire-specific health problem 
a Visit windows of +/- 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose. 
c Vital signs (blood pressure, pulse rate, and temperature) are to be measured prior to blood sampling, and prior to dosing, where applicable. 
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug. 
e All blood samples taken prior to dosing. 
i During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window. 
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 131 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline. 
h The pp-IGA will only be assessed in subjects with palmoplantar involvement at Baseline. 
i The PGADA is assessed only for subjects with PsA at Baseline. 
k The minimum time between doses should be no less than 24 days and no more than 32 days. 
Has been changed to: 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
eC-SSRS 
X 
X 
X 
X 
X 
Urine drug screen 
 
 
 
X 
 
Physical exam 
 
 
 
X 
X 
Body Weight 
X 
 
 
X 
 
Vital signsc 
X 
X 
X 
X 
X 
Hematology and biochemistry 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
X 
X 
ECG 
 
 
 
X 
 
Pregnancy testingd 
X 
X 
X 
X 
X 
IGRA Tuberculosis test 
 
 
 
X 
 
Tuberculosis questionnaire 
 
 
 
X 
X 
Blood sample for bimekizumab plasma concentrationse 
X 
X 
X 
X 
X 
Blood sample for anti-bimekizumab antibodiese 
X 
X 
X 
X 
X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 132 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
Blood sample for genomic, proteomic, metabolomics, and , candidate 
biomarker analysese 
X 
 
 
X 
 
Blood sample for genetic/epigenetic analysese 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
 
PHQ-9 
X 
X 
X 
X 
 
scalp IGAf 
X 
X 
X 
X 
 
mNAPSIg 
X 
X 
X 
X 
 
pp-IGAh 
X 
X 
X 
X 
 
EQ-5D-3L 
X 
 
 
X 
 
SF-36 
X 
 
 
X 
 
Patient Global Assessment of PSOi 
X 
 
 
X 
 
PASE 
X 
 
 
X 
 
PGADAj 
X 
X 
X 
X 
 
WPAI-SHP V2.0 
X 
 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
IRT 
X 
X 
X 
X 
X 
Bimekizumab administrationk 
X 
X 
X 
 
 
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ-5D-3L=Euro-Quality of Life 5-Dimensions, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 133 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
                 Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; SF-36=Short Form 36-item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis; 
WPAI-SHP=Work Productivity and Activity Impairment Questionnaire-specific health problem 
a Visit windows of +/- 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enrolled in the open-label study. 
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug. 
e All blood samples taken prior to dosing. 
f During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion  
f  The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline. 
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline. 
h The pp-IGA will only be assessed in subjects with palmoplantar involvement at Baseline. 
i The PGADA is assessed only for subjects with PsA at Baseline. 
k   The dosing window is ±7 days relative to the scheduled dosing visit. The minimum time between doses should be no less than 24 days and no more 
than 32 days. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 134 of 209 
Change #20  
Figure 5-1 Schematic diagram 
 
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safety Follow-Up 
Note: Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will be allocated to an escape arm and receive open-label 
bimekizumab 320mg Q4Wfor 12 weeks 
          Bimekizumab 320mg Q8W
Bimekizumab 
320mg Q4W
Screening
N=240
N=80
Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long-term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study
12-week, open-label escape 
arm: Bimekizumab 
320mg Q4W
Bimekizumab 320mg Q4W
Randomized - Withdrawal Period
<PASI90
<PASI90
          Placebo Q4W
  PASI90
Randomize 
1:1:1
relapse
Week
16
Co-Primary 
Endpoint: PASI90 
Response
IGA response
Randomization
56
Baseline
N=560
Relapse: <PASI75 at 
Week 20 or later
Ustekinumab
  PASI90
N=240
12-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20
          Bimekizumab 320mg Q8W
          Bimekizumab 320mg Q4W
  PASI90
Randomize 
1:1
<PASI50: Mandatory study withdrawal at Week 28 
or later
28
      Placebo
         Placebo Q4W
  PASI90
<PASI90
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 135 of 209 
Note: Subjects who do not achieve a PASI90 response at Week 16 will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4W for 
12 weeks 
Note: Relapse is defined as not achieving a PASI75 response. Subjects in the bimekizumab 320 Q4W treatment arm in the Initial Treatment Period who get re-
randomized at Week 16 and who relapse at Week 20 or later will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4Wfor 12 weeks. 
Note: Subjects in either the ustekinumab treatment arm or the placebo treatment arm in the Initial Treatment Period who get re-randomized at Week 16 and who 
do not achieve a PASI50 response at Week 28 or later will be withdrawn from the study at the time point when the PASI50 response is not achieved. 
Has been changed to: 
          Bimekizumab 320mg Q8W
Bimekizumab 
320mg Q4W
Screening
N=320
Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long-term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study
          Bimekizumab 320mg Q4W
Randomized - Withdrawal Period
<PASI90
          Placebo Q4W
  PASI90
Randomize 
1:1:1
relapse
Week
16
Co-Primary 
Endpoint: PASI90 
Response
IGA response
Randomization
56
Baseline
N=400
Relapse: <PASI75 at 
Week 20 or later
Placebo
  PASI90
N=80
12-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20
          Placebo
28
<PASI90
relapse
Relapse: <PASI75 at 
Week 20 or later
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safety Follow-Up 
Note: Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will be allocated to an escape arm and receive open-
label bimekizumab 320mg Q4Wfor 12 weeks 
Note: Subjects who do not achieve a PASI90 response at Week 16 will be allocated to an escape arm and receive open-label bimekizumab 320mg Q4Wfor 
12 weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 136 of 209 
Note: Relapse is defined as not achieving a PASI75 response. All subjects in the bimekizumab 320mg Q4W and ustekinumab treatment arms in the Initial 
Treatment Period who get re-randomized at Week 16 and who relapse at Week 20 or later will be allocated to an escape arm and receive open-label 
bimekizumab 320mg Q4Wfor 12 weeks. 
Note: Subjects in either the ustekinumab treatment arm or the placebo treatment arm in the Initial Treatment Period will continue to receive placebo Q4W 
at Week 16 and later visits provided a PASI90 response was achieved at Week 16who get re-randomized at Week 16 and who do not achieve a PASI50 
response at Week 28 or later will be withdrawn from the study at the time point when the PASI50 response is not achieved. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 137 of 209 
Change #21 
Section 5.8.1 Study design 
A randomized, double-blind, placebo- and active-controlled study design has been selected in 
order to demonstrate efficacy and safety of bimkeizumab for regulatory approval. The study 
population will include adults with moderate to severe chronic plaque PSO and allow subjects 
who have received previous biologic treatment as well as those who are biologic treatment naïve. 
The primary efficacy outcome measures (based on PASI and IGA) and other efficacy 
assessments included in this study are consistent with those used for other PSO studies and are 
considered appropriate for establishing efficacy of bimekizumab. An initial treatment period of 
16 weeks will be used to demonstrate the efficacy of bimekizumab over PBO and ustekinumab. 
The study duration extends beyond the initial treatment period (to 56 weeks) to collect 
information on dosing beyond initial treatment, including the impact on efficacy and safety of 
withdrawing bimekizumab treatment from those who responded at Week 16. 
At Week 16, subjects on ustekinumab treatment are re-allocated to treatment with bimekizumab 
320mg Q4W or Q8W. This allows for a controlled evaluation of the safety and efficacy of 
switching from a product with one mechanism of action to another, which is known to occur in 
clinical practice due to either loss of response or access. In a recent PSO study in which subjects 
underwent a switch to a treatment with a different mechanism of action there was no evidence of 
an increased safety risk following the switch (Reich 2017). 
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PASI90). Subjects 
who do not achieve a PASI90 response at Week 16 are allocated to a 12-week escape treatment 
with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a PASI90 on placebo or 
ustekinumab to the bimekizumab 320mg Q4W escape arm provides them with the opportunity to 
potentially achieve a higher level of efficacy. Beyond just achieving a higher level of skin 
clearance, there is evidence that PASI90 is associated with higher levels of patient satisfaction 
(as measured by DLQI) compared with a lower PASI75 threshold (Puig et al, 2017). If Week 16 
PASI90 responders initially randomized to ustekinumab or placebo lose response over time, the 
mandatory withdrawal criterion for subjects who do not achieve a PASI50 response at Week 28 
or later will ensure that subjects do not continue to receive prolonged exposure to study 
treatment that is providing a sub-optimal response, regardless of their initial randomized 
treatment. 
Has been changed to: 
A randomized, double-blind, placebo- and active-controlled study design has been selected in 
order to demonstrate efficacy and safety of bimekizumab for regulatory approval. The study 
population will include adults with moderate to severe chronic plaque PSO and allow subjects 
who have received previous biologic treatment as well as those who are biologic treatment naïve. 
The primary efficacy outcome measures (based on PASI and IGA) and other efficacy 
assessments included in this study are consistent with those used for other PSO studies and are 
considered appropriate for establishing efficacy of bimekizumab. An initial treatment period of 
16 weeks will be used to demonstrate the efficacy of bimekizumab over placeboPBO and 
ustekinumab. The study duration extends beyond the initial treatment period (to 56 weeks) to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 138 of 209 
collect information on dosing beyond initial treatment, including the impact on efficacy and 
safety of withdrawing bimekizumab treatment from those who responded at Week 16. 
At Week 16, subjects on ustekinumab treatment are re-allocated to treatment with 
bimekizumab 320mg Q4W or Q8W. This allows for a controlled evaluation of the safety 
and efficacy of switching from a product with one mechanism of action to another, which is 
known to occur in clinical practice due to either loss of response or access. In a recent PSO 
study in which subjects underwent a switch to a treatment with a different mechanism of 
action there was no evidence of an increased safety risk following the switch (Reich 2017). 
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PASI90). Subjects 
who do not achieve a PASI90 response at Week 16 in PS0013 are allocated to a 12-week escape 
treatment with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a PASI90 on 
placebo or ustekinumab to the bimekizumab 320mg Q4W escape arm provides them with the 
opportunity to potentially achieve a higher level of efficacy. Beyond just achieving a higher level 
of skin clearance, there is evidence that PASI90 is associated with higher levels of patient 
satisfaction (as measured by DLQI) compared with a lower PASI75 threshold (Puig et al, 2017). 
If Week 16 PASI90 responders initially randomized to ustekinumab or placebo lose 
response over time, the mandatory withdrawal criterion for subjects who do not achieve a 
PASI50 response at Week 28 or later will ensure that subjects do not continue to receive 
prolonged exposure to study treatment that is providing a sub-optimal response, regardless 
of their initial randomized treatment.All subjects who relapse at Week 20 or later will be 
allocated to an escape arm and receive open-label bimekizumab 320mg Q4Wfor 12 weeks. 
Subjects in the placebo treatment arm in the Initial Treatment Period who are >PASI90 at 
Week 16 and >PASI75 at Week 20 or later will continue to receive placebo at Week 16 and 
later visits.  
  
Change #22 
Section 6.1 Inclusion criterion #6 
6. Subject has a known hypersensitivity to any excipients of bimekizumab or ustekinumab. 
Has been changed to: 
6. Subject has a known hypersensitivity to any excipients of bimekizumab or ustekinumab. 
 
Change #23 
Section 6.1 Inclusion criterion #7 
The following criterion has been deleted: 
7. Subject must be considered, in the opinion of the Investigator, to be a suitable candidate for 
treatment with ustekinumab per regional labeling and has no contraindications to receive 
ustekinumab as per the local label. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 139 of 209 
Change #24 
Section 6.2 
Exclusion criterion #21 
The following criteria have been deleted: 
21. Subject has had previous exposure to ustekinumab. 
22. Subject has been exposed to more than 3 biological response modifiers (including no more 
than 1 IL-17). 
 
Change #25 
Section 6.2 Exclusion criterion #23 
23. Subject has experienced one primary failure to an IL-17 biological response modifier (no 
response within 12 weeks). 
Has been changed to: 
23. Subject has experienced one primary failure to an IL-17 biological response modifier (no 
response within 12 weeks) to 1 or more  IL-17 biologic response modifier (eg, 
brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier 
other than an IL-17. 
 
Change #26 
Section 6.2 Exclusion criterion #27 
27. Subject has presence of severe depression, indicated by a score ≥15 using the screening 
PHQ-9. Medication used to treat depression should be stable for 4 weeks prior to baseline. 
Has been changed to: 
27. Subject has presence of severe depression, indicated by a score ≥of 15 to 19 using the 
screening Patient Health Questionnaire 9 (PHQ-9). Medication used to treat depression 
should be stable for 4 weeks prior to Baseline. 
 
Change #27 
Section 6.3 Withdrawal criterion #3  
The following criterion has been deleted: 
3. Subject who was in the ustekinumab or placebo arm in the Initial Treatment Period does not 
achieve a PASI50 response at Week 28 or later. 
 
Change #28 
Section 6.3 Withdrawal criterion #8  
The following criterion has been deleted: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 140 of 209 
8. Subjects who do not achieve at least a PASI50 response after 12 weeks of escape treatment 
should be withdrawn (see Section 5.2.5), and will have a SFU Visit 20 weeks after their last 
dose of IMP. 
 
Change #29 
Section 6.3 Withdrawal Criteria, Mental Health Criterion #2 
2. Moderately severe depression as indicated by a PHQ-9 score ≥ 15 if this represents an 
increase of 3 points compared to last visit. 
Has been changed to: 
2. Moderately severe depression as indicated by a PHQ-9 score ≥of 15 to 19 if this represents 
an increase of 3 points compared to last visit. 
 
Change #30 
Section 7.1 Treatment(s) to be administered 
The IMPs used in this study are bimekizumab, ustekinumab, and placebo. 
 Bimekizumab will be supplied in a 
 
 for sc 
injection. 
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection. 
 Ustekinumab is commercially available and will be supplied in a 0.5mL PFS at a 
concentration of 45mg/0.5ml. 
Has been changed to: 
The IMPs used in this study are bimekizumab, ustekinumab, and placebo. 
 Bimekizumab will be supplied in a 
 
 for sc 
injection. 
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection. 
 Ustekinumab is commercially available and will be supplied in a 0.5mL PFS at a 
concentration of 45mg/0.5ml. 
 
Change #31 
Section 7.2 Treatment(s) to be administered 
Double-blind Initial Treatment Period dosing 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 141 of 209 
Because of differences in the dosing schedule between bimekizumab and ustekinumab, all 
subjects will receive 2 injections sc Q4W based on the following dosing scheme: 
 Subjects randomized to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W. 
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline and 
Week 4, followed by placebo (2 placebo injections sc) at Week 8 and Week 12. Because 
ustekinumab dosing is based on weight, on ustekinumab treatment weeks subjects ≤100kg 
(220lbs) will receive 1 ustekinumab 45mg sc injection and 1 placebo injection and subjects 
>100kg (220lbs) will receive 2 ustekinumab 45mg sc injections. 
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W. 
Randomized-Withdrawal Period dosing 
Investigational medicinal product treatment during the Randomized-Withdrawal Period will be 
based on treatment group assignment at randomization (see Section 5.2.3). 
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W. 
 Subjects reallocated to receive bimekizumab 320mg Q8W will alternate between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by placebo (2 
placebo injections sc). 
 Subject who are to receive placebo will receive 2 placebo injections sc Q4W. 
Subjects who do not achieve a PASI90 response at Week 16 and subjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse at 
Week 20 or later during the Randomized-Withdrawal Period (up to Week 56) will receive open-
label bimekizumab 320mg Q4W for 12 weeks (escape treatment, see Section 5.2.5). 
The dosing scheme is depicted in Table 7-1.  
Subjects who do not achieve a PASI90 response at Week 16 and all subjects who relapse at 
Week 20 or later during the Randomized-Withdrawal Period (up to Week 56) will receive open-
label bimekizumab 320mg Q4W for 12 weeks (escape treatment, see Section 5.2.5). 
The dosing scheme is depicted in Table 7‒1.  
Table 7-1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
Bimekizumab 320mg 
Q4W/Q4W 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
Bimekizumab 320mg 
Q4W/Q8W 
●● 
●● 
●● 
●● 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
Ustekinumab 45mg 
(subjects ≤100kg) 
▲○ 
▲○ 
○○ 
○○ 
n/a 
Ustekinumab 90mg 
▲▲ 
▲▲ 
○○ 
○○ 
n/a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 142 of 209 
Table 7-1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
(subjects >100kg) 
Placebo 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks 
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).A ustekinumab 45mg injection is depicted by a black triangle (▲). 
Note: Subjects who do not achieve a PASI90 response at Week 16 and and subjects who were in the bimekizumab 
320mg Q4W treatment arm in the Initial Treatment Period and who relapse (defined not achieving a PASI75 
response at Week 20 or later) during the Randomized-Withdrawal Period (up to Week 52) will receive open-label 
bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). 
Has been changed to: 
Double-blind Initial Treatment Period dosing 
Because of differences in the dosing schedule between bimekizumab and ustekinumab, all 
subjects will receive 2 injections sc Q4W based on the following dosing scheme: 
 Subjects randomized to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W. 
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline 
and Week 4, followed by placebo (2 placebo injections sc) at Week 8 and Week 12. 
Because ustekinumab dosing is based on weight, on ustekinumab treatment weeks 
subjects ≤100kg (220lbs) will receive 1 ustekinumab 45mg sc injection and 1 placebo 
injection and subjects >100kg (220lbs) will receive 2 ustekinumab 45mg sc injections. 
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W. 
Randomized-Withdrawal Period dosing 
Investigational medicinal product treatment during the Randomized-Withdrawal Period will be 
based on treatment group assignment at randomization (see Section 5.2.3). 
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W. 
 Subjects reallocated to receive bimekizumab 320mg Q8W will alternate between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by placebo (2 
placebo injections sc). 
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 
at Week 16 and ≥PASI75 at Week 20 or later will continue to receive placebo Q4W at 
Week 16 and later visitswho are to receive placebo will receive 2 placebo injections sc 
Q4W. 
Subjects who do not achieve a PASI90 response at Week 16 and all subjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse 
at Week 20 or later during the Randomized-Withdrawal Period (up to Week 56) will receive 
open-label bimekizumab 320mg Q4W for 12 weeks (escape treatment, see Section 5.2.5). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 143 of 209 
The dosing scheme is depicted in Table 7-1.  
Table 7-1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
Bimekizumab 320mg 
Q4W/Q4W 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
Bimekizumab 320mg 
Q4W/Q8W 
●● 
●● 
●● 
●● 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
Placebo 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks 
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).A ustekinumab 45mg injection is depicted by a black triangle (▲). 
Note: Subjects who do not achieve a ≥PASI90 response at Week 16 and andallsubjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse (defined not 
achieving a ≥PASI75 response at Week 20 or later) during the Randomized-Withdrawal Period (up to Week 52) 
will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Period that are >PASI90 at Week 16 and >PASI 75 at Week 20 or 
later will continue to receive placebo Q4W at Week 16 and later visits. 
 
Change #32 
Section 7.3 Packaging 
Bimekizumab, ustekinumab, and placebo will be packaged and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP 
Handling Manual. 
Has been changed to: 
Bimekizumab, ustekinumab, and placebo will be packaged and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP 
Handling Manual. 
 
Change #33 
Section 7.4 Labeling 
Bimekizumab, ustekinumab, and placebo will be labeled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
GMP and will include any locally required statements. If necessary, labels will be translated into 
the local language. 
Has been changed to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 144 of 209 
Bimekizumab, ustekinumab, and placebo will be labeled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
GMP and will include any locally required statements. If necessary, labels will be translated into 
the local language. 
 
Change #34 
Table 7-2 Prohibited PSO medications 
Anti-TNFs: 
adalimumab (including biosimilar) 
etanercept (including biosimilar) 
infliximab (including biosimilar), golimumab, 
certolizumab pegol 
 
Any exposure to adalimumab 
1 month for etanercept 
3 months for everything other than 
etanercept and adalimumab 
Other biologics and other systemic therapies: 
ustekinumab 
apremilast, tofacitinib 
alefacept, efalizumab, guselkimab 
 
briakinumab 
rituximab 
 
Any exposure for ustekinumab 
2 weeks for apremilast and tofacitinib 
3 months for alefacept, efalizumab, and 
guselkimab 
6 months for ustekinumab and briakinumab 
12 months for rituximab 
Anti-IL-17 therapy 
 
3 months 
(bimekizumab is excluded per exclusion 
criteria) 
Has been changed to: 
Anti-TNFs: 
adalimumab (including biosimilar) 
etanercept (including biosimilar) 
infliximab (including biosimilar), golimumab, 
certolizumab pegol, adalimumab (including 
biosimilar) 
 
Any exposure to adalimumab 
1 month for etanercept 
3 months for everything other than 
etanercept and adalimumab 
Other biologics and other systemic therapies: 
ustekinumab 
apremilast, tofacitinib 
alefacept, efalizumab, guselkumab 
 
briakinumab 
rituximab 
 
6 monthsAny exposure for ustekinumab 
2 weeks for apremilast and tofacitinib 
3 months for alefacept, efalizumab, and 
guselkumab 
6 months for ustekinumab and 
briakinumab 
12 months for rituximab 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 145 of 209 
Anti-IL-17 therapy 
brodalumab 
ixekizumab 
secukinumab 
3 months 
(bimekizumab is excluded per exclusion 
criteria) 
 
Change #35 
Section 7.8.1 Permitted concomitant treatments (medications and therapies) 
The following has been deleted: 
The following concomitant medications are permitted during the study. 
 
Change #36 
Section 7.9 Blinding 
The following paragraph has been deleted: 
Due to differences in presentation between bimekizumab and ustekinumab, special precautions 
will be taken to ensure study blinding and study sites will have blinded and unblinded personnel. 
 
Change #37 
Section 7.9.1.1 Maintenance of the IMP blind 
All subject treatment details (bimekizumab, ustekinumab, or placebo) will be allocated and 
maintained by the IRT system. 
Has been changed to: 
All subject treatment details (bimekizumab, ustekinumab, or placebo) will be allocated and 
maintained by the IRT system. 
 
Change #38 
Section 7.10 Randomization and numbering of subjects 
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule. Efforts should be made to limit the enrollment of subjects with 
prior biologic exposure to approximately 30% of the total study population. 
Has been changed to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 146 of 209 
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule. Efforts should be made to limit the enrollment of subjects 
with prior biologic exposure to approximately 30% of the total study population. 
 
Change #39 
Section 7.10 Randomization and numbering of subjects 
At Week 16, subjects may be reallocated to a new treatment group based on their PASI response. 
Has been changed to: 
At Week 16, subjects who received bimekizumab Q4W during the Initial Treatment Period 
may be reallocated to a new treatment group based on their PASI response. 
 
Change #40 
Section 8 Study Procedures by Visit 
The minimum time between doses should be no less than 21 days and no more than 35 days. 
Has been changed to: 
The dosing window is ±7 days relative to the scheduled dosing visit. The minimum time 
between doses should be no less than 21 days and no more than 34 days. 
 
Change #41 
Section 8.1 Screening Visit (2 to 4 Weeks) and Section 8.2.5 Week 16 (±3 days relative to 
Baseline) 
The following bullets have been added: 
 Percentage of BSA 
 Patient Symptom Diary (daily)  
 
Change #42 
Section 8.2.1 Baseline Visit, Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline), 
Section 8.2.3 Weeks 4 and 8 (±3 days relative to Baseline), Section 8.2.4 Week 12 (±3 days 
relative to Baseline), Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days 
relative to Baseline), Section 8.3.2 Week 56 (±3 days relative to Baseline), Section 8.4.1 
Escape Baseline Visit, Section 8.4.2 Escape Weeks 4 and 8 (±3 days), Section 8.4.3 Escape 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 147 of 209 
Visit-Week 12/Premature End of Treatment (±3 days relative to Baseline), and Section 8.6 
Safety Follow-Up Visit (20 weeks after last dose, -3 days/+7 days) 
The following bullet has been added: 
 Percentage of BSA 
 
Change #43 
Section 8.2.1 Baseline Visit 
After completion of the above-mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur. 
Has been changed to: 
After completion of the above-mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur. 
 
Change #44 
Section 8.2.1 Baseline Visit 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses  
 Genetic/epigenetic analysis 
 PGADA (only for subjects with PsA) 
Has been changed to: 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (participating 
subjects only) 
 Genetic/epigenetic analysis (participating subjects only) 
 PGADA (only for subjects with PsA) 
 
Change #45 
Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline) 
The following bullet has been deleted: 
 pp-IGA 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 148 of 209 
Change #46 
Section 8.2.3 Weeks 4 and 8 (±3 days relative to Baseline) 
The following bullet has been added: 
 PGADA (Week 4 only) 
 
Change #47 
Section 8.2.3 Weeks 4 and 8 (±3 days relative to Baseline) 
After completion of the above-mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur. 
Has been changed to: 
After completion of the above-mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur. 
 
Change #48 
Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline), Section 8.2.3 Weeks 4 and 8 (±3 
days relative to Baseline), Section 8.2.4 Week 12 (±3 days relative to Baseline), Section 8.2.5 
Week 16 (±3 days relative to Baseline), Section 8.3.2 Week 56 (±3 days relative to Baseline), 
Section 8.4.1 Escape Baseline Visit, and Section 8.4.3 Escape Visit-Week 12/Premature End 
of Treatment (±3 days relative to Baseline) 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (Week 1 only)  
Has been changed to: 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genomic, proteomic, metabolomics, and candidate biomarker analyses (Week 1 only) 
(participating subjects only) 
 
Change #49 
Section 8.2.5 Week 16 (±3 days relative to Baseline) 
After completion of the above-mentioned procedures, administration of bimekizumab or placebo 
will occur. 
Has been changed to: 
After completion of the above-mentioned procedures, the Randomized-Withdrawal Period will 
begin with administration of bimekizumab or placebo will occur. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 149 of 209 
 
Change #50 
Section 8.2.5 Week 16 (±3 days relative to Baseline), Section 8.3.1 8.3.1 Weeks 20, 24, 28, 32, 
36, 40, 44, 48, and 52 (±3 days relative to Baseline), Section 8.3.2 Week 56 Visit (±3 days 
relative to Baseline), and Section 8.4.1 Escape Baseline Visit 
 PGADA (only for subjects with PsA)  
Has been changed to: 
 PGADA (only for subjects with PsA at Baseline)  
 
Change #51 
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline) 
 DLQI (Weeks 20, 28, 40, and 48 only) 
Has been changed to: 
 DLQI (Weeks 20, 248, 32, 40, and 48 only) 
 
Change #52 
Section 8.3.2 Week 56 (±3 days relative to Baseline) and Section 8.4.3 Escape Visit-Week 
12/Premature End of Treatment (±3 days relative to Baseline) 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genetic/epigenetic analysis  
Has been changed to: 
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing: 
 Genetic/epigenetic analysis (participating subjects only) 
 
Change #53 
Section 8.4 Escape Treatment Period 
As described in Section 5.2.3, subjects who do not achieve a PASI90 response at Week 16 and 
subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treatment 
Period and who relapse (defined as not achieving a PASI75 response) at Week 20 or later during 
the Randomized-Withdrawal Period (up to Week 56) will receive open-label bimekizumab 
320mg Q4W for 12 weeks (ie, escape treatment). 
Has been changed to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 150 of 209 
As described in Section 5.2.3, subjects who do not achieve a PASI90 response at Week 16 and 
all subjects who relapse at Week 20 or later will be allocated to an escape arm and receive 
open-label bimekizumab 320mg Q4W for 12 weeks subjects who were in the bimekizumab 
320mg Q4W treatment arm in the Initial Treatment Period and who relapse (defined as not 
achieving a PASI75 response) at Week 20 or later during the Randomized-Withdrawal 
Period (up to Week 56) will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, 
escape treatment). Subjects should complete all visit procedures for their scheduled 
treatment visit and then only complete unique procedures for the escape baseline visit. No 
duplicate assessments should be performed when a subject enters the escape arm. 
 
Change #54 
Section 8.4.2 Escape Weeks 4 and 8 (±3 days) 
 Scalp IGA for subjects with scalp involvement at Baseline (Week 4 only) 
 pp-IGA for subjects with palmoplantar involvement at Baseline (Week 4 only) 
 Concomitant medication 
Has been changed to: 
 Scalp IGA for subjects with scalp involvement at Baseline (Week 4 only) 
 mNAPSI for subjects with nail involvement at Baseline 
 pp-IGA for subjects with palmoplantar involvement at Baseline (Week 4 only) 
 PGADA for subjects with PsA at Baseline 
 Concomitant medication 
 
Change #55 
Section 9 Assessment of Efficacy 
The following text has been added: 
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably the same assessor should evaluate the subject at each 
assessment. 
 
Change #56 
Section 9.1 Psoriasis Area and Severity Index 
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a 
given region as a percentage (0-100%) which will then be mapped into a grade on a scale of 0-6 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 151 of 209 
(0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 4=50% to 
<70% affected, 5=70% to <90% affected, 6=90% to 100% affected) (Table 9-1). 
Has been changed to: 
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a 
given region as a percentage (0-100%) which will then be mapped into a grade on a scale of 
0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 
4=50% to <70% affected, 5=70% to <90% affected, 6=90% to 100% affected) (Table 9-1). 
 
Change #57 
Section 9.1 Psoriasis Area and Severity Index 
The total BSA affected by PSO will be derived based on the regional BSA values provided when 
assessing the PASI score. 
Has been changed to: 
The total BSA affected by PSO will be entered as a percentage from 0 to 100.derived based 
on the regional BSA values provided when assessing the PASI score. 
 
Change #58 
Section 9.4 Patient Health Questionnaire 9 
A of 15 to 19 is considered to indicate moderately severe major depression, and a score >20 is 
considered to be severe major depression. 
Has been changed to: 
A score of 15 to 19 is considered to indicate moderately severe major depression, and a score 
≥20 is considered to be severe major depression. 
 
Change #59 
Section 9.11 Patient Symptom Diary responses 
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
participating subjects on the use of the electronic PRO (ePRO) diary at the BaselineVisit, 
following which the device will be dispensed to the subject for home use until the Week 16 Visit. 
The ePRO diary will be administered on a daily basis from Baseline to the Week 16 Visit. 
Has been changed to: 
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 152 of 209 
participating subjects on the use of the electronic PRO (ePRO) diary at the ScreeningBaseline 
Visit, following which the device will be dispensed to the subject for home use until the Week 16 
Visit. The ePRO diary will be administered on a daily basis from ScreeningBaseline to the 
Week 16 Visit. 
 
Change #60 
Section 9.14 WPAI-SHP V2.0 
The section has been deleted: 
The WPAI SHP V2.0 is a patient-reported questionnaire that assesses subject’s employment 
status, work absenteeism, work impairment while working (presenteeism), overall work, and 
daily activity impairment attributable to a specific health problem (WPAI:SHP) (Reilly et al, 
1993). It has been used in several clinical studies of biologic therapy in subjects with plaque PSO 
(Kimball et al, 2012; Vender et al, 2012). 
Five out of 6 items of the WPAI-SHP are regrouped into the 4 dimensions, with scores expressed 
as percentage, where higher numbers indicate greater impairment and less productivity, ie, worse 
outcomes, as described in the WPAI-SHP scoring rules. 
The WPAI-SHP V2.0 will be assessed at the visits specified in Table 5‒1 and Table 5‒2. 
 
Change #61 
Section 10.1 Pharmacokinetic variables 
The following text has been deleted: 
Pharmacokinetic samples from subjects receiving ustekinumab will not be analyzed, but stored 
for potential future PK analysis and anti-drug antibody determination. 
 
Change #62 
Section 12.1.1.4 Other safety topics of interest 
The following paragraph has been deleted: 
The following safety topics are prespecified as being of interest for this study, based on findings 
from the IMP clinical program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medicines belonging to the same class of drugs. 
There are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activities, and/or enhanced signal detection activities (within UCB), are 
in place. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 153 of 209 
Change #63 
Section 12.2 Laboratory measurements 
Clinical laboratory assessments consist of serum chemistry, hematology, and urinalysis. A 
centralized laboratory will be used to supply all laboratory test supplies and analyze all blood 
and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using the central laboratory. Testing to rule out 
hepatitis B, hepatitis C, and HIV (see Exclusion Criterion #9, Section 6.2) will be performed at 
Screening in addition to those measurements listed in Table 12-2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals. 
The following laboratory parameters will be measured: 
Table 12-2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Basophils 
Calcium 
pH 
Eosinophils 
Chloride 
Albumin (protein) 
Lymphocytes 
Magnesium 
Glucose 
Atypical lymphocytes 
Potassium 
Blood 
Monocytes 
Sodium 
Leukocyte esterase 
Neutrophils 
Glucose 
Nitrite 
Hematocrit 
BUN 
 
Hemoglobin 
Creatinine 
Urine dipstick for pregnancy testingb 
MCH 
ALP 
 
MCHC 
AST 
 
MCV 
ALT 
 
Platelet count 
GGT 
 
RBC count 
Total bilirubin 
 
WBC count 
LDH 
 
 
Serum pregnancy testingb 
 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; ; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; 
WBC=white blood cell 
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates. 
b Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits. 
Has been changed to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 154 of 209 
Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen. A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all blood and urine samples for hematology, biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion #9, Section 6.2) will be 
performed at Screening in addition to those measurements listed in Table 12-2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals. 
The following laboratory parameters will be measured: 
Table 12-2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Basophils 
Calcium 
pH 
Eosinophils 
Chloride 
Albumin (protein) 
Lymphocytes 
Magnesium 
Glucose 
Atypical lymphocytes 
Potassium 
Blood 
Monocytes 
Sodium 
Leukocyte esterase 
Neutrophils 
Glucose 
Nitrite 
Hematocrit 
BUN 
Urine dipstick for pregnancy testingb 
Hemoglobin 
Creatinine 
Urine drug screenc 
MCH 
ALP 
 
MCHC 
AST 
 
MCV 
ALT 
 
Platelet count 
GGT 
 
RBC count 
Total bilirubin 
 
WBC count 
LDH 
 
 
Serum pregnancy testingb 
 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; PEOT=Premature End of 
Treatment; RBC=red blood cell; WBC=white blood cell 
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates. 
b Pregnancy testing will consist of serum testing at the Screening Visit. The pregnancy test will be urine at all other 
visits. 
c Urine drug screen will be performed at Screening Visit, and Week 56 or PEOT Visit. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 155 of 209 
Change #64 
Section 12.3.1 Assessment and management of TB and TB risk factors, Item d 
d. Current or history of NTMB infection despite prior or current therapy. 
Has been changed to: 
d. NTMB infection is defined as a clinical infection caused by mycobacterial species other 
than those belonging to the Mycobacterium tuberculosis complexCurrent or history of 
NTMB infection despite prior or current therapy. 
 
Change #65 
Section 12.3.1.1 Tuberculosis assessment by IGRA 
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5-1  and Table 5-2 for all subjects. The 
test results will be reported as positive, negative, or indeterminate. Positive TB test results must 
be reported as an adverse event and appropriately updated once the final diagnosis is known (e.g. 
active TB, latent TB, or false positive TB test). UCB also recommends that a TB specialist be 
consulted where TB (latent or active) is suspected or if there are doubts regarding test results. If 
latent or active TB is identified, subject must undergo appropriate study-specified withdrawal 
procedures. The retest during Screening must be done during the protocol-defined Screening 
window. 
Has been changed to: 
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5-1 and Table 5-2 for all subjects. The 
test results will be reported as positive, negative, or indeterminate. Positive and indeterminate 
TB test results must be reported as an adverse event and appropriately updated once the final 
diagnosis is known (eg, active TB, latent TB, or false positive TB test). UCB also recommends 
that a TB specialist be consulted where TB (latent or active) is suspected or if there are doubts 
regarding test results. If latent or active TB is identified, subject must undergo appropriate study-
specified withdrawal procedures. The retest during Screening must be done during the protocol-
defined Screening window. 
 
Change #66 
Section 14.1 Definition of analysis sets 
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week 16 or 
experiencing a relapse after entering the Randomized-Withdrawal Period. 
The Week 16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week 16 and receive at least 1 dose of the IMP during the Randomized-Withdrawal 
Period at Week 16 or later. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 156 of 209 
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab or ustekinumab). The AMS will be used for summaries of safety 
that include all data from Baseline (Week 0) to Week 52. 
Has been changed to: 
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week 16 or 
experiencing a relapse after entering the Randomized-Withdrawal Period. Summaries based on 
the ESS will be split between subjects who enter the escape arm: 1) due to PASI90 non-
response at Week 16 or 2) due to relapse during the Maintenance Period (after achieving 
PASI90 response at Week 16). 
The Week 16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week 16 and receive at least 1 dose of the IMP during the Randomized-Withdrawal 
Period at Week 16 or later. 
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab or ustekinumab). The AMS will be used for summaries of safety 
that include all data from the Initial Treatment Period and/or Randomized-Withdrawal 
PeriodBaseline (Week 0) to Week 52. 
 
Change #67 
Section 14.2 General statistical considerations 
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo, or for non-inferiority or superiority relative to 
ustekinumab. Note that while subjects randomized to ustekinumab may receive either the 45mg 
or 90mg dose (according to weight at Baseline), all subjects randomized to ustekinumab will be 
analyzed as a single group (and not broken out by dose) since the proposed strategy is consistent 
with the recommended weight-based dosing for ustekinumab. See Figure 14-1 for details on this 
procedure. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 157 of 209 
 
Has been changed to: 
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo, or for non-inferiority or superiority 
relative to ustekinumab. Note that while subjects randomized to ustekinumab may receive 
either the 45mg or 90mg dose (according to weight at Baseline), all subjects randomized to 
ustekinumab will be analyzed as a single group (and not broken out by dose) since the 
proposed strategy is consistent with the recommended weight-based dosing for 
ustekinumab. See Figure 14-1 for details on this procedure. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 158 of 209 
 
Change #68 
Section 14.3.1.1 Sensitivity analyses 
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 21 subjects will be considered acceptable for a center to be included in the model 
without pooling. Given the 3:3:1 randomization allocation scheme, this should provide a 
minimum of about 9 subjects in each of the bimekizumab and ustekinumab arms and 3 subjects 
in the placebo arm. Centers with fewer than 21 subjects will be eligible for pooling. 
The following center pooling algorithm will be used for each geographic region: 
 If a center has 21 or more subjects, then no pooling will be done for that center. 
 Centers with fewer than 21 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner: 
 Two or more centers will be combined until the cumulative subject total is at least 21. 
 Once a pooled center has at least 21 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 21 subjects has been reached in the previous pool. 
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 21 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration. 
Has been changed to: 
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 1521 subjects will be considered acceptable for a center to be included in the model 
without pooling. Given the 4:3:3:1 randomization allocation scheme, this should provide a 
minimum of about 129 subjects in each of the bimekizumab and ustekinumab arms and 3 
subjects in the placebo arm. Centers with fewer than 1521 subjects will be eligible for pooling. 
The following center pooling algorithm will be used for each geographic region: 
 If a center has 1521 or more subjects, then no pooling will be done for that center. 
 Centers with fewer than 1521 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner: 
 Two or more centers will be combined until the cumulative subject total is at least 1521. 
 Once a pooled center has at least 1521 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 1521 subjects has been reached in the previous pool. 
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 1521 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 159 of 209 
Change #69 
Section 14.3.2.1.1 Initial Treatment Period 
For the binary secondary efficacy variables assessing the superiority of bimekizumab versus 
placebo or ustekinumab, the stratified CMH test as specified for the primary analysis will be 
implemented. As in the primary analysis, NRI will be used to account for missing data. For the 
assessment of non-inferiority, a non-inferiority margin of 10% will be used and evaluated based 
on the confidence interval for the stratified Mantel-Haenszel risk difference between 
bimekizumab and ustekinumab. A non-inferiority margin of 10% has been selected as this is 
considered to be a clinically relevant difference that could influence the choice of interventions 
used to treat chronic plaque PSO. Therefore, a difference within the 10% non-inferiority margin 
would suggest a similar impact on efficacy between the treatments. 
Has been changed to: 
For the binary secondary efficacy variables assessing the superiority of bimekizumab versus 
placebo or ustekinumab, the stratified CMH test as specified for the primary analysis will be 
implemented. As in the primary analysis, NRI will be used to account for missing data. For the 
assessment of non-inferiority, a non-inferiority margin of 10% will be used and evaluated 
based on the confidence interval for the stratified Mantel-Haenszel risk difference between 
bimekizumab and ustekinumab. A non-inferiority margin of 10% has been selected as this 
is considered to be a clinically relevant difference that could influence the choice of 
interventions used to treat chronic plaque PSO. Therefore, a difference within the 10% 
non-inferiority margin would suggest a similar impact on efficacy between the treatments. 
 
Change #70 
Section 14.3.2.2 Analysis of the other efficacy variables 
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented using the Kaplan-Meier product-limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achieving a response 
will be censored at the date of IMP discontinuation. Subjects who reach the Week 16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week 16 Visit. The median time to response, including the 
2-sided 95% CI, will be calculated for each treatment. Between-group differences (bimekizumab 
vs placebo and bimekizumab vs ustekinumab)will be analyzed with the log-rank statistic. 
Has been changed to: 
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented using the Kaplan-Meier product-limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achieving a response 
will be censored at the date of IMP discontinuation. Subjects who reach the Week 16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week 16 Visit. The median time to response, including the 
2-sided 95% CI, will be calculated for each treatment. Between-group differences 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 160 of 209 
(bimekizumab vs placebo and bimekizumab vs ustekinumab)will be analyzed with the log-
rank statistic. 
 
Change #71 
Section 14.5.1  Safety analyses 
Safety variables will be analyzed for all subjects in the SS. Additional summaries focusing on 
safety during the Randomized-Withdrawal Period will also be prepared and will be based on the 
WK16ResS. 
Has been changed to: 
Safety variables will be analyzed for all subjects in the SS. The AMS will be used for 
summaries of safety that include data from the Initial Treatment Period and/or 
Randomized-Withdrawal Period. Additional summaries focusing on safety during the 
Randomized-Withdrawal Period will also be prepared and will be based on the WK16ResS. 
 
Change #72 
Section 14.9 Determination of sample size 
A total of 560 subjects will be randomly assigned in a 3:3:1 ratio to the following treatment 
groups: 
 Bimekizumab 320mg (240 subjects) 
 Ustekinumab (240 subjects) 
 Placebo (80 subjects) 
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co-
primary efficacy variables of PASI90 response and IGA response at Week 16. However, as 
described in Section 14.3.2.1.1 , Week 16 comparisons of bimekizumab against ustekinumab for 
PASI90 response and IGA response will also be part of a fixed sequence testing procedure to 
control for multiplicity. Therefore, this study has been powered to show statistical superiority to 
ustekinumab based on the co-primary endpoints. 
The assumed responder rates for PASI90 at Week 16 are 75%, 58%, and 2% for bimekizumab, 
ustekinumab, and placebo, respectively. Additionally, the assumed responder rates for IGA are 
85%, 68%, and 5% for bimekizumab, ustekinumab, and placebo, respectively. The assumed 
responder rates for bimekizumab are based on the Phase 2b PS0010 data. The assumptions 
related to the responder rates for ustekinumab are based on those observed in the CLEAR study 
(Thaci et al, 2015). The power to show statistical superiority of bimekizumab relative to placebo 
under these assumptions is >99% for the co-primary endpoints. 
The power to detect a statistically significant difference between bimekizumab and ustekinumab 
at a 2-sided significance level of 0.05 is 97% for PASI90 response and >99% for IGA response. 
Because both co-primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power for achieving superiority on both 
co-primary endpoints is not calculated here as it is similar to the lower of the individual tests. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 161 of 209 
Note that the power for the non-inferiority testing between bimekizumab and ustekimumab for 
both PASI90 and IGA responses is >99% based on a 1-sided significance level of 0.025 and a 
non-inferiority margin of 10%. 
Has been changed to:  
A total of 400560 subjects will be randomly assigned in a 3:34:1 ratio to the following treatment 
groups: 
 Bimekizumab 320mg (320240 subjects) 
 Ustekinumab (240 subjects) 
 Placebo (80 subjects) 
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co-
primary efficacy variables of PASI90 response and IGA response at Week 16. However, as 
described in Section 14.3.2.1.1 , Week 16 comparisons of bimekizumab against 
ustekinumab for PASI90 response and IGA response will also be part of a fixed sequence 
testing procedure to control for multiplicity. Therefore, this study has been powered to 
show statistical superiority to ustekinumab based on the co-primary endpoints. 
The assumed responder rates for PASI90 at Week 16 are 75%, 58%, and 2% for bimekizumab, 
ustekinumab, and placebo, respectively. Additionally, the assumed responder rates for IGA are 
85%, 68%, and 5% for bimekizumab, ustekinumab, and placebo, respectively. The assumed 
responder rates for bimekizumab are based on the Phase 2b PS0010 data. The assumptions 
related to the responder rates for ustekinumab are based on those observed in the CLEAR 
study (Thaci et al, 2015). The power to show statistical superiority of bimekizumab relative to 
placebo under these assumptions is >99% for the co-primary endpoints. 
The power to detect a statistically significant difference between bimekizumab and 
ustekinumab at a 2-sided significance level of 0.05 is 97% for PASI90 response and >99% 
for IGA response. Because both co-primary endpoints are highly powered independently, 
and because PASI and IGA response tend to be highly correlated, the overall power for 
achieving superiority on both co-primary endpoints is not calculated here as it is similar to 
the lower of the individual tests. Note that the power for the non-inferiority testing between 
bimekizumab and ustekimumab for both PASI90 and IGA responses is >99% based on a 1-
sided significance level of 0.025 and a non-inferiority margin of 10%. 
 
Change #73 
The following references have been deleted: 
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective 
multiple test procedure. Statistics in Medicine. 2009;28:586-604. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol 
Venereol. 2009;23(12):1374-82. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 162 of 209 
International Menopause Society. Cornwall, UK: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016. 
Kimball AB, Yu AP, Signorovitch J, Xie, J, Tsaneva M, Gupta SR, et al. The effects of 
adalimumab treatment and psoriasis severity on self-reported work productivity and activity 
impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67-
e75. 
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-
23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate 
to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, 
double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 
2017; 76:418-31. 
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of 
subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am 
Acad Dermatol 2015; 73:400-09. 
Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work Productivity and Healthcare 
Resource Utilizatioin Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque 
Psoriasis: Results from a 1-Year, Multicentre, Open-Lable, Single-Arm Study in a Clinical 
Setting. Appl Health Econ Health Policy. 2012:10(5):343-53. 
18.2 
Protocol Amendment 2 
Rationale for the amendment 
The purpose of this amendment was the following:   
 Update name and contact information for Clinical Project Manager 
 Extend the duration of the Screening Period, and therefore the overall study duration, by 
1 week 
 Update list of current treatment for PSO to reflect changes in labeling and approved countries 
 Update list of completed and ongoing bimekizumab studies to reflect completion of study 
UP0042 
 Clarify calculation of PASI responder rates 
 Remove references to PD assessments as they will not be conducted in this study 
 Update Schedule of study assessments to modify the visits at which the physical 
examination, TB questionnaire, body weight, ECG, and the Patient Symptom Diary (daily) 
are assessed 
 Clarify that all visits from first dose to Week 24 would have a ±3 day visit window, while all 
visits from Week 28 to end of study would have a ±7 day window 
 Clarify the dosing window 
 Modify exclusion criterion to clarify exclusion of subjects who have participated in other 
studies of bimekizumab, other medications (systemic or topical), or devices 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 163 of 209 
 Modify exclusion criteria pertaining to history of malignancy, systemic disease, and major 
depression 
 Add new withdrawal criteria for subjects with newly diagnosed IBD 
 Clarify withdrawal criteria for subjects with depression or suicidal ideation or behavior 
 Update prohibited concomitant medications to include tildrakizumab and risankizumab 
 Corrected discrepancies between Section 8 Study procedures by visit and Table 5-1 Schedule 
of study assessments 
 Revise PASE questionnaire scoring 
 Clarify definition of abortion 
 Updated laboratory measurements to be performed 
 Provide additional details for requirements for IMP rechallenge in the event of PDILI 
 Update the definition of the FAS Set 
 Clarify regions for analyses  
In addition, minor spelling, editorial, and formatting changes were made, and the List of 
abbreviations was updated. 
 
Change #1 
Clinical Project Manager 
Name: 
 
Address: 
UCB BioPharma SPRL, Allée de la Recherche, 60, Brussels, 
Belgium, B-1070 
Phone: 
 
Fax: 
 
Clinical Project Manager 
Name: 
 
 
Address: 
UCB BioPharma SPRL, Allée de la Recherche, 60, Brussels, 
Belgium, B-1070UCB Biosciences GmbH, Alfred Nobel 
Strasse, Monheim am Rhein, 40789, Germany 
Phone: 
 
Fax: 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 164 of 209 
Change #2 
Section 1 
Summary, second and third paragraphs 
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5-point scale]) who are candidates for adalimumab or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy. 
Approximately 535 subjects will be screened in order to have a total of 400 subjects randomized 
in the study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. For each subject, the study will last a maximum of 76 
weeks and will consist of 4 periods, a Screening Period (2 to 4 weeks), a double-blind, active 
comparator-controlled Initial Treatment Period (16 weeks), a dose-blind Maintenance Treatment 
Period (40 weeks), and a Safety Follow-Up (SFU) Period (20 weeks after the last dose of the 
investigational medicinal product [IMP]).  
Has been changed to:  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5-point scale]) who are candidates for adalimumab or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy. 
Approximately 535 subjects will be screened in order to have a total of 400 subjects randomized 
in the study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. For each subject, the study will last a maximum of 76 77 
weeks and will consist of 4 periods, a Screening Period (2 to 4 5 weeks), a double-blind, active 
comparator-controlled Initial Treatment Period (16 weeks), a dose-blind Maintenance Treatment 
Period (40 weeks), and a Safety Follow-Up (SFU) Period (20 weeks after the last final dose of 
the investigational medicinal product [IMP]).  
 
Change #3 
Section 1 
Summary 
The following text has been added after the sixth paragraph:  
Subjects who complete the Randomized Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll 
in an open-label study. Placebo-randomized subjects, who receive placebo during the entire 
Initial and Randomized-Withdrawal periods, that complete Week 56 without relapse into 
the open-label escape arm will not be eligible for the open-label study. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 165 of 209 
Change #4 
Section 2.1.2 Current treatments for psoriasis, first paragraph 
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photochemotherapy, methotrexate, 
cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic agents, such 
as tumor necrosis factor (TNF) antagonists, interleukin (IL)-12/23 inhibitors, IL-23p19 inhibitors 
and IL-17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication include the IL-12/23 antagonist ustekinumab, the IL-23p19 antagonist 
guselkumab (in the US only) the IL-17A inhibitors secukinumab and ixekizumab, and the 
IL-17 receptor antagonist brodalumab. 
Has been changed to:  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photochemotherapy phototherapy, 
methotrexate, cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic 
agents, such as tumor necrosis factor (TNF) antagonists, interleukin (IL)-12/23 inhibitors, IL-
23p19 inhibitors and IL-17A inhibitors. The effectiveness of TNF inhibitors in the treatment of 
PSO has been demonstrated in many Phase 3 clinical studies and has led to the approval of 
multiple TNF inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors 
approved for this indication include the IL-12/23 antagonist ustekinumab, the IL-23p19 
antagonist guselkumab (in the US only), the IL-17A inhibitors secukinumab and ixekizumab, 
and the IL-17 receptor antagonist brodalumab. 
 
Change #5 
Section 2.1.2 Current treatments for psoriasis, third bullet 
 Chemophototherapy is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and varying efficacy limits its use in the market. 
Has been changed to:  
 Phototherapy Chemophototherapy is a frequent option for moderate to severe patients, but 
the inconvenience of multiple treatment visits and varying efficacy limits its use in the 
market. 
 
Change #6 
Section 2.1.2 Current treatments for psoriasis, final bullet, second and fourth sub-bullets 
 Ustekinumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 166 of 209 
binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T-cell differentiation and 
activation.  
 Guselkumab has been approved in the US for the treatment of adult patients with 
moderate to severe plaque PSO who are candidates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a 
naturally occurring cytokine that is involved in normal inflammatory and immune 
responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines. 
Has been changed to:  
 Ustekinumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that 
binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T-cell differentiation and 
activation.  
 Guselkumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for systemic therapy or 
phototherapy. It is a human monoclonal IgG1λ antibody that selectively binds to the p19 
subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. 
IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and 
immune responses. Guselkumab inhibits the release of proinflammatorypro-
inflammatory cytokines and chemokines. 
 
Change #7 
Section 2.2.1.1 Completed studies 
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers.  
Has been changed to: 
Four Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with 
mild to moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with 
PsA, and UP0031 in 12 healthy volunteers, and UP0042 in 48 healthy volunteers.  
And the following paragraph has been added: 
UP0042 was a randomized double-blind, placebo-controlled, single-dose, parallel-group 
study to evaluate the safety, tolerability, and pharmacokinetics of bimekizumab 
administered as subcutaneous injection to Japanese and Caucasian healthy subjects. This 
study demonstrated that the PK profiles following single administration of 80mg, 160mg, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 167 of 209 
and 320mg with sc injection were dose proportional with a linear elimination in both 
Japanese and Caucasian subjects and that the PK profiles of Japanese and Caucasian 
subjects were considered to be generally similar. A single dose of bimekizumab (80mg, 
160mg, or 320mg) administered as sc injection was generally safe and well tolerated in 
healthy Japanese and Caucasian subjects and no major differences in safety findings were 
observed between Japanese and Caucasian subjects. 
 
Change #8 
Section 2.2.1.2 Ongoing studies 
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing.  
 PS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and PD of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. 
 PS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab. 
 PS0016 is a Phase 2a, subject-blind, Investigator-blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. 
 PS0018 is a long-term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab. 
 UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese and 
Caucasian healthy subjects. 
Has been changed to:  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing.  
 PS0010 is a Phase 2b, double-blind, placebo-controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO. 
 PS0011 is a long-term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab. 
 PS0016 is a Phase 2a, subject-blind, Investigator-blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. 
 PS0018 is a long-term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 168 of 209 
 UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese 
and Caucasian healthy subjects. 
 
Change #9 
Section 4.3 Other variables 
The following text has been added: 
The other variables are listed below and will be evaluated according to the planned 
assessments in Table 5-1. 
 
Change #10 
Section 4.3.1 Other efficacy variables, last sentence in the last paragraph 
Note that PASI responder rates will always be calculated relative to the Baseline (first dose) 
Visit. 
Has been changed to:  
Note that Unless otherwise stated PASI responder rates will always be calculated relative to 
the Baseline Visit (first dose). 
 
Change #11 
Section 4.4 Pharmacokinetic variable 
Section 4.5 Pharmacogenomic variables 
Section 4.6 Immunological variable 
Have been changed to:  
Section 4.3.3 Pharmacokinetic variable 
Section 4.3.4 Pharmacogenomic variables 
Section 4.3.5 Immunological variable 
 
Change #12 
Section 5.1 Study description 
PS0013 is a Phase 3, multicenter study consisting of a 16-week, randomized, double-blind, 
parallel-group, active-comparator-controlled Initial Treatment Period followed by a 40-week, 
Maintenance Treatment Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5-point scale]) who are candidates for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 169 of 209 
systemic PSO therapy and/or phototherapy and/or photochemotherapy. Adalimumab will be 
administered per the local label. Up to 30% of subjects may have been previously exposed to a 
biologic therapy (see Exclusion Criterion #23, Section 6.2). 
Has been changed to:  
PS0013 is a Phase 3, multicenter study consisting of a 16-week, randomized, double-blind, 
parallel-group, active-comparator-controlled Initial Treatment Period followed by a 40-week, 
Maintenance Treatment Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5-point scale]) who are candidates for 
systemic PSO therapy and/or phototherapy and/or photochemotherapy. Adalimumab will be 
administered per the local label. Up to 30% of subjects may have been previously exposed to a 
biologic therapy (see Exclusion Criterion #23, Section 6.2). 
 
Change #13 
Section 5.2 
Study periods 
This study will include 4 periods, a Screening Period (2 to 4 weeks), an Initial Treatment Period 
(16 weeks), a Maintenance Treatment Period (40 weeks), and a SFU Period (20 weeks after the 
last dose of IMP). After completing the study, eligible subjects will be allowed to enroll in an 
open-label study. Subjects enrolling into the open-label study will not have the PS0013 SFU 
Visit. 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 5.2.5). All subjects who relapse at Week 20 or later 
during the Randomized-Withdrawal Period (up to Week 56) will be allocated to escape treatment 
(see Section 5.2.5). Relapse is defined as not achieving a PASI75 response. Subjects who 
achieve a PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in 
the open-label study.  
Has been changed to:  
This study will include 4 periods, a Screening Period (2 to 4 5 weeks), an Initial Treatment 
Period (16 weeks), a Maintenance Treatment Period (40 weeks), and a SFU Period (20 weeks 
after the last final dose of IMP). After completing the study, eligible subjects will be allowed to 
enroll in an open-label study. Subjects enrolling into the open-label study will not have the 
PS0013 SFU Visit. 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 5.2.5). All subjects who relapse at Week 20 or later 
during the Randomized-Withdrawal Period (up to Week 56) will be allocated to escape treatment 
(see Section 5.2.5). Relapse is defined as not achieving a PASI75 response. Subjects who 
achieve a PASI50 response at Week 12 of the open-label escape arm will be allowed to enroll in 
the open-label study. 
Subjects who complete the Randomized Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 170 of 209 
in an open-label study. Placebo-randomized subjects, who receive placebo during the entire 
Initial and Randomized-Withdrawal periods, that complete Week 56 without relapse into 
the open-label escape arm will not be eligible for the open-label study. 
 
Change #14 
Section 5.2.1 Screening Period 
The Screening Period will last 2 weeks, but can be extended up to a total of 4 weeks. 
Has been changed to:  
The Screening Period will last 2 weeks, but can be extended up to a total of 4 5 weeks in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications. 
 
Change #15 
Section 5.3 Study duration per subject 
For each subject, the study will last a maximum of up to 76 weeks, as follows: 
 Screening Period: 2 to 4 weeks 
Has been changed to:  
For each subject, the study will last a maximum of up to 76 77 weeks, as follows: 
 Screening Period: 2 to 4 5 weeks 
 
Change #16 
Section 5.3 Study duration per subject 
After the 40-week Randomized-Withdrawal Period, subjects will be allowed to enroll in an open-
label study, in which case subjects will undergo the Week 56 study assessments before receiving 
their first open-label IMP dose. Subjects who achieve a PASI50 response in the open-label 
escape arm will also be allowed to enroll in the open-label study.  
Has been changed to:  
After the 40-week Randomized-Withdrawal Period, subjects will be allowed to enroll in an open-
label study, in which case subjects will undergo the Week 56 study assessments before receiving 
their first open-label IMP dose. Subjects who achieve a PASI50 response in the open-label 
escape arm will also be allowed to enroll in the open-label study. Subjects who complete the 
Randomized Withdrawal Period (after a Week 16 response [≥PASI90] on bimekizumab 
during the Initial Treatment Period) will be allowed to enroll in an open-label study. 
Placebo-randomized subjects, who receive placebo during the entire Initial and 
Randomized-Withdrawal periods, that complete Week 56 without relapse into the open-
label escape arm will not be eligible for the open-label study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 171 of 209 
Change #17 
Section 5.5 Anticpated regions and countries 
The regions planned for study conduct are Europe, Canada, and the US, with possible extension 
to other regions and countries.   
Has been changed to:  
The regions planned for study conduct are North America, Western Europe, Canada, and the 
US Central/Eastern Europe, and Asia/Australia, with possible extension to other regions and 
countries. 
 
Change #18 
Section 5.6 Schedule of study assessments  
The schedule of study assessments for all subjects enrolled in the study is presented in Table 5-1. 
The Schedule of Study Assessments for subjects allocated to escape treatment is presented in 
Table 5-2. 
Has been changed to: 
The schedule of study assessments for all subjects enrolled in the study is presented in Table 5-1. 
The Schedule of Study Assessments for subjects allocated to escape treatment is presented in 
Table 5-2. At each visit, all study assessments should be performed prior to administration 
of IMP. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 172 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xd 
 
 
Inclusion/exclusion 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant past medical 
history and concomitant 
diseases 
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examf, g 
X 
 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
X 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and 
biochemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
X 
Urinalysis 
X 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
ECG 
X 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
Pregnancy testingi 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hepatitis B and C testingj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV testingk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest x-rayl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 173 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
IGRA Tuberculosis test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tuberculosis 
questionnaire 
X 
X 
 
 
 
 
 
X 
 
X 
 
 
X 
 
 
 
X 
X 
X 
Blood sample for 
bimekizumab plasma 
concentrationsm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
anti-bimekizumab 
antibodiesm 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m 
 
X 
X 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
X 
 
Blood sample for 
genetic/ epigenetic 
analysesc,m 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IGA  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
 
X 
 X 
X  
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
PHQ-9 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X  
X 
X 
X 
X 
X 
 
eC-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 174 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Patient Symptom Diary 
(daily) 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
 
 
 
 
 
 
 
Scalp IGA 
 
X 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
mNAPSI 
 
X 
 
 
Xo 
Xo 
Xo 
Xo 
Xo 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
pp-IGA 
 
X 
 
 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
EQ-5D-3L 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
SF-36 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Patient Global 
Assessment of PSOq 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
PASE 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PGADAr 
 
X 
 
 
X 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IRTs,t 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bimekizumab or placebo 
administrations,t 
 
X 
 
 
X 
X 
X 
Xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
BSA=body surface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic 
Columbia-Suicide Severity Rating Scale; EQ-5D-3L= Euro-Quality of Life 5-Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index; PD=pharmacodynamics; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global Assessment of Disease 
Activity; PHQ-9=Patient Health Questionnaire 9; pp-IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF-36=Short 
Form 36 item Health Survey; SFU=Safety Follow-Up; scalp IGA=scalp-specific Investigator’s Global Assessment; TB=tuberculosis;  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 175 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
a Visit windows of ± 3 days from the first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open-label study. 
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The Informed 
Consent Form must be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up to 20 
years. 
d  
e Ensure no significant changes in medical history. 
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB. 
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI. 
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits 
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) and negative for anti-hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti-hepatitis B surface antibody. 
k The HIV test results will not be recorded in the eCRF. 
l Screening chest x-ray must occur within 3 months prior to the Screening Visit. 
m All blood samples taken prior to dosing. 
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline. 
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline. 
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline. 
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Screening through the Initial 
Treatment Period with a +3 day completion window. During the Randomized-Withdrawal Period this assessment will be completed at each clinic visit specified 
with a ±3 day completion window. 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47). 
s IMP administration is based on randomization. 
t The dosing window is ±7 days relative to the scheduled dosing visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 176 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
u At Week 16, subjects will be re-allocated based on original treatment and response to treatment and will receive their first Randomized-Withdrawal Period dose. 
 
Has been changed to:  
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Xd 
 
 
Inclusion/exclusion 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urine drug screen 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
Demographic data 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Psoriasis history 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant past medical 
history and concomitant 
diseases 
X 
Xe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examf, g 
X 
X 
 
 
 
 
X 
X 
 
X 
 
 
X 
 
 
X 
 
X 
X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 177 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Height 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Body weight 
 
X 
 
 
 
 
X 
X 
 
X 
 
 
X 
 
 
X 
 
X 
 
Vital signsh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and 
biochemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
X 
Urinalysis 
X 
X 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
X 
ECG 
X 
 
 
 
 
 
X 
X 
 
 
 
X 
 
 
 
X 
 
X 
 
Pregnancy testingi 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hepatitis B and C testingj 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV testingk 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest x-rayl 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IGRA Tuberculosis test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
Tuberculosis 
questionnaire 
X 
X 
 
 
 
 
X 
X 
 
X 
 
 
X 
 
 
X 
X 
X 
X 
Blood sample for 
bimekizumab plasma 
concentrationsm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
Blood sample for 
anti-bimekizumab 
antibodiesm 
 
X 
 
 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
X 
 
X 
X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 178 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m 
 
X 
X 
 
 
X 
X 
X 
 
X 
 
 
 
 
 
 
 
X 
 
Blood sample for 
genetic/ epigenetic 
analysesc,m 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IGA  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
 
X 
 X 
X  
X 
X 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
PHQ-9 
X 
X 
 
 
X 
X 
X 
X 
X 
X 
X 
X 
X  
X 
X 
X 
X 
X 
 
eC-SSRS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Patient Symptom Diary 
(daily) 
X 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
 
 
 
 
 
 
 
Scalp IGA 
 
X 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
Xn 
 
mNAPSI 
 
X 
 
 
Xo 
Xo 
Xo 
Xo 
Xo 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
Xo 
 
pp-IGA 
 
X 
 
 
Xp 
Xp 
Xp 
Xp 
Xp 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
Xp 
 
EQ-5D-3L 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
SF-36 
 
X 
 
 
X 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Patient Global 
Assessment of PSOq 
 
 
 
 
 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 179 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
PASE 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
PGADAr 
 
X 
 
 
X 
 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
IRTs,t 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bimekizumab or placebo 
administrations,t 
 
X 
 
 
X 
X 
X 
Xu 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
BSA=body surface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC-SSRS=electronic 
Columbia-Suicide Severity Rating Scale; EQ-5D-3L= Euro-Quality of Life 5-Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index; PD=pharmacodynamics; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global Assessment of Disease 
Activity; PHQ-9=Patient Health Questionnaire 9; pp-IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF-36=Short 
Form 36 item Health Survey; SFU=Safety Follow-Up; scalp IGA=scalp-specific Investigator’s Global Assessment; TB=tuberculosis;  
a Visit windows of ± 3 days from the first dose at all visits except SFU to the Week 24 visit. Visit windows of ±7 days from the Week 28 visit to the Week 52 
visit. The SFU Visit window is ±7 days -3 and +7 days from last final dose. 
b The SFU Visit will occur 20 weeks after the last final dose for subjects who do not enroll in the open-label study. 
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The 
Informed Consent Form must be signed prior to collecting any samples for the substudy. All genomic, proteomic, and metabolomics samples will be 
stored at -80°C at the central biorepository for up to 20 years. 
d A separate ICF will be required to be completed for the open-label study. 
e Ensure no significant changes in medical history. 
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB. 
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI be performed as per 
Section 12.3.5. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 180 of 209 
Table 5-1: 
Schedule of study assessments 
Visita/ 
Week 
 
Protocol activity 
Screening 
 
Initial Treatment Period 
(weeks after first dose) 
Randomized-Withdrawal Period 
(weeks after first dose) 
W56/ 
PEOT 
SFUb 
Baseline 
(first dose) 
1 
2 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
 
 
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits 
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) and negative for anti-hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti-hepatitis B surface antibody. 
k The HIV test results will not be recorded in the eCRF. 
l Screening chest x-ray must occur within 3 months prior to the Screening Visit. 
m All blood samples taken prior to dosing. 
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline. 
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline. 
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp-IGA score >0) at Baseline. 
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Screening through the Initial 
Treatment Period with a +3 day completion window. During the Randomized-Withdrawal Period this assessment will be completed at each clinic visit the 
specified visitswith a ±3 day completion window. 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47). 
s IMP administration is based on randomization. 
t The dosing window is ±3 ±7 days relative to the scheduled dosing visit through Week 24. The dosing window is ±7 days from Week 28 through the end of 
the study. 
u At Week 16, subjects will initially randomized to BKZ 320mg Q4W who achieve PASI90 response be re-allocated based on original treatment and re-
randomized 1:1:1 to either BKZ 320mg Q4W, BKZ 320mg Q8W or placebo; subjects initially randomized to placebo who achieve PASI90 response at 
Week 16 will continue to treatment receive placebo; and subjects who do not achieve PASI90 response at Week 16 will receive their first Randomized-
Withdrawal Period dose be allocated to the escape arm. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 181 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
eC-SSRS 
X 
X 
X 
X 
X 
Urine drug screen 
 
 
 
X 
 
Physical exam 
 
 
 
X 
X 
Body Weight 
X 
 
 
X 
 
Vital signsc 
X 
X 
X 
X 
X 
Hematology and biochemistry 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
X 
X 
ECG 
 
 
 
X 
 
Pregnancy testingd 
X 
X 
X 
X 
X 
IGRA Tuberculosis test 
 
 
 
X 
 
Tuberculosis questionnaire 
 
 
 
X 
X 
Blood sample for bimekizumab plasma concentrationse 
X 
X 
X 
X 
X 
Blood sample for anti-bimekizumab antibodiese 
X 
X 
X 
X 
X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker analysese 
X 
 
 
X 
 
Blood sample for genetic/epigenetic analysese 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
 
PHQ-9 
X 
X 
X 
X 
 
scalp IGAf 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 182 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
mNAPSIg 
X 
X 
X 
X 
 
pp-IGAh 
X 
X 
X 
X 
 
EQ-5D-3L 
X 
 
 
X 
 
SF-36 
X 
 
 
X 
 
Patient Global Assessment of PSOi 
X 
 
 
X 
 
PASE 
X 
 
 
X 
 
PGADAj 
X 
X 
X 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
IRT 
X 
X 
X 
X 
X 
Bimekizumab administrationk 
X 
X 
X 
 
 
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ-5D-3L=Euro-Quality of Life 5-Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; SF-36=Short Form 36-item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis 
a Visit windows of +/- 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose. 
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open-label study. 
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug. 
e All blood samples taken prior to dosing. 
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline. 
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline. 
h The pp-IGA will only be assessed in subjects with palmoplantar involvement at Baseline. 
i During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window. 
j The PGADA is assessed only for subjects with PsA at Baseline. 
k The dosing window is ±7 days relative to the scheduled dosing visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 183 of 209 
 
Has been changed to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 184 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
eC-SSRS 
X 
X 
X 
X 
X 
Urine drug screen 
 
 
 
X 
 
Physical exam 
 
 
 
X 
X 
Body Weight 
X 
 
 
X 
 
Vital signsc 
X 
X 
X 
X 
X 
Hematology and biochemistry 
X 
X 
X 
X 
X 
Urinalysis 
X 
 
 
X 
X 
ECG 
 
 
 
X 
 
Pregnancy testingd 
X 
X 
X 
X 
X 
IGRA Tuberculosis test 
 
 
 
X 
 
Tuberculosis questionnaire 
 
 
 
X 
X 
Blood sample for bimekizumab plasma concentrationse 
X 
X 
X 
X 
X 
Blood sample for anti-bimekizumab antibodiese 
X 
X 
X 
X 
X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker analysese 
X 
 
 
X 
 
Blood sample for genetic/epigenetic analysese 
 
 
 
X 
 
PASI 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
Percentage of BSA 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
 
PHQ-9 
X 
X 
X 
X 
 
scalp IGAf 
X 
X 
X 
X 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 185 of 209 
Table 5-2: 
Schedule of study assessments for subjects allocated to escape treatment 
Visita/ Week 
 
Protocol activity 
Open-label Escape Treatment(weeks after first dose) 
Escape 
Week 12/ 
PEOT 
  
Escape BL  
(first dose) 
Escape 
Week 4 
Escape 
Week 8 
SFUb 
mNAPSIg 
X 
X 
X 
X 
 
pp-IGAh 
X 
X 
X 
X 
 
EQ-5D-3L 
X 
 
 
X 
 
SF-36 
X 
 
 
X 
 
Patient Global Assessment of PSOi 
X 
 
 
X 
 
PASE 
X 
 
 
X 
 
PGADAj 
X 
X 
X 
X 
 
Concomitant medication 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
IRT 
X 
X 
X 
X 
X 
Bimekizumab administrationk 
X 
X 
X 
 
 
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ-5D-3L=Euro-Quality of Life 5-Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon-gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ-9=Patient Health Questionnaire 9; SF-36=Short Form 36-item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis 
a Visit windows of +/- 3 days ±7 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days ±7 days from last final dose. 
b The SFU Visit will occur 20 weeks after the last final dose for subjects who do not enroll in the open-label study. 
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable. 
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug. 
e All blood samples taken prior to dosing. 
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline. 
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline. 
h The pp-IGA will only be assessed in subjects with palmoplantar involvement at Baseline. 
i During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window. 
j The PGADA is assessed only for subjects with PsA at Baseline. 
k The dosing window is ±7 days relative to the scheduled dosing visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 186 of 209 
Change #19 
Section 5.7 Schematic diagram, Figure 5-1, final note after the figure 
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to 
receive placebo Q4W at Week 16 and later visits provided a PASI90 response was achieved at 
Week 16. All subjects initially randomized to placebo who achieve a PASI90 response at Week 
16 will continue to receive placebo (Q4W).6. Subject is a candidate for systemic PSO therapy 
and/or phototherapy and/or photochemotherapy. 
Has been changed to: 
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to 
receive placebo Q4W at Week 16 and later visits provided a PASI90 response was achieved at 
Week 16. All subjects initially randomized to placebo who achieve a PASI90 response at 
Week 16 will continue to receive placebo (Q4W). 
 
Change #20 
Section 6.1 
Inclusion criteria 
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed at the Baseline Visit: 
6. Subject is a candidate for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy. 
Have been changed to: 
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed at the Baseline Visit: 
6a. Subject is a candidate for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy. 
 
Change #21 
Section 6.2 
Exclusion criteria 
3. Subject previously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at least 5 half-lives prior to the Screening Visit, 
whichever is greater, or is currently participating in another study of a medication (systemic) 
under investigation. 
4. Subject previously participated in another study of a topical medication under investigation 
within the 4 weeks prior to the Screening Visit, or is currently participating in another study 
of a topical medication under investigation. 
5. Subject previously participated in another study of a medical device under investigation 
within the 4 weeks prior to the Screening Visit, or is currently participating in another study 
of a medical device under investigation. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 187 of 209 
14. Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer, or ductal carcinoma in situ of the breast. 
17. Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, 
diabetes) considered by the Investigator to be uncontrolled, unstable, or likely to progress to 
a clinically significant degree during the course of the study. 
27. Subject has presence of severe depression, indicated by a score of 15 to 19 using the 
screening PHQ 9. Medication used to treat depression should be stable for 4 weeks prior to 
Baseline. 
Have been changed to: 
3a. Subject previously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at least 5 half-lives prior to the Screening Visit, 
whichever is greater, or is currently participating in another study of a medication 
(systemic) under investigation. Subject must be washed out of the medication for 12 
weeks or at least 5 half-lives prior to the Baseline Visit, whichever is greater. 
4a. Subject previously participated in another study of a topical medication under 
investigation within the 4 weeks prior to the Screening Visit, or is currently participating 
in another study of a topical medication under investigation. Subject must be washed out of 
the medication for 4 weeks prior to the Baseline Visit. 
5a. Subject previously participated in another study of a medical device under investigation 
within the 4 weeks prior to the Screening Visit, or is currently, or was within the 4 weeks 
prior to the Baseline Visit, participating in another study of a medical device under 
investigation. 
14a. 
Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer, or ductal carcinoma in situ of the breast. 
17a. 
Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver 
disease, diabetes ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematological, immunological, etc.) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study. 
27a. 
Subject has presence of moderately severe major depression or severe major 
depression, indicated by a score of >/=15 using the screening PHQ-9. Medication used to 
treat depression should be stable for 4 8 weeks prior to Baseline. 
 
Change #22 
Section 6.2 
Exclusion criteria 
The following text has been added: 
30. Subject is taking or has taken prohibited psoriasis medications without meeting the 
mandatory washout period relative to the Baseline Visit (Table 7-2). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 188 of 209 
 
Change #23 
Section 6.3 Withdrawal criteria  
The following withdrawal criteria have been added, modified, and/or renumbered: 
11. Subjects with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares 
during the study must: 
 Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist 
 Discontinue IMP and be followed-up until resolution of active IBD symptoms 
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study. 
12. Subjects must be referred immediately to a mental health care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk for either 
of the following: 
 Active suicidal ideation as indicated by a positive response (“Yes”) to Questions 4 or 5 or to 
the suicidal behavior questions of the “Since Last Visit” version of the eC-SSRS. 
 Moderately severe major depression as indicated by a PHQ-9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit. 
13. Subjects must be referred immediately to a mental healthcare professional and must be 
withdrawn in case of: 
 Any suicidal behavior since last visit. 
 Severe major depression as indicated by a PHQ-9 score ≥20. 
The mental health consultation will be documented must be recorded in source 
documentation. 
 
Change #24 
Section 7.2 Treatment(s) to be administered 
Randomized-Withdrawal Period dosing 
Investigational medicinal product treatment during the Randomized-Withdrawal Period will be 
based on treatment group assignment at randomization (see Section 5.2.3). 
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 189 of 209 
 Subjects reallocated to receive bimekizumab 320mg Q8W will alternate between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by placebo (2 
placebo injections sc). 
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75 at Week 20 or later will continue to receive placebo Q4W at 
Week 16 and later visits. 
Has been changed to: 
Randomized-Withdrawal Period dosing 
Investigational medicinal product treatment during the Randomized-Withdrawal Period will be 
based on treatment group assignment at randomization (see Section 5.2.3). 
 Subjects who are re-randomized to receive bimekizumab 320mg Q4W will receive 2 
bimekizumab 160mg injections sc Q4W. 
 Subjects reallocated re-randomized to receive bimekizumab 320mg Q8W will alternate 
between receiving bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks 
later by placebo (2 placebo injections sc). 
 Subjects re-randomized to receive placebo will receive 2 placebo injections Q4W. 
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75 at Week 20 or later will continue to receive placebo Q4W at 
Week 16 and later visits. 
 
Change #25 
Section 7.2 Treatment(s) to be administered 
Table 7-1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
Bimekizumab 320mg 
Q4W/Q4W 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
Bimekizumab 320mg 
Q4W/Q8W 
●● 
●● 
●● 
●● 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
Placebo 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks 
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week 16 and all subjects who relapse (defined not 
achieving a ≥PASI75 response at Week 20 or later) during the Randomized-Withdrawal Period (up to Week 52) 
will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Period that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 190 of 209 
Has been changed to: 
Table 7-1: 
Dosing Scheme 
Week 
Dose Assignment 
0 
4 
8 
12 
16 
20 
24 
28 
32 
36 
40 
44 
48 
52 
Bimekizumab 320mg 
Q4W/Q4W 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
●● 
Bimekizumab 320mg 
Q4W/Q8W 
●● 
●● 
●● 
●● 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
●● 
○○ 
Bimekizumab 320mg 
Q4W/placebo 
●● 
●● 
●● 
●● 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
Placebo 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks 
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week 16 and all subjects who relapse (defined not 
achieving a ≥PASI75 response at Week 20 or later) during the Randomized-Withdrawal Period (up to Week 52) 
will receive open-label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Period that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits. 
 
Change #26 
Section 7.8.2 Prohibited concomitant treatments (medications and therapies)  
Table 7-2: 
Prohibited psoriasis medications 
Drug 
Washout period relative to Baseline Visit 
Topicals except for those permitted (Section 7.8.1.1) 
2 weeks 
Systemic retinoids 
3 months  
Systemic treatment (nonbiological): 
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, 
thioguanine) 
fumaric acid esters specifically used for the 
treatment of PSO 
systemic corticosteroids 
phototherapy or photochemotherapy 
1 month 
Anti-TNFs: 
adalimumab (including biosimilar) 
etanercept (including biosimilar) 
infliximab (including biosimilar), golimumab, 
certolizumab pegol 
 
Any exposure to adalimumab 
1 month for etanercept 
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol 
Other biologics and other systemic therapies, eg: 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 191 of 209 
Table 7-2: 
Prohibited psoriasis medications 
Drug 
Washout period relative to Baseline Visit 
apremilast, tofacitinib 
2 weeks for apremilast and tofacitinib 
alefacept, efalizumab, guselkumab 
3 months for alefacept, efalizumab, and 
guselkumab 
ustekinumab, briakinumab 
6 months for ustekinumab and briakinumab 
rituximab 
12 months for rituximab 
Anti-IL-17 therapy: 
brodalumab 
ixekizumab 
secukinumab 
3 months 
(bimekizumab is excluded per exclusion 
criteria) 
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is 
approved) 
3 months or 5 half-lives, whichever is greater 
Any other antipsoriatic agent (topical) under 
investigation 
1 month 
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor 
Has been changed to:  
Table 7-2: 
Prohibited psoriasis PSO medications 
Drug 
Washout period relative to Baseline Visit 
Topicals except for those permitted (Section 7.8.1.1) 
2 weeks 
Systemic retinoids 
3 months  
Systemic treatment (nonbiological): 
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, 
thioguanine) 
fumaric acid esters specifically used for the 
treatment of PSO 
systemic corticosteroids 
phototherapy or photochemotherapy 
1 month 
Anti-TNFs: 
adalimumab (including biosimilar) 
etanercept (including biosimilar) 
infliximab (including biosimilar), golimumab, 
certolizumab pegol 
 
Any exposure to adalimumab 
1 month for etanercept 
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol 
Other biologics and other systemic therapies, eg: 
 
apremilast, tofacitinib 
2 weeks for apremilast and tofacitinib 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 192 of 209 
Table 7-2: 
Prohibited psoriasis PSO medications 
Drug 
Washout period relative to Baseline Visit 
alefacept, efalizumab, guselkumab 
3 months for alefacept, efalizumab, and 
guselkumab 
tildrakizumab, risankizumab 
5 months for tildrakizumab and 
risankizumab 
ustekinumab, briakinumab 
6 months for ustekinumab and briakinumab 
rituximab 
12 months for rituximab 
Anti-IL-17 therapy: 
brodalumab 
ixekizumab 
secukinumab 
3 months 
(bimekizumab is excluded per exclusion 
criteria) 
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is 
approved) 
3 months or 5 half-lives, whichever is greater 
Any other antipsoriatic agent (topical) under 
investigation 
1 month 
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor 
 
Change #27 
Section 7.10 Randomization and numbering of subjects, first and fourth paragraphs 
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biologic exposure (yes/no). The 
IRT will generate individual assignments for subject kits of IMP, as appropriate, according to the 
visit schedule.  
At Week 16, subjects who received bimekizumab Q4W during the Initial Treatment Period may 
be reallocated to a new treatment group based on their PASI response. 
Have been changed to:  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biologic exposure (yes/no). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 193 of 209 
The IRT will generate individual assignments for subject kits of IMP, as appropriate, according 
to the visit schedule.  
At Week 16, subjects who received bimekizumab Q4W during the Initial Treatment Period may 
be reallocated re-randomized to a new treatment group based on their PASI response. 
 
Change #28 
Section 8 Study Procedures by Visit 
 Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3-day window must be discussed with the Medical Monitor. 
 The dosing window is ±7 days relative to the scheduled dosing visit. 
 For the SFU Visit (20 weeks after the last dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3 days/+7 days). 
Has been changed to: 
 From the Week 1 Visit to the Week 24 Visit, visit windows of ±3 days on either side of 
the scheduled dosing are permitted; however, the Investigator should try to keep the 
subjects on the original dosing schedule. From the Week 28 Visit to the Week 52 Visit, 
visit windows are ±7 days. Visit windows of ±3 days on either side of the scheduled 
dosing are permitted; however, the Investigator should try to keep the subjects on the 
original dosing schedule. The window of ±3 days is relative to Baseline and applicable 
for all subsequent visits.  Changes to the dosing schedule outside of the 3-day visit window 
must be discussed with the Medical Monitor. 
 The dosing window is ±7 days ±3 days relative to the scheduled dosing visit through 
Week 24. The dosing window is ±7 days relative to the scheduled dosing visit from Week 
28 through the end of the study. 
 For the SFU Visit (20 weeks after the last final dose), the visit window should occur no 
more than 3 days prior to the is ±7 days relative to the scheduled visit date. 
 
Change #29 
Section 8.1 Screening Visit (2 to 4 weeks) 
Has been changed to:  
Section 8.1 Screening Visit (2 to 4 5 weeks) 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 194 of 209 
Change #30 
Sections 8.1 Screening Visit (2 to 4 5 weeks) and 8.2.1 Baseline 
The following text has been added: 
 Patient Global Assessment of PSO 
 
Change #31 
Sections 8.2.1 Baseline Visit  
The following has been added to the bulleted list: 
 Physical examination including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Patient Global Assessment of PSO 
 
Change #32 
Section 8.2.4 Week 12 (±3 days relative to Baseline) 
The following have been added to the bulleted list: 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Body weight 
 Record 12-lead ECG 
 TB questionnaire 
 PGADA 
 
Change #33 
Sections 8.2.5 Week 16 (±3 days relative to Baseline) 
The following has been deleted from the bulleted list: 
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB 
 Body weight 
 Record 12-lead ECG 
 TB questionnaire 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 195 of 209 
Change #34 
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline) 
Has been changed to: 
8.3.1 Weeks 20 and 24 (±3 days relative to Baseline) and Weeks, 28, 32, 36, 40, 44, 48, and 
52 (±3 ±7 days relative to Baseline) 
 
Change #35 
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline) 
The following have been modified: 
 Tuberculosis questionnaire (Weeks 24, 36, and 52 48 only) 
 Patient Global Assessment of PSO (Weeks 24, 32, 40, and 48 only only) 
 PGADA for subjects with PsA at Baseline (Weeks 24, 32, 40, and 48 only only) 
The following have been deleted from the bulleted list: 
 Patient Symptom Diary (daily) (Week 24 only) 
 
Change #36 
Section 8.6 Safety Follow Up Visit (20 weeks after last dose ±-3/+7 days) 
Has been changed to: 
Section 8.6 Safety Follow Up Visit (20 weeks after last final dose ±-3/+7 days ±7 days) 
 
Change #37 
Section 9 ASSESSMENT OF EFFICACY 
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably, the same assessor should evaluate the subject at each 
assessment. 
Has been changed to: 
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp-IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably, the The same assessor should evaluate the subject at each 
assessment. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 196 of 209 
Change #38 
Section 9.10 Patient Global Assessment of psoriasis, second and third paragraphs and last 
sentence 
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline through the Initial Treatment Period; the assessment is to completed within a +3 
day completion window at each of the visits specified in Table 5-1. 
During the Randomized-Withdrawal Period, this assessment will be completed within a +3 day 
completion window at the visits specified in Table 5-1. 
During escape treatment, this assessment will be completed within a +3 day completion window 
at the visits specified in Table 5-1. 
Has been changed to:  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline Screening through the Initial Treatment Period; the assessment is to completed 
at each of the visits specified in Table 5-1. 
During the Randomized-Withdrawal Period, this assessment will be completed within a +3 day 
completion window at the visits specified in Table 5-1. 
During escape treatment, this assessment will be completed within a +3 day completion 
window at the visits specified in Table 5-1. 
 
Change #39 
Section 9.11 Patient Symptom Diary responses, second paragraph 
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diaryeach evening. The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be performed at the study sites. 
Has been changed to:  
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diaryeach evening. The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be performed at the study sites. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 197 of 209 
Change #40 
Section 9.12 PASE questionnaire 
Standardized responses are based on 5 categories relating to agreement (strongly agree [1], agree 
[2], no idea [3], disagree [4], and strongly disagree [5]). The total maximum score is 75 points 
(symptom score: 35 points and function score: 40 points).  
Has been changed to:  
Standardized responses are based on 5 categories relating to agreement (strongly agree [1 5], 
agree [2 4], no idea [3], disagree [4 2], and strongly disagree [5 1]). The total maximum score 
is 75 points (symptom score: 35 points and function score: 40 points).  
 
Change #41 
Section 12.1.4 Pregnancy, second bullet and fourth paragraph 
 The subject should immediately stop the intake of the IMP or be down-titrated as instructed 
at the PEOT visit. 
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form. 
Have been changed to:  
 The subject should immediately stop the intake of the IMP or be down-titrated as 
instructed at the PEOT visit. 
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective 
or spontaneous elective abortion when medically indicated (e.g. when pregnancy is 
endangering life or health of woman or when fetus will be born with severe abnormalities), 
unintended pregnancy after hormonal contraceptive failure (if the hormonal contraceptive was 
correctly used), ectopic pregnancy, fetal demise, or any congenital anomaly/birth defect of the 
baby. Those SAEs must be additionally reported using the Investigator SAE Report Form. 
 
Change #42 
Section 12.2 Laboratory measurements 
Table 12-2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Basophils 
Calcium 
pH 
Eosinophils 
Chloride 
Albumin (protein) 
Lymphocytes 
Magnesium 
Glucose 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 198 of 209 
Table 12-2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Atypical lymphocytes 
Potassium 
Blood 
Monocytes 
Sodium 
Leukocyte esterase 
Neutrophils 
Glucose 
Nitrite 
Hematocrit 
BUN 
Urine dipstick for pregnancy testingb 
Hemoglobin 
Creatinine 
Urine drug screend 
MCH 
ALP 
 
MCHC 
AST 
 
MCV 
ALT 
 
Platelet count 
GGT 
 
RBC count 
Total bilirubin 
 
WBC count 
LDH 
 
 
Serum pregnancy testingb 
 
Has been changed to:  
Table 12-2: Laboratory measurements 
Hematology 
Chemistry 
Urinalysis dipsticka 
Basophils 
Calcium 
pH 
Eosinophils 
Chloride 
Albumin (protein) 
Lymphocytes 
Magnesium 
Glucose 
Atypical lymphocytes 
Potassium 
Blood 
Monocytes 
Sodium 
Leukocyte esterase 
Neutrophils 
Glucose 
Nitrite 
Hematocrit 
BUN 
Urine dipstick for pregnancy testingb 
Hemoglobin 
Creatinine 
Urine drug screend 
MCH 
ALP 
 
MCHC 
AST 
 
MCV 
ALT 
 
Platelet count 
GGT 
 
RBC count 
Total bilirubin 
 
WBC count 
LDH 
 
 
Serum pregnancy testingb 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 199 of 209 
 
Change #43 
Section 12.2.1 Evaluation of PDILI 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur. 
Has been changed to:  
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, 
may be fatal, and must not occur. 
 
Change #44 
Section 12.2.1.2.1 IMP restart/rechallenge (if applicable) 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur. 
Has been changed to:  
Section 12.2.1.2.1 IMP restart/rechallenge (if applicable) 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, 
may be fatal, and must not occur. Rechallenge with IMP can occur only if ALL of the 
following requirements are met: 
 The results of additional testing and monitoring described in Section 12.2.1.3 and 
Section 12.2.1.4 confirm a nondrug-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP. 
 Subject’s ALT or AST elevations do not exceed ≥5xULN. 
 Subject’s total bilirubin is <2xULN. 
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechallenge is approved by the UCB responsible physician, DMC, and a 
hepatologist. The hepatologist must be external to UCB but may be a member of the 
DMC. It is recommended that the hepatologist be a local hepatology expert or the 
hepatologist treating the subject. 
 Subject agrees to the Investigator-recommended monitoring plan. 
 
Change #45 
Section 12.3.1 Assessment and management of TB and TB risk factors 
b. High risk of acquiring TB infection: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 200 of 209 
 Known exposure to another person with active TB infection within the 3 months prior to 
Screening. 
Has been changed to: 
b. High risk of acquiring TB infection: 
 Known close exposure to another person with active TB infection within the 3 months 
prior to Screening. 
 
Change #46 
Section 12.3.1.1 Tuberculosis assessment by IGRA 
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5-1 for all subjects. 
Has been changed to:  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD test is 
recommended) will be performed as described in Table 5-1 for all subjects. 
 
Change #47 
Section 12.3.1.3 Tuberculosis questionnaire, last paragraph 
Subjects with a latent or active TB infection must be withdrawn from the study. 
Has been deleted: 
Subjects with a latent or active TB infection must be withdrawn from the study. 
 
Change #48 
Section 12.3.1.4 Tuberculosis management, second paragraph 
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy. 
Has been changed to: 
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 201 of 209 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy. 
 
Change #49 
Section 12.3.2 Pregnancy testing 
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP and at all subsequent postdosing visits. 
.Has been changed to:  
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP and at all subsequent postdosing visitsat the visits specified in 
Table 5-1. 
 
Change #50 
Section 13.3.1.1 Electronic Health Record extraction pilot 
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ Electronic 
Healthcare Record (EHR) at specific sites as part of a small EHR Pilot. Retrieve Form for Data 
Capture (RFD) will be used to extract the selected data points from the EHR and imported into 
the EDC system. An archive of selected data points, at the time of extraction, will be stored at 
the sites. 
Has been deleted: 
Section 13.3.1.1 Electronic Health Record extraction pilot 
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ Electronic 
Healthcare Record (EHR) at specific sites as part of a small EHR Pilot. Retrieve Form for 
Data Capture (RFD) will be used to extract the selected data points from the EHR and 
imported into the EDC system. An archive of selected data points, at the time of extraction, 
will be stored at the sites. 
 
Change #51 
Section 14.1 Definition of analysis sets 
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement of the co-primary efficacy variables at Baseline. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 202 of 209 
Has been changed to:  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each of the co-primary efficacy variables at 
Baseline. 
 
Change #52 
Section 14.2 General statistical considerations 
Figure 14-1: Sequence of testing 
 
Has been changed to:  
Figure 14-1: Sequence of testing 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 203 of 209 
 
 
Change #53 
Section 14.4 Subgroup analyses 
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index (BMI), prior systemic chemotherapy or photochemotherapy, prior biologic exposure, prior 
systemic therapy of any kind, Baseline disease severity, and antibody positivity. These 
summaries will be based on imputed data (NRI) and will include descriptive statistics only. 
Has been changed to:  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index (BMI), prior systemic chemotherapy or photochemotherapy phototherapy, prior 
biologic exposure, prior systemic therapy of any kind, Baseline disease severity, and antibody 
positivity. These summaries will be based on imputed data (NRI) and will include descriptive 
statistics only. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 204 of 209 
Change #54 
Section 14.5.2 Pharmacokinetic/pharmacodynamic analyses 
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit. 
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma concentration 
will be explored via graphical and a model based (PK-PD) approach quantify the time course of 
dose/exposure response. In addition, the relationship between safety and exposure will also be 
explored. The data will be combined with that from other Bimekizumab trials in psoriasis for a 
pooled, cross trial analysis. The details of this analysis will be described in a data analysis plan, 
and the analysis itself will be reported separately from the Clinical Study Report (CSR). 
Candidate biomarkers may include, but are not limited to: IL-17A/IL-17F pathway signaling and 
PSO biology (eg, IL-17A, IL-17F, IL-23, IL-6, TNF, DC-STAMP, and circulating osteoclast 
precursors). The details of the model and the approach will be specified in a data analysis plan. 
Pharmacodynamic variables will be analyzed for all subjects in the PD-PPS. 
Has been changed to:  
Section 14.5.2 Pharmacokinetic/pharmacodynamic analyses 
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit. 
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma 
concentration will be explored via graphical and a model based (PK-PD) approach to 
quantify the time course of dose/exposure response. In addition, the relationship between 
safety and exposure will also be explored. The data will be combined with that from other 
Bimekizumab trials in psoriasis for a pooled, cross trial analysis. The details of this analysis 
will be described in a data analysis plan, and the analysis itself will be reported separately 
from the Clinical Study Report (CSR). Candidate biomarkers may include, but are not 
limited to: IL-17A/IL-17F pathway signaling and PSO biology (eg, IL-17A, IL-17F, IL-23, 
IL-6, TNF, DC-STAMP, and circulating osteoclast precursors). The details of the model 
and the approach will be specified in a data analysis plan. 
Pharmacodynamic variables will be analyzed for all subjects in the PD-PPS. 
 
Change #55 
Section 14.6 Handling of protocol deviations 
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD outcomes 
for an individual subject. 
Has been changed to:  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD 
outcomes for an individual subject. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 205 of 209 
Change #56 
Section 17 References 
The following reference has been added: 
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improvement with anti-TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90-5. 
 
18.3 
Protocol Amendment 3 
Rationale for the amendment 
The purpose of this amendment was to update the secondary and “other” efficacy variables to be 
consistent with the wording in the statistical analysis plan (SAP). The secondary and “other” 
efficacy variables for the scalp IGA response, and the “other” efficacy variable for the IGA 
response were updated to clarify that the response required “at least a 2-category improvement 
from Baseline,” as it is described in the SAP. 
For the Patient Symptom Diary, the secondary and “other” efficacy variables were updated from 
“change from Baseline” to “response” on the items of itch, pain, and scaling in order to align the 
protocol with the planned responder analyses described in the SAP which define clinically 
meaningful thresholds of change for defining treatment response, rather than change from 
Baseline. The hierarchy figure (Figure 14.1) was also updated to reflect this change. There is no 
change to the frequency of diary assessments or how the diary assessments are performed.  
The name and contact information of the Clinical Trial Biostatistician was also changed. 
Change #1 
Clinical Trial Biostatistician 
Name: 
 
Address: 
8010 Arco Corporate Drive, Raleigh, NC 27617 
Phone: 
 
Fax: 
 
Have been changed to:  
Name: 
 
Address: 
208 Bath Road, Slough, SL1 3WE, UK 
Phone: 
 
Fax: 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 206 of 209 
Change #2 
Section 4.2.1  Secondary efficacy variables 
The following 2 bullets: 
 Change from Baseline in the Patient Symptom Diary responses for itch, pain, and scaling at 
Week 16 
 Scalp IGA response (Clear or Almost Clear) at Week 16 for subjects with scalp PSO at 
Baseline 
Have been changed to:  
 Change from Baseline in the Patient Symptom Diary responses for itch, pain, and scaling at 
Week 16 
 Scalp IGA response (Clear or Almost Clear with at least a 2-category improvement from 
Baseline) at Week 16 for subjects with scalp PSO at Baseline 
Change #3 
Section 4.3.1 Other efficacy variable(s) 
The following 2 bullets: 
 IGA response (Clear)  
 Change from Baseline in the Patient Symptom Diary responses 
 Scalp-specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear) for subjects with scalp PSO at Baseline 
Have been changed to:  
 IGA response (Clear with at least a 2-category improvement from Baseline)  
 Change from Baseline in the Patient Symptom Diary responses 
 Scalp-specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear with at least a 2-category improvement relative to Baseline) for subjects with scalp 
PSO at Baseline 
Change #4 
Section 9.11 Patient Symptom Diary responses 
A third paragraph has been added: 
The Patient Symptom Diary responses for itch, pain, and scaling at Week 16 will be 
computed based on the responder definition as well as the absolute and percent change 
from Baseline. Each of the Patient Symptom Diary response scores included in the 
statistical testing procedure (itch, pain, and scaling) will be characterized in terms of the 
cumulative percent of subjects demonstrating a pre-specified point improvement at 
Week16. The threshold for the Patient Symptom Diary response score of itch, pain, and 
scaling is 2.39, 1.98, and 2.86, respectively. The responder analysis will be limited to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 207 of 209 
subjects with a Baseline Patient Symptom Diary response score at or above the applicable 
threshold score (ie, at least 2.39, 1.98, and 2.86 for itch, pain, and scaling, respectively). 
Change #5 
Figure 14-1: Sequence of testing 
 
BL=Baseline; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom 
diary; PSO=psoriasis; PSSI=Psoriasis Scalp Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks. 
Has been changed to:  
 
BL=Baseline; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom 
diary; PSO=psoriasis; PSSI=Psoriasis Scalp Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 208 of 209 
19 
DECLARATION AND SIGNATURE OF INVESTIGATOR 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements. 
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol. 
I have received and read all study-related information provided to me. 
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB. 
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract. 
Investigator: 
 
 
 
 
Printed name  
 
Date/Signature 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
21 May 2019 
Clinical Study Protocol 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 209 of 209 
20 
SPONSOR DECLARATION 
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


Approval Signatures
Name:
ps0013-protocol-amend-3
Version:
1. 0
Document Number:
CLIN-000134878
Title:
PS0013 Protocol Amendment 3
Approved Date:
23 May 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 22-May-2019 20:10:38 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 23-May-2019 05:32:06 GMT+0000
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 23-May-2019 08:25:11 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 

SAP_001.pdf: 
UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 1 of 122 
STATISTICAL ANALYSIS PLAN  
Study: PS0013 
Product: Bimekizumab 
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH 
AN INITIAL TREATMENT PERIOD FOLLOWED BY A RANDOMIZED-WITHDRAWAL 
PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT 
SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS 
 
 
Confidentiality Statement 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB. 
SAP/Amendment Number Date 
Final SAP 
30 Aug 2018 
Amendment 1 
16 Sep 2019 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 2 of 122 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS .................................................................................................... 7 
1 
INTRODUCTION ........................................................................................................... 11 
2 
PROTOCOL SUMMARY ............................................................................................... 11 
2.1 
Study objectives ........................................................................................................... 11 
2.1.1 
Primary objective ................................................................................................. 11 
2.1.2 
Secondary objectives ........................................................................................... 11 
2.1.3 
Other objectives ................................................................................................... 11 
2.2 
Study variables ............................................................................................................. 12 
2.2.1 
Efficacy variables ................................................................................................ 12 
2.2.1.1 
Primary efficacy variables ......................................................................... 12 
2.2.1.2 
Secondary efficacy variables ..................................................................... 12 
2.2.1.3 
Other efficacy variables ............................................................................. 13 
2.2.2 
Pharmacokinetic variable ..................................................................................... 14 
2.2.3 
Safety variables .................................................................................................... 14 
2.2.3.1 
Secondary safety variables ........................................................................ 14 
2.2.3.2 
Other safety variables ................................................................................ 15 
2.2.4 
Pharmacogenomic variables ................................................................................ 15 
2.2.5 
Immunological variable ....................................................................................... 15 
2.3 
Study design and conduct ............................................................................................ 15 
2.3.1 
Study description ................................................................................................. 15 
2.3.2 
Study periods ....................................................................................................... 15 
2.3.2.1 
Screening Period ........................................................................................ 16 
2.3.2.2 
Initial Treatment Period ............................................................................. 16 
2.3.2.3 
Randomized-Withdrawal Period ............................................................... 16 
2.3.2.4 
Safety Follow-Up Period ........................................................................... 17 
2.3.2.5 
Escape Treatment Period ........................................................................... 17 
2.3.2.6 
Premature End of Treatment ..................................................................... 17 
2.3.3 
Study duration per subject ................................................................................... 17 
2.3.4 
Planned number of subjects and sites .................................................................. 18 
2.3.5 
Anticipated regions and countries ....................................................................... 18 
2.4 
Determination of sample size ....................................................................................... 18 
3 
DATA ANALYSIS CONSIDERATIONS ...................................................................... 18 
3.1 
General presentation of summaries and analyses ........................................................ 18 
3.2 
Definition of Baseline values ....................................................................................... 20 
3.3 
Mapping of data from early withdrawal visits ............................................................. 21 
3.4 
Protocol deviations....................................................................................................... 21 
3.5 
Analysis sets................................................................................................................. 21 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 3 of 122 
3.5.1 
Enrolled Set ......................................................................................................... 21 
3.5.2 
Randomized Set ................................................................................................... 21 
3.5.3 
Safety Set ............................................................................................................. 21 
3.5.4 
Full Analysis Set .................................................................................................. 21 
3.5.5 
Escape Subject Set ............................................................................................... 21 
3.5.6 
Week 16 Responder Set ....................................................................................... 22 
3.5.7 
Active Medication Set ......................................................................................... 22 
3.5.8 
Per-Protocol Set ................................................................................................... 22 
3.5.9 
Pharmacokinetics Per-Protocol Set ...................................................................... 22 
3.6 
Treatment assignment and treatment groups ............................................................... 22 
3.6.1 
Subjects Incorrectly Entering Randomized-Withdrawal or Escape Period ......... 22 
3.7 
Center pooling strategy ................................................................................................ 23 
3.8 
Coding dictionaries ...................................................................................................... 24 
3.9 
Relative day ................................................................................................................. 24 
3.10 
Changes to protocol-defined analyses ......................................................................... 24 
4 
STATISTICAL/ANALYTICAL ISSUES ....................................................................... 25 
4.1 
Adjustments for covariates .......................................................................................... 25 
4.2 
Handling of dropouts or missing data .......................................................................... 25 
4.2.1 
Handling missing data for efficacy variables ...................................................... 25 
4.2.1.1 
Handling missing data for the primary efficacy variable .......................... 26 
4.2.1.2 
Handling missing data for the secondary efficacy variables ..................... 26 
4.2.1.3 
Handling missing data for the other efficacy variables ............................. 26 
4.2.1.4 
Handling missing data for subgroup analyses ........................................... 26 
4.2.1.5 
Missing Data Overview and Summary...................................................... 26 
4.2.1.6 
Missing data algorithms ............................................................................ 27 
4.2.2 
Handling missing data for safety variables .......................................................... 31 
4.3 
Interim analyses and data monitoring .......................................................................... 32 
4.4 
Multicenter studies ....................................................................................................... 32 
4.5 
Multiple comparisons/multiplicity ............................................................................... 33 
4.6 
Use of an efficacy subset of subjects ........................................................................... 34 
4.7 
Active-control studies intended to show equivalence .................................................. 34 
4.8 
Examination of subgroups ........................................................................................... 34 
5 
STUDY POPULATION CHARACTERISTICS ............................................................. 35 
5.1 
Subject disposition ....................................................................................................... 35 
5.2 
Protocol deviations....................................................................................................... 35 
6 
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................ 35 
6.1 
Demographics .............................................................................................................. 35 
6.2 
Other Baseline characteristics ...................................................................................... 36 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 4 of 122 
6.3 
Medical history and concomitant diseases ................................................................... 37 
6.4 
Prior and concomitant medications .............................................................................. 37 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE ............................................... 38 
8 
EFFICACY ANALYSES ................................................................................................ 38 
8.1 
Statistical analysis of the primary efficacy variables ................................................... 38 
8.1.1 
Derivations of co-primary efficacy variables ...................................................... 38 
8.1.1.1 
Psoriasis Area and Severity Index (PASI) ................................................ 38 
8.1.1.2 
PASI90 Response at Week 16 ................................................................... 40 
8.1.1.3 
Investigator’s Global Assessment (IGA) Response at Week 16 ............... 40 
8.1.2 
Primary analysis of the co-primary efficacy variables ........................................ 40 
8.1.3 
Sensitivity analyses of the co-primary efficacy variables ................................... 41 
8.1.3.1 
Sensitivity Analysis #1 .............................................................................. 41 
8.1.3.2 
Sensitivity Analysis #2 .............................................................................. 41 
8.1.3.3 
Sensitivity Analysis #3 .............................................................................. 42 
8.1.3.4 
Sensitivity Analysis #4 .............................................................................. 42 
8.1.3.5 
Sensitivity Analysis #5 .............................................................................. 42 
8.1.3.6 
Sensitivity Analysis #6 .............................................................................. 42 
8.1.3.7 
Sensitivity Analysis #7 .............................................................................. 42 
8.2 
Statistical analysis of the secondary efficacy variables ............................................... 43 
8.2.1 
Derivations of Secondary efficacy variables ....................................................... 43 
8.2.1.1 
PASI100 Response at Week 16 ................................................................. 43 
8.2.1.2 
IGA Response at Week 16 ........................................................................ 43 
8.2.1.3 
PASI75 Response at Week 4 ..................................................................... 43 
8.2.1.4 
Patient Symptom Diary (PSD) .................................................................. 43 
8.2.1.5 
Scalp IGA Response (Clear or Almost Clear) at Week 16 ....................... 44 
8.2.1.6 
PASI90 Response at Week 56 among Week 16 PASI90 Responders ...... 44 
8.2.2 
Primary analysis of the secondary efficacy variables .......................................... 45 
8.2.2.1 
PASI responses .......................................................................................... 45 
 
IGA Response ............................................................................................ 45 
8.2.2.2 
45 
8.2.2.3 
Scalp IGA response ................................................................................... 45 
8.2.2.4 
PSD 46 
8.2.3 
Sensitivity analyses of the secondary efficacy variables ..................................... 46 
8.3 
Statistical analysis of Other Efficacy Variables........................................................... 47 
8.3.1 
PASI ..................................................................................................................... 48 
8.3.1.1 
PASI50, PASI75, PASI90, and PASI100 response ................................... 48 
8.3.1.2 
Time to PASI50, PASI75, PASI90, and PASI100 response ..................... 48 
8.3.1.3 
Time to relapse .......................................................................................... 48 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 5 of 122 
8.3.1.4 
Percentage of subjects who relapse ........................................................... 49 
8.3.1.5 
Percentage of subjects who rebound ......................................................... 49 
8.3.1.6 
PASI score ................................................................................................. 49 
8.3.1.7 
Modified Nail Psoriasis Severity Index (mNAPSI) score ......................... 49 
8.3.2 
IGA response ....................................................................................................... 50 
8.3.3 
BSA 51 
8.3.4 
Product of IGA and BSA (IGAxBSA) ................................................................ 51 
8.3.5 
Dermatology Life Quality Index (DLQI) ............................................................ 51 
8.3.6 
Patient’s Global Assessment of Disease Activity (PGADA) for arthritis visual 
analog scale (VAS) .............................................................................................. 53 
8.3.7 
Patient Global Assessment of PSO score ............................................................ 53 
8.3.8 
Patient Symptom Diary (PSD) ............................................................................. 53 
8.3.9 
Psoriatic Arthritis Screening and Evaluation (PASE) ......................................... 53 
8.3.10 
Short Form 36-item Health Survey (SF-36) ........................................................ 54 
8.3.11 
Euro-Quality of Life 5-Dimensions, 3 levels (EQ-5D-3L) ................................. 54 
8.4 
Additional statistical analysis of other efficacy variables ............................................ 55 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS .......................................... 56 
9.1 
Pharmacokinetics ......................................................................................................... 56 
9.2 
Immunogenicity ........................................................................................................... 57 
9.2.1 
Auto-antibodies .................................................................................................... 57 
9.2.2 
Anti-bimekizumab antibodies .............................................................................. 57 
10 SAFETY ANALYSES ..................................................................................................... 59 
10.1 
Extent of exposure ....................................................................................................... 60 
10.1.1 
Exposure during the Initial Treatment Period for SS .......................................... 60 
10.1.2 
Exposure during the Randomized-Withdrawal Period for WK16ResS .............. 61 
10.1.3 
Exposure during the Escape Period for ESS ........................................................ 62 
10.1.4 
Exposure during the Initial and Randomized-Withdrawal for AMS ................... 63 
10.2 
Adverse events ............................................................................................................. 66 
10.2.1 
Data considerations .............................................................................................. 66 
10.2.2 
AE Summaries ..................................................................................................... 68 
10.2.3 
Other Safety topics of interest ............................................................................. 69 
10.2.3.1 
Infections (serious, opportunistic, fungal and TB) .................................... 69 
10.2.3.2 
Malignancies ............................................................................................. 71 
10.2.3.3 
Major adverse cardiac event ...................................................................... 72 
10.2.3.4 
Neutropenia ............................................................................................... 72 
10.2.3.5 
Suicidal Ideation and Behavior ................................................................. 73 
10.2.3.6 
Inflammatory bowel disease ...................................................................... 73 
10.2.3.7 
Hypersensitivity (including anaphylaxis) .................................................. 73 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 6 of 122 
10.2.3.8 
Hepatic events and DILI ............................................................................ 73 
10.3 
Clinical laboratory evaluations .................................................................................... 74 
10.4 
Vital signs, physical findings, and other observations related to safety ...................... 76 
10.4.1 
Vital signs ............................................................................................................ 76 
10.4.2 
Physical examination ........................................................................................... 77 
10.4.3 
Electrocardiograms .............................................................................................. 77 
10.4.4 
Other safety variables .......................................................................................... 77 
10.4.4.1 
Assessment and management of TB and TB risk factors .......................... 77 
10.4.4.2 
Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) .............. 78 
10.4.4.3 
Pregnancy testing ...................................................................................... 78 
10.4.4.4 
Childbearing potential and Lifestyle ......................................................... 78 
10.4.4.5 
Patient Health Questionnaire (PHQ)-9 scores ........................................... 78 
11 REFERENCES ................................................................................................................ 79 
12 APPENDIX ...................................................................................................................... 80 
12.1 
Appendix A: MedDRA algorithmic approach to anaphylaxis ..................................... 80 
12.2 
Appendix B: Definition of CTCAE grades .................................................................. 83 
13 AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN ................................. 83 
13.1 
AMENDMENT 1......................................................................................................... 83 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE ................................................... 122 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 7 of 122 
LIST OF ABBREVIATIONS 
ADAb 
anti-bimekizumab antibodies 
AE 
adverse event 
AH 
abnormal high 
AL 
abnormal low 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AMS 
Active Medication Set 
ANCOVA 
analysis of covariance 
AST 
aspartate aminotransferase 
ATC 
Anatomical Therapeutic 
BKZ 
bimekizumab 
BLQ 
below level of quantification 
BMI 
body mass index 
BSA 
body surface area 
CDF 
cumulative distribution function 
CI 
confidence interval 
CMH 
Cochran-Mantel-Haenszel 
CSR 
Clinical Study Report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
cardiovascular 
DILI 
drug-induced liver injury 
DLQI 
Dermatology Life Quality Index 
DMC 
Data Monitoring Committee 
EAER 
exposure adjusted event rate 
EAIR 
exposure adjusted incidence rate 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
eC-SSRS 
electronic Columbia Suicide Severity Rating Scale 
ePRO 
electronic Patient-Reported Outcome 
EQ-5D-3L 
Euro-Quality of Life 5-Dimensions, 3 levels 
ES 
Enrolled Set 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 8 of 122 
ESS 
Escape Subject Set 
EudraCT 
European Union Drug Regulating Authorities Clinical Trials 
FAS 
Full Analysis Set 
GGT 
gamma-glutamyltransferase 
HLT 
High Level Term 
ICF 
Informed Consent Form 
IDC 
Infectious Disease Committee 
IGA 
Investigator’s Global Assessment 
IGRA 
interferon-gamma release assay 
IL 
interleukin 
IMP 
investigational medicinal product 
LLOQ 
Lower level of quantification 
LOCF 
last observation carried forward  
LFT 
liver function test 
mNAPSI 
Modified Nail Psoriasis Severity Index Score 
MACE 
Major cardiovascular events 
MAR 
missing at random 
MCID 
minimal clinically important difference 
MCMC 
Markov-Chain Monte Carlo 
MCS 
Mental Component Summary 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
multiple imputation 
MNAR 
missing not at random 
nADAb 
Neutralizing anti-bimekizumab antibodies 
NRI 
nonresponder imputation 
OC 
Observed case 
PASE 
Psoriatic Arthritis Screening and Evaluation 
PASI 
Psoriasis Area Severity Index 
PCS 
Physical Component Summary 
PEOT 
Premature End of Treatment 
PF 
physical functioning 
PGA 
Physician’s Global Assessment 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 9 of 122 
PGADA 
Patient’s Global Assessment of Disease Activity 
PHQ-9 
Patient Health Questionnaire 9 
PK 
pharmacokinetics 
PK-PPS 
Pharmacokinetics Per-Protocol Set 
pp-IGA 
palmoplantar Investigator’s Global Assessment 
PPS 
Per-Protocol Set 
PRO 
patient-reported outcome 
PS 
Patient Safety 
PsA 
psoriatic arthritis 
PSD 
patient symptom diary 
PSO 
psoriasis 
PT 
preferred term 
Q4W 
every 4 weeks 
Q8W 
every 8 weeks 
QOL 
quality of life 
RS 
Randomized Set 
SAE 
serious adverse event 
SIB 
suicidal ideation and behavior 
SAP 
Statistical Analysis Plan 
sc 
subcutaneously 
scalp IGA 
scalp-specific IGA 
SD 
standard deviation 
SF-36 
Short Form 36-item Health Survey 
SFU 
Safety Follow-Up 
SMQ 
Standard MedDRA query 
SOC 
system organ class 
SS 
Safety Set 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event 
TNF 
tumor necrosis factor 
ULN 
upper limit of normal 
VAS 
visual analog scale 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 10 of 122 
WBC 
white blood cell 
WHO-DD 
World Health Organization Drug Dictionary 
WK16ResS Week 16 Responder Set 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 11 of 122 
1 
INTRODUCTION 
This statistical analysis plan (SAP) defines the scope of statistical analyses and provides a 
detailed description of statistical methodology for the statistical analyses to support the final 
clinical study report (CSR). The SAP is based on the following study document: Protocol 
Amendment 3, 21 May 2019. 
2 
PROTOCOL SUMMARY 
2.1 
Study objectives 
2.1.1 
Primary objective 
The primary objective of the study is to compare the efficacy of bimekizumab (BKZ) 
administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of subjects with 
moderate to severe chronic plaque psoriasis (PSO). 
2.1.2 
Secondary objectives 
The secondary objectives of the study are to: 
 Evaluate the efficacy of bimekizumab compared to placebo at achieving complete clearance 
(Psoriasis Area and Severity Index [PASI]100) after 16 weeks of treatment 
 Evaluate the efficacy of bimekizumab compared to placebo after 4 weeks of treatment 
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subjects using the Patient Symptom Diary 
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline 
 Evaluate the efficacy of continuous treatment with bimekizumab versus treatment withdrawal 
(placebo) as defined by PASI90 at Week 56 for subjects who responded to bimekizumab 
treatment at Week 16 
 Assess the maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56 
 Assess treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and 
TEAEs leading to withdrawal adjusted by duration of subject exposure to study treatment 
2.1.3 
Other objectives 
The other objectives of the study are to demonstrate the effects of bimekizumab on aspects of the 
disease: 
 Assess the time to relapse among subjects who responded to bimekizumab treatment at 
Week 16 
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab in subjects who 
relapse (defined as not achieving a PASI75 response) during the Randomized-Withdrawal 
Period 
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab for subjects who do 
not achieve a PASI90 response (defined as a subject that does not achieve 90% reduction in 
the PASI score) at Week 16 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 12 of 122 
 Assess the efficacy of bimekizumab over time 
 Assess the efficacy of bimekizumab dosing Q4W versus Q8W during the Randomized-
Withdrawal Period 
 Assess the change of skin-related quality of life (QOL) 
 Assess the change of general health-related QOL 
 Assess the change in nail PSO over time in subjects with nail PSO at Baseline 
 Assess the change in scalp PSO over time in subjects with scalp PSO at Baseline 
 Assess the change in palmoplantar PSO over time in subjects with palmoplantar PSO at 
Baseline 
 Assess the symptoms of psoriatic arthritis (PsA) as measured by the Psoriatic Arthritis 
Screening and Evaluation (PASE) questionnaire 
 Assess the change of patient-reported joint symptoms in subjects with PsA at Baseline 
 Assess the change in symptoms of PSO as reported by subjects using the Patient Symptom 
Diary (all items) through Week 16 
 Assess depression  
 Assess the pharmacokinetics (PK) of bimekizumab 
 Assess the immunogenicity of bimekizumab 
 Assess the effect of bimekizumab on gene and protein expression, and explore the 
relationship between genomic, genetic, and proteomic biomarkers and disease biology, drug 
treatment and inflammatory and immune responses (from consenting subjects who agree to 
participate in the biomarker substudy) 
 Assess the safety and tolerability of bimekizumab  
2.2 
Study variables 
2.2.1 
Efficacy variables 
2.2.1.1 
Primary efficacy variables 
The co-primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% reduction from Baseline in the PASI score) at Week 16 and the Investigator’s Global 
Assessment (IGA) response (defined as Clear or Almost Clear with at least a 2-category 
improvement relative to Baseline) at Week 16. 
2.2.1.2 
Secondary efficacy variables 
The secondary efficacy variables are: 
 PASI100 response at Week 16 
 IGA response (defined as Clear with at least a 2-category improvement relative to Baseline) 
at Week 16 
 PASI75 response at Week 4 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 13 of 122 
 Patient Symptom Diary responses for itch, pain, and scaling at Week 16 
 Scalp IGA response (Clear or Almost Clear with at least a two-category improvement from 
Baseline) at Week 16 for subjects with scalp PSO at Baseline 
 PASI90 response at Week 56 among Week 16 PASI90 responders 
2.2.1.3 
Other efficacy variables 
Change from Baseline variables evaluated during the Initial Treatment Period are relative to the 
Baseline (first dose) Visit. For subjects who are re-randomized at the Week 16 Visit, change 
from Baseline variables during the Randomized-Withdrawal Period may be evaluated relative to 
both the Baseline (first dose) Visit and the Week 16 Visit. Similarly, for subjects who initiate 
escape treatment with bimekizumab (either due to lack of response at Week 16 or loss of 
response [relapse] during the Randomized-Withdrawal Period), these variables during the 
12-week escape treatment period may be evaluated relative to both the Baseline Visit (first dose) 
and the visit at which escape treatment was initiated. 
For simplicity, “change from Baseline” is used below for all such variables and applies to all 
scheduled visits where the assessments were performed (whether during the Initial Period, 
Randomized-Withdrawal Period, or Escape Treatment Period). Greater detail on the definition of 
Baseline for different summaries is provided in the Section 3.2. Unless otherwise stated, PASI 
responder rates will be calculated relative to the Baseline (first dose) Visit. 
The other efficacy variables are listed below and will be summarized for all time points specified 
in the protocol schedule of assessments, with the exception of the previously defined primary 
and secondary efficacy variables (which will be summarized separately): 
 PASI50, PASI75, PASI90, and PASI100 response 
 Time to PASI50, PASI75, PASI90, and PASI100 response during the Initial Treatment 
Period 
 Time to relapse during the Randomized-Withdrawal Period 
 Percentage of subjects who relapse during the Randomized-Withdrawal Period 
 Percentage of subjects who rebound (defined as a ≥25% increase from Baseline in PASI 
score occurring within 2 months of stopping therapy) during the Randomized-Withdrawal 
Period 
 Absolute and percent change from Baseline in PASI score 
 Percent of subjects with absolute PASI score ≤1, ≤2, ≤3, and ≤5 
 IGA response (Clear with at least 2-category improvement from Baseline) 
 IGA response (Clear or Almost Clear with at least 2-category improvement from Baseline) 
 Shift from Baseline in IGA score 
 Absolute and percent change from Baseline in the body surface area (BSA) affected by PSO 
 Percent of subjects with absolute BSA=0%, ≤1%, ≤3%, and ≤5% 
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 14 of 122 
 Change from Baseline in Dermatology Life Quality Index (DLQI) 
 Percentage of subjects achieving a DLQI total score of 0 or 1 
 Percentage of subjects achieving a minimal clinically important difference (MCID) 
(improvement from Baseline of 4 or more) in the DLQI 
 Change from Baseline in the Patient’s Global Assessment of Disease Activity (PGADA) for 
the arthritis visual analog scale (VAS) in the subgroups of subjects with PsA as defined by 
PASE score at Baseline 
 Change from Baseline in Patient Global Assessment (PGA) of PSO score 
 Patient Symptom Diary responses 
 Scalp-specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear with at least 2-category improvement relative to Baseline) for subjects with scalp PSO 
at Baseline 
 Change from Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) score for 
subjects with nail PSO at Baseline 
 mNAPSI75 response (defined as a subject that achieves at least a 75% reduction from 
Baseline in the mNAPSI score) 
 mNAPSI90 response (defined as a subject that achieves at least a 90% reduction from 
Baseline in the mNAPSI score) 
 mNAPSI100 response (defined as a subject that achieves at least a 100% reduction from 
Baseline in the mNAPSI score) 
 Palmoplantar Investigator’s Global Assessment (pp-IGA) response (Clear or Almost Clear 
with at least 2-category improvement relative to Baseline) for subjects with palmoplantar 
PSO at Baseline 
 Change from Baseline in the PASE questionnaire scores (function score, symptom score, and 
total score) 
 Shift from Baseline in PASE score suggestive of PsA (<47 versus ≥47) 
 Change from Baseline in Short Form 36-item Health Survey (SF-36) Physical Component 
Summary (PCS) score, and Mental Component Summary (MCS) score, and individual 
domains 
 Responses to Euro-Quality of Life 5-Dimensions, 3 levels (EQ-5D-3L), absolute and changes 
from Baseline in EQ-5D-3L VAS scores 
2.2.2 
Pharmacokinetic variable 
The PK variable is the plasma concentration of bimekizumab. 
2.2.3 
Safety variables 
2.2.3.1 
Secondary safety variables 
 TEAEs adjusted by duration of subject exposure to study treatment 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 15 of 122 
 SAEs adjusted by duration of subject exposure to study treatment 
 TEAEs leading to withdrawal adjusted by duration of subject exposure to study treatment 
2.2.3.2 
Other safety variables 
 Severity and frequency of AEs (including serious AEs) 
 Change from Baseline in vital signs 
 Electrocardiogram (ECG) results 
 Change from Baseline in clinical laboratory values (chemistry and hematology) 
 Change from Baseline in Patient Health Questionnaire (PHQ)-9 scores 
2.2.4 
Pharmacogenomic variables 
Additional blood samples will be collected from subjects who consent to participate in the 
substudy at specific time points and stored at -80°C for up to 20 years. 
Genomic, genetic, epigenetic, proteins, and metabolite biomarkers may be measured to evaluate 
the relationship with response to treatment with bimekizumab, PSO disease biology, and 
inflammatory and immune response processes. The nature and format of these tentative substudy 
analyses will be determined when the results of the main study are made available. 
The candidate exploratory variables are the blood or blood derivative (e.g., serum) 
concentrations of cytokines and chemokines of relevance to IL-17A/F signaling pathway and 
PSO biology. Additional variables may include but will not be limited to serum complement 
concentrations. 
2.2.5 
Immunological variable 
The immunological variable is the anti-bimekizumab antibody level prior to and following 
investigational medicinal product (IMP). 
2.3 
Study design and conduct 
2.3.1 
Study description 
PS0013 is a Phase 3, multicenter, randomized, double-blind placebo-controlled study consisting 
of a 16-week Initial Treatment Period followed by a 40-week Randomized-Withdrawal Period to 
evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. To be eligible to participate in this study, subjects must be adults with a 
diagnosis of moderate to severe PSO (Baseline PASI ≥12 and BSA affected by PSO ≥10% and 
IGA score ≥3 [on a 5-point scale]) who are a candidate for systemic PSO therapy and/or 
phototherapy. Subjects may have been previously exposed to a biologic therapy. 
2.3.2 
Study periods 
This study will include 4 periods, a Screening Period (2 to 5 weeks), a placebo-controlled Initial 
Treatment Period (16 weeks), a placebo-controlled Randomized-Withdrawal Period (40 weeks), 
and a Safety Follow-Up (SFU) Period (20 weeks after the last dose of IMP). After completing 
the study, eligible subjects will be allowed to enroll in an open-label study. Subjects enrolling 
into the open-label study will not have the PS0013 SFU Visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 16 of 122 
Subjects who do not achieve a PASI90 response at Week 16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section 2.3.2.5). All subjects who relapse at Week 20 or 
later during the Randomized-Withdrawal Period (up to Week 56) will be allocated to escape 
treatment (see Section 2.3.2.5). Relapse is defined as not achieving a PASI75 response. Subjects 
who achieve a PASI50 response at Week 12 of the open-label escape arm will be allowed to 
enroll in the open-label study. 
Subjects who complete the Randomized-Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll in an 
open-label study. Placebo-randomized subjects, who receive placebo during the entire Initial and 
Randomized-Withdrawal periods, that complete Week 56 without relapse into the open-label 
escape arm will not be eligible for the open-label study. 
2.3.2.1 
Screening Period 
The Screening Period will last 2 weeks, but can be extended up to a total of 5 weeks in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications. During this time, eligible subjects will be informed about the study and sign the 
Informed Consent Form (ICF), laboratory data (hematology, urine, and biochemistry tests) will 
be obtained, and the doses of medications used to treat PsA, will be verified as stable. The 
Screening Period will also enable washout of any medications not permitted for use during the 
study. Subjects who require prophylaxis for latent tuberculosis infection must be on treatment for 
at least 8 weeks prior to their first dose of IMP. These subjects may be rescreened once they have 
completed the first 8 weeks of prophylaxis treatment. 
One rescreening may be allowed after consultation with the Medical Monitor. 
2.3.2.2 
Initial Treatment Period 
During the placebo-controlled Initial Treatment Period, approximately 400 subjects will be 
randomized 4:1 to receive the following blinded IMP regimens: 
 Bimekizumab 320mg administered Q4W (320 subjects) 
 Placebo administered Q4W (80 subjects) 
Subjects will be followed in a double-blind fashion. Subjects may receive placebo injections at 
certain visits in order to blind the IMP.  
Subjects withdrawing early from the study will undergo the Premature End of Treatment (PEOT) 
Visit assessments and will enter the SFU Period. Subjects withdrawing early from the study will 
not be eligible for inclusion in the open-label study. 
2.3.2.3 
Randomized-Withdrawal Period 
At the Week 16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double-blind, placebo-controlled Randomized-Withdrawal Period lasting 40 weeks. 
Subjects who do not achieve a PASI90 response at the Week 16 study visit will be allocated to 
the escape arm (see Section 2.3.2.5). 
During the Randomized-Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 17 of 122 
 Subjects initially randomized to bimekizumab 320mg Q4W will be re-randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (i.e., treatment 
withdrawal) 
 All subjects initially randomized to placebo who achieve a PASI90 response at Week 16 will 
continue to receive placebo (Q4W) 
Investigational medicinal product will be administered in the clinic at Week 16 and Q4W 
thereafter through Week 52.  
All subjects who relapse at Week 20 or later during the Randomized-Withdrawal Period (up to 
Week 56) will be allocated to the escape arm (see Section 2.3.2.5). Relapse is defined as not 
achieving a PASI75 response. 
At the end of the Randomized-Withdrawal Period, all subjects enrolling in the open-label study 
(after signing a new ICF) will undergo the Week 56 study assessments before receiving their first 
dose of IMP in the open-label study. All subjects not enrolling in the open-label study will have 
the Week 56 study assessments and will enter the SFU Period. 
2.3.2.4 
Safety Follow-Up Period 
All subjects not continuing in the open-label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their last dose of IMP. 
2.3.2.5 
Escape Treatment Period 
As described above, subjects who do not achieve a PASI90 response at Week 16 of the Initial 
Treatment Period and all subjects who relapse at Week 20 or later during the Randomized-
Withdrawal Period (up to Week 56) will receive open-label bimekizumab 320mg Q4W for 
12 weeks (i.e. escape treatment). 
For subjects who relapse during the Randomized-Withdrawal Period, the subject should 
complete the 12-week escape treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped). 
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open-label study.  
2.3.2.6 
Premature End of Treatment 
Subjects withdrawing early from the study will undergo PEOT Visit assessments and will enter 
the SFU Period. 
2.3.3 
Study duration per subject 
For each subject (of those not entering Escape treatment), the study will last a maximum of up to 
77 weeks, as follows: 
 Screening Period: 2 to 5 weeks 
 Double-blind, placebo-controlled Initial Treatment Period: 16 weeks 
 Double-blind, placebo-controlled Randomized-Withdrawal Period: 40 weeks 
 Escape treatment (if required): 12 weeks 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 18 of 122 
 Safety Follow-Up Period: a SFU Visit is planned 20 weeks after the last dose of IMP (for 
subjects not enrolling in the open-label study) 
After the 40-week Randomized-Withdrawal Period, subjects will be allowed to enroll in an open-
label study, in which case subjects will undergo the Week 56 study assessments before receiving 
their first open-label IMP dose. Subjects who achieve a PASI50 response in the open-label 
escape arm will also be allowed to enroll in the open-label study. The SFU Visit will not be 
required for subjects who enroll in the open-label study. Subjects who complete the 
Randomized-Withdrawal Period (after a Week 16 response [≥PASI90] on bimekizumab during 
the Initial Treatment Period) will be allowed to enroll in an open-label study. Placebo-
randomized subjects who receive placebo during the entire Initial and Randomized-Withdrawal 
periods, that complete Week 56 without relapse into the open-label escape arm will not be 
eligible for the open-label study. 
The end of the study is defined as the date of the last visit of the last subject in the study.  
2.3.4 
Planned number of subjects and sites 
Approximately 535 subjects will be screened in order to have 400 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. The planned number of study sites is approximately 100. 
Every eligible subject who signs an ICF will be randomized. 
2.3.5 
Anticipated regions and countries 
The regions planned for study conduct are Western Europe, Central/Eastern Europe, North 
America and Asia/Australia, with possible extension to other regions and countries. 
2.4 
Determination of sample size 
A total of 400 subjects will be randomly assigned in a 4:1 ratio to the following treatment 
groups: 
 Bimekizumab 320mg (320 subjects) 
 Placebo (80 subjects) 
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co-
primary efficacy variables of PASI90 response and IGA response at Week 16. The assumed 
responder rates for PASI90 at Week 16 are 75% and 2% for bimekizumab and placebo, 
respectively. Additionally, the assumed responder rates for IGA are 85% and 5% for 
bimekizumab and placebo, respectively. The assumed responder rates for bimekizumab are 
based on the Phase 2b PS0010 data. The power to show statistical superiority of bimekizumab 
relative to placebo under these assumptions is >99% for the co-primary endpoints. 
3 
DATA ANALYSIS CONSIDERATIONS 
3.1 
General presentation of summaries and analyses 
Statistical analysis and generation of tables, figures, subject data listings, and statistical output 
will be performed using SAS Version 9.3 or higher. All tables and listings will use Courier New 
font size 9.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 19 of 122 
Descriptive statistics will be displayed to provide an overview of the study results. For 
continuous variables, descriptive statistics will include number of subjects with available 
measurements (n), mean, standard deviation (SD), median, minimum, and maximum.  
For categorical variables, the number and percentage of subjects in each category will be 
presented. Unless otherwise noted, the denominator for percentages should be based on the 
number of subjects included in the respective analysis set. Subjects with missing data will be 
accounted for using the following approaches: 
 For summaries of demographics and Baseline characteristics: summarize percentages based 
on all subjects in the analysis set and include a “Missing” category (corresponding to subjects 
with missing data for the variable being summarized) as the last row in the list of categories 
being summarized. 
 For summaries of efficacy and safety endpoints unless otherwise specified: summarize 
percentages based only on those subjects with observed data for the variable being 
summarized. As the denominator may be different from the number of subjects in the 
analysis set being considered, the denominator will be displayed in the table. The general 
format for displaying this will be “n/Nsub (%).” 
Percentages will be presented to 1 decimal place.  If the percentage is 100%, do not present a 
decimal. If the percentage is 0, do not present the percentage. Typically, the % sign should be 
presented in the column header, but not with each individual value. 
For bimekizumab PK concentrations, summary statistics will include geometric mean, geometric 
coefficient of variation (CV), 95% confidence intervals for geometric mean, arithmetic mean, 
SD, median, minimum, and maximum.  All summaries of PK variables will be based on the 
observed values. No imputation will be used. 
Decimal places for descriptive statistics will always apply the following rules: 
 “n” will be an integer 
 Mean, SD, and median will use one additional decimal place compared to the original data 
 CV [%] will be presented with one decimal place 
 Minimum and maximum will have the same number of decimal places as the original value. 
Derived variables in general will display the mean, SD and median to 1 more decimal place than 
the variables used in the derivation. If the number of decimal places reported in the raw data is 
varied then use either the maximum raw number of reported decimal places or 3, whichever is 
the lowest, as a guide for the descriptive statistics. 
Statistical tests of efficacy variables will be presented as two-sided p-values rounded to three 
decimal places. P-values less than 0.001 will be presented as “<0.001” and p-values greater than 
0.999 will be presented as “>0.999.” Statistical comparisons will be two-sided and will be 
performed at the 0.05 level of significance. 
Per protocol, visit windows of ±3 days from the first dose to Week 24 and ±7 days from Week 
28 to Week 52 are permissible. For the Week 56 visit, the visit window is±3 days. For the SFU 
Visit, visit window is ±7 days from final dose.  All by-visit summaries will contain nominal (i.e. 
scheduled) visits only. Unscheduled visits will not be mapped to scheduled visits except for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 20 of 122 
assessments that occur within a 3-day time window of a scheduled visit. In that case, the 
assessment will be mapped to the corresponding scheduled visit and will be used for the analysis. 
This will only occur for some vendor data. 
A complete set of data listings containing all documented data as well as calculated data (e.g., 
change from Baseline) will be generated. 
3.2 
Definition of Baseline values 
A Baseline value for a subject is defined as the latest measurement for that subject up to and 
including the day of administration of first study medication, unless otherwise stated. If a 
Baseline assessment is taken on the same day as first administration of study medication, it is 
eligible to be used as the Baseline value, even in the case that the time of the assessment is 
recorded as taking place after the time of first study medication administration. This is 
considered acceptable as this measurement is still the best representation of the Baseline value of 
the given assessment since it is highly unlikely that the study medication could have an impact 
on any measurement in such a short period of time. However, such cases should be rare as study 
center personnel are instructed to do all assessments at the Baseline visit prior to administering 
study medication. One exception to this rule is plasma concentration. If Baseline plasma 
concentration is measured at a time after the first administration of study medication, then it 
should not be eligible to be considered as a Baseline plasma concentration. Such cases should be 
discussed with the quantitative clinical pharmacologist. If a Baseline visit measurement is 
missing, and a Screening visit measurement is available, the Screening value will be utilized as 
Baseline. 
For subjects who are re-randomized at the Week 16 Visit, change from Baseline variables during 
the Randomized-Withdrawal Period may be evaluated relative to both the Baseline (first dose) 
Visit and the Week 16 Visit. For the latter, the Baseline is defined as the latest measurement on 
or prior to the first dose in the Randomized-Withdrawal Period (intended to be Week 16). 
Similarly, for subjects who initiate escape treatment with bimekizumab (either due to lack of 
response at Week 16 or loss of response [relapse] during the Randomized-Withdrawal Period), 
these variables during the 12-week escape treatment period may be evaluated relative to both the 
Baseline Visit (first dose) and the visit at which escape treatment was initiated. For the latter, the 
Baseline is defined as the latest measurement on or prior to the first dose in the Escape  Period 
(for those who escape due to lack of response at Week 16) or the latest measurement on or prior 
to the visit at which escape treatment is initiated.  
An additional Baseline for Week 16 and the visit at which escape treatment was initiated (as 
described above) are defined for the following variables: 
 PASI score 
 DLQI 
 Laboratory data 
Baseline values for component scores should be computed using components from the same visit 
where the relevant measurements were recorded prior to dosing. For example, if the Screening 
visit has all of the components, but the Baseline visit is missing one or more components, the 
Baseline value for the component score should be calculated using the Screening visit values.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 21 of 122 
3.3 
Mapping of data from early withdrawal visits 
If the early withdrawal visit occurs at a scheduled visit as outlined in the schedule of 
assessments, then no mapping is necessary, and any early withdrawal assessments should 
correspond to that scheduled visit. Premature study withdrawal visit assessments that occur on a 
date after a scheduled visit will be assigned to the next scheduled site visit per the protocol 
following the last visit where assessments were available. This approach means that there is a 
chance that data will be mapped to a visit where a given assessment was not actually collected 
per the protocol schedule of assessments. Such data will not be summarized in by-visit tables 
(though it will be available in the listings).  
The only exception to the above rule is for anti-bimekizumab antibody assessments, in which all 
early withdrawal visit assessments will be assigned to the next scheduled visit at which anti-
bimekizumab antibodies are assessed. All by-visit summaries will contain nominal visits only. 
Unscheduled visits will not be mapped to scheduled visits. Note that based on the early 
withdrawal mapping conventions described above, a mapped early withdrawal visit is considered 
as observed at that visit and should be summarized as such in the tables.   
3.4 
Protocol deviations 
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct or on the primary efficacy, key safety, or PK outcomes for 
an individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document at study start. Important protocol deviations 
will be reviewed as part of the ongoing data cleaning process. Important protocol deviations 
including those that lead to exclusion from the analysis sets will be identified and documented 
prior to unblinding. 
3.5 
Analysis sets 
For all analysis sets, each unique subject is only counted once, even if the same subject has more 
than one unique subject identifier. 
3.5.1 
Enrolled Set 
The Enrolled Set (ES) will consist of all subjects who have given informed consent. 
3.5.2 
Randomized Set 
The Randomized Set (RS) will consist of all randomized subjects. 
3.5.3 
Safety Set 
The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.    
3.5.4 
Full Analysis Set 
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each of the co-primary efficacy variables at 
Baseline. 
3.5.5 
Escape Subject Set 
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week 16 or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 22 of 122 
experiencing a relapse after entering the Randomized-Withdrawal Period. Summaries based on 
the ESS will be split between subjects who enter the escape arm: 1) due to PASI90 non-response 
at Week 16 or 2) due to relapse during the Randomized-Withdrawal Period (after achieving 
PASI90 response at Week 16). 
3.5.6 
Week 16 Responder Set 
The Week 16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week 16 and receive at least 1 dose of the IMP during the Randomized-Withdrawal 
Period at Week 16 or later. 
3.5.7 
Active Medication Set 
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab). The AMS will be used for summaries of safety that include all 
data from the Initial Treatment Period and/or Randomized-Withdrawal Period. 
3.5.8 
Per-Protocol Set 
The Per-Protocol Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the co-primary efficacy variables. Important protocol deviations will be pre-
defined and subjects with important protocol deviations will be evaluated during ongoing data 
cleaning meetings prior to unblinding of the data.  
3.5.9 
Pharmacokinetics Per-Protocol Set 
The Pharmacokinetics Per-Protocol Set (PK-PPS) consists of all randomized subjects who 
received at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration 
post-dose without important protocol deviations that would affect the concentration. 
3.6 
Treatment assignment and treatment groups 
It is expected that subjects receive treatment as randomized and hence safety analyses will be 
based on the SS, as randomized. However, if after unblinding it is determined that subjects 
randomized to placebo received bimekizumab at any time, then for safety analyses these subjects 
will be reallocated to the appropriate bimekizumab treatment group, unless otherwise specified.  
Subjects randomized to bimekizumab will only be reallocated to the placebo treatment group if 
they never received bimekizumab. Efficacy analyses will be according to randomized treatment 
and not actual treatment received. 
3.6.1 
Subjects Incorrectly Entering Randomized-Withdrawal or Escape 
Period 
Subjects who enter the Escape Period without meeting the escape criteria, or subjects who meet 
the criteria but don’t enter the Escape Period, will be summarized as follows for efficacy 
analyses: 
1. If a subject meets escape criterion at Week 16 (<PASI90) but does not enter into the Escape 
Period at Week 16, then their data during the Randomized-Withdrawal Period will not be 
summarized in any table as they did not fulfill the definition for inclusion in the WK16ResS. 
Selected data from the Randomized-Withdrawal Period will be listed only. 
2. If a subject meets escape criterion during the Randomized-Withdrawal Period (<PASI75) but 
does not enter into the Escape Period at the corresponding visit, then their data following the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 23 of 122 
visit at which they meet the escape criterion will be treated as missing in summaries based on 
the WK16ResS and will be subject to imputation as appropriate.  
3. If a subject enters the Escape Period without meeting escape criterion at the corresponding 
visit, they will not be in the ESS. These subjects also do not qualify for inclusion in the 
WK16ResS. Selected data corresponding to the Randomized Withdrawal Period and Escape 
Period for these subjects will be listed only. 
4. For subjects incorrectly entered into the Randomized-Withdrawal or Escape Period, a listing 
for some efficacy variables (e.g. PASI and IGA) and listing for all TEAE will be provided.  
3.7 
Center pooling strategy 
The subject treatment assignment is stratified by prior biologic exposure and region. Geographic 
regions have been categorized as North America, Western Europe, Central/Eastern Europe and 
Asia/Australia. Below is a table of geographic regions with corresponding countries.  
Table 3‒1: 
Geographic regions and corresponding countries 
Region 
Countries 
North America 
Canada, United States 
Western Europe 
Germany, United Kingdom 
Central/Eastern Europe 
Hungary, Poland, Russian Federation 
Asia/Australia 
Australia, Republic of Korea  
The following center pooling algorithm will be used for each geographic region: 
 If a center has 15 or more subjects, then no pooling will be done for that center. 
 Centers with fewer than 15 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner: 
 Two or more centers will be combined until the cumulative subject total is at least 15. 
 Once a pooled center has at least 15 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 15 subjects has been reached in the previous pool. 
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 15 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration. 
This procedure is only to be performed within a geographic region – there will be no pooling of 
centers across regions. 
In the event that the percentage of randomized subjects is less than 10% in either of the 
Asia/Australia or Western Europe region, then the two regions will be combined as a geographic 
region stratum for all efficacy modeling, so that there are no modeling convergence issues across 
efficacy variables.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 24 of 122 
3.8 
Coding dictionaries 
All medications other than study drug will be classified by WHO Anatomical Therapeutic 
Chemical (ATC) Classification, presenting Anatomical Main Group (ATC Level 1), 
Pharmacological Subgroup (ATC level 3), and preferred term, using version SEP/2015 of the 
World Health Organization Drug Dictionary (WHO-DD), according to UCB standard operating 
procedures 
All AEs will be classified by primary system organ class (SOC), high level term (HLT) and 
preferred term (PT) using version 19.0 of MedDRA® according to UCB standard operating 
procedures.  
Previous and ongoing medical history will be classified by version 19.0 of MedDRA® SOC and 
PT. 
3.9 
Relative day 
The relative day will be included in different listings and will be calculated as follows: 
 If the start (stop) date occurred on or after the first dose, but prior to the  drug stop date, 
relative day is calculated as start (stop) date minus first dose date + 1 
 If the start (stop) date occurred after the last dose of  drug, the relative day to the most recent 
dose is calculated as start (stop) date minus most recent dose date. The relative day in this 
situation should be preceded by a ‘+’ 
 If the start (stop) date occurred before the first dose, the relative day is calculated as start 
(stop) date minus first dose date. The relative day in this situation should be preceded by a 
‘-‘. 
For AEs, relative days for start and stop dates will be calculated as the number of days since the 
first injection of the medication. For non-treatment emergent AEs, relative day of onset will be 
negative if the event started and stopped before the first dose. Relative day will only be 
computed for fully completed dates and will be missing for partial dates. 
3.10 
Changes to protocol-defined analyses 
The following variable was added as a secondary efficacy variable and added to the sequential 
testing procedure:  
 IGA response (defined as Clear with at least a 2-category improvement relative to Baseline) 
at Week 16 
For the following variables, the definition of response has been clarified: 
 Palmoplantar Investigator’s Global Assessment (pp-IGA) response (clear or almost clear 
with at least a two-category improvement from Baseline) for subjects with palmoplantar PSO 
at Baseline 
 Change from Baseline in Patient Global Assessment (PGA) of PSO score 
The following variables are not listed in the protocol, but have been added to the SAP in order to 
achieve consistency with other studies from the program: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 25 of 122 
 Percentage of subjects who rebound (defined as a ≥25% increase from Baseline in PASI 
score occurring within 2 months of stopping therapy) during the Randomized-Withdrawal 
Period 
 mNAPSI75/90/100 response (defined as a subject that achieves at least a 75%, 90% and 
100% reduction from Baseline in the mNAPSI score) 
 Percent of subjects with absolute PASI score ≤1, ≤2, ≤3, and ≤5 
 Percent of subjects with absolute BSA=0%, ≤1%, ≤3%, and ≤5%  
 Change from Baseline in clinical laboratory values (chemistry and hematology) will be 
summarized, urinalysis results will be listed 
The following additional changes were made: 
 The calculation of nominal p-values has been added for selected of the other efficacy 
variables. 
 Modifications have been made to the text regarding the multiple imputation algorithm for 
clarity. 
 Change from Baseline in PHQ-9 score is listed an efficacy variable in the protocol. However, 
it is considered as a safety variable in this SAP.    
 Subgroup analyses will be performed for PASI75/90/100 and IGA variables only and not all 
co-primary and secondary efficacy variables for the Initial Treatment Period that are part of 
the fixed sequence testing procedure. 
 Prior primary failure to biologic (yes/no) was removed as a subgroup. 
 Selected TEAE tables were added to include calculation of risk differences. 
 Selected summaries of safety during the Escape Period will also be presented and will be 
based on the ESS. 
4 
STATISTICAL/ANALYTICAL ISSUES 
4.1 
Adjustments for covariates 
The primary efficacy analyses and selected secondary analyses will be adjusted for the following 
covariates: 
 Prior biologic exposure 
 Region 
4.2 
Handling of dropouts or missing data 
4.2.1 
Handling missing data for efficacy variables 
Based on previous studies of biologics in subjects with moderate to severe chronic plaque 
psoriasis, it is expected that the number of subjects who discontinue prior to Week 16 will be 
low. For the small percentage of subjects for whom primary endpoint data are unavailable at 
Week 16, this lack of data is suggestive of an ineffective study treatment, thereby supporting the 
imputation of nonresponse. Achieving the clinical response and making it through 16 weeks of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 26 of 122 
study treatment are both critical components of the primary outcome. Therefore, non-responder 
imputation (NRI) will be used as the method for handling missing data in the primary analysis 
for binary efficacy variables. 
If a subject discontinued study treatment without terminating from the study and still continued 
with scheduled assessments, all efficacy data after discontinuation of study treatment will be 
treated as missing and subject to imputation as applicable. 
4.2.1.1 
Handling missing data for the primary efficacy variable 
Missing data for the co-primary efficacy variables will be imputed using NRI as primary method. 
That is, subjects with missing data at Week 16 or who discontinue treatment prior to Week 16 
will be counted as non-responders for the analysis. 
In addition, sensitivity analyses using multiple imputation (Markov-Chain Monte Carlo method) 
(MI-MCMC)/monotone regression, MI-MCMC/reference-based methods, last observation 
carried forward (LOCF) and observed case (OC) methods will be performed, which will assess 
the impact of different methods of handling missing data. These methods are described in 
Section 8.1.3.1 - Section 8.1.3.3. 
4.2.1.2 
Handling missing data for the secondary efficacy variables 
For secondary binary efficacy variables, missing data will be imputed using NRI as primary 
method. MI-MCMC/monotone regression and OC methods will be performed as sensitivity 
analysis. 
For secondary continuous efficacy variables, MI-MCMC/monotone regression is the primary 
method for imputing missing data. If the imputation model cannot converge, LOCF will be used. 
The OC method will be performed as a sensitivity analysis. 
4.2.1.3 
Handling missing data for the other efficacy variables 
For other binary efficacy variables, missing data will be imputed using NRI as the primary 
method. 
For other continuous efficacy variables, the MI-MCMC/monotone regression method will be 
used to impute missing data as the primary method except for analysis based on the ES where the 
OC method will be used due to the short duration of the Escape Period and the impact of missing 
data in the period. If the imputation model cannot converge, LOCF will be used.  
For other ordinal variables (shift in IGA score, EQ-5D-3L and Patient Global Assessment of 
PSO), the OC method will be applied as the primary analysis method. No imputation is applied. 
For those other efficacy variables that were included in the sequence testing procedure, OC 
method will also be applied as sensitivity analysis. 
4.2.1.4 
Handling missing data for subgroup analyses 
For subgroup analyses specified in Section 4.8, NRI will be used for responder variables. Only 
descriptive statistics will be provided. 
4.2.1.5 
Missing Data Overview and Summary 
In summary, the approaches listed below will be used in this study for handling missing data for 
efficacy variables as appropriate: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 27 of 122 
 Non-responder imputation (NRI): Subjects who have missing data at the time point of 
interest are treated as though they did not respond to the treatment. 
 Multiple Imputation (MI) – Markov Chain Monte Carlo (MCMC) / Monotone Regression: 
Using multiple imputation methodology, intermittent missing data are imputed based on the 
MCMC method, and monotone missing data are imputed using monotone regression. 
 MI – MCMC / Reference-based imputation: Using multiple imputation methodology, 
intermittent missing data are imputed based on the MCMC method, and monotone missing 
data are imputed using an imputation model based on placebo (reference) data. 
 Last observation carried forward (LOCF): Post-Baseline missing data are imputed by 
carrying forward the last available observation (including Baseline). 
 Observed case (OC): Missing data are not imputed. Only subjects with available data who 
have not discontinued study treatment at the given time point are considered. 
The following table depicts which missing data handling approaches should be used based on 
variable priority (primary, secondary, other) and variable type (responder, continuous, ordinal).  
 
Table 4‒1: 
Missing data handling approach by variable priority and type 
Variable 
Priority 
Variable Type 
NRI 
MI 
(MCMC/ 
Monotone 
Regression) 
MI  
(MCMC/ 
Reference-
based) 
LOCF 
OC 
Primary 
Responder 
P 
Sa 
Sa 
S 
S 
Secondary 
Responder 
P 
Sa 
 
 
S 
Continuous 
 
P 
 
B 
S 
Other 
Responder 
P 
 
 
 
Sb, c 
Continuous e 
 
P 
 
B 
  
Ordinal 
 
 
 
 
Pd 
P=Primary method, S=Sensitivity method, B=Backup method, NRI-Nonresponder imputation, MI=multiple 
imputation, MCMC=Markov Chain Monte Carlo, LOCF=Last observation carried forward, OC=Observed case 
Note: Backup method is only applicable when the primary method is unable to converge due to challenges with the 
imputation model. 
a Imputation method is applied on continuous data, and responder variable is derived from the continuous variable 
based on complete data set. 
b Only applies to by-visit summaries of variables that are in the multiplicity-controlled testing procedure. 
c Includes IGA responses, Scalp IGA, PASI75, PASI90, PASI100 and PSD of PSO for pain, itch and scaling.  
d Includes Patient Global Assessment of PSO, IGA score and EQ-5D-3L responses. 
e For PASE and analysis of the Escape Period, OC is the primary analysis method. 
4.2.1.6 
Missing data algorithms 
MI – MCMC / Monotone Regression 
Investigators will be given discretion to discontinue study treatment for subjects not responding 
in order to provide them with alternative therapy to treat the condition. Therefore, in many cases, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 28 of 122 
missing efficacy data due to study treatment discontinuation should be dependent on the 
observed efficacy scores, but independent of unobserved data. This would be consistent with a 
missing at random (MAR) pattern of missingness. To investigate the efficacy results under the 
assumption of data being MAR, a multiple imputation method will be applied as follows: 
1. Create a data set, one for each treatment group (note that a separate imputation procedure 
must be invoked in SAS for each treatment group as the seed cannot be set for by groups 
beyond the first when using a by statement), of subjects with observed values and those 
needing estimation by multiple imputation. The intermittent missing PASI/IGA values in 
each data set (i.e., missing values for a given subject that has available data before and 
after the missing time point) will be filled in using the MCMC method, with a total of 
100 sets of imputations being performed. The seed used for these imputations will be 852 
(note that all other multiple imputation procedures described in this SAP related to 
MCMC/Monotone regression analyses will use this same seed as well). For monotone 
missing data (i.e., where all subject data is missing after a given time point), monotone 
regression will then be used to impute missing data. This will be based on the100 sets of 
imputations already created using the MCMC method such that there will be 100 
imputation in total. In both cases, biologic exposure, geographic region and PASI/IGA 
values at Baseline and at each post-Baseline visit (in chronological order, see notes below 
about visits to include for different analysis sets) will be included in the imputation 
model. Note that PASI scores at earlier visits will also be used as predictors for the model 
of PASI at later visits. The resulting data sets for each treatment arm will be combined 
into one complete data set based on each of the 100 imputations. 
Note: The imputation model will only allow continuous variables. Therefore, prior 
biologic exposure and region will be re-coded as indicator variables. For prior biologic 
exposure, this will simply be 0 for biologic-naïve subjects and 1 for biologic-exposed 
subjects. For region, which has 4 levels, one indicator variable will be defined as 0 for 
regions other than North America and 1 for North America. Two more indicator variables 
will be defined similarly replacing North America with Central/Eastern Europe, and 
Western Europe respectively. An indicator variable for Asia/Australia is not needed as 
the fourth region will be adequately represented by the other region indicator variables all 
being 0. In the event that the numbers of randomized subjects is less than 10% in either of 
the Asia/Australia or Western Europe region, then the two regions will be combined as a 
geographic region stratum for efficacy modeling, so that there are no modeling 
convergence issues across efficacy variables. In order to achieve model convergence, 
prior biologic exposure may be dropped from the model. If convergence is still not 
obtained, then region may also be dropped from the model.  
2. For each complete imputed data set, the dichotomous responder variable (PASI90/IGA 0 
or 1) based on the PASI/IGA scores will be computed. Each complete imputed data set 
will then be analyzed based on the stratified CMH test. 
Note: For derivation of PASI90 response, the PASI value at Week 16 in the imputed data 
sets will be compared directly to the observed Baseline PASI value to determine whether 
or not a reduction of at least 90% was achieved. If values outside of the pre-defined range 
of values for PASI (0-72) are imputed, they will be cut off as appropriate after the 
multiple imputation procedure but before deriving the responder variable. For example, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 29 of 122 
an imputed PASI value of -0.5 would be changed to 0 before deriving the PASI90 
responder variable. 
Note: Standard rounding rules will be applied to the imputed IGA values in order to 
derive the binary IGA 0/1 responder variable. In addition, if values outside of the pre-
defined range of values for IGA (0-4) are imputed, they will be cut off as appropriate 
after the multiple imputation procedure but before deriving the responder variable. For 
example, if a subject has an IGA score imputed as 1.4 (and assuming a Baseline IGA 
score of 3), this imputed value would be rounded down to 1, and the minimum change 
from Baseline of 2 would have been met. Therefore, this subject would be considered an 
IGA 0/1 responder. Additional ranges for values for secondary and other variables are 
defined in Table 4-2.   
 
Table 4‒2: 
Imputation allowable ranges by variable 
Variable 
Minimum Value 
Maximum Value 
Integer Values Only 
PASI 
0 
72 
No 
IGA 
0 
4 
Yes 
PSD item 
0 
10 
No 
Scalp IGA 
0 
4 
Yes 
mNAPSI 
0 
130 
No 
BSA 
0 
100 
Yes 
IGAxBSA 
0 
400 
Yes 
DLQI 
0 
30 
Yes 
PGADA 
0 
100 
Yes 
SF-36 
0 
100 
No 
EQ-5D-3L VAS 
0 
100 
Yes 
PHQ-9 
0 
27 
Yes 
3. The Week 16 results from the specified statistical analysis (e.g. stratified CMH, logistic 
regression) of each of the 100 imputed data sets will be combined for overall inference 
using Rubin’s rules, which account for the uncertainty associated with the imputed values 
(Rubin, 1987). This will be done using SAS PROC MIANALYZE. 
Note that this procedure indicates that the imputation model will be applied for each treatment 
group separately in PROC MI, which will be the default method. However, in the event there are 
computational challenges with the imputation model (e.g., due to a standard deviation of 0 for 
responses of a given imputation), it is acceptable to modify the imputation model to include 
treatment as a variable in the model rather than running a separate model for each treatment 
group. It should be noted that doing so assumes that treatment does not interact with any of the 
other variables in the imputation model. 
Some key points to consider relative to the calculation of the odds ratios and corresponding 
confidence intervals are noted below: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 30 of 122 
If stratified CMH or logistic regression are used, the estimates of the odds ratios from the logistic 
regression model in step 3 follow a log-normal distribution, and a log transformation is needed to 
normalize these estimates since the procedures for combining results from multiple imputed 
datasets are based on the assumption that the statistics estimated from each imputed dataset are 
normally distributed. Therefore, the log of the odds ratio estimates from the logistic regression 
model are used when combining into a single inference (the use of PROC MIANALYZE in step 
3). Appropriate transformations to the standard errors and p-values should also be made in order 
to get the correct confidence intervals, for the CMH test using the p-value for the general 
association the Wilson-Hilferty transformation should be used (Ratitch, 2013).  
Missing data for continuous primary or secondary efficacy variables will be imputed using MI as 
appropriate. The MI procedure for continuous variables will be similar to that described above 
with the following differences:  
1. The absolute value of the given variable will be imputed. Once imputation has been 
performed across the 100 iterations specified, any values outside of the range of the given 
variable will be truncated accordingly. 
2. The change from Baseline values will be computed based on the complete data sets. 
3. The analysis model will be based on ANCOVA (see above) as opposed to the CMH test. 
For other continuous efficacy variables, MI will be used to impute missing data when possible. If 
the imputation model cannot converge, LOCF will be used. The MI procedure will also be 
similar to that described above with the following differences: 1) no dichotomization will be 
necessary; 2) instead of using the stratified CMH test or logistic regression, the imputed data sets 
will be combined and simple means and standard errors will be calculated using Rubin’s rules 
(via SAS PROC MIANALYZE). For calculation of other descriptive statistics such as the 
median, min and max, Rubin's rules do not apply. Multiple imputation estimates will be 
computed by simply averaging the estimates from the multiple repetitions of the imputation 
algorithm. This is the same approach that will be used when summarizing continuous secondary 
efficacy variables by subgroup. 
Further details about imputation for different analysis sets are below: 
 Randomized Set: When programming multiple imputation based on the RS, PROC MI will 
be used with a separate data set for each of the 2 randomized treatment groups (placebo, 
Bimekizumab 320mg Q4W) including all scheduled assessment visits from Baseline to Week 
16. 
 Wk16ResS: When programming multiple imputation based on the Wk16ResS, PROC MI 
will be used with a separate data set for each of the 3 re-randomized treatment groups 
(Bimekizumab 320mg Q4W/Placebo, Bimekizumab 320mg Q4W/Q8W, Bimekizumab 
320mg Q4W/Q4W) including all scheduled assessment visits from Week 16 to Week 56. 
Note: The Placebo/Placebo responders will not be included in these tables or in the MI 
procedure. 
MI – MCMC / Reference-based imputation 
In this case, placebo will be described as the reference arm.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 31 of 122 
This procedure will use an imputation model developed based on data from the placebo group 
only (Mallinckrodt, 2013). Reference-based multiple imputation assumes that the statistical 
behavior of the bimekizumab and placebo-treated subjects after discontinuing study medication 
becomes that of the placebo-treated subjects. All time points after discontinuation of the double-
blind study treatment for both the bimekizumab and placebo groups will be considered missing. 
Multiple imputations are used to replace missing outcomes for bimekizumab- and placebo-
treated subjects who discontinued using multiple draws from the posterior predictive distribution 
estimated from the placebo arm. For binary efficacy variables (e.g., PASI90 at Week 16), 
imputation will be done on the raw PASI before assessing the imputed results for PASI90 
response. 
The steps for the procedure are as follows: 
1. For non-monotone (intermittent) missing data, MCMC will be used to impute PASI, with 
biologic exposure, geographic region, and PASI values at Baseline and at each post-
Baseline visit (in chronological order) being included in the imputation model. This will 
be done only once for each subject in order to provide a dataset with monotone missing 
data. 
2. Data will be processed sequentially by repeatedly calling SAS® PROC MI to impute 
missing outcome data at visits t=1, … T, where T is Week 16 for PASI90. 
a. Initialization. Set t=1 (Baseline visit) 
b. Iteration. Set t=t+1. Create a data set combining records from bimekizumab- and 
placebo-treated subjects with columns for covariates (prior biologic exposure and 
geographic region) and outcomes at visits 1 to t. Outcomes for all bimekizumab-
treated subjects are set to missing at visit t and set to observed or previously 
imputed values at visits 1 to t-1. Outcomes for placebo-treated subjects are set to 
observed at visit t or observed or previously imputed values at visits 1 to t-1. 
c. Imputation. Run MCMC to impute missing values for visit t using previous 
outcomes for visits 1 to t-1, prior biologic exposure, and geographic region. Note 
that only placebo data will be used to estimate the imputation model since no 
outcome is available for bimekizumab-treated subjects at visit t. 
d. Repeat steps 2a-2c, 100 times with different seed values (seeds ranging from 853 
to 952) to create 100 imputed complete data sets. 
e. Analysis. For each completed data set, the outcome (response or change from 
Baseline) will be calculated using the complete datasets (with no missing data). 
3. Each complete imputed data set will then be analyzed based on the statistical model 
specified in this study (stratified CMH test). The Week 16 results from stratified CMH 
test of each of the 100 imputed data sets will be combined for overall inference using 
Rubin’s rules, which account for the uncertainty associated with the imputed values 
(Rubin, 1987). This will be done using SAS PROC MIANALYZE. 
4.2.2 
Handling missing data for safety variables 
For analyses of AEs and concomitant medication usage, a complete date must be established in 
order to correctly identify the AE or medication as occurring during treatment or not. For 
purposes of imputing missing components of partially-reported start and stop dates for AEs and 
for medication use, the algorithms listed below will be followed. Start and stop dates of AEs or 
concomitant medication will be displayed as reported in the subject data listings (i.e., no imputed 
values will be displayed in data listings). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 32 of 122 
Partial AE and concomitant medication start dates will be imputed as follows: 
Imputation of Partial Start Dates 
 If only the month and year are specified and the month and year of first dose is not the same 
as the month and year of the start date, then use the 1st of the month 
 If only the month and year are specified and the month and year of first dose is the same as 
the month and year of the start, then use the date of first dose 
 If only the year is specified, and the year of first dose is not the same as the year of the start 
date, then use the 1st of January of the year of the start date 
 If only the year is specified, and the year of first dose is the same as the year of the start date, 
then use the date of first dose 
 If the start date is completely unknown and the stop date is unknown or not prior to the date 
of first dose, then use the date of first dose. 
Imputation of Partial Stop Dates 
 If only the month and year are specified, then use the last day of the month 
 If only the year is specified, then use December 31st of that year 
 If the stop date is completely unknown, do not impute the stop date. 
In the event of ambiguity or incomplete data which makes it impossible to determine whether a 
medication was concomitant, or an adverse event was treatment emergent, the medication will be 
considered as concomitant or the adverse event will be considered treatment emergent. 
4.3 
Interim analyses and data monitoring 
After the final Week 56 visit, an interim analysis will be performed on all available data at that 
time point (including all subjects who are in the Escape Period when the interim data cut is 
taken) and a corresponding interim clinical study report (CSR) will be written. A final analysis 
and updated final CSR will be prepared once all data (through the safety follow-up (SFU) visit) 
have been collected.  
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor the safety data from this study and advise UCB. Further details related to the DMC will 
be outlined in a separate analysis plan. 
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor relevant safety data from this study and advise UCB. Details will be provided in the 
DMC Charter and in the Adjudication Committee Charters. 
4.4 
Multicenter studies 
The center-by-treatment interaction will be tested by replacing region with center in the logistic 
regression model used for the sensitivity analysis (Section 8.1.3.6) and adding a center-by-
treatment interaction term. In the model, center will be based on the original centers prior to 
pooling (Section 3.7). However, if the model is unable to converge due to a low number of 
subjects at a given center, a pooling by center will be applied in order to allow the model to 
converge. If convergence is still not achieved a pooling by region will be applied. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 33 of 122 
4.5 
Multiple comparisons/multiplicity 
The statistical analysis of the co-primary efficacy variables and selected secondary efficacy 
variables will account for multiplicity and control the familywise Type I error rate at a 2-sided 
alpha level of 0.05 by using a fixed sequence testing procedure. 
The hypotheses (H1, H2, H3, H4, H5, H6, H7, H8, H9 and H10) comparing bimekizumab vs. placebo 
will be tested at a 2 -sided alpha level of 0.05. 
The first 2 hypotheses (H1 and H2) test whether bimekizumab is superior to placebo for PASI90 
response and IGA response at Week 16. These are the hypothesis tests corresponding to the co-
primary endpoints. If both are rejected at a 2-sided alpha level of 0.05, that alpha will be passed 
to the next test in the sequence, allowing the testing procedure to proceed. 
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo. The pairwise comparisons will follow the 
sequential testing sequence in Figure 4-1 and the formal evaluation of statistical significance of 
each comparison is dependent upon the previous comparison achieving statistical significance at 
the 2-sided alpha level of 0.05. 
Figure 4-1: Sequence of testing 
 
 
BL=Baseline; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom 
diary; PSO=psoriasis; Q4W=every 4 weeks; Q8W=every 8 weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 34 of 122 
4.6 
Use of an efficacy subset of subjects 
The primary efficacy analysis (described in Section 8.1.2) will be repeated based on the FAS and 
the PPS as a sensitivity analysis.  
4.7 
Active-control studies intended to show equivalence 
Not applicable. 
4.8 
Examination of subgroups 
Subgroup analyses will be performed on PASI75/90/100 and IGA. The following subgroups for 
analysis will be determined using Baseline data:  
 Age (<40 years, 40 to <65 years, ≥65 years) 
 Gender (male, female) 
 Disease duration (<median, ≥median) 
 Region (North America [Canada, USA], Western Europe [Germany, United Kingdom], 
Central/Eastern Europe [Hungary, Poland, Russian Federation], Asia/Australia [Australia, 
Korea, Taiwan]) 
 Weight (≤100 kg, >100 kg) 
 BMI (<25 kg/m2, 25 to <30 kg/m2, ≥30 kg/m2) 
 Prior systemic phototherapy or chemotherapy (yes, no) 
 Prior biologic exposure (yes, no) 
 Prior systemic therapy of any kind (yes, no) 
 Baseline disease severity (PASI<20, PASI≥20) 
 Antibody positivity (negative, positive) 
Antibody positivity is the only subgroup that is not determined by Baseline data. It will be 
presented in a separate table. 
The definition of prior systemic therapy of any kind is if a subject received previous biologic 
therapy, previous systemic therapy (non-biologic), or previous systemic chemotherapy or 
phototherapy. Subjects who never received previous biologic therapy, previous systemic therapy 
(non-biologic), or previous systemic chemotherapy or phototherapy will be classified as not 
receiving prior systemic treatment for psoriasis. 
In addition, a subgroup analysis will be performed on PASI90/100 and IGA to assess 
predictability of future response at Week 4 and Week 16 using the following subgroups:  
 PASI75 responders (OC) at Week 4 (yes, no) to predict PASI90/100 and IGA (NRI) through 
Week 56 
 PASI90 responders (OC) at Week 16 (yes, no) to predict PASI100 (NRI) through Week 56 
For responder analysis, the definition of subgroups of the PASI75/90/100 will be based on 
observed values. All summaries will be based on imputed data as appropriate and will include 
descriptive statistics only.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 35 of 122 
5 
STUDY POPULATION CHARACTERISTICS 
5.1 
Subject disposition 
Summaries of reasons for screen failures (for all subjects screened), disposition of subjects (for 
all subjects screened), disposition of analysis sets (for RS and ESS), disposition and 
discontinuation reasons in the Initial Treatment period (for RS) and in the Randomized-
Withdrawal period (for WK16ResS) and Escape Treatment period (for ESS), as well as the 
subjects who discontinued due to AEs in the Initial Treatment period (for RS) and in the 
Randomized-Withdrawal period (for WK16ResS) and Escape Treatment period (for ESS) will be 
produced. The disposition of subjects for all subjects screened will include the number of 
subjects included in each analysis set (ES, RS, SS, FAS, ESS, WK16ResS, AMS, PPS, and PK-
PPS) overall and by site. 
The following listings for subject disposition will be provided: subjects who did not meet study 
eligibility criteria (all subjects screened), subject disposition (all subjects screened), study 
discontinuation (RS), visit dates (RS), subjects excluded from efficacy analysis (RS).  
5.2 
Protocol deviations 
A summary, using the RS, displaying the number and percentage of subjects with an important 
protocol deviation (including a summary of subjects excluded from the PPS or PK-PPS due to 
important protocol deviations) by treatment group in the Initial Treatment Period, the 
Randomized-Withdrawal Period, and in the Escape Treatment Period will be provided. 
A by-subject listing of important protocol deviations will be provided. 
6 
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS 
All summaries detailed in this section will be performed on the RS by treatment group. 
Summaries for demographics and other baseline characteristics will also be repeated on SS, 
WK16ResS and ESS. If the RS and SS analysis sets are identical, the SS summary will not be 
produced. 
6.1 
Demographics 
Demographic variables will be summarized by treatment group and overall. 
The following continuous variables will be summarized using descriptive statistics (number of 
subjects, mean, SD, minimum, median and maximum). 
 Age at the time of study entry (years) 
 Height (cm) 
 Weight (kg) 
 BMI (kg/m2)  
BMI (kg/m2) will be calculated as: 
BMI = Weight (kg)
(Height (m))2. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 36 of 122 
The following categorical variables will be summarized using frequency counts and percentages. 
 Age group (18-<65, 65-<85, ≥85 years) 
 Age group (≤18, 19-<65, ≥65 years)  
 Age group (<40, 40-<65, ≥65 years) 
 Body weight (≤100 kg, >100 kg) 
 BMI (<25 kg/m2, 25 to <30 kg/m2, ≥30 kg/m2) 
 Gender 
 Race 
 Ethnicity  
By-subject listings of demographics for all subjects screened will be provided. 
6.2 
Other Baseline characteristics 
Baseline characteristics (including Baseline clinical measures) will be summarized by treatment 
group and overall. 
Generally, the following continuous variables will be summarized using descriptive statistics 
(number of subjects, mean, SD, minimum, median and maximum). 
 Psoriasis Body Surface Area (BSA; %) 
 Psoriasis Area and Severity Index (PASI) score 
 Modified Nail Psoriasis Severity Index (mNAPSI) total score 
 Modified Nail Psoriasis Severity Index (mNAPSI) total score for subjects with nail 
involvement (i.e. mNAPSI>0) 
 Patient Global Assessment of Disease Activity (PGADA) for arthritis visual analogue scale 
(VAS) score 
 Dermatology Life Quality Index (DLQI) total score 
 Duration of disease (years) 
Duration of disease (years) will be calculated as: 
Disease Duration =
(Date of randomization−Date of onset of Plaque Psoriasis1)
365.25
. 
1If the date of onset of plaque psoriasis is partial, it should be imputed to the most recent feasible 
date (i.e., last day of the month if only day is missing, or the last day of the year if day and month 
are missing). Note that if the date of randomization is missing then the duration of disease will be 
derived using the date of screening.  
The following categorical variables will be summarized using frequency counts and percentages. 
 Region (North America [Canada, USA], Western Europe [Germany, United Kingdom], 
Central/Eastern Europe [Hungary, Poland, Russian Federation], Asia/Australia [Australia, 
Korea]) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 37 of 122 
 Country 
 Duration of disease (<median, ≥median) 
 Investigator’s Global Assessment (IGA) score 
 Baseline disease severity (PASI<20, PASI≥20)  
 Nail involvement (yes, no) 
 Scalp involvement (yes, no) 
 Palmoplantar involvement (yes, no) 
 Prior biologic therapy (yes, no) 
 Prior anti-TNF therapy (yes, no) 
 Prior primary failure to biologic (yes, no) 
 Prior phototherapy or chemotherapy (yes, no) 
 Any prior systemic therapy (yes, no) 
 PSD items: Pain, Itch, Scaling 
Baseline nail, scalp, and palmoplantar involvement are based on the number of subjects 
achieving mNAPSI>0, Scalp IGA>0, and pp-IGA>0, respectively. The categorization of whether 
or not subjects received prior biologic therapy will be based on the Psoriasis Treatment History 
CRF module. Prior anti-TNFs include etanercept, adalimumab, infliximab, certolizumab pegol, 
and golimumab. 
By subject listings of Baseline characteristics will be provided. 
6.3 
Medical history and concomitant diseases 
Previous and ongoing medical history will be summarized by treatment groups, system organ 
class (SOC) and preferred term (PT) using MedDRA®. Medical procedures are not coded.  
The following listings for medical history and concomitant diseases will be provided: medical 
history, psoriasis history, concomitant medical procedures, previous and ongoing medical history 
glossary, previous and ongoing medical history conditions, and procedure history.  
6.4 
Prior and concomitant medications 
Medication start and stop dates will be compared to the date of first dose of treatment to allow 
medications to be classified as either Prior or Concomitant. 
Details of imputation methods for missing or partial dates are described in Section 4.2.2. 
Prior medications include any medications that started prior to the start date of study medication.  
Concomitant medications are medications taken at least one day in common with the study 
medication dosing period.  
The number and percentage of subjects taking prior medications (excluding past psoriasis 
medications) will be summarized by treatment group, overall and by Anatomical Therapeutic 
Chemical classification (ATC) class, presenting Anatomical Main Group (ATC Level 1), 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 38 of 122 
Pharmacological Subgroup (ATC level 3), and preferred term. The number and percentage 
taking concomitant medications will be summarized similarly.  
Past psoriasis medications will be captured separately and will also be summarized by treatment 
group. These medications are not subject to dictionary coding. In addition, subjects who failed 
past psoriasis biologic treatment will be summarized by reason of failure as captured on the 
Psoriasis Treatment History CRF module.  
By-subject listings of all Prior and Concomitant medications, prior and concomitant medications 
glossary, and psoriasis treatment history will be provided.    
7 
MEASUREMENTS OF TREATMENT COMPLIANCE 
Due to the method of administration of the treatments, compliance will be examined in terms of 
completed injections. 
Treatment compliance will be calculated as: 
total number of completed injections
total number of expected injections  ×  100% 
where the total number of expected injections is derived relative to when the subject finishes 
treatment.  In this study, Baseline visit and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 
are dosing visits. Two injections are administered at each given visit either with active dosing or 
placebo injection. It is expected that a subject should complete total 28 injections by the end of 
study, if they do not enter the open-label escape arm. If a subject enters and completes the open 
label escape arm, they will receive an additional 6 open-label injections during the Escape 
Treatment Period beyond what they have already received. If a subject discontinues early, then 
the number of expected injections is based on the time of early discontinuation relative to the 
dosing visits. For example, if a subject discontinues after Week 8 visit and prior to Week 12 
visit, the total number of expected injections will be 6. 
A summary of percent treatment compliance categorized as <75% and ≥75% will be provided by 
treatment group and study periods (Initial Treatment Period for the RS, Randomized-Withdrawal 
Period for the WK16ResS, Escape Treatment Period for the ESS, and the Initial and 
Randomized-Withdrawal Period for the AMS). 
A by-subject listing of treatment compliance will be provided. 
8 
EFFICACY ANALYSES 
All efficacy analyses of primary and secondary variables will be performed on the RS unless 
otherwise specified. All efficacy analyses of other efficacy variables will be performed on the 
RS, WK16ReS and ESS unless otherwise specified.  All efficacy summary tables will be 
displayed by treatment group unless otherwise specified. 
8.1 
Statistical analysis of the primary efficacy variables 
8.1.1 
Derivations of co-primary efficacy variables 
8.1.1.1 
Psoriasis Area and Severity Index (PASI) 
PASI90 is defined to be equal to 1 if the percentage improvement from Baseline in the PASI 
scores is 90% or greater and 0 if the percentage improvement from Baseline is less than 90%. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 39 of 122 
This definition is introduced for the purpose of identifying subjects who respond to the treatment 
(1 = responder, 0 = non-responder). 
PASI scoring of psoriatic plaques is based on three criteria: redness (R), thickness (T), and 
scaliness (S). Severity is rated for each index (R, T, S) on a 0-4 scale (0 for no involvement up to 
4 for very marked involvement). The body is divided into four areas comprising the head (h), 
upper extremities (u), trunk (t), and lower extremities (l). In each of these areas, the fraction of 
total surface area affected is graded on a 0-6 scale (0 for no involvement; up to 6 for 90% - 100% 
involvement). 
The various body regions are weighted to reflect their respective proportion of BSA. The 
composite PASI score is then calculated by multiplying the sum of the individual-severity scores 
for each area by the weighted area-of-involvement score for that respective area, and then 
summing the four resulting quantities as follows (note for R, T, and S scores are as follows: 0 = 
none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked):  
PASI = (0.1 × (Rh + Th + Sh) × Ah) + (0.2 × (Ru + Tu + Su) × Au)
+ (0.3 × (Rt + Tt + St) × At) + (0.4 × (Rl + Tl + Sl) × Al) 
where  
Rh, Ru, Rt, Rl = redness score of plaques on the head, upper extremities, trunk, and lower 
extremities, scored 0-4 respectively;  
Th, Tu, Tt, Tl = thickness score of plaques on the head, upper extremities, trunk, and lower 
extremities, scored 0-4 respectively;  
Sh, Su, St, Sl = scaliness score of plaques on the head, upper extremities, trunk, and lower 
extremities, scored 0-4 respectively;  
Ah, Au, At, Al = numerical value translation of % area of psoriatic involvement score for the 
head, upper extremities, trunk, and lower extremities, respectively (where 0 = 0% [clear], 1 = 
>0% to <10%, 2 = 10% to <30%, 3 = 30% to <50%, 4 = 50% to <70%, 5 = 70% to <90%, and 6 
= 90% to 100%). 
The highest potential PASI score is 72 for severe disease; the lowest is 0 for no psoriasis lesions. 
PASI scores are treated as continuous. The percent improvement in PASI scores from Baseline 
will be computed as:  
Percent improvement from Baseline = 100 × Baseline PASI −Post Baseline PASI
Baseline PASI
. 
If a subject has experienced an improvement, this measure will be positive. If a subject has 
experienced a worsening in their condition, this measure will be negative.  
If a subject is missing 1 or 2 severity measurements for a certain region, the average of the 
remaining severity measurement(s) within that region will be utilized to substitute for the 
missing severity measurement(s) in that region. If the area of affected skin and/or all severity 
measurements for up to 2 regions are missing, then the missing (R+T+S) x A for a region will be 
substituted by the average of the available (R+T+S) x A. Otherwise, the PASI will be set to 
missing. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 40 of 122 
8.1.1.2 
PASI90 Response at Week 16  
A categorical response variable, PASI90 at Week 16 is defined to be equal to 1 if the percentage 
improvement from Baseline to Week 16 in the PASI scores is 90% or greater and 0 if the 
percentage improvement from Baseline to Week 16 is less than 90%. This definition is 
introduced for the purpose of identifying subjects who respond to the treatment (1 = responder, 0 
= non-responder).  
8.1.1.3 
Investigator’s Global Assessment (IGA) Response at Week 16 
A static IGA for psoriasis will be used to assess disease severity in all subjects during the study. 
The Investigator will assess the overall severity of psoriasis using the following five-point scale: 
Table 8‒1: 
Investigator’s Global Assessment 
Score 
Short Descriptor 
Definition 
0 
Clear 
No signs of psoriasis; post-inflammatory hyperpigmentation may 
be present 
1 
Almost clear 
No thickening; normal to pink coloration; no to minimal focal 
scaling 
2 
Mild 
Just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling 
3 
Moderate 
Clearly distinguishable to moderate thickening; dull to bright red, 
clearly distinguishable to moderate thickening; moderate scaling 
4 
Severe 
Severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions 
IGA response is defined as clear [0] or almost clear [1] with at least a 2-category improvement 
from Baseline at Week 16.    
8.1.2 
Primary analysis of the co-primary efficacy variables 
The co-primary efficacy variables for this study are PASI90 response and IGA response at Week 
16, and the corresponding analyses are based on the RS. A subject will be classified as a PASI90 
responder if the PASI score at Week 16 has improved at least 90% from Baseline, and IGA 
responder is any subject with a score of 0 or 1 (Clear or Almost Clear) with at least a 2-category 
improvement from Baseline to Week 16 in IGA score.   
The primary analysis will be based on the stratified Cochran-Mantel-Haenszel (CMH) test where 
region and prior biologic exposure (yes/no) will be used as stratification variables. Pairwise 
treatment comparisons will be made based on the CMH test using the p-value for the general 
association. The odds ratio and associated confidence interval (CI) based on the Wald test will be 
provided. If one of the treatment groups has zero or very low response where the CMH odds 
ratio can no longer be calculated, the logit method will be applied instead.  
Non-responder imputation will be used to account for missing data in the primary analysis. 
Specifically, any subject who withdraws from IMP prior to Week 16 or who has missing data for 
the co-primary efficacy variables at the Week 16 time point will be considered as a non-
responder. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 41 of 122 
The number and percentage of subjects who are PASI90 responders at Week 16 will be 
summarized. IGA response will be summarized in the same manner as PASI90 responder 
variable.  
A line plot of the percentage improvement from Baseline in PASI score over time by treatment 
group will be produced.  
By-subject listings of PASI and IGA responder variables, PASI and IGA data will be provided. 
8.1.3 
Sensitivity analyses of the co-primary efficacy variables 
The following sensitivity analyses for the co-primary efficacy variables will be performed to 
evaluate the assumptions related to the handling of missing data: 
8.1.3.1 
Sensitivity Analysis #1 
Missing data will be addressed by using MI (Markov-Chain Monte Carlo [MCMC] method) for 
intermittent missing data, followed by monotone regression for monotone missing data, see 
(Section 4.2.1.6) to evaluate the effect of the method for handling missing data on the analysis. 
The actual PASI/IGA scores will be imputed and then dichotomized to obtain the response 
status. The treatment differences for each imputed data set will subsequently be evaluated using 
the stratified CMH test as used in the primary analysis. If one of the treatment groups has zero or 
very low response where the CMH odds ratio can no longer be calculated, the logit method will 
be applied instead as for the primary analyses. The results from each of the imputed data sets will 
be combined for overall inference using Rubin’s rules, which account for the uncertainty 
associated with the imputed values (Rubin, 1987). This will be done using SAS PROC 
MIANALYZE. This procedure assumes a missing at random (MAR) pattern of missingness and 
corresponds to an estimand of the difference in outcome improvement if all subjects tolerated or 
adhered to treatment (Mallinckrodt et al, 2012). This is an estimand of efficacy to evaluate the de 
jure hypothesis. 
8.1.3.2 
Sensitivity Analysis #2  
Deviations from the MAR pattern assumed above will be evaluated. A sensitivity analysis will 
be performed in which, as with the above analysis, intermittent missing data will be imputed 
using MI based on the MCMC method. However, the remaining monotone missing data will be 
assumed to follow a missing not at random (MNAR) pattern. These data will be imputed using 
reference-based imputation in which the imputation model is based on data from the placebo 
group (see Section 4.2.1.6), thereby assuming that monotone missing data follow a trajectory 
similar to the placebo group (Mallinckrodt et al, 2012). As specified in the previous procedure, 
actual PASI/IGA scores will be imputed and then dichotomized to get the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test as used in the primary analysis. If one of the treatment groups has zero or 
very low response where the CMH odds ratio can no longer be calculated, the logit method will 
be applied instead as for the primary analyses. The estimand in this procedure is the difference in 
outcome improvement in all randomized subjects at the planned endpoint of the study 
attributable to the initially randomized medication (Mallinckrodt et al, 2012). This is an estimand 
of effectiveness to evaluate the de facto hypothesis. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 42 of 122 
8.1.3.3 
Sensitivity Analysis #3  
This sensitivity analysis will be based on observed data at Week 16. Subjects with missing data 
or who have prematurely discontinued IMP will be treated as missing (see Section 4.2.1.5). The 
same stratified CMH test as in the primary efficacy analysis will be used.  
8.1.3.4 
Sensitivity Analysis #4  
The primary efficacy analyses from Section 8.1.2 will be repeated using LOCF as the imputation 
method (see Section 4.2.1.5).  
8.1.3.5 
Sensitivity Analysis #5  
The primary efficacy analyses from Section 8.1.2 will be repeated based on the FAS and the 
PPS.  
8.1.3.6 
Sensitivity Analysis #6  
As a sensitivity analysis to the primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week 16 will be estimated and tested between 
treatment groups using a logistic regression model with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated confidence interval (CI), and p-value 
based on the Wald test will be presented. If the logistic regression model is unable to converge, 
then prior biologic exposure may be dropped from the model to facilitate convergence. If the 
model is still unable to converge, then region may be removed from the model as well. In 
addition, if the logistic regression model cannot converge, then Fisher’s exact test will be used 
for inferential comparisons. As with the primary analysis, missing data will be handled using 
NRI. 
8.1.3.7 
Sensitivity Analysis #7  
The center-by-treatment interaction will be tested by replacing region with center in the logistic 
regression model described above and adding a  center-by-treatment interaction term. In the 
model, center will be based on the original centers prior to pooling. However, if the model is 
unable to converge due to a low number of subjects at a given center, a pooling (see Section 3.7) 
will be applied in order to allow the model to converge. In order to obtain reasonable estimates 
of variability for a treatment arm at a given center, a minimum of 15 subjects will be considered 
acceptable for a center to be included in the model without pooling. Given the 4:1 randomization 
allocation scheme, this should provide a minimum of about 12 subjects in the bimekizumab arm 
and 3 subjects in the placebo arm. Centers with fewer than 15 subjects will be eligible for 
pooling. The pooling algorithm used is described in Section 3.7. 
In order to achieve model convergence, prior biologic exposure may be dropped from the model. 
If convergence still cannot be achieved, this analysis will not be performed. 
If the center-by-treatment interaction is not found to be significant (α=0.10), then no further 
analyses will be performed. On the other hand, if the interaction is significant, further analyses 
will be conducted to determine which center or centers may be the source of the interaction. This 
will be done by running the logistic regression model (including the interaction term) where each 
center will be systematically removed from the model. The impact of a given center will be 
based on the change in the interaction p-value when that center is removed. The center or centers 
that appear to be driving the significant interaction effect will then be removed from the model to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 43 of 122 
verify that conclusions remain the same with or without the influential center(s). This sensitivity 
analysis will be based on RS with NRI for missing data. 
8.2 
Statistical analysis of the secondary efficacy variables 
8.2.1 
Derivations of Secondary efficacy variables 
8.2.1.1 
PASI100 Response at Week 16  
A categorical response variable, PASI100 at Week 16 is defined to be equal to 1 if the 
percentage improvement from Baseline to Week 16 in the PASI scores is 100% and 0 if the 
percentage improvement from Baseline to Week 16 is less than 100%. This definition is 
introduced for identifying subjects who respond to the treatment (1 = responder, 0 = non-
responder). The definition of percentage improvement from Baseline is given in Section 8.1.1.1. 
8.2.1.2 
IGA Response at Week 16 
A categorical response variable, IGA response (Clear with at least 2-category improvement from 
Baseline) is defined as an IGA score of zero (Table 8-1) with at least 2-category improvement 
from Baseline. 
 
8.2.1.3 
PASI75 Response at Week 4  
A categorical response variable, PASI75 at Week 4 is defined to be equal to 1 if the percentage 
improvement from Baseline to Week 4 in the PASI scores is 75% or greater and 0 if the 
percentage improvement from Baseline to Week 4 is less than 75%. This definition is introduced 
for the purpose of identifying subjects who respond to the treatment (1 = responder, 0 = non-
responder). The definition of percentage improvement from Baseline is given in Section 8.1.1.1. 
8.2.1.4 
Patient Symptom Diary (PSD) 
A patient reported outcome (PRO) measure, the PSD, will be used to assess key symptoms 
relevant to subjects with moderate to severe chronic plaque PSO. The ePRO diary will be 
administered on a daily basis from Screening to the Week 16 Visit. 
The PSD consists of 14 different items, each measuring an aspect of the disease and its impact on 
the subject’s quality of life. Each item will be scored separately on a 0-10 scale with 0 for no 
symptom and 10 for very severe or worst symptom. Weekly averages will be derived for each of 
the 14 items of the Psoriasis Diary up to Week 16. A weekly average is the sum of the scored 
item over the course of the study week divided by the number of days on which the item was 
completed. The weekly averages should be relative to the respective visit date except for baseline 
which should follow the usual convention and should be based on at least 4 non-missing values 
(do not need to be consecutive). Otherwise, the PSD will be set to missing. The Baseline value 
will be computed in the same manner. 
The PSD will be computed based on the responder definition. Each of the 3 PSD response scores 
included in the statistical testing procedure (itch, pain, and scaling) will be characterized in terms 
of the cumulative percent of subjects demonstrating a pre-specified point improvement at Week 
16. The threshold for the PSD response score of itch, pain, and scaling is 2.39, 1.98, and 2.86, 
respectively. The responder analysis will be limited to the subjects with a Baseline PSD response 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 44 of 122 
score at or above the applicable threshold score (i.e., at least 2.39, 1.98, and 2.86 for itch, pain, 
and scaling, respectively). 
The derivations for absolute change from Baseline is as follows: 
 Change from Baseline in PSD responses for itch, pain, and scaling at Week 16 is defined as 
Week 16 PSD response minus Baseline PSD response.  
8.2.1.5 
Scalp IGA Response (Clear or Almost Clear) at Week 16  
A static IGA for PSO will be used to assess disease severity on the scalp in all subjects during 
the study. 
All subjects will complete the scalp IGA at Baseline. Only subjects with scalp involvement at 
Baseline will complete the scalp IGA at the other visits specified in the schedule of assessments. 
Subjects with scalp involvement at Baseline are defined as those with a scalp IGA score >0 at 
Baseline. 
Scalp lesions will be assessed in terms of clinical signs of redness, thickness, and scaliness using 
a 5-point scale as outlined in the Table 8-2 below. This is the same scale with corresponding 
descriptors used for the overall IGA, but this will be specific to the scalp. 
Table 8‒2: 
Scalp IGA 
Score 
Short Descriptor 
Detailed Descriptor 
0 
Clear 
Scalp has no signs of PSO; post-inflammatory hyperpigmentation may 
be present 
1 
Almost clear 
Scalp has no thickening; normal to pink coloration; no to minimal 
focal scaling 
2 
Mild 
Scalp has just detectable to mild thickening; pink to light red 
coloration; predominately fine scaling 
3 
Moderate 
Scalp has clearly distinguishable to moderate thickening; dull to bright 
red, moderate scaling 
4 
Severe 
Scalp has severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions 
Scalp IGA response at Week 16 is defined as clear [0] or almost clear [1] with at least a 2-
category improvement from Baseline to Week 16. The evaluation of scalp IGA will be limited to 
subjects with a Baseline scalp IGA of at least 2. Therefore, if a subject has a score of 2 at 
Baseline, they can only be considered a responder if their IGA is 0 (thereby meeting the criterion 
for a 2-category improvement from Baseline). Subjects with a Baseline scalp IGA of 1 will be 
assessed per the protocol but will not be part of the scalp IGA analysis. 
8.2.1.6 
PASI90 Response at Week 56 among Week 16 PASI90 Responders  
A categorical response variable, PASI90 at Week 56 is defined to be equal to 1 if the percentage 
improvement from Baseline to Week 56 in the PASI scores is 90% or greater and 0 if the 
percentage improvement from Baseline to Week 56 is less than 90%. This definition is 
introduced for the purpose of identifying subjects who respond to the treatment (1 = responder, 0 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 45 of 122 
= non-responder). The definition of percentage improvement from Baseline is given in Section 
8.1.1.1. 
8.2.2 
Primary analysis of the secondary efficacy variables 
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit. Continuous variables will be summarized using descriptive statistics by treatment 
group for each visit. Primary analysis for secondary efficacy variables will be summarized based 
on imputed data (NRI), unless otherwise specified. 
8.2.2.1 
PASI responses  
The secondary efficacy variables for time points during the initial Treatment Period will be 
analyzed for all subjects in the RS. 
For binary secondary variables, including PASI100 at Week 16 and PASI75 at Week 4, the 
stratified CMH test as specified for the primary analysis will be implemented to test for 
superiority. As in the primary analysis, NRI will be used to account for missing data.   
PASI90 response at Week 56 for subjects in the WK16ResS will be evaluated using a stratified 
CMH test where region and prior biologic exposure will be used as stratification variables, 
similar to the approach specified for the primary analysis. In this analysis, both dose regimens 
(Q4W and Q8W) within a given bimekizumab dose will be pooled such that each bimekizumab 
dose (regardless of regimen) will be compared to placebo (based on subjects who have switched 
to placebo from bimekizumab at Week 16, to evaluate the efficacy of continuous treatment with 
bimekizumab versus treatment withdrawal (placebo)). Missing data will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has met the criterion for relapse during the Randomized-Withdrawal Period, they will be treated 
as a non-responder at Week 56 for this analysis. 
While not part of the fixed sequence testing procedure, it is a secondary objective to assess the 
maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56. While multiple 
variables and analyses will be used to assess this objective, the secondary efficacy variable that 
will be used for this assessment is also PASI90 response at Week 56 for subjects in the 
WK16ResS. This analysis will be based on simple percentages of PASI90 responders at Week 
56 for each dosing regimen (Q4W and Q8W). Subjects with missing data at Week 56 or who 
meet the criterion for relapse will be counted as non-responders. 
8.2.2.2 
IGA Response 
For IGA response (clear) at Week 16, the stratified CMH test similar to the primary analysis will 
be applied. 
A line plot of IGA responder rate (clear) over time, by treatment group will be produced.  
8.2.2.3 
Scalp IGA response 
For scalp IGA (Clear or Almost Clear) at Week 16, the stratified CMH test similar to the primary 
analysis will be applied. 
A line plot of scalp IGA responder rate over time, by treatment group will be produced.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 46 of 122 
8.2.2.4 
PSD 
For each of the three PSD response scores of itch, pain, and scaling, the following analyses will 
be performed for the purpose of supporting each item as individual key secondary variables.  
The PSD response variables will be characterized in terms of the cumulative percent of subjects 
demonstrating a pre-specified point improvement at Week 16. The threshold for the PSD 
response score of itch, pain, and scaling is 2.39, 1.98, and 2.86, respectively. This responder 
analysis will be limited to the subjects with a Baseline PSD response score at or above the 
applicable threshold score (i.e., at least 2.39, 1.98, and 2.86 for itch, pain and scaling 
respectively). The stratified CMH test, similar to the primary efficacy analysis, will be applied to 
each of these responder analyses. These are the inferential analyses that will be used in the 
multiplicity-controlled testing procedure for itch, pain, and scaling. 
Additionally, the entire distribution of responses for each of PSD response scores of itch, pain 
and scaling will be evaluated via continuous plots showing the absolute and percent change from 
Baseline on the X-axis and the percent of subjects experiencing that change on the Y-axis. This 
distribution curve will reveal the extent to which overall results are driven by outliers who 
improve or worsen more than others. The cumulative distribution function (CDF) is the 
probability that the variable takes a value less than or equal to x. That is: 
 
where the right-hand side represents the probability that the random variable X takes on a value 
less than or equal to x. The probability that X lies in the interval [a, b] is therefore: 
 
FX(b) − FX(a) if a < b 
Note that cumulative distribution plots will be provided for absolute and percent change from 
Baseline PSD to Week 16 for itch, pain, and scaling.  
8.2.3 
Sensitivity analyses of the secondary efficacy variables 
Sensitivity analyses for the handling of missing data will be performed for the binary and 
continuous secondary efficacy variables that are part of the fixed sequence testing procedures in 
Figure 4-1. 
For binary response variables (PASI100 at Week 16, PASI75 at Week 4,  Scalp IGA at Week 16, 
and PSD response for itch, pain and scaling), sensitivity analyses #1 and #3 (Section 8.1.3.1, 
Section 8.1.3.3) will be performed. 
Missing data for these PSD variables will use the MI procedure similar to the sensitivity analysis 
#1 (Section 8.1.3.1) for the co-primary efficacy variables with the following differences:  
1. The data included in the imputation model will be limited only to those subjects with 
sufficiently high Baseline values to achieve the response for a given item (based on observed 
cases). 
2. The PSD item value will be imputed. Once imputation has been performed across the 100 
iterations specified, any values below 0 and above 10 will be truncated to 0 and 10, 
respectively. 
3. The change from Baseline values will be computed based on the complete data sets. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 47 of 122 
The analysis model will be based on the CMH test.There may be cases where the multiple 
imputation model fails to converge. In such situations, the LOCF approach will instead be used 
to impute the missing data. If LOCF is used instead of multiple imputation for this reason, this 
will be clearly specified in the corresponding table summary. Note that for LOCF imputation, 
any missing data or data collected following discontinuation of IMP will be imputed with the 
most recent previous value.  
Missing data for binary secondary efficacy variables during the Initial Period will be imputed 
using NRI. 
Missing data for the binary secondary efficacy variable during the Randomized-Withdrawal 
Period (PASI90 at Week 56 among Week 16 PASI90 responders) will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has met the criterion for relapse during the Randomized-Withdrawal Period, they will be treated 
as a non-responder at Week 56 for this analysis. 
8.3 
Statistical analysis of Other Efficacy Variables 
The other efficacy variables are listed below and will be evaluated according to the planned 
assessments in the protocol, this excludes the timepoints for the primary and secondary variables 
specified above in Section 8.1.1 and Section 8.2.1.  
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit. Continuous variables will be summarized using descriptive statistics by treatment 
group for each visit. All other efficacy variables will be summarized based on imputed data (NRI 
and MCMC/Monotone Regression for binary and continuous variables, respectively), unless 
otherwise specified. 
Missing data for continuous secondary efficacy variables will be imputed using MI. The MI 
procedure for continuous variables will be similar to sensitivity analysis #1 described in 
Section 8.1.3.1 for the co-primary efficacy endpoints with the following difference – no 
dichotomization will be necessary. Also, no requirement of meeting minimum threshold at 
baseline is needed to be included in imputation for a continuous variable 
For variables that are part of the sequence testing procedure, summaries based on observed case 
data will also be provided. There may be cases where the multiple imputation model fails to 
converge. In such situations, the LOCF approach will instead be used to impute the missing data. 
If LOCF is used instead of multiple imputation for this reason, this will be clearly specified in 
the corresponding table summary. Should there be no missing data for a study variable, then only 
observed case data will be produced. Note that for LOCF imputation, any missing data or data 
collected following discontinuation of IMP will be imputed with the most recent previous value. 
Note that in addition, for subjects who change treatment at Week 16, change from two Baselines 
(i.e Initial Treatment Period Baseline and Randomized Withdrawal Period Baseline) will be 
summarized in the WK16ResS for PASI and DLQI. 
For subjects that enter the escape arm at Week 16 or later, change from two Baselines (i.e. Initial 
Period Baseline and Baseline at which escape treatment was initiated) will be summarized in the 
ESS for PASI and DLQI. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 48 of 122 
8.3.1 
PASI 
8.3.1.1 
PASI50, PASI75, PASI90, and PASI100 response 
Binary response variables, PASI50, PASI75, PASI90 and PASI100 over time are defined to be 
equal to 1 if the percentage improvement from Baseline to visit timepoint in the PASI scores is 
50%, 75%, 90% and 100% respectively or greater and 0 if the percentage improvement from 
Baseline to visit timepoint is less than 50%, 75%, 90% and 100% respectively. This definition is 
introduced for the purpose of identifying subjects who respond to the treatment (1 = responder, 0 
= non-responder). The definition of percentage improvement from Baseline is given in Section 
8.1.1.1. 
A line plot of the PASI responder (PASI75, PASI90, and PASI100) rate over time, by treatment 
group will be produced. 
8.3.1.2 
Time to PASI50, PASI75, PASI90, and PASI100 response 
Time to PASI50, PASI75, PASI90, and PASI100 response (in days) during the Initial Treatment 
Period will each be calculated as: 
Min (Date of first PASIxx response, Date of Week 16 visit) – Date of Baseline visit + 1, here xx 
represents 50, 75, 90, 100 respectively. All visits including unscheduled visits are considered. 
Subjects who discontinue study treatment without achieving a given PASI response prior to 
Week 16 visit will be censored at the date of the last observed PASI assessment on or prior to the 
study treatment discontinuation. Subjects who reach the Week 16 Visit without achieving the 
given response will be censored at the date of the last observed PASI assessment on or prior to 
the Week 16 Visit. Subjects will be censored at Baseline if there is no Baseline PASI assessment 
or no Post Baseline PASI assessment. 
Time to PASI50, PASI75, PASI90, and PASI100 response during Initial Treatment Period will 
each be estimated and presented using the Kaplan-Meier product-limit method for each treatment 
group.  
Kaplan-Meier plots of time to PASI responses will be presented by treatment group. In these 
Kaplan-Meier plot, the line will start at 0 (since there are no responders at Week 0) and will 
increase over time, representing time to achieving the response. 
The median time to response, including the two-sided 95% confidence interval, will be 
calculated for each treatment. Comparisons of bimekizumab vs placebo will be analyzed using a 
log-rank test stratified by region and prior biologic exposure. 
8.3.1.3 
Time to relapse 
Relapse is defined as not achieving a PASI75 response at Week 20 or later during the 
Randomized-Withdrawal Period for subjects in the WK16ResS. 
Time to relapse (in days) is defined as: Date of relapse - Date of first re-randomized IMP 
treatment + 1.  
Time to relapse will be estimated and presented using the Kaplan-Meier product-limit method 
for each treatment (excluding subjects who were treated with placebo in both Initial Treatment 
Period and Randomized-Withdrawal Period as they cannot relapse by definition). Subjects who 
discontinue IMP prior to a recorded relapse will be considered as having relapsed on the date of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 49 of 122 
early discontinuation. Subjects who reach the Week 56 Visit without relapsing will be censored 
at the date of the Week 56 Visit. 
The median time to relapse, including the two-sided 95% CI, will be calculated for each 
treatment. Between-group differences will be analyzed with the log-rank test stratified by region 
and prior biologic exposure. These between-group differences will compare each bimekizumab 
dose (separately for each regimen as well as pooled regimen) to placebo based on the re-
randomized treatment groups (i.e., independent of the initial randomization). 
8.3.1.4 
Percentage of subjects who relapse 
Percentage of subjects who relapse during the Randomized-Withdrawal Period is defined as: 
(Number of subjects who relapse / Number of subjects in WK16ResS) × 100 
The percentage of subjects who relapse will be presented by treatment group over time 
(excluding subjects who were treated with placebo in both Initial Treatment Period and 
Randomized-Withdrawal Period as they cannot relapse by definition).. 
8.3.1.5 
Percentage of subjects who rebound 
Rebound is defined as when a subject experiences a >=25% increase from Initial Treatment 
Period Baseline in PASI score occurring within 2 months (60 days) of stopping therapy. The 
percentage of subjects who rebound during the Randomized-Withdrawal Period is defined as:  
(Number of subjects who rebound / Number of subjects in WK16ResS) × 100 
The percentage of subjects who rebound will be presented  for subjects re-randomized to placebo 
over time. 
8.3.1.6 
PASI score 
Absolute and percentage change from Baseline in PASI score is defined in Section 8.1.1.1. 
The percent of subjects with absolute PASI score ≤1, ≤2, ≤3 and ≤5 will be presented over time 
using NRI. 
8.3.1.7 
Modified Nail Psoriasis Severity Index (mNAPSI) score 
Psoriatic nail disease will be evaluated at the Baseline visit using the mNAPSI. All affected nails 
will be scored (0 to 3) for onycholysis/oil drop dyschromia, nail plate crumbling, and pitting and 
will be scored (0 for “no” or 1 for “yes”) for leukonychia, nail bed hyperkeratosis, splinter 
haemorrhages and red spots in the lunula. The score for an individual nail ranges from 0 to 13 
with higher scores indicative of more severe nail disease. The total mNAPSI score is the sum of 
the scores for each individual nail. If a nail is unaffected, it will be recorded as such and will not 
contribute to the total mNAPSI score. 
If any of the 7 response items that contribute to mNAPSI is present, while other items are 
missing (i.e., partial mNAPSI data), then the missing items are assumed to be 0 for the mNAPSI 
calculation. In some cases, the data may be captured in such a way that only non-zero component 
scores are present in the database. Again, those components that are not present are simply 
assumed to be 0 for the mNAPSI calculation. 
Change from Baseline in mNAPSI score for subjects with nail PSO at Baseline is defined as 
Post-Baseline mNAPSI score minus Baseline mNAPSI. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 50 of 122 
An mNAPSI responder is defined as a subject who achieved at least a 75% improvement from 
Baseline in the mNAPSI score. mNAPSI90 and mNAPSI100 are defined accordingly. The 
proportion of mNAPSI75/90/100 responders over time will be summarized for each treatment 
group. 
8.3.2 
IGA response  
 IGA response (Clear with at least 2-category improvement from Baseline) is defined as an 
IGA score of zero (Table 8-1) with at least 2-category improvement from Baseline. Shift 
from Baseline in IGA score is defined at each Post-Baseline visit timepoint relative to 
Baseline. 
 IGA response (Clear or Almost Clear with at least 2-category improvement from Baseline) is 
defined as an IGA score of zero (Clear) or an IGA score of 1 (Almost Clear) with at least a 2-
category improvement from Baseline. 
 Scalp-specific IGA response (Clear or Almost Clear with at least 2-category improvement 
from Baseline) definition and derivation are outlined in Section 8.2.1.4. 
 Palmoplantar Investigator’s Global Assessment (pp-IGA) response (Clear or Almost Clear 
with at least 2-category improvement from Baseline) 
A static IGA for palmoplantar PSO will be used to assess palmoplantar disease severity. 
Only subjects with scalp involvement at Baseline will complete the pp-IGA at the other visits 
specified in the protocol. Subjects with palmoplantar involvement at Baseline are defined as 
those with a pp-IGA score >0 at Baseline. 
Palmoplantar disease will be assessed in terms of clinical signs of redness, thickness, and 
scaliness using a 5-point scale as outlined in the table below. 
Table 8‒4: 
Palmoplantar IGA 
Score 
Short Descriptor 
Detailed Descriptor 
0 
Clear 
Palmoplantar has no signs of PSO; post-inflammatory 
hyperpigmentation may be present 
1 
Almost clear 
Palmoplantar has no thickening; normal to pink coloration; no to 
minimal focal scaling 
2 
Mild 
Palmoplantar has just detectable to mild thickening; pink to light red 
coloration; predominately fine scaling 
3 
Moderate 
Palmoplantar has clearly distinguishable to moderate thickening; dull to 
bright red and clearly distinguishable coloration; moderate scaling 
4 
Severe 
Palmoplantar has severe thickening with hard edges; bright to deep dark 
red coloration; severe/coarse scaling covering almost all or all lesions; 
numerous fissures 
PSO=psoriasis; pp-IGA=palmoplantar-specific Investigator’s Global Assessment 
Palmoplantar IGA response is defined as clear [0] or almost clear [1] with at least a 2-category 
improvement from Baseline. For analysis purposes, the evaluation of pp-IGA will be limited to 
subjects with a Baseline pp-IGA of at least 2. Therefore, if a subject has a score of 2 at Baseline, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 51 of 122 
they can only be considered a responder if their IGA is 0 (thereby meeting the criterion for a 2-
category improvement from Baseline). Subjects with a Baseline pp-IGA of 1 will be assessed per 
the protocol but will not be part of the scalp IGA analysis. 
A line plot of the IGA (both clear or almost clear and clear) and scalp IGA responder rate over 
time, by treatment group will be produced.  
8.3.3 
BSA 
 Absolute change from Baseline in the BSA affected by PSO is defined as Post Baseline BSA 
minus Baseline BSA affected by PSO.  
 Percent change from Baseline in BSA affected by PSO is defined as 
Percent change from Baseline = 100 × Post Baseline BSA −Baseline BSA
Baseline BSA
. 
The percent of subjects with absolute BSA=0%, ≤1%, ≤3% and ≤5% will be presented over time. 
8.3.4 
Product of IGA and BSA (IGAxBSA) 
 Absolute change from Baseline in the product IGAxBSA is defined as Post Baseline 
IGAxBSA minus product of Baseline IGAxBSA.  
 Percent change from Baseline in the product of IGAxBSA is defined as 
Percent change from Baseline = 100 × Post Baseline IGAxBSA −Baseline IGAxBSA
Baseline IGAxBSA
. 
8.3.5 
Dermatology Life Quality Index (DLQI) 
The DLQI questionnaire is used for patients with psoriasis and consists of 10-questions. This is 
validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, 
daily activities, leisure, work and school, personal relationships, and treatment, as assessed over 
the past week.   
The scoring of each answer for the DLQI is as follows: 
Table 8‒3: 
Dermatology Life Quality Index  
DLQI Scoring 
Response 
Score 
Very much 
3 
A lot 
2 
A little 
1 
Not at all 
0 
Not relevant 
0 
Question unanswered 
0 
Q7: ‘prevented work or studying’ = yes 
3 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 52 of 122 
The DLQI is calculated by adding the score of each question. The maximum score is 30, and the 
minimum score is 0. The higher the score, the more quality of life is impaired. 
Meaning of DLQI Scores 
0-1 = no effect at all on patient’s life 
2-5 = small effect on patient’s life 
6-10 = moderate effect on patient’s life 
11-20 = very large effect on patient’s life 
21-30 = extremely large effect on patient’s life 
This categorization will not be utilized in the analysis. 
Because Q7 has a sub-question (referred to as Q7a here) after the leading yes/no question, some 
clarifying rules for scoring are provided: 
 If Q7 is marked as “yes”, a score of 3 is given regardless of the responses to Q7a. 
 If Q7 is marked as “no”, “not relevant”, or is missing and Q7a is “A lot”, a score of 2 is 
given. 
 If Q7 is marked as “no”, “not relevant”, or is missing and Q7a is “A little”, a score of 1 is 
given. 
 If Q7 is marked as “no”, “not relevant”, or is missing and Q7a is “Not at all”, a score of 0 is 
given. 
 If Q7 is marked as “no” or “not relevant” and Q7a is missing, a score of 0 is given. 
 If Q7 is missing and Q7a is missing, Q7 is considered unanswered (see below for details on 
how this impacts the overall DLQI score). 
If 1 question is left unanswered, this is scored 0 and the scores are summed and expressed as 
usual out of a maximum of 30. If 2 or more questions are left unanswered, the questionnaire is 
not scored. 
A subject is considered to have achieved the minimally clinical important difference (MCID) if 
their individual improvement from Baseline score is > 4.  A 4-point improvement in the DLQI 
score (DLQI response) has been reported to be meaningful for the subject (within-subject 
MCID).   
A DLQI absolute score of 0 or 1 indicates no or small impact of the disease on health-related 
quality of life. 
The DLQI related efficacy variables are defined as follows: 
 Change from Baseline in DLQI is defined as Post-Baseline DLQI minus Baseline DLQI. 
 Percent of subjects achieving a DLQI total score of 0 or 1 is defined as the number of 
subjects with DLQI absolute score of 0 or 1 divided by the number of subjects in RS. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 53 of 122 
 Percent of subjects achieving a minimal clinically important difference (MCID) in DLQI is 
defined as the number of subjects with improvement from Baseline score of 4 or more 
divided by the number of subjects in RS that have a Baseline DLQI of at least 4. 
8.3.6 
Patient’s Global Assessment of Disease Activity (PGADA) for 
arthritis visual analog scale (VAS) 
The PGADA for arthritis VAS will be used to provide an overall evaluation of arthritis disease 
symptoms. Subjects will respond to the question, “Considering all the ways your arthritis affects 
you, please mark a vertical line on the scale below to show how you are feeling today,” using a 
VAS where 0 is “very good, no symptoms” and 100 is “very poor, severe symptoms. 
All subjects will complete the PGADA at Baseline. Subjects with PsA at Baseline (defined as a 
past medical history of PsA or PASE ≥47) will complete the PGADA at the visits specified in 
the protocol. Change from Baseline in the PGADA for the arthritis VAS in subjects with PsA at 
Baseline is defined as Post-Baseline PGADA minus Baseline PGADA. 
8.3.7 
Patient Global Assessment of PSO score 
The Patient Global Assessment of PSO is a PSO-specific item in which the patient responds to 
the multiple-choice question, “How severe are your psoriasis-related symptoms right now?” 
Possible response to the question are “no symptoms”, “mild symptoms”, “moderate symptoms”, 
“severe symptoms”, or “very severe symptoms”. 
The Patient Global Assessment of psoriasis will be summarized based on OC as the primary 
analysis. No imputation is applied. 
Shift from Baseline in PGA (Patient Global Assessment) of PSO score is defined to each Post-
Baseline visit timepoint relative to Baseline. 
8.3.8 
Patient Symptom Diary (PSD) 
Absolute and percent changes from Baseline PSD for each item will be summarized by visit for 
each treatment group.  
For PSD response score of redness, burning, cracking, dryness, irritation, sensitivity, lesions, 
thickening, fatigue, embarrassment, choice of clothing, the responder criterions in terms of 
change from Baseline are set to 3.05, 1.99, 2.01, 3.04, 2.82, 2.60, 2.69, 2.68, 1.51, 2.43, and 2.14 
respectively. Number and percentage of subjects who are responders will be summarized based 
on each of these items. 
In addition, cumulative distribution plots will be provided for absolute and percent change from 
Baseline PSD at Week 16 for each item. 
8.3.9 
Psoriatic Arthritis Screening and Evaluation (PASE) 
The PASE questionnaire is a self-administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7-item 
symptoms subscale and an 8-item functions subscale. Standardized responses are based on 5 
categories relating to agreement (strongly agree [5], agree [4], no idea [3], disagree [2], and 
strongly disagree [1]). The total maximum score is 75 points (symptom score: 35 points and 
function score: 40 points). Psoriatic Arthritis Screening and Evaluation questionnaire scores ≥47 
points are indicative of active PsA.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 54 of 122 
PASE will be collected at Baseline and Week 56/PEOT visit. PASE will be summarized based 
on OC only. No imputation is applied. 
 Change from Baseline in the PASE questionnaire scores (function score, symptom score, and 
total score) is defined as Post-Baseline PASE questionnaire score (function, symptom, and 
total) minus Baseline PASE questionnaire score (function, symptom, and total). 
 Shift from Baseline in PASE score suggestive of PsA (<47 versus ≥47) is defined to Week 
56/PEOT visit timepoint relative to Baseline. 
8.3.10 
Short Form 36-item Health Survey (SF-36)  
The SF-36v2, standard recall, measures the following 8 health domains as rated by the subjects 
over the past four weeks: Physical Functioning, Role Physical, Bodily Pain, General Health, 
Vitality, Social Functioning, Role Emotional, and Mental Health (Maruish, 2011).  
The SF-36 Physical and Mental Component Summary scores (PCS and MCS, respectively) are 
used to measure the two broad components, or aspects, of health-physical and mental. PCS and 
MCS are based on the aggregate of 8 health concepts described above and all of the 8 health 
domain scales are used to score both components summary measures. 
One additional item asks respondents about health change over the past year. 
The SF-36 will be used using QualityMetric’s Health Outcomes™ Scoring Software Version 5.1 
or later. The software uses updated 2009 U.S. population norms and applies a Full Missing Score 
Estimation (Full MSE) method as follows: 
 A health domain score (except the physical functioning (PF) domain) will be estimated 
provided that at least one non-missing response is available within that domain  
 For the PF domain item response theory will be used to develop a model for estimates of 
the missing score (Thomas and Cyr, 2002) 
 Regression methods are then applied to estimate the PCS and the MCS on the basis of the 
available domains. 
 Change from Baseline in Short Form 36-item Health Survey PCS score, and MCS score, and 
individual domains is defined as respective score at Post-Baseline timepoint minus the 
Baseline score.  
8.3.11 
Euro-Quality of Life 5-Dimensions, 3 levels (EQ-5D-3L) 
The EQ-5D-3L health questionnaire provides a descriptive profile and a single index value for 
health status. The instrument is comprised of a 5-item health status measure and a VAS.  
Responses to EQ-5D-3L are scored as 1 for “no problem”, 2 for “some or moderate problems”, 
and 3 for “extreme problems” 
Absolute EQ-5D-3L VAS score records the respondent’s self-rated health status on a vertical 
20cm scale, 0 to 100 graduated (0=worst imaginable health status, 100=best imaginable health 
status) 
Change from Baseline in EQ-5D-3L VAS scores is defined as Post-Baseline EQ-5D-3L VAS 
score minus Baseline EQ-5D-3L VAS score. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 55 of 122 
Responses to EQ-5D-3L will be summarized based on OC only as primary analysis. No 
imputation is applied to responses to EQ-5D-3L but is applied to EQ-5D-3L VAS scores. 
8.4 
Additional statistical analysis of other efficacy variables 
For selected of the other efficacy variables, it is of interest to perform statistical tests and to 
calculate inferential statistics. As these tests are not part of the multiplicity-controlled procedure, 
the associated p-values are considered nominal and are not controlled for multiplicity. 
For responder variables, the analysis will follow what was specified for the primary analysis. 
Specifically, a stratified Cochran-Mantel-Haenszel (CMH) test will be used, where region and 
prior biologic exposure (yes/no) will be stratification variables. The p-value will be based on the 
CMH test for a general association. Missing values will be imputed using NRI. 
For continuous variables, the MI – MCMC / Monotone Regression approach used for other 
continuous variables will be applied for the imputation model. The analysis model will be based 
on analysis of covariance (ANCOVA) with fixed effects of treatment, region, and prior biologic 
exposure and Baseline value as a covariate.  
Below is a list of variables for which these nominal p-values will be calculated (with the time 
points in parentheses). The results of these inferential tests will all be presented in a single table 
summarizing the testing performed outside of the multiplicity-controlled testing procedure. 
 PASI90 
 Bimekizumab vs Placebo (Weeks 1, 2, 4, 8, and 12) 
 IGA Clear or Almost Clear 
 Bimekizumab vs Placebo (Weeks 1, 2, 4, 8, and 12) 
 PASI100 
 Bimekizumab vs Placebo (Weeks 4, 8, and 12) 
 IGA Clear 
 Bimekizumab vs Placebo (Weeks 4, 8, and 12) 
 PASI75 
 Bimekizumab vs Placebo (Weeks 1, 2, and 16) 
 PSD Response – Pain 
 Bimekizumab vs Placebo (Weeks 1, 2, and 4) 
 PSD Response – Itch 
 Bimekizumab vs Placebo (Weeks 1, 2, and 4) 
 PSD Response – Scaling 
 Bimekizumab vs Placebo (Weeks 1, 2, and 4) 
 Scalp IGA Clear or Almost Clear (subjects with Baseline Scalp IGA ≥2) 
 Bimekizumab vs Placebo (Weeks 1, 2, and 4) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 56 of 122 
 pp-IGA Clear or Almost Clear (subjects with Baseine pp-IGA ≥2) 
 Bimekizumab vs Placebo (Week 16) 
 mNAPSI change from Baseline (subjects with Baseline mNAPSI>0) 
 Bimekizumab vs Placebo (Week 16) 
 mNAPSI75 response (subjects with Baseline mNAPSI>0) 
 Bimekizumab vs Placebo (Week 16) 
 mNAPSI90 response (subjects with Baseline mNAPSI>0) 
 Bimekizumab vs Placebo (Week 16) 
 mNAPSI100 response (subjects with Baseline mNAPSI>0) 
 Bimekizumab vs Placebo (Week 16) 
 DLQI change from Baseline 
 Bimekizumab vs Placebo (Week 16) 
 DLQI 0/1 response 
 Bimekizumab vs Placebo (Week 16) 
 SF-36 PCS change from Baseline 
 Bimekizumab vs Placebo (Week 16) 
 SF-36 MCS change from Baseline 
 Bimekizumab vs Placebo (Week 16) 
 PASI percentage change from Baseline 
 Bimekizumab vs Placebo (Weeks 1, 2, 4, 8, 12, and 16) 
 PASI ≤2 response 
 Bimekizumab vs Placebo (Weeks 1, 2, 4, 8, 12, and 16) 
 PASI ≤5 response 
 Bimekizumab vs Placebo (Weeks 1, 2, 4, 8, 12, and 16) 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS  
9.1 
Pharmacokinetics 
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit. 
PK summaries will be based on observed values. No imputation will be used. However, if 
plasma concentration measurements are below the level of quantification (BLQ), then for 
calculation of the derived statistics the result will be set to ½ of the lower level of quantification 
(LLOQ). Descriptive statistics including geometric mean, geometric coefficient of variation, and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 57 of 122 
geometric mean 95% CI if applicable will be calculated if at least 2/3 of the values of interest are 
above the LLOQ. If this is not the case, only median, minimum, and maximum will be presented.  
In addition, geometric mean plasma concentration will be plotted by treatment group, and by 
cumulative antibody status for subjects randomized to bimekizumab on linear and log linear 
scale.  
If the dosing for a visit is +/- 21 days out of window, then the plasma concentration from that 
visit and all subsequent visits will be excluded from the PK summary. In addition, if the PK 
sampling date is >1 day after the dosing date, then the plasma concentration from that visit will 
be excluded from the PK summary. 
However, all PK concentrations will also be listed.  
The PK will be subject to a population PK analysis, pooling data across phase 2 and  3 trials and 
will be described in a separate analysis plan and reported independently.  
9.2 
Immunogenicity 
The analysis of immunogenicity will be performed on SS. 
9.2.1 
Auto-antibodies 
Not applicable.  
9.2.2 
Anti-bimekizumab antibodies 
Anti-bimekizumab antibodies (ADAb) will be measured using a 3-tiered assay approach: 
screening assay, confirmatory assay and titration assay. Samples confirmed as positive within the 
confirmatory assay, will be further evaluated in a neutralizing assay to evaluate the potential of 
the ADAb to neutralize the activity of bimekizumab (IL-17A or IL-17F, or both) in-vitro. 
Samples were taken at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 
36, Week 48, Week 56 and in subjects who do not enter into the open label extension study 
(PS0014) a sample at SFU (20 weeks after the last dose) . For the interim analysis, the SFU visit 
(after Week 56) will be excluded in the analyses. 
In subjects randomized to placebo and have a PASI90 response and remain on placebo for 56 
weeks, no samples will be analyzed or reported. 
Screening, confirmatory and titer cut points of the respective assays will be determined by the 
bioanalytical laboratory based either on using commercially available drug-naïve samples or on 
the pre-dose samples of the study itself. In case cut point is being set on commercially available 
samples, the representative for the study population is being checked. The screening cut point 
will be used to determine the status of ADAb in test sample as above the cut point (ACP) or 
below the cut point (BCP). Samples presenting ADAb levels above the cut point, will be further 
evaluated in the confirmatory assay, the result of which will be reported as either “confirmed 
positive” (CP) or “not confirmed positive” (NCP).  
 Values ≤ screening cut point (BCP) or above the screening cut point and confirmed negative 
(NCP) are defined as anti-bimekizumab antibody negative 
 Values > predefined screening cut point (ACP) and confirmed positive (CP) are defined as 
anti-bimekizumab antibody positive 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 58 of 122 
 Confirmed positive samples will be titrated, and the titer (reciprocal dilution factor including 
MRD) reported. The samples (or a subset) will also be subject to a neutralizing assay to 
evaluate whether the anti-bimekizumab antibody neutralizes the activity of bimekizumab (IL-
17A or IL-17F or both) in- vitro. This will be reported subsequent to the main DBL and CSR. 
Subject Classification: 
 For subjects who are negative at baseline, and antibody negative at all sampling points post 
initial treatment (including SFU) - pre ADAb negative - treatment emergent ADAb 
negative 
 For subjects who are negative at baseline, and antibody positive at any sampling point post 
initial treatment (including SFU) - pre ADAb negative - treatment emergent ADAb 
positive.  If a subject has a missing pre-treatment sample (either missing or insufficient 
volume) at baseline with one or more ADAb positive post-initial treatment samples will be 
also classified as pre ADAb negative - treatment emergent ADAb positive 
 For subjects who are positive at baseline, and antibody negative at all sampling points post 
initial treatment (including SFU) - pre ADAb positive - treatment emergent reduced 
ADAb 
 For subjects who are positive at baseline, and are positive at any sampling point post initial 
treatment (including SFU) with titer values of the same magnitude as baseline (i.e. ≤ then a 
2.07 fold difference from the baseline value) - pre ADAb positive - treatment emergent 
unaffected ADAb positive 
 For subjects who are positive at baseline, and are positive at any sampling point post initial 
treatment (including SFU) with increased titer values compared to baseline (above a 2.07 
fold difference increase from baseline value which will be defined within the validation of 
the assay and will be included in the TFLs and/or SAP when available) - pre ADAb positive 
- treatment emergent ADAb boosted positive. 
 For Subjects who have a positive pre-treatment sample and some post- initial treatment 
samples are missing, while other post-initial treatment samples are ADAb negative, the 
subject will be classed as inconclusive. 
Derivation for above classification will be different for the interim analysis and the final 
analysis. For the interim analysis no SFU data will be considered. Only for the final analysis, 
when all SFU data will be available, data from the SFU visits will be considered. 
Analysis 
Immunogenicity will be assessed through summary tables and figures, and listing of individual 
results by subject. All analyses will be run on the SS, WK16ResS, ESS and AMS. 
 Number and percentage of subjects with anti-bimekizumab antibody level above the 
specified cut point at the time of each visit, separated by treatment group 
 Number and percentage of subjects with anti-bimekizumab antibody level above the 
specified cut point at any visit during the treatment period, separated by treatment group. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 59 of 122 
 The time-point of the first occurrence of anti-bimekizumab anti-body positivity during the 
treatment period) will be summarized for each treatment group. A plot of the Titre versus 
elapsed time will be plotted 
 All individual subject-level anti-bimekizumab antibody results will be listed. 
 The number and percentage of subject in each of the 6 categories will be tabulated and 
separated by treatment group, with an additional category combining subjects in categories 2 
and 5, summarized as total treatment emergent. In addition, the counts and percentage of 
subjects who are pre-anti-bimekizumab positive will be calculated (this is the sum of 
categories 3,4, and 5).  
 The prevalence of immunogenicity, separated by treatment group, and defined sub-category, 
will be reported per time point, defined as (cumulative) proportion of subjects having 
confirmed positive ADAb samples at any point up to and including that time point. Missing 
samples will not be included in the denominator.  
 The time to achieving treatment-emergent ADAb positivity, separated by treatment group 
and defined sub-category, will be analyzed based on Kaplan-Meier approach, subjects will be 
considered to have an event at time where treatment emergent ADAb positive is first 
achieved. Subjects classified as treatment-emergent ADAb negative will be censored at time 
of last available ADAb result. 
 A summary of PASI 90 responders, separated by treatment group and defined sub-category, 
at weeks 16 and 24 as a function of ADAb titer will be presented graphically. This will be 
repeated for PASI 100 and 75 responders. 
 Individual plots of Bimekizumab Concentrations/ADAb titer and % Change from baseline 
(all Y-axes) versus time (x-axis) for the full treatment period (excluding SFU for interim 
analyses and including SFU for final analyses), where a subject has not progressed into the  
open label extension study (PS0014). Plots should be labeled and grouped into the 6 sub-
categories. 
 Spaghetti plots of ADAb titer (Y-axis) against time (X-axis), separated by treatment group 
for all ADAb positive subjects, including baseline positive subjects. 
 Box plots of all Bimekizumab concentrations where ADA titers exists versus ADA titer 
classification (group 1 >; group 2 >; group 3 >) presented on a linear scale. Cut-points will be 
determined on availability of titre data 
10 
SAFETY ANALYSES 
All safety summaries and listings will be performed using all subjects in the SS. 
The AMS will be used for summaries of safety that include data from the Initial Treatment 
Period and/or Randomized-Withdrawal Period. 
Additional summaries focusing on safety during the Randomized-Withdrawal Period will also be 
prepared and will be based on the WK16ResS. Selected summaries of safety during the Escape 
Period will also be presented and will be based on the ESS.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 60 of 122 
10.1 
Extent of exposure 
Summaries for exposure will be provided. This consists of a descriptive summary of study 
medication duration in days. In addition, total study medication duration and time at risk will be 
summarized in years by treatment group and treatment period (i.e., the Initial Treatment Period, 
the Randomized-Withdrawal Period, and Initial and Randomized-Withdrawal Period). The 
cumulative study medication duration will be summarized for subjects exposed for given 
durations of time, the following categories for duration will be used: 
 >0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks; ≥ 16 weeks for Initial Treatment Period 
>0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks; ≥ 16 weeks; ≥ 20 weeks; ≥ 40 weeks for 
Randomized-Withdrawal Period >0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks for Escape Period 
Definitions for study medication duration and time at risk in days are provided below for each 
period. Time at risk will be summarized in years. Time at risk in years is calculated by dividing 
the time at risk in days by 365.25.  
Throughout this section, date of last clinical contact for each subject is defined as the maximum 
of (last visit date including SFU visit, last imputed AE start date, date of study termination or 
completion, last date of study drug administration). 
10.1.1 
Exposure during the Initial Treatment Period for SS 
Definitions for study medication duration (days) and time at risk (days) during the Initial Period 
are provided as follows: 
Study medication duration (days) 
 Date of last dose in the Initial Treatment Period – date of first dose in the Initial Period + 
28 days.  
Note: If date of last dose in the Initial Period + 28 days extends to a date beyond the date 
of first dose in the Randomized-Withdrawal Period, then this calculation reverts to:  
o Date of first dose in the Randomized-Withdrawal Period – date of first dose in the 
Initial Period + 1.  
Note: For subjects who die during the Initial Period, if date of last dose in the Initial 
Period + 28 days extends to a date beyond the date of death, then this calculation reverts 
to:  
o Date of death – date of first dose in the Initial Period + 1. 
Time at risk (days) 
 For subjects who complete the final visit of the Initial Period and continue to the 
Randomized-Withdrawal Period: Date of first dose in the Randomized-Withdrawal 
Period – date of first dose in the Initial Period + 1. 
 For subjects who discontinue on or prior to the final visit of the Initial Period, use the 
minimum of the following:  
o Date of last dose in the Initial Treatment Period – date of first dose in the Initial 
Period + 140 days. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 61 of 122 
o The total number of days in the Initial Treatment Period (112 days). For AEs that 
emerged after 112 days but still within the 140 days window, those AEs would be 
classified as TEAE, but will be excluded from the output based on the Initial 
Treatment Period. However these AEs will be included in the AE summaries for 
Randomized-Withdrawal Period or Escape Period for subjects in the WK16ResS 
and ESS respectively. 
o Date of last clinical contact – date of first dose in the Initial Treatment Period + 1.  
 For subjects who die prior to the final visit of the Initial Treatment Period: Date of death 
– date of first dose in the Initial Period +1. 
10.1.2 
Exposure during the Randomized-Withdrawal Period for WK16ResS  
Definitions for study medication duration (days) and time at risk (days) during the Initial Period 
are provided as follows: 
Study medication duration (days) 
 Date of last dose in the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 28 days.  
 Note: The use of 28 days assumes a Q4W dosing interval. This should be adjusted based 
on the dosing interval (i.e., use 56 days for a Q8W dosing interval). 
Note: If date of last dose in the Randomized-Withdrawal Period + 28 days (or 56 days in 
the case of Q8W dosing) extends to a date beyond the final visit date of the Randomized-
Withdrawal Period (not including SFU), then this calculation reverts to:  
o Final visit date of the Randomized-Withdrawal Period (not including SFU) – date 
of first dose in the Randomized-Withdrawal Period + 1.  
 
Note: If date of last dose in the Randomized-Withdrawal Period + 28 days (or 56 
days in the case of Q8W dosing) extends to a date beyond the date of the first 
dose in the 12-Week Escape Period, then this calculation reverts to:  
 
Date of first dose in the 12-Week Escape Period – date of first dose in the 
Randomized-Withdrawal Period + 1. 
 
Note: For subjects who die during the Randomized-Withdrawal Period, then this 
calculation reverts to:  
o Date of death – date of first dose in the Randomized-Withdrawal Period + 1. 
Time at risk (days) 
 For subjects who complete the Randomized-Withdrawal Period as planned and continue 
into an open-label study (and, therefore, do not have the SFU visit in the feeder study): 
Final visit date of the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 1. 
 For subjects who die prior to the final visit of the Randomized-Withdrawal Period: Date 
of death – date of first dose in the Randomized-Withdrawal Period + 1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 62 of 122 
 For all other subjects, use the minimum of the following:  
o Date of last dose in the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 140 days. 
o Date of first dose in the 12-Week Escape Period – date of first dose in the 
Randomized-Withdrawal Period + 1.  
o Date of last clinical contact – date of first dose in the Randomized-Withdrawal 
Period + 1.  
Note: This group could include subjects who discontinue the Randomized-Withdrawal 
Period early, subjects who complete the Randomized-Withdrawal Period as scheduled 
but choose not to continue into an open-label study, or subjects who are ongoing in the 
SFU period at the time of the data snapshot. 
10.1.3 
Exposure during the Escape Period for ESS 
There are some summaries for exposure and TEAEs that are based only on the Escape Period. 
Definitions for study medication duration (days) and time at risk (days) during the Escape Period 
are provided as follows: 
Study medication duration (days) 
 Date of last dose in the Escape Period – date of first dose in the Escape Period + 28 days.  
Note: If date of last dose in the Escape Period + 28 days extends to a date beyond the date 
of last visit in the Escape Period, then this calculation reverts to:  
o Date of last visit in the Escape Period – date of first dose in the Escape Period + 1.  
Note: For subjects who die during the Escape Period, if date of last dose in the Escape 
Period + 28 days extends to a date beyond the date of death, then this calculation reverts 
to:  
o Date of death – date of first dose in the Escape Period + 1. 
Time at risk (days) 
 For subjects who complete the final visit of the Escape Period: Date of last visit in the 
Escape Period – date of first dose in the Escape Period + 1. 
 For subjects who discontinue on or prior to the final visit of the Escape Period, use the 
minimum of the following:  
o Date of last dose in the Escape Period – date of first dose in the Escape Period + 
140 days. 
o The total number of days in the Escape Period (84 days). 
o Date of last clinical contact – date of first dose in the Escape Period + 1.  
 For subjects who die prior to the final visit of the Escape Period: Date of death – date of 
first dose in the Escape Period +1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 63 of 122 
10.1.4 
Exposure during the Initial and Randomized-Withdrawal for AMS 
Definitions for study medication duration (days) and time at risk (days) entire study treatment 
period (the Initial and the Randomized-Withdrawal Period) are provided as follows: 
Study medication duration (days) 
For subjects who do not switch study treatments and do not enter the 12-Week Escape Period: 
 Date of last dose – date of first dose + 28 days.  
Note: If date of last dose + 28 days extends to a date beyond the final visit date (not 
including SFU), then this calculation reverts to:  
o Final visit date (not including SFU) – date of first dose + 1.  
Note: For subjects who die, if date of last dose + 28 days extends to a date beyond the 
date of death, then this calculation reverts to:  
o Date of death – date of first dose + 1. 
For subjects who switch study treatments (between Initial and Randomized-Withdrawal Periods) 
and do not enter the 12-Week Escape Period: 
 Initial Period (attributed to initially randomized treatment): 
o Date of last dose in the Initial Period – date of first dose in the Initial Period + 28 
days.  
Note: If date of last dose in the Initial Treatment Period + 28 days extends to a 
date beyond the date of first dose in the Randomized-Withdrawal Period, then this 
calculation reverts to:  
 Date of first dose in the Randomized-Withdrawal Period – date of first 
dose in the Initial Period + 1.  
 Randomized-Withdrawal Period (attributed to the treatment initiated in the Randomized-
Withdrawal Period): 
o Date of last dose in the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 28 days.  
Note: The use of 28 days assumes a Q4W dosing interval. This should be adjusted 
based on the dosing interval (i.e., use 56 days for a Q8W dosing interval). 
Note: If date of last dose in the Randomized-Withdrawal Period + 28 days (or 56 
days in the case of Q8W dosing) extends to a date beyond the final visit date of 
the Randomized-Withdrawal Period (not including SFU), then this calculation 
reverts to:  
 Final visit date of the Randomized-Withdrawal Period (not including 
SFU) – date of first dose in the Randomized-Withdrawal Period + 1.  
Note: For subjects who die during the Randomized-Withdrawal Period, then this 
calculation reverts to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 64 of 122 
 Date of death – date of first dose in the Randomized-Withdrawal Period + 
1. 
For subjects who enter the 12-Week Escape Period due to not achieving a PASI90 response at 
Week 16: 
 Initial Period (attributed to initially randomized treatment): 
o Date of last dose in the Initial Period – date of first dose in the Initial Period + 28 
days.  
Note: If date of last dose in the Initial Treatment Period + 28 days extends to a 
date beyond the date of first dose in the 12-Week Escape Period, then this 
calculation reverts to:  
 Date of first dose in the 12-Week Escape Period – date of first dose in the 
Initial Period + 1.  
For subjects who enter the 12-Week Escape Period due to relapsing during the Randomized 
Withdrawal Period: 
 Initial Period (attributed to initially randomized treatment): 
o Date of last dose in the Initial Period – date of first dose in the Initial Period + 28 
days.  
Note: If date of last dose in the Initial Treatment Period + 28 days extends to a 
date beyond the date of first dose in the Randomized Withdrawal Period, then this 
calculation reverts to:  
 Date of first dose in the Randomized Withdrawal Period – date of first 
dose in the Initial Period + 1.  
 Randomized-Withdrawal Period (attributed to the treatment initiated in the Randomized-
Withdrawal Period): 
o Date of last dose in the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 28 days.  
Note: The use of 28 days assumes a Q4W dosing interval. This should be adjusted 
based on the dosing interval (i.e., use 56 days for a Q8W dosing interval). 
Note: If date of last dose in the Randomized-Withdrawal Period + 28 days (or 56 
days in the case of Q8W dosing) extends to a date beyond the date of the first 
dose in the 12-Week Escape Period, then this calculation reverts to:  
 Date of first dose in the 12-Week Escape Period – date of first dose in the 
Randomized-Withdrawal Period + 1.  
Time at risk (days):  
For subjects who do not switch study treatments and do not enter the 12-Week Escape Period: 
 For subjects who complete the Randomized-Withdrawal Period as planned and continue 
into an open-label study (and, therefore, do not have the SFU visit in the feeder study): 
Final visit date – date of first dose + 1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 65 of 122 
 For subjects who die prior to the final visit: Date of death – date of first dose in the + 1. 
 For all other subjects, use the minimum of the following:  
o Date of last dose – date of first dose + 140 days. 
o Date of last clinical contact – date of first dose + 1.  
Note: This group could include subjects who discontinue early, subjects who complete 
the Randomized-Withdrawal Period as scheduled but choose not to continue into an 
open-label study, or subjects who are ongoing in the SFU period at the time of the data 
snapshot (in the case of the interim analysis). 
For subjects who switch study treatments (between Initial and Randomized-Withdrawal Periods) 
and do not enter the 12-Week Escape Period: 
 Initial Treatment Period (attributed to initially randomized treatment): 
o Date of first dose in the Randomized-Withdrawal Period – date of first dose in the 
Initial Period + 1. (Note: This assumes that anyone in this category has completed 
the Initial Treatment Period and doses [with a new study treatment] in the 
Randomized-Withdrawal Period.) 
 Randomized-Withdrawal Period (attributed to the treatment initiated in the Randomized-
Withdrawal Period): 
o For subjects who complete the Randomized-Withdrawal Period as planned and 
continue into an open-label study (and, therefore, do not have the SFU visit in the 
feeder study): Final visit date of the Randomized-Withdrawal Period – date of 
first dose in the Randomized-Withdrawal Period + 1. 
o For subjects who die prior to the final visit of the Randomized-Withdrawal 
Period: Date of death – date of first dose in the Randomized-Withdrawal Period + 
1. 
o For all other subjects, use the minimum of the following:  
 Date of last dose in the Randomized-Withdrawal Period – date of first 
dose in the Randomized-Withdrawal Period + 140 days. 
 Date of last clinical contact – date of first dose in the Randomized-
Withdrawal Period + 1.  
Note: This group could include subjects who discontinue the Randomized-
Withdrawal Period early, subjects who complete the Randomized-Withdrawal 
Period as scheduled but choose not to continue into an open-label study, or 
subjects who are ongoing in the SFU period at the time of the data snapshot. 
For subjects who enter the 12-Week Escape Period due to not achieving a PASI90 response at 
Week 16: 
 Initial Treatment Period (attributed to initially randomized treatment): 
o Date of first dose in the 12-Week Escape Period – date of first dose in the Initial 
Period + 1. (Note: This assumes that anyone in this category has completed the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 66 of 122 
Initial Treatment Period and doses [with BKZ 320mg Q4W] in the 12-Week 
Escape Period.) 
For subjects who enter the 12-Week Escape Period due to relapsing during the Randomized 
Withdrawal Period: 
 Initial Period (attributed to initially randomized treatment): 
o Date of first dose in the Randomized-Withdrawal Period – date of first dose in the 
Initial Period + 1. (Note: This assumes that anyone in this category has completed 
the Initial Treatment Period and doses [with a new study treatment] in the 
Randomized-Withdrawal Period.) 
 Randomized-Withdrawal Period (attributed to the treatment initiated in the Randomized-
Withdrawal Period): 
o Date of first dose in the 12-Week Escape Period – date of first dose in the 
Randomized-Withdrawal Period + 1.  
10.2 
Adverse events 
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA version 19.0).  
For subjects who switch from placebo to bimekizumab at Week 16 or who relapse on placebo 
during the Randomized-Withdrawal Period and enter the Escape Period, AEs will be allocated to 
the treatment the subject was on the day the event occurred. If the event occurs on the day of the 
switch, it will be attributed to placebo. The only exception to this is if the AE fulfills the criteria 
for an anaphylactic reaction as defined in the bimekizumab safety topics of interest document. 
Specifically, this includes the following: 
 Events that fulfill the anaphylaxis criteria for acute events (refer to Appendix A in Section 
12.1) 
 Events with a reported term containing the term “hypersensitivity” 
 Events with an HLT of “Administration site reactions NEC” 
 Events with an HLT of “Injection site reactions” . 
10.2.1 
Data considerations 
Treatment-emergent AEs (TEAEs) are defined as those AEs that have a start date on or 
following the first dose of study treatment through the final dose of study treatment + 140 days 
(covering the 20-week SFU period). If it is not possible (due to partial dates) to determine 
whether an AE is treatment-emergent then it will be assumed to be a TEAE.  
The rules for imputing partial start or stop dates are outlined in the Section 4.2.2. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 67 of 122 
If the intensity of an adverse event is unknown, it is considered as severe. If the relationship to 
study drug is missing, it is considered as related. 
AEs will be presented as “number of subjects (percentage of subjects) [number of events]”.  In 
this style of output, “[number of events]” will include all cases of an AE including repeat 
occurrences in individual subjects, while “number of subjects” will count each subject only once. 
Subject time at risk represents the time a subject is at risk for having an AE. The definitions for 
subject time at risk (in days) are outlined in Section 10.1. These definitions will be used for 
exposure-adjusted AE summaries. 
Selected AE summaries will include the exposure adjusted incidence rate (EAIR) with associated 
95% confidence interval and the exposure adjusted event rate (EAER). 
The EAIR is defined as the number of subjects (n) with a specific AE adjusted for the exposure 
and will be scaled to 100 patient-years: 
EAIR = 100 × n/ ∑(TExp(i))
N
i=1
 
If a subject has multiple events, the time of exposure is calculated to the first occurrence of the 
AE being considered. If a subject has no events, the total time at risk is used. 
Exact Poisson 95% confidence intervals for incidence rates are calculated using the relationship 
between the Poisson and the Chi-square distribution (Ulm, 1990; Fay and Feuer, 1997): 
 
 
 
where n is the number of subjects with a specific AE for the incidence rate of interest and is the 
basis for the number of the degrees of freedom for the chi-square quantile for the upper tail 
probability χ2. 
The EAER will be the number of AEs including repeat occurrences in individual subjects 
divided by the total time at risk scaled to 100 patient-years and calculated using: 
EAER = 100 × NAE/ ∑(TRisk(i))
𝑁
𝑖=1
 
where NAE is the total number of AEs. 
No confidence interval will be computed for EAER. 
Selected summaries, as specified in Section 10.2.2, will include the risk difference between 
bimekizumab and placebo. The risk difference is calculated as: 
𝑅𝐷= 𝐼𝑃𝐵𝐾𝑍−𝐼𝑃𝑃𝐵𝑂 
where 𝐼𝑃𝐵𝐾𝑍 is the incidence proportion for the bimekizumab-treated group and 𝐼𝑃𝑃𝐵𝑂 is the 
incidence proportion for the placebo group. Note that incidence proportion simply refers to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 68 of 122 
percentage of subjects within the specified treatment group that experienced a given adverse 
event. 
The standard error for the risk difference is calculated as follows: 
𝑆𝐸𝑅𝐷= √(𝐼𝑃𝐵𝐾𝑍× (1 −𝐼𝑃𝐵𝐾𝑍
𝑛𝐵𝐾𝑍
)) + (𝐼𝑃𝑃𝐵𝑂× (1 −𝐼𝑃𝑃𝐵𝑂
𝑛𝑃𝐵𝑂
)) 
where 𝑛𝐵𝐾𝑍 is the number of subjects in the bimekizumab-treated group and 𝑛𝑃𝐵𝑂 is the number 
of subjects in the placebo group.  
The corresponding confidence interval for the risk difference is as follows: 
𝐶𝐼𝑅𝐷= 𝑅𝐷 ± 𝑍1−𝛼2
⁄ × (𝑆𝐸𝑅𝐷)  
where 𝑍1−𝛼2
⁄  is the 𝑍 statistic for the corresponding level of alpha. For the risk difference 
confidence intervals calculated in this SAP, 1.96 will be used (corresponding to a two-sided 
alpha of 0.05 and 95% confidence interval). The risk difference and corresponding CI will be 
displayed as percentage. 
10.2.2 
AE Summaries 
The following summaries will be provided by treatment group for the Initial Treatment Period, 
Randomized-Withdrawal Period, and the Initial and Randomized-Withdrawal Period combined 
based on the SS, the WK16ResS, and the AMS, respectively. In addition, all summaries of 
TEAEs based on “100 subject years” will include EAIR (with 95% confidence interval) and 
EAER. Additional summaries for the ESS will include only the TEAE overview, TEAEs and 
SAEs per 100 subject years, and TEAEs tables for safety topics of interest. For AEs that emerged 
after 112 days but still within the 140 days window, those AEs would be classified as TEAE. 
These AEs will be excluded from the outputs based on the Initial Period but included in the AE 
summaries for Initial and Randomized-Withdrawal Period.  
 Incidence of TEAEs – Overview 
 Incidence of TEAEs per 100 subject years by SOC, HLT, and PT  
 Incidence of Serious TEAEs per 100 subject years by SOC, HLT, and PT  
 Incidence of TEAEs Leading to Discontinuation per 100 subject years by SOC, HLT, and PT  
 Incidence of TEAEs Leading to Death by SOC, HLT, and PT  
 Incidence of TEAEs by Maximum Relationship by SOC, HLT, and PT  
 Incidence of Serious TEAEs by Relationship SOC, HLT, and PT – Note: For EudraCT 
reporting purposes 
 Incidence of Related Serious TEAEs by SOC, HLT, and PT 
 Incidence of TEAEs Leading to Death by Relationship by SOC, HLT, and PT – Note: For 
EudraCT reporting purposes  
 Incidence of TEAEs by Maximum Severity, SOC, HLT, and PT 
 Incidence of TEAEs by decreasing frequency of PT 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 69 of 122 
 Incidence of TEAEs Above Reporting Threshold of 5% by SOC and PT 
 Incidence of Non-Serious TEAEs by SOC, HLT, and PT 
 Incidence of Non-Serious TEAEs by Maximum Relationship SOC, HLT, and PT 
 Incidence of Non-Serious TEAEs Above Reporting Threshold of 5% by SOC and PT 
 Incidence of Non-Serious TEAEs Above Reporting Threshold of 5% by Relationship SOC 
and PT 
 Incidence of Related TEAEs by SOC, HLT, and PT 
 Incidence of Related TEAEs Above Reporting Threshold of 5% by SOC and PT 
 Incidence of TEAEs Above Reporting Threshold of 5% with Risk Differences by SOC and 
PT 
 Incidence of Serious TEAEs and Risk Differences by SOC and PT  
 Incidence of TEAEs per 100 subject years by SOC, HLT, and PT and by Time of Onset 
Relative to Anti-bimekizumab Antibody Status  
The tables with risk differences will also be accompanied by figures (dot plots) which show the 
incidence of the adverse events and corresponding 95% risk difference confidence intervals. 
These will be ordered by descending order of risk difference (bimekizumab vs placebo). 
10.2.3 
Other Safety topics of interest 
The following are AEs of other safety topics of interest that require special statistical analyses. 
Along with the tables described, there will be a table which displays the risk difference and 95% 
confidence intervals for each of the topics of interest. A corresponding figure (with dot plots) 
will be prepared. 
10.2.3.1 
Infections (serious, opportunistic, fungal and TB) 
 Incidence of Serious Infection TEAEs per 100 subject years by SOC, HLT and PT  
Serious infections will be identified based on MedDRA classification (SOC “Infections and 
infestations”) using the “Any SAE” table. A separate table does not need to be produced to 
summarize these events. 
 Incidence of Fungal Infection TEAEs per 100 subject years by SOC, HLT and PT 
Fungal infections will be summarized in a stand-alone table. The table will include all 
TEAEs (serious and non-serious) which code into the High Level Group Term “Fungal 
infectious disorders” 
 Incidence of Opportunistic Infection TEAEs per 100 subject years by SOC, HLT and 
PT  
Opportunistic infections (including tuberculosis) will be summarized in a stand-alone table. 
The table will include all TEAEs identified using UCB-defined search criteria (refer to Excel 
spreadsheet on “OI - MedDRA v19.0.xlsx” in “Bimekizumab-Safety-Topics-of-
Interest.docx”). 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 70 of 122 
The following steps are followed for identifying and reviewing opportunistic infections: 
 
Identification Process 
 
The two steps below outline two ways in which opportunistic infections (or potential 
opportunistic infections) can be identified: 
 
Step 1: Refer to column B of the spreadsheet which identifies the Preferred Terms (PTs) to be 
classified as opportunistic infections using either a single ‘x’ or a double ‘xx’. 
 
TEAEs which code to a PT flagged with a single ‘x’ need to also be serious to be considered an 
opportunistic infection. 
All TEAEs which code to a PT flagged with a double ‘xx’ are considered to be an opportunistic 
infection, regardless of seriousness.  
Step 2: Refer to column C of the spreadsheet which identifies the PTs that need to be evaluated 
on a case-by-case basis by the study physician to determine whether or not it is an opportunistic 
infection. If Column C has a single ‘x’, then the corresponding preferred term should be flagged 
for case-by-case review by the study physician.  
 
Review Process 
 
Opportunistic infections for a given study will be reviewed on the following occasions: 
 
At quarterly Infectious Disease Committee (IDC) Meetings, listings will be produced for each 
study (see details below) and reviewed by the corresponding study physician ahead of the IDC 
Meeting. These listings will be posted as part of the broader SSD deliverable to a folder named 
for the given quarter (eg, 2018Q4) on the SharePoint. They should be based on the same data cut 
as the one used for SSD and should be delivered at the same time as the SSD outputs. The IDC 
will then agree on the final adjudication for each potential opportunistic infection. 
For each study, a final listing for opportunistic infections (in the format described below) will be 
produced and agreed upon between the study physician and the IDC prior to finalizing the 
database. 
In each of the circumstances described above, the study programming team will produce an 
Excel listing that will be provided to the project lead statistician, project lead programmer, and to 
the study physician (who will subsequently provide it to the IDC). The Excel listing will contain 
the following columns (using the descriptions below as the column headings in the Excel listing): 
 
Study ID 
Unique Subject ID 
AE Term (Verbatim) 
AE Preferred Term 
AE System Organ Class 
AE High Level Term 
AE Low Level Term 
Date of Onset 
Outcome of Adverse Event 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 71 of 122 
Date of Outcome 
TEAE Flag 
Serious Adverse Event? 
Relationship to Study Medication  
Intensity 
Action Taken with IMP 
Opportunistic Infection – Automatic 
Opportunistic Infection – Manual Review 
Flag 
Data Cut Date 
Opportunistic Infection – Final Adjudication 
Note the following about the final 5 variables in this listing: 
 
Opportunistic Infection – Automatic: This is flagged as “Y” if the criteria for automatic selection 
as described in “Step 1” of the identification process are met. 
Opportunistic Infection – Manual Review: This is flagged as “Y” if the criteria for case-by-case 
selection as described in “Step 2” of the identification process are met. 
Flag – This has a value of either “NEW” or “OLD”. It is marked as “NEW” if the event is 
appearing for the first time in that run of the listing. Otherwise, if it has appeared previously, it is 
marked as “OLD”. Unique records are determined by USUBJID AESPID for purposes of 
identifying whether an event has been modified from a previous run. 
Date – Only for cases where Flag is “NEW”, this field will be populated with the data cut date 
for that particular run of the listing. 
Opportunistic Infection – Final Adjudication – For new events, this is always left blank by the 
programmers. It should be completed by the study physician/IDC for every event that appears in 
the listing. For events adjudicated as opportunistic, the field should be populated with a “Y”.  
Following each review by the study physician and IDC, the Opportunistic Infection – Final 
Adjudication column will be completed (as described above), and the spreadsheets for each study 
will be returned to the study programming team via e-mail (coordinated by the IDC secretary). 
Then, for subsequent runs of the listing, the study programming teams will incorporate 
adjudications from previous runs. 
10.2.3.2 
Malignancies 
 Incidence of Malignant or Unspecified Tumours TEAEs per 100 subject years by SOC, 
HLT and PT 
These events will be presented in the following tables: 
 One table will be based on the criteria Standardized MedDRA Query (SMQ) = 
“Malignant or unspecified tumours (SMQ)”  
 One table will be based on the criteria SMQ = “Malignant tumours (SMQ)”. 
SMQ search should include all TEAEs which code to a PT included in the Scope=Narrow group 
within each SMQ. 
Note that the events included in the “Malignant tumours” table will be a subset of the events 
included in the “Malignant or unspecified tumours” table. While the “Malignant tumours 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 72 of 122 
(SMQ)” is most relevant, “Malignant or unspecified tumours (SMQ)” must be reviewed for 
potential malignancies. 
The output table based on the SMQ = “Malignant or unspecified tumours (SMQ)” will include 2 
different overall incidence rows: 
 The first overall incidence row will summarize “Any malignancies (including 
unspecified)” and this row will summarize the incidence of all TEAEs flagged for 
inclusion in the table, regardless of the High Level Term (HLT) it codes to.  
 The second overall incidence row will summarize “Any malignancy (including 
unspecified, excluding non-melanomic skin cancers)” and this row will summarize the 
incidence of AEs flagged for inclusion in the table, excluding those which code to an 
HLT of “skin neoplasms malignant and unspecified (excl melanoma)”. 
10.2.3.3 
Major adverse cardiac event  
 Incidence of Adjudicated Major Cardiac Event (MACE) TEAEs per 100 subject years 
by SOC, HLT and PT 
Adjudicated major adverse cardiac events (MACE) will be presented in a table. The 
classification of an event as MACE is determined by an external cardiovascular event 
adjudication committee. 
A separate table and listing will present the adjudicated cardiovascular events by  type. For each 
cardiovascular event type (24 total), the individual PTs which fall within each event type will be 
summarized. 
Additionally, a listing of all events identified for potential review by the cardiovascular event 
adjudication committee will be produced. This listing will indicate whether each event was 
escalated to the committee for formal review/adjudication.   
 
10.2.3.4 
Neutropenia  
 Incidence of Neutropenia TEAEs per 100 subject years by SOC, HLT and PT 
This table will be based on the following PTs (regardless of seriousness): 
 Autoimmune neutropenia 
 Band neutrophil count decreased 
 Cyclic neutropenia 
 Febrile neutropenia 
 Idiopathic neutropenia 
 Neutropenia 
 Neutropenic infection 
 Neutropenic sepsis 
 Neutrophil count decreased 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 73 of 122 
10.2.3.5 
Suicidal Ideation and Behavior  
 Incidence of Suicidal Ideation or Behavior  TEAEs per 100 subject years by SOC, HLT 
and PT 
An external neuropsychiatric adjudication committee will evaluate potential neuropsychiatric 
events and determine whether any of those events were associated with suicidal ideation and 
behavior (SIB). If an event is adjudicated as SIB, further information will be provided. A table 
and a listing for SIB events as determined by the adjudication committee will be included. 
Additionally, a listing of all events identified for potential review by the neuropsychiatric 
adjudication committee will be produced. This listing will indicate whether each event was 
escalated to the committee for formal review/adjudication.   
10.2.3.6 
Inflammatory bowel disease 
 Incidence of Inflammatory Bowel Disease TEAEs per 100 subject years by SOC, HLT 
and PT 
These events will be presented in a stand-alone table which will include all TEAEs which code 
into the HLT of “Colitis excl infective”.   The table will be stratified by subjects with or without 
a previous medical history of inflammatory bowel disease. Previous medical history of 
inflammatory bowel disease will be determined using the information recorded on the Extra-
Articular Assessment at Screening CRF page ("Does subject have a history of IBD?”). 
10.2.3.7 
Hypersensitivity (including anaphylaxis) 
 Incidence of Anaphylactic Reaction TEAEs per 100 subject years by SOC, HLT and PT 
A separate table will be prepared based on the MedDRA anaphylaxis algorithm (refer to 
Appendix A in Section 12) for acute anaphylactic events (reported on either the same day as 
when an injection was administered or one day after).  
A separate table will be prepared to summarize hypersensitivity events, identified using the SMQ 
“Hypersensitivity (SMQ)”. All TEAEs which code to a PT included in the Scope=Narrow search 
will be included in this table.  
Furthermore, injection site reactions will be evaluated based on the any TEAE table (no separate 
table needed) by looking under the following HLTs: “Administration site reactions NEC” and 
“Injection site reactions”. 
10.2.3.8 
Hepatic events and DILI 
 Incidence of hepatic events TEAEs per 100 subject years by SOC, HLT and PT 
A table for hepatic events will be created based on the SMQ of “Drug related hepatic disorders - 
comprehensive search (SMQ)”. However, these 2 sub-SMQs are to be excluded: “Liver 
neoplasms, benign (incl cysts and polyps) (SMQ)” and “Liver neoplasms, malignant and 
unspecified (SMQ)”.  
Note that all AEs meeting the above criteria are to be included. It should not be limited to events 
that the investigator determined to be related to study drug. 
Cases of Hy’s Law will be reported separately in a liver function test table. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 74 of 122 
A by-subject listing of all AEs of safety topics of interest will be presented by type of safety 
topics of interest. 
10.3 
Clinical laboratory evaluations 
Laboratory values, including markedly abnormal laboratory values will be presented 
descriptively by treatment group for the SS, WK16ResS and AMS. In addition, the ESS will be 
summarized for only markedly abnormal laboratory values and Hy’s Law outputs. 
The markedly abnormal tables and those based on CTCAE grade will be produced only for 
selected laboratory variables. 
For tables where data are summarized by visit, unscheduled and repeat visits will not be 
summarized, but these data will be included in listings. For tables where multiple measurements 
over a period of time are considered (as in shift tables), unscheduled and repeat visits will be 
considered as long as they were collected in the period being summarized. All summaries will be 
presented in SI units and will be based on observed case values. In the case where laboratory 
values are below the lower limit of quantification, then these will be set to the midpoint between 
0 and the lower limit of quantification for the purpose of summarizing the data. The following 
summaries are required: 
 A summary of the absolute and change from Baseline values in each laboratory variable by 
treatment group and visit 
 A summary of the number and percentage of subjects experiencing markedly abnormal 
values at any time while on treatment (assessment on or following the first dose of study 
treatment through the minimum of period of interest (Week 16) or date of last dose + 140 
days) ) by laboratory variable and treatment group 
 A summary of the number and percentage of subjects with a given CTCAE grade (0,1,2,3, or 
4) based on minimum/maximum post-baseline value by laboratory variable and treatment 
group 
 A shift table of the number and percentage of subjects experiencing  CTCAE grade 0,1,2,3, 
or 4 values (as applicable) at Baseline to maximum post-Baseline  CTCAE grade, by 
laboratory variable and treatment group 
 A by-subject listing of all laboratory data (including urinanalysis) will be provided. This 
listing will be presented by treatment group and will include: center, subject identifier, age, 
sex, race, weight, visit, laboratory variable, result (with abnormal values flagged as “L” or 
“H” accordingly) and unit. 
Markedly abnormal values are defined as those with a severity of Grade 3 and above based on 
the common terminology criteria for adverse events (CTCAE) criteria (U.S. Department of 
Health and Human Services 2017). Definitions of markedly abnormal values using the Grade 3 
cut points are given in the tables below for age ranges of ≥17 years (Table 10-1 for markedly 
abnormal liver function test values, Table 10-2 for markedly abnormal biochemistry values and 
Table 10-3 for markedly abnormal hematology values). Tables summarizing markedly abnormal 
values should include a summary (counts and percentages) of markedly abnormal labs observed 
at any time while on treatment (ie, treatment-emergent markedly abnormal [TEMA]). For this 
summary, Baseline values and values observed more than 140 days after the last administration 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 75 of 122 
of study medication are not considered. The laboratory results classified as Grade 3 or Grade 4 
will be summarized and listed separately. 
Table 10‒1: Definitions of Markedly Abnormal Liver Function Values 
 
Parameter name 
Conventional 
Standard 
Abnormal 
Designation 
Unit 
Criteria 
Unit 
Criteria 
Alkaline Phosphatase 
U/L 
>5.0 x ULN 
U/L 
>5.0 x ULN 
AH 
ALT 
U/L 
>5.0 x ULN 
U/L 
>5.0 x ULN 
AH 
AST 
U/L 
>5.0 x ULN 
U/L 
>5.0 x ULN 
AH 
Total Bilirubin 
mg/dL 
>3.0 x ULN 
umol/L 
>3.0 x ULN 
AH 
GGT 
U/L 
>5.0 x ULN 
U/L 
>5.0 x ULN 
AH 
 
Table 10‒2: Definitions of Markedly Abnormal Biochemistry Values 
 
Parameter name 
Conventional 
Standard 
Abnormal 
Designation 
Unit 
Criteria 
Unit 
Criteria 
Creatinine 
mg/dL 
> 3.0 x ULN 
mmol/L 
> 3.0 x ULN 
AH 
Glucose 
mg/dL 
<40 
>250 
mmol/L 
<1.7 
>13.9 
AL 
AH 
Calcium 
mg/dL 
>12.5 
<7.0 
mmol/L 
>3.1 
<1.75 
AH 
AL 
Magnesium 
mg/dL 
>3.0 
<0.9 
mmol/L 
>1.23 
<0.4 
AH 
AL 
Potassium 
mmol/L 
>6.0 
<3.0 
mmol/L 
>6.0 
<3.0 
AH 
AL 
Sodium 
mmol/L 
>155 
<130 
mmol/L 
>155 
<130 
AH 
AL 
 
Table 10‒3: Definitions of Markedly Abnormal Hematology Values 
 
Parameter name 
Conventional 
Standard 
Abnormal 
Designation 
Unit 
Criteria 
Unit 
Criteria 
Hemoglobin 
g/dL 
<8.0 
>4.0 above ULN  
g/L 
<80 
>40 above ULN  
AL 
AH 
Lymphocytes Absolute 
109/L 
<0.5 
>20.0 
109/L 
<0.5 
>20.0 
AL 
AH 
Neutrophils Absolute 
109/L 
<1.0 
109/L 
<1.0 
AL 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 76 of 122 
 
Parameter name 
Conventional 
Standard 
Abnormal 
Designation 
Unit 
Criteria 
Unit 
Criteria 
Platelets 
109/L 
<50 
109/L 
<50 
AL 
WBC/Leukocytes 
109/L 
<2.0 
>100 
109/L 
<2.0 
>100 
AL 
AH 
Abbreviations: AH=abnormal high; AL=abnormal low; ALT= alanine aminotransferase; AST = aspartate 
aminotransferase; dL = deciliter; GGT: gamma-glutamyltransferase; L = liter; mg = milligram; mmol = millimoles; 
μg = microgram; ULN = upper limit of normal. 
 
The table for markedly abnormal liver function tests (LFTs) will contain data beyond the 
CTCAE Grade 3 thresholds outlined in Table 10-1 above in order to allow for a more thorough 
review of elevated LFTs. There will be one table which will list the count and percentage of 
subjects meeting the below criteria at any time during the study: 
 AST: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 AST or ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 Bilirubin: >1.5xULN, >2xULN 
In addition, a table will be produced to summarize potential Hy’s Law cases. The following two 
definitions will be used in that table: 
  [AST ≥3xULN or ALT ≥3xULN] and Total Bilirubin ≥2xULN in the absence of ALP 
≥2xULN  
In order to meet the above criteria, a subject must experience the elevation in bilirubin and ALT 
or AST (and the absence of ALP elevation, if applicable) at the same visit. For example, a 
subject who experiences a ≥2 x ULN elevation of bilirubin at one visit and a ≥3xULN elevation 
in ALT (or AST) at a subsequent visit has not fulfilled the Hy’s law criteria. 
10.4 
Vital signs, physical findings, and other observations related to 
safety 
10.4.1 
Vital signs 
The following vital signs variables should be summarized: systolic blood pressure (mmHg), 
diastolic blood pressure (mmHg), body temperature (°C) and heart rate (beats/min). The 
following summaries will be provided for the SS, WK16ResS, and AMS: 
 A summary of the absolute and change from Baseline value for each vital sign variable by 
treatment group and visit 
 A summary of the number and percentage of subjects experiencing at least one markedly 
abnormal value for a vital sign variable as defined in Table 10-4, by treatment group and 
visit. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 77 of 122 
Table 10‒4: Definitions of Markedly Abnormal Blood Pressure Values 
Parameter (unit) 
Markedly Abnormal Low 
Markedly Abnormal High 
Systolic blood pressure (mmHg) 
<90 and a decrease from 
Baseline of ≥20 
>180 and an increase from 
Baseline of ≥20 
Diastolic blood pressure (mmHg) 
<50 and a decrease from 
Baseline of ≥15 
>105 and an increase from 
Baseline of ≥15 
A by-subject listing of all vital signs data will be provided. This listing should be presented by 
treatment group and will include: center, subject identifier, age, sex, race, weight, visit, vital sign 
variable and result (with abnormal values flagged as “L” or “H” accordingly). 
10.4.2 
Physical examination 
Abnormal results of the physical examination together with details of abnormalities: abnormality 
clinically significant or not, will be listed by subject and visit for SS. 
10.4.3 
Electrocardiograms  
Electrocardiogram data will be analyzed by treatment group and visit for the SS, WK16ResS and 
AMS.  
A summary of the number and percentage of subjects with normal, abnormal ECG results, as 
determined by the central reader, will be presented for all applicable visits. 
The following ECG variables will be summarized (absolute values and change from Baseline) by 
visit: QTcF, RR, PR, QRS and QT. 
QTc outliers are defined as QTcF values following dosing that are greater than 450 ms or are 
increases from Baseline greater than 30 ms.  QTcF outliers will be highlighted in the data listing 
and summarized using the following categories: 
 Values >450 ms, >480 ms, >500 ms 
 Increase from Baseline of >30 ms, increase from Baseline of >60 ms, increase from Baseline 
of >90 ms 
 Values >450 ms and increases of >30 ms.  Values >500 ms and increases of >60 ms 
The number and percentage of subjects who meet the ECG outlier criteria at any assessment post 
first dose will be summarized. 
Two separate by-subject listing of all 12-lead ECG data will be provided based on interpretation 
from central reader and from site, respectively. 
10.4.4 
Other safety variables 
10.4.4.1 
Assessment and management of TB and TB risk factors 
A summary of the number and percentage of subjects with negative, positive, and indeterminate   
IGRA (Interferon-Gamma Release Assay) results at all applicable visits will be presented for the 
Initial and Randomized-Withdrawal Period. 
A by-subject listing of the “Evaluation of signs and symptoms of tuberculosis” questionnaire 
data and IGRA results will be provided by treatment group. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 78 of 122 
By-subject listing of the result of chest x-ray for tuberculosis will be provided by treatment 
group. 
10.4.4.2 
Electronic Columbia Suicide Severity Rating Scale (eC-SSRS) 
eC-SSRS questionnaire will be self-administered by the subject and assessed by trained study 
personnel. This scale will be used to assess suicidal ideation and behavior that may occur during 
the study. Results of the eC-SSRS will be summarized using the number of subjects and 
percentage with (i) suicidal ideation, (iii) suicidal behavior, (iii) suicidal ideation or behavior, 
and (iv) self-injurious behavior without suicidal intent. 
Suicidal ideation is defined as an event in any of the following 5 categories: 
 
  
 
 
 
 
Suicidal behavior is defined as an event in any of the following 4 categories: 
Suicidal behavior or ideation is defined as an event in any of the above 9 categories. 
Self-injurious behavior without suicidal intent is defined as an event in the category non-suicidal 
self-injurious injuries. 
The incidence of subjects with suicidal ideation, suicidal behavior, suicidal ideation or behavior, 
and self-injurious behavior will be summarized by treatment group.   
A by-subject listing of the eC-SSRS questionnaire data will be provided by treatment group. 
10.4.4.3 
Pregnancy testing 
Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine 
at all other visits. 
A by-subject listing of the pregnancy test data will be provided by treatment group. 
10.4.4.4 
Childbearing potential and Lifestyle 
Childbearing potential and lifestyle will be collected at Screening. A by-subject listing will be 
provided for all the subjects screened. 
10.4.4.5 
Patient Health Questionnaire (PHQ)-9 scores 
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression. The PHQ-9 scores for depression range from 0 to 27 with higher 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 79 of 122 
scores indicating worse state. A score of 5-9 is considered to be minimal symptoms of 
depression. If any of the 9 questions are missing, then the score is treated as missing.  A score of 
10 to 14 is considered minor depression, dysthymia, or mild major depression. A score of 15 to 
19 is considered to indicate moderately severe major depression, and a score ≥20 is considered to 
be severe major depression.  
Change from Baseline in PHQ-9 is derived as post-Baseline score minus Baseline score.  
 
Different to other safety variables, PHQ-9 will be summarized using the MCMC/monotone 
regression approach described for continuous variable. 
11 
REFERENCES 
Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: A method based on the 
gamma distribution. Statistics in Medicine 1997; 16(7):791-801 
 
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evalutation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
 
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improvement with anti-TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90-5. 
 
Mallinckrodt CH, Lin Q, Lipkovich I, and Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharmaceutical Statistics 2012; 11:456-
61. 
 
Mallinckrodt CH, Watkin JG, Molenberghs G, Carroll RJ. Choice of the primary analysis in 
longitudinal clinical trials. Pharmaceutical Statistics 2004; 3:161-69 
 
Mallinckrodt CH. Preventing and Treating Missing Data in Longitudinal Clinical Trials: A 
Practical Guide. New York, NY: Cambridge University Press; 2013. 
 
Maruish, M. E., User’s manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: Quality 
Metric Incorporated, 2011. 
 
Ratitch, B., Lipkovich, I., O’Kelly, M. Combining Analysis Results from Mutiply Imputed 
Categorical Data, PharmaSUG, 2013, SP03. 
 
Rubin D.B. 1987. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley and 
Sons. 
 
Thomas, D. Roland and Cyr, Andre. Applying Item Response Theory Methods to Complex 
Survey Data. SSC Annual Meeting, May 2002. 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 80 of 122 
Ulm, K., A simple method to calculate the confidence interval of a standardized mortality ratio. 
American Journal of Epidemiology, 1990; 131(12), 373-375 
 
U.S. Department of Health and Human Services, Common Terminology Criteria for Adverse 
Events (CTCAE), Version 5.0, June 2017. 
12 
APPENDIX 
12.1 
Appendix A: MedDRA algorithmic approach to anaphylaxis 
The SMQ Anaphylactic reaction consists of three parts:  
 A narrow search containing PTs that represent core anaphylactic reaction terms  
 
 A broad search that contains additional terms that are added to those included in the narrow 
search. These additional terms are signs and symptoms possibly indicative of anaphylactic 
reaction and categorized in B, C or D  
 Cat B   
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 81 of 122 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 82 of 122 
 Cat C 
 
 
 
 
 Cat D 
 
 An algorithmic approach which combines a number of anaphylactic reaction symptoms in 
order to increase specificity. A case must include either (on either the same day as when an 
injection was administered or one day after):  
 A narrow term or a term from Category A;  
 A term from Category B - (Upper Airway/Respiratory) AND a term from Category C - 
(Angioedema/Urticaria/Pruritus/Flush);  
 A term from Category D - (Cardiovascular/Hypotension) AND [a term from Category B - 
(Upper Airway/Respiratory) OR a term from Category C - (Angioedema/Urticaria/ 
Pruritus/Flush)]  
 Hypersensitivity events will be identified using the “Hypersensitivity (SMQ)”. All TEAEs 
which code to a PT included in the Scope=Narrow search will be included.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 83 of 122 
12.2 
 Appendix B: Definition of CTCAE grades 
Table 12‒1:  Definitions of CTCAE grades by biochemistry parameter 
Parameter (unit) 
Definition 
Unit 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Creatinine 
High 
mmol/L 
>ULN-1.5 x 
ULN 
(>1.5 – 3.0) 
x ULN 
(>3.0 – 6.0) 
x ULN 
6.0 x ULN 
Sodium 
Low 
mmol/L 
130-<LLN 
N/A 
120-<130 
<120 
Sodium 
High 
mmol/L 
>ULN-150 
>150-155 
>155-160 
>160 
Potassium 
Low 
mmol/L 
3.0-<LLN 
3.0-<LLN 
2.5-<3.0 
<2.5 
Potassium 
High 
mmol/L 
>ULN-5.5 
>5.5-6.0 
>6.0-7.0 
>7.0 
Calcium 
Low 
mmol/L 
2.0-<LLN 
1.75-<2.0 
1.5-<1.75 
<1.5 
Calcium 
High 
mmol/L 
>ULN-2.9 
>2.9-3.1 
>3.1-3.4 
>3.4 
Magnesium 
Low 
mmol/L 
0.5-<LLN 
0.4-<0.5 
0.3-<0.4 
<0.3 
Magnesium 
High 
mmol/L 
>ULN-1.23 
N/A 
>1.23-3.30 
>3.30 
Table 12‒2:  Definitions of CTCAE grades by hematology parameter 
Parameter (unit) 
Definition 
Unit 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Hemoglobin 
Low 
g/L 
100-<LLN 
80-<100 
<80 
N/A 
Hemoglobin 
High 
g/L 
>0-20 above 
ULN 
>20-40 
above ULN 
>40 above 
ULN 
N/A 
Platelets 
Low 
109/L 
75-<LLN 
50-<75 
25-<50 
<25 
WBC 
Low 
109/L 
3-<LLN 
2-<3 
1-<2 
<1 
WBC 
High 
109/L 
N/A 
N/A 
>100 
N/A 
Lymphocytes 
Low 
109/L 
0.8-<LLN 
0.5-<0.8 
0.2-<0.5 
<0.2 
Lymphocytes 
High 
109/L 
N/A 
>4-20 
>20 
N/A 
Neutrophils 
Low 
109/L 
1.5-<LLN 
1.0-<1.5 
0.5-<1.0 
<0.5 
Note that subjects who meet the decreased potassium criterion of 3.0< LLN, which is specified 
as the decreased potassium lab criterion for both CTCAE Grade 1 and Grade 2, will be counted 
as Grade 2.  
 
13 
AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN  
13.1 
AMENDMENT 1 
Rationale for the amendment 
The main purpose of this amendment is to align the SAP with protocol amendment 2 and to 
achieve consistency with other SAP of the program. 
Global Changes 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 84 of 122 
Typos and formatting were updated throughout the document. 
Specific changes 
Change #1 
Title page   
 Draft SAP 30Aug2018  
Has been changed to: 
 Final SAP 30Aug2018 
 Amendment 1 16 Sep 2019 
Change #2  
List of abbreviation  
The following abbreviations have been added: 
 LFT = liver function test 
 SIB = suicidal ideation and behavior 
The following abbreviations have been deleted: 
 ADR = adverse drug reaction 
 DAP = data analysis plan  
 HLGT= Higher level group term  
 LTB = latent tuberculosis  
 SOP = standard operation procedure  
Change#3 
Section 1 Introduction 
 This SAP is based on the following study document: Protocol Amendment 2, 06 Apr 2018. 
Has been changed to: 
 This SAP is based on the following study document: Protocol Amendment 3, 21 May 2018. 
Change #4 
Section 2.2.1.2 Secondary efficacy variables 
 Change from Baseline in the Patient Symptom Diary responses for itch, pain, and scaling at 
Week 16 
Has been changed to: 
 Patient Symptom Diary responses for itch, pain, and scaling at Week 16 
Change #5 
Section 2.2.1.2 Secondary efficacy variables 
The following variable has been added: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 85 of 122 
 IGA response (defined as Clear with at least a 2-category improvement relative to Baseline) 
at Week 16 
Change #6 
Section 2.2.1.3 Other efficacy variables 
 Percentage of subjects who rebound (defined as a >125% increase from Baseline in PASI 
score occurring within 2 months of stopping therapy) during the Randomized-Withdrawal 
Period 
Has been changed to: 
 Percentage of subjects who rebound (defined as a ≥25% increase from Baseline in PASI 
score occurring within 2 months of stopping therapy) during the Randomized-Withdrawal 
Period 
Change #7 
Section 2.2.1.3 Other efficacy variables 
The following has been moved from Other efficacy variable to Other safety variable: 
 Change from Baseline in Patient Health Questionnaire (PHQ)-9 scores 
Change #8 
Section 2.2.1.3 Other efficacy variables 
 Change from Baseline in the Patient Symptom Diary 
Has been changed to: 
 Patient Symptom Diary responses 
Change #9 
Section 2.2.1.3 Other efficacy variables 
 IGA response (Clear) 
Has been changed to: 
 IGA response (Clear with at least 2 category improvement from Baseline) 
Change #10 
Section 2.2.3.2 Other safety variables 
 Change from Baseline in clinical laboratory values (chemistry, hematology, and urinalysis) 
Has been changed to: 
 Change from Baseline in clinical laboratory values (chemistry and hematology) 
Change #11 
Section 3.1 General presentation of summaries and analyses   
The following has been added: 
 Per protocol, visit windows of ±3 days from the first dose to Week 24 and ±7 days from 
Week 28 to Week 52 are permissible. For the Week 56 visit, the visit window is±3 days. For 
the SFU Visit, visit window is ±7 days from final dose.  All by-visit summaries will contain 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 86 of 122 
nominal (i.e. scheduled) visits only. Unscheduled visits will not be mapped to scheduled 
visits except for assessments that occur within 3-day time window of a scheduled visit. In 
that case, the assessment will be mapped to the corresponding scheduled visit and will be 
used for the analysis. This will only occur for some vendor data. 
Change #12 
Section 3.2 Definition of Baseline Values 
The following clarification has been added:  
 A Baseline value for a subject is defined as the latest measurement for that subject up to and 
including the day of administration of first study medication, unless otherwise stated. If a 
Baseline assessment is taken on the same day as first administration of study medication, it is 
eligible to be used as the Baseline value, even in the case that the time of the assessment is 
recorded as taking place after the time of first study medication administration. This is 
considered acceptable as this measurement is still the best representation of the Baseline 
value of the given assessment since it is highly unlikely that the study medication could have 
an impact on any measurement in such a short period of time. However, such cases should be 
rare as study center personnel are instructed to do all assessments at the Baseline visit prior to 
administering study medication. One exception to this rule is plasma concentration. If 
Baseline plasma concentration is measured at a time after the first administration of study 
medication, then it should not be eligible to be considered as a Baseline plasma 
concentration. Such cases should be discussed with the quantitative clinical pharmacologist. 
Change #13 
Section 3.2 Definition of Baseline Values 
 For subjects who are re-randomized at the Week 16 Visit, change from Baseline variables 
during the Randomized-Withdrawal Period may be evaluated relative to both the Baseline 
(first dose) Visit and the Week 16 Visit. For the latter, the Baseline is defined as the 
measurement at Week 16. 
 Has been edited to  
 For subjects who are re-randomized at the Week 16 Visit, change from Baseline variables 
during the Randomized-Withdrawal Period may be evaluated relative to both the Baseline 
(first dose) Visit and the Week 16 Visit. For the latter, the Baseline is defined as the latest 
measurement on or prior to the first dose in the Randomized-Withdrawal Period 
(intended to be Week 16). 
Change #14 
Section 3.2 Definition of Baseline Values 
 For the latter, the Baseline is defined as the measurement at Week 16 or the visit at which 
escape treatment is initiated. If the Week 16 measurement or measurement at the visit at 
which escape treatment is initiated is missing, the subject will be excluded from the 
respective change from Baseline summaries for that measurement.  
Has been edited to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 87 of 122 
  For the latter, the Baseline is defined as the latest measurement on or prior to the first 
dose in the Escape Period (for those who escape due to lack of response at Week 16) or 
the latest measurement on or prior to the visit at which escape treatment is initiated.  
Change #15 
Section 3.2 Definition of Baseline Values 
 For the variables listed below, additional baselines for Week 16 and the visit at which escape 
treatment is initiated are defined as well. 
Has been edited to 
 An additional Baseline for Week 16 and the visit at which escape treatment was initiated (as 
described above) are defined for the following variables: 
Change #16 
Section 3.2 Definition of Baseline Values 
The following sentences have been deleted:  
 Unless otherwise specified the last valid measurement before study medication 
administration in the initial period will be used as the baseline value 
 If a scheduled baseline assessment is taken on the same day as first administration of study 
medication and no time is collected, it will be assumed to have been taken prior to study 
medication. 
Change #17 
Section 3.2 Definition of Baseline Values 
‘Laboratory data’ has been added in the list of variables and additional baseline value for Week 
16 and the visit at which escape treatment is initiated are defined: 
Baseline values for component scores should be computed using components from the same visit 
where the relevant measurements were recorded prior to dosing. For example, if the Screening 
visit has all of the components, but the Baseline visit is missing one or more components, the 
Baseline value for the component score should be calculated using the Screening visit values.  
Change #18 
A new section ‘Section 3.6.1 Subjects incorrectly entered Randomized-Withdrawal or Escape 
period’ has been added with clarification on handling of such subjects 
Subjects who enter the Escape Period without meeting the escape criteria, or subjects who meet 
the criteria but don’t enter the Escape Period, will be summarized as follows for efficacy 
analyses: 
4. If a subject meets escape criterion at Week 16 (<PASI90) but does not enter into the Escape 
Period at Week 16, then their data during the Randomized-Withdrawal Period will not be 
summarized in any table as they did not fulfill the definition for inclusion in the WK16ResS. 
Selected data from the Randomized-Withdrawal Period will be listed only. 
5. If a subject meets escape criterion during the Randomized-Withdrawal Period (<PASI75) but 
does not enter into the Escape Period at the corresponding visit, then their data following the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 88 of 122 
visit at which they meet the escape criterion will be treated as missing in summaries based on 
the WK16ResS and will be subject to imputation as appropriate.  
6. If a subject enters the Escape Period without meeting escape criterion at the corresponding 
visit, they will not be in the ESS. These subjects also do not qualify for inclusion in the 
WK16ResS. Selected data corresponding to the Randomized Withdrawal Period and Escape 
Period for these subjects will be listed only. 
For subjects incorrectly entered into the Randomized-Withdrawal or Escape Period, a listing for 
some efficacy variables (e.g. PASI and IGA) and listing for all TEAE will be provided. 
Change #19 
Section 3.7 Center pooling strategy 
Taiwan was removed from table 3-1. 
Change #20 
Section 3.8 Coding dictionaries  
 SOP  
Has been changed to: 
 Standard operation procedure 
Change #21 
Section 3.9 Relative Day 
The following has been removed: 
 If the start (stop) date occurred on or after the first dose, but prior to the double-blind drug 
stop date, relative day is calculated as start (stop) date minus first dose date + 1 
 If the start (stop) date occurred after the last dose of double-blind drug, the relative day to the 
most recent dose is calculated as start (stop) date minus most recent dose date. The relative 
day in this situation should be preceded by a ‘+’ 
Change #22 
Section 3.10 Changes to Protocol-defined analysis 
The following text has been added: 
The following variables were added as a secondary efficacy variable and added to the sequential 
testing procedure:  
 IGA response (defined as Clear with at least a 2-category improvement relative to Baseline) 
at Week 16 
For the following variables, the definition of response has been clarified: 
 Palmoplantar Investigator’s Global Assessment (pp-IGA) response (clear or almost clear 
with at least a two-category improvement from Baseline) for subjects with palmoplantar PSO 
at Baseline 
 Change from Baseline in Patient Global Assessment (PGA) of PSO score 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 89 of 122 
The following variables are not listed in the protocol, but have been added to the SAP in order to 
achieve consistency with other studies from the program: 
 Percentage of subjects who rebound (defined as a ≥25% increase from Baseline in PASI 
score occurring within 2 months of stopping therapy) during the Randomized-Withdrawal 
Period 
 mNAPSI75/90/100 response (defined as a subject that achieves at least a 75%, 90% and 
100% reduction from Baseline in the mNAPSI score) 
 Percent of subjects with absolute PASI score ≤1, ≤2, ≤3, and ≤5 
 Percent of subjects with absolute BSA=0%, ≤1%, ≤3%, and ≤5%  
 Change from Baseline in clinical laboratory values (chemistry and hematology) will be 
summarized, urinalysis results will be listed 
The following additional changes were made: 
 The calculation of nominal p-values has been added for selected of the other efficacy 
variables. 
 Modifications have been made to the text regarding the multiple imputation algorithm for 
clarity. 
 Subgroup analyses will be performed for PASI75/90/100 and IGA variables only and not all 
co-primary and secondary efficacy variables for the Initial Treatment Period that are part of 
the fixed sequence testing procedure. 
 Prior primary failure to biologic (yes/no) was removed as a subgroup. 
 Selected TEAE tables were added to include calculation of risk differences. 
 Selected summaries of safety during the Escape Period will also be presented and will be 
based on the ESS. 
Change #23 
Section 4.2.1 Handling of missing data for efficacy variables 
The following text was added: 
If a subject discontinued study treatment without terminating from the study and still continued 
with scheduled assessments, all efficacy data after discontinuation of study treatment will be 
treated as missing and subject to imputation as applicable. 
Change #24 
Section 4.2.1.3 Handling missing data for the other efficacy variables  
 For other continuous efficacy variables, the MI-MCMC/monotone regression method will be 
used to impute missing data as the primary method. 
Has been edited to  
 For other continuous efficacy variables, the MI-MCMC/monotone regression method will be 
used to impute missing data as the primary method, except for analysis based on the ES 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 90 of 122 
where the OC method will be used due to the short duration of the Escape Period and the 
impact of missing data in this period. 
Change #25 
Section 4.2.1.5 Missing Data Overview and Summary 
The sensitivity OC analysis for other continuous variables was removed from Table 4-1.  
Superscripts have been updated to reflect the changes in footnotes. 
Table 4-1 in Footnote 
PSD of PSO for pain, itch, and scaling has been moved to 
 
c Includes IGA response, Scalp IGA, PASI75, PASI90, PASI100 and PSD of PSO for pain, 
itch and scaling.  
 
f For PASE, OC is the primary analysis method. 
Has been modified to: 
 
f For PASE and analysis of the Escape Period, OC is the primary analysis method. 
The following text has been added: 
d Includes Patient Global Assessment of PSO, IGA score and EQ-5D-3L responses. 
Change #26 
Section 4.2.1.6 Missing Data algorithms 
 Create a data set, one for each treatment of subjects with observed values and those needing 
estimation by multiple imputation. The intermittent missing PASI/IGA values in each data 
set (i.e., missing values for a given subject that has available data before and after the 
missing time point) will be filled in using the MCMC method, with a total of 100 sets of 
imputations being performed. The seed used for these imputations will be 852 (note that all 
other multiple imputation procedures described in this SAP related to analyses will use this 
same seed as well). For monotone missing data (i.e., where all subject data is missing after a 
given time point), monotone regression will be used to impute missing data. Again, this will 
be based on 100 sets of imputations. In both cases, biologic exposure, geographic region and 
PASI/IGA values at Baseline and at each post-Baseline visit (in chronological order) will be 
included in the imputation model. Note that PASI scores at earlier visits will also be used as 
predictors for the model of PASI at later visits. The resulting data sets for each treatment arm 
will be combined into one complete data set based on each of the 100 imputations. 
Has been reworded to: 
 Create a data set, one for each treatment group (note that a separate imputation procedure 
must be invoked in SAS for each treatment group as the seed cannot be set for by groups 
beyond the first when using a by statement), of subjects with observed values and those 
needing estimation by multiple imputation. The intermittent missing PASI/IGA values in 
each data set (i.e., missing values for a given subject that has available data before and after 
the missing time point) will be filled in using the MCMC method, with a total of 100 sets of 
imputations being performed. The seed used for these imputations will be 852 (note that all 
other multiple imputation procedures described in this SAP related to MCMC/Monotone 
regression analyses will use this same seed as well). For monotone missing data (i.e., where 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 91 of 122 
all subject data is missing after a given time point), monotone regression will then be used to 
impute missing data. This will be based on the100 sets of imputations already created using 
the MCMC method such that there will be 100 imputation in total. In both cases, biologic 
exposure, geographic region and PASI/IGA values at Baseline and at each post-Baseline visit 
(in chronological order, see notes below about visits to include for different analysis sets) 
will be included in the imputation model. Note that PASI scores at earlier visits will also be 
used as predictors for the model of PASI at later visits. The resulting data sets for each 
treatment arm will be combined into one complete data set based on each of the 100 
imputations. 
Change #27 
Section 4.2.1.6 Missing Data algorithms 
 Three more indicator variables will be defined similarly replacing North America with 
Central/Eastern Europe, and Western Europe, and Asia/Australia. 
Has been reworded to: 
 Two more indicator variables will be defined similarly replacing North America with 
Central/Eastern Europe, and Western Europe respectively.  An indicator variable for 
Asia/Australia is not needed as the fourth region will be adequately represented by the other 
region indicator variables all being 0. 
Change #28 
Section 4.2.1.6 Missing Data algorithms 
 Note: Standard rounding rules will be applied to the imputed IGA values in order to derive 
the binary IGA 0/1 responder variable. For example, if a subject has an IGA score imputed as 
1.4 (and assuming a Baseline IGA score of 3), this imputed value would be rounded down to 
1, and the minimum change from Baseline of 2 would have been met. Therefore, this subject 
would be considered an IGA 0/1 responder. 
Has been modified to: 
 Note: Standard rounding rules will be applied to the imputed IGA values in order to derive 
the binary IGA 0/1 responder variable. In addition, if values outside of the pre-defined range 
of values for IGA (0-4) are imputed, they will be cut off as appropriate after the multiple 
imputation procedure but before deriving the responder variable For example, if a subject has 
an IGA score imputed as 1.4 (and assuming a Baseline IGA score of 3), this imputed value 
would be rounded down to 1, and the minimum change from Baseline of 2 would have been 
met. Therefore, this subject would be considered an IGA 0/1 responder. Additional ranges of 
values for other variables are defined in Table 4-2. 
Change #29 
Section 4.2.1.6 Missing Data algorithms 
The following has been added: 
Additional ranges for values for secondary and other variables are defined in Table 4-2.   
The following table has been added: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 92 of 122 
Table 13‒5: Imputation allowable ranges by variable 
Variable 
Minimum Value 
Maximum Value 
Integer Values Only 
PASI 
0 
72 
No 
IGA 
0 
4 
Yes 
PSD item 
0 
10 
No 
Scalp IGA 
0 
4 
Yes 
mNAPSI 
0 
130 
No 
BSA 
0 
100 
Yes 
IGAxBSA 
0 
400 
Yes 
DLQI 
0 
30 
Yes 
PGADA 
0 
100 
Yes 
SF-36 
0 
100 
No 
EQ-5D-3L VAS 
0 
100 
Yes 
PHQ-9 
0 
27 
Yes 
Change #30 
Section 4.2.1.6 Missing data algorithms 
If logistic regression is used, the estimates of the odds ratios from the logistic regression model 
in step 3 follow a log-normal distribution, and a log transformation is needed to normalize these 
estimates since the procedures for combining results from multiple imputed datasets are based on 
the assumption that the statistics estimated from each imputed dataset are normally distributed. 
Has been changed to 
If stratified CMH or logistic regression are used, the estimates of the odds ratios from the logistic 
regression model in step 3 follow a log-normal distribution, and a log transformation is needed to 
normalize these estimates since the procedures for combining results from multiple imputed 
datasets are based on the assumption that the statistics estimated from each imputed dataset are 
normally distributed. 
Change #31 
Section 4.2.1.6 Missing Data algorithms 
The following text has been added for CMH test:  
 Appropriate transformations to the standard errors should also be made in order to get the 
correct confidence intervals. 
Has been updated to 
 Appropriate transformations to the standard errors and p-values should also be made in order 
to get the correct confidence intervals, for the CMH test using the p-value for the general 
association the Wilson-Hilferty transformation should be used (Ratitch, 2013).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 93 of 122 
Change #32 
Section 4.2.1.6 Missing Data algorithms 
The followings have been added: 
7. The absolute value of the given variable will be imputed. Once imputation has been 
performed across the 100 iterations specified, any values outside of the range of the given 
variable will be truncated accordingly. 
8. The change from Baseline values will be computed based on the complete data sets. 
9. The analysis model will be based on ANCOVA (see above) as opposed to the CMH test. 
Change #33 
Section 4.2.1.6 Missing Data algorithms 
The following sentence has been deleted: 
1) the imputation model will use the change from Baseline (instead of actual) values by visit and 
no dichotomization will be necessary; and 2) the analysis model will be based on an analysis of 
covariance (ANCOVA) model. 
Change #34 
The MI procedure will also be similar to that described above with the following differences: 1) 
the imputation model will use the change from Baseline (instead of actual) values by and no 
dichotomization will be necessary; 
Has been updated to  
The MI procedure will also be similar to that described above with the following differences: 1) 
no dichotomization will be necessary; 
Change #35 
Section 4.2.1.6 Missing Data algorithms 
The following has been added: 
Further details about imputation for different analysis sets are below: 
 Randomized Set: When programming multiple imputation based on the RS, PROC MI will 
be used with a separate data set for each of the 2 randomized treatment groups (placebo, 
Bimekizumab 320mg Q4W) including all scheduled assessment visits from Baseline to Week 
16. 
 WK16ResS: When programming multiple imputation based on the WK16ResS, PROC MI 
will be used with a separate data set for each of the 3 re-randomized treatment groups 
(Bimekizumab 320mg Q4W/Placebo, Bimekizumab 320mg Q4W/Q8W, Bimekizumab 
320mg Q4W/Q4W) including all scheduled assessment visits from Week 16 to Week 56. 
Note: The Placebo/Placebo responders will not be included in these tables or in the MI 
procedure. 
Change #36 
Section 4.3 Interim analyses and data monitoring 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 94 of 122 
After the final Week 56 visit, an interim analysis will be performed and a corresponding interim 
clinical study report (CSR) may be written. Note that some subjects may still be ongoing in the 
Escape Period when the interim data cut if taken, after the final subject completes the Week 56 
visit. A final analysis and updated final CSR will be prepared once all data (through the safety 
follow-up (SFU) visit) have been collected.  
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor the safety data from this study and advise UCB.  
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor relevant safety data from this study and advise UCB. Details will be provided in the 
DMC Charter and in the Adjudication Committee Charters. 
Futher details related to the DMC will be outlines in a separate analysis plan. 
Has been changed to: 
After the final Week 56 visit, an interim analysis will be performed on all available data at that 
time point (including all subjects who are in the Escape Period when the interim data cut is 
taken) and a corresponding interim clinical study report (CSR) will be written. A final analysis 
and updated final CSR will be prepared once all data (through the safety follow-up (SFU) visit) 
have been collected.  
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor the safety data from this study and advise UCB. Further details related to the DMC will 
be outlined in a separate analysis plan. 
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor relevant safety data from this study and advise UCB. Details will be provided in the 
DMC Charter and in the Adjudication Committee Charters. 
Change #37 
Section 4.4 Multicenter studies 
However, if the model is unable to converge due to a low number of subjects at a given center, a 
pooling by region will be applied in order to allow the model to converge. 
Has been changed to 
However, if the model is unable to converge due to a low number of subjects at a given center, a 
pooling by center will be applied in order to allow the model to converge. If convergence is still 
not achieved a pooling by region will be applied. 
Change #38 
Section 4.5 Multiple comparison/multiplicity  
H10 Has been added in the following sentence: 
The hypotheses (H1, H2, H3, H4, H5, H6, H7, H8, H9 and H10) comparing bimekizumab vs. placebo 
will be tested at a 2 -sided alpha level of 0.05. 
Figure 4-1 was updated to add H10. 
Change # 39  
Section 4.8 Examination of subgroups 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 95 of 122 
 
The following characteristic has been removed: 
 Prior primary failure to biologic (yes, no) 
Change #40  
Section 4.8 Examination of subgroups 
 
In addition, a subgroup analysis will be performed on PASI90/100 and IGA to assess 
predictability of future response at Week 4 using the following subgroups:  
 PASI75 responders at Week 4 (yes, no) to predict PASI90/100 and IGA through Week 56 
 PASI90 responders at Week 16 (yes, no) to predict PASI100 through Week 56 
For responder analysis, the definition of subgroups of the PASI75/90/100 should be based on 
observed values. All summaries will be based on imputed data as appropriate and will include 
descriptive statistics only.  
 
Has been updated to  
 
In addition, a subgroup analysis will be performed on PASI90/100 and IGA to assess 
predictability of future response at Week 4 and Week 16 using the following subgroups:  
 PASI75 responders (OC) at Week 4 (yes, no) to predict PASI90/100 and IGA (NRI) through 
Week 56 
 PASI90 responders (OC) at Week 16 (yes, no) to predict PASI100 (NRI) through Week 56 
For responder analysis, the definition of subgroups of the PASI75/90/100 will be based on 
observed values. All summaries will be based on imputed data as appropriate and will include 
descriptive statistics only.  
Change #41 
Section 4.8 Examination of subgroups 
 
The following text has been added: 
Antibody positivity is the only subgroup that is not determined by Baseline data. It will be 
presented in a separate table. 
Change #42 
Section 5.1 Subject disposition 
ESS was added for an additional summary of disposition of analysis sets: 
Summaries of reasons for screen failures (for all subjects screened), disposition of subjects (for 
all subjects screened), disposition of analysis sets (for RS and ESS), disposition and 
discontinuation reasons in the Initial Treatment period (for RS) and in the Randomized-
Withdrawal period (for WK16ResS) and Escape Treatment period (for ESS), as well as the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 96 of 122 
subjects who discontinued due to AEs in the Initial Treatment period (for RS) and in the 
Randomized-Withdrawal period (for WK16ResS) and Escape Treatment period (for ESS) will be 
produced. 
Change # 43 
Section 6.2 Other Baseline characteristics  
 
The following characteristics have been added:  
 Nail involvement (yes, no) 
 Scalp involvement (yes, no) 
 Palmoplantar involvement (yes, no) 
 Prior primary failure to biologic (yes, no) 
 Baseline nail, scalp, and palmoplantar involvement are based on the number of subjects 
achieving mNAPSI>0, Scalp IGA>0, and pp-IGA>0, respectively. 
 PSD items: Pain, Itch, Scaling 
Baseline nail, scalp, and palmoplantar involvement are based on the number of subjects 
achieving mNAPSI>0, Scalp IGA>0, and pp-IGA>0, respectively. 
Change # 44 
Section 7 Measurement of treatment compliance  
 
The following sentence has been deleted:  
 All summaries detailed in this section will be performed on the SS 
Change # 45 
Section 7 Measurement of treatment compliance  
 A summary of percent treatment compliance categorized as ≤80% and >80% will be 
provided by treatment group and study periods (Initial Treatment Period, Randomized-
Withdrawal Period and the Initial and Randomized-Withdrawal Period). 
Has been changed to: 
 A summary of percent treatment compliance categorized as <75% and ≥75% will be 
provided by treatment group and study periods (Initial Treatment Period for the RS, 
Randomized-Withdrawal Period for the WK16ResS and ESS, and the Initial and 
Randomized-Withdrawal Period for the AMS). 
Change # 46 
Section 8 Efficacy analysis  
 
All efficacy analyses will be performed on the RS unless otherwise specified. All efficacy 
summary tables will be displayed by treatment group unless otherwise specified. 
Has been updated to  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 97 of 122 
All efficacy analyses of primary and secondary variables will be performed on the RS unless 
otherwise specified. All efficacy analyses of other efficacy variables will be performed on the 
RS, Wk16ReS and ESS unless otherwise specified.  All efficacy summary tables will be 
displayed by treatment group unless otherwise specified. 
 
Change # 47 
Section 8.1.2 Primary analysis of the co-primary efficacy variables; section 8.1.3.1 Sensitivity 
analysis #1 and section 8.1.3.2 Sensitivity analysis #2   
 
The following sentence has been added: 
 If one of the treatment groups has zero or very low response where the CMH odds ratio can 
no longer be calculated, the logit method will be applied instead. 
Change #38 
Section 8.1.2 Primary analysis of the co-primary efficacy variables 
The following text was deleted: 
The number and percentage of subjects who are PASI90 responders and those who are non-
responders at Week 16 will be summarized. 
Change # 48 
Section 8.1.3.7 Sensitivity Analysis #7  
The following has been added: 
 In order to achieve model convergence, prior biologic exposure may be dropped from the 
model.  If convergence still cannot be achieved, this analysis will not be performed. 
Change # 49 
A new section 8.2.1.2 IGA response at Week 16 has been added with the following sentence: 
 A categorical response variable, IGA response (Clear with at least 2-category improvement 
from Baseline) is defined as an IGA score of zero (Table 8-1) with at least 2-category 
improvement from Baseline. 
Change #50 
Section 8.2.1.3 Patient Symptom Diary (PSD) 
 A weekly average is the sum of the scored item over the course of the study week divided by 
the number of days on which the item was completed and will be set to missing if four or 
more daily assessments (irrespective of whether these are consecutive or not) were missing 
of the corresponding question 
Has been changed to:  
 A weekly average is the sum of the scored item over the course of the study week divided by 
the number of days on which the item was completed. The weekly averages should be 
relative to the respective visit date except for baseline which should follow the usual 
convention and should be based on at least 4 non-missing values (do not need to be 
consecutive). Otherwise, the PSD will be set to missing. The Baseline value will be 
computed in the same manner. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 98 of 122 
Change #51  
Section 8.2.1.3 Patient Symptom Diary (PSD) 
 
The followings sentences have been added: 
 The PSD will be computed based on the responder. Each of the 3 PSD response scores 
included in the statistical testing procedure (itch, pain, and scaling) will be characterized in 
terms of the cumulative percent of subjects demonstrating a pre-specified point improvement 
at Week 16. The threshold for the PSD response score of itch, pain, and scaling is 2.39, 1.98, 
and 2.86, respectively. The responder analysis will be limited to the subjects with a Baseline 
PSD response score at or above the applicable threshold score (i.e., at least 2.39, 1.98, and 
2.86 for itch, pain, and scaling, respectively). 
 The derivations for absolute and percent change from Baseline are as follows: 
Change #52  
Section 8.2.1.3 Patient Symptom Diary (PSD) 
 
The following paragraph has been deleted: 
 In addition, each of three PSD response scores -itch, pain, and scaling, will be characterized 
in terms of the cumulative percent of subjects demonstrating a pre-specified point 
improvement at Week 16. The threshold for the PSD response score of itch, pain, and scaling 
is 2.39, 1.98, and 2.86, respectively. For this responder analysis, it will be limited to the 
subjects with a Baseline PSD response score at or above the applicable threshold score (i.e., 
at least 2.39, 1.98, and 2.86 for itch, pain and scaling respectively). 
Change #53 
Section 8.2.1.3 Patient Symptom Diary (PSD) 
The following bullet was deleted: 
 Percent change from Baseline in PSD responses for itch, pain, and scaling at Week 16 is 
defined as 
Percent change from Baseline = 100 × Post Baseline PSD score −Baseline PSD score
Baseline PSD score
 
 
Change #53 
Section 8.2.1.3 Patient Symptom Diary (PSD) 
 
The following paragraph has been deleted: 
 Weekly average score of PSD response for itch, pain and scaling will be included in the 
analysis for secondary efficacy variables. Baseline in PSD response is defined as the average 
score of the last 7 days before study medication administration at Baseline visit as long as at 
least 1 day is available. In the event there are no values for days prior to Baseline, the diary 
score from the day of Baseline will be used as Baseline 
Change #54 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 99 of 122 
Section 8.2.2 Primary analysis of the secondary efficacy variables 
 
The following text was deleted: 
Primary analysis for secondary efficacy variables will be summarized based on imputed data 
(NRI and MCMC/Monotone Regression for binary and continuous variables, respectively), 
unless otherwise specified. 
 
Change #55 
Section 8.2.2.1 PASI responses 
 
The following text was added: 
(based on subjects who have switched to placebo from bimekizumab at Week 16, to evaluate the 
efficacy of continuous treatment with bimekizumab versus treatment withdrawal (placebo)) 
Change #56 
A new section 8.2.2.2 IGA response has been added.  
 For IGA response (clear) at Week 16, the stratified CMH test similar to the primary analysis 
will be applied. A line plot of IGA responder rate (clear) over time, by treatment group will 
be produced.  
Change #57  
Section 8.2.2.3 PSD 
 
The following has been added: 
 The PSD response variables will be characterized in terms of the cumulative percent of 
subjects demonstrating a pre-specified point improvement at Week 16. The threshold for the 
PSD response score of itch, pain, and scaling is 2.39, 1.98, and 2.86, respectively. This 
responder analysis will be limited to the subjects with a Baseline PSD response score at or 
above the applicable threshold score (i.e., at least 2.39, 1.98, and 2.86 for itch, pain and 
scaling respectively). The stratified CMH test, similar to the primary efficacy analysis, will 
be applied to each of these responder analyses. These are the inferential analyses that will be 
used in the multiplicity-controlled testing procedure for itch, pain, and scaling. 
Change #58  
Section 8.2.2.3 PSD 
 
The following has been deleted: 
 The percentage change as well as the absolute change from Baseline to the Week 16 for the 
weekly average will be analyzed in separate analyses of covariance (ANCOVA) with fixed 
effects of treatment, region and prior biologic exposure, and Baseline value as a covariate. 
The analysis based on the absolute change from Baseline will be the primary analysis that 
will be considered in the fixed sequence testing procedure. Difference between treatment 
groups will be determined using least square means and t-tests using the pooled error term 
from the linear model. 95% confidence intervals for the treatment difference will be 
calculated based on differences in least squares means estimates. All continuous variables in 
the model will be centered with respect to their mean values. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 100 of 122 
 1) The imputation model will use change from Baseline (instead of actual) values by visit 
and no dichotomization will be necessary; and  
 2) The analyses model will be based on analysis of covariance (ANCOVA) as opposed to the 
Cochran-Mantel-Haenszel (CMH) test. 
Change #59  
Section 8.2.2.3 PSD 
 
The followings have been deleted: 
 Absolute and percent changes from Baseline PSD for itch, pain and scaling will be 
summarized by visit for each treatment group. Also, the number and percentage of subjects 
who have worsened or no improvement, at least 1 point, at least 2 points, at least 3 points, at 
least 4 points, and at least 5 points improvement at Week 16 visit will be summarized for 
each of the itch, pain and scaling scores.  
 In addition, each of three PSD response scores - itch, pain, and scaling, will be characterized 
in terms of the cumulative percent of subjects demonstrating a pre-specified point 
improvement at week16. The threshold for the PSD response score of itch, pain, and scaling 
is 2.39, 1.98, and 2.86, respectively. For this responder analysis, it will be limited to the 
subjects with a Baseline PSD response score at or above the applicable threshold score (i.e., 
at least 2.39, 1.98, and 2.86 for itch, pain and scaling respectively). Stratified CMH test, 
similar to the primary efficacy analysis, will be applied within each of these responder 
analyses. 
Change #60  
Section 8.2.3 Sensitivity analyses of the secondary efficacy variables 
 
The following text was updated: 
For binary response variables (PASI100 at Week 16, PASI75 at Week 4, and Scalp IGA at Week 
16, and PSD response for itch, pain and scaling), sensitivity analyses #1 and #3 (Section 
8.1.3.1, Section 8.1.3.3) will be performed. 
Change #61 
Section 8.2.3 Sensitivity analyses of the secondary efficacy variables 
 
The following text was added: 
Missing data for these PSD variables will use the MI procedure similar to the sensitivity analysis 
#1 (Section 8.1.3.1) for the co-primary efficacy variables with the following differences:  
10. The data included in the imputation model will be limited only to those subjects with 
sufficiently high Baseline values to achieve the response for a given item (based on observed 
cases). 
11. The PSD item value will be imputed. Once imputation has been performed across the 100 
iterations specified, any values below 0 and above 10 will be truncated to 0 and 10, 
respectively. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 101 of 122 
12. The change from Baseline values will be computed based on the complete data sets. 
13. The analysis model will be based on the CMH test.There may be cases where the multiple 
imputation model fails to converge. In such situations, the LOCF approach will instead be 
used to impute the missing data. If LOCF is used instead of multiple imputation for this 
reason, this will be clearly specified in the corresponding table summary. Note that for LOCF 
imputation, any missing data or data collected following discontinuation of IMP will be 
imputed with the most recent previous value.  
Change #62  
Section 8.2.3 Sensitivity analyses of the secondary efficacy variables 
 
The following text was added: 
Missing data for continuous secondary efficacy variables will be imputed using MI. The MI 
procedure for continuous variables will be similar to sensitivity analysis #1 described in 
Section 8.1.3.1 for the co-primary efficacy endpoints with the following difference – no 
dichotomization will be necessary. Also, no requirement of meeting minimum threshold at 
baseline is needed to be included in imputation for a continuous variable.  
Change #63 
Section 8.3 Statistical analysis of the secondary efficacy variables  
 Note that in addition, for subjects who change treatment at Week 16, change from two 
Baselines (i.e Baseline at Week 0 visit and Baseline at Week 16) will be summarized in the 
WK16ResS. 
For subjects that enter the escape arm at Week 16 or later, change from two Baselines (i.e. 
Baseline at Week 0 visit and Baseline at which escape treatment was initiated) will be 
summarized in the ESS. 
Have been edited to: 
 Note that in addition, for subjects who change treatment at Week 16, change from two 
Baselines (i.e Initial Period Baseline and Randomized Withdrawal Period Baseline) will be 
summarized in the WK16ResS for PASI and DLQI. 
For subjects that enter the escape arm at Week 16 or later, change from two Baselines (i.e. 
Initial Period Baseline and Baseline at which escape treatment was initiated) will be 
summarized in the ESS for PASI and DLQI. 
Change #64 
Section 8.3 Statistical analysis of the secondary efficacy variables  
The following has been deleted: 
 Missing data for continuous secondary efficacy variables will be imputed using MI. The MI 
procedure for continuous variables will be similar to sensitivity analysis #1 described in 
Section 8.1.3.1 for the co-primary efficacy endpoints with the following differences: 1) the 
imputation model will use the change from Baseline (instead of actual) values by visit and no 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 102 of 122 
dichotomization will be necessary; and 2) the analysis model will be based on ANCOVA as 
opposed to the stratified CMH test 
Change #65 
Section 8.3.1.2 Time to PASI50, PASI75, PASI90, and PASI100 response 
The following has been added: 
 All visits including unscheduled visits are considered. 
Change #53 
Section 8.3.1.2 Time to PASI50, PASI75, PASI90, and PASI100 response 
 
The following text has been added: 
Subjects who discontinue study treatment without achieving a given PASI response prior to 
Week 16 visit will be censored at the date of the last observed PASI assessment on or prior to 
the study treatment discontinuation. Subjects who reach the Week 16 Visit without achieving the 
given response will be censored at the date of the last observed PASI assessment on or prior 
to the Week 16 Visit. Subjects will be censored at Baseline if there is no Baseline PASI 
assessment or no Post Baseline PASI assessment. 
 
Change #66 
Section 8.3.1.3 Time to relapse and section 8.3.1.4 Percentage of subjects who relapse  
The following has been added: 
 (excluding subjects who were treated with placebo in both Initial Treatment Period and 
Randomized-Withdrawal Period as they cannot relapse by definition). 
Change #67 
Section 8.3.1.5 Percentage of subjects who rebound 
 
Rebound is defined as when a subject experience a >=125% increase from Baseline in PASI 
score occurring within 2 months (60 days) of stopping therapy 
 
Has been changed to  
 
Rebound is defined as when a subject experiences a >=25% increase from Initial Treatment 
Period Baseline in PASI score occurring within 2 months (60 days) of stopping therapy 
 
Change #68 
Section 8.3.1.5 Percentage of subjects who rebound 
 
The percentage of subjects who rebound will be presented by treatment group over time. 
Has been updated to  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 103 of 122 
The percentage of subjects who rebound will be presented for subjects re-randomized to placebo 
over time. 
Change #69 
Section 8.3.1.6 PASI score 
 
The following text was added:  
using NRI 
Change # 70 
Section 8.3.1.7 Modified Nail Psoriasis Severity Index (mNAPSI) score 
 
The following clarification has been added.  
 If any of the 7 response items that contribute to mNAPSI is present, while other items are 
missing (i.e., partial mNAPSI data), then the missing items are assumed to be 0 for the 
mNAPSI calculation. In some cases, the data may be captured in such a way that only non-
zero component scores are present in the database. Again, those components that are not 
present are simply assumed to be 0 for the mNAPSI calculation. 
Change #71 
Section 8.3.1.7 Modified Nail Psoriasis Severity Index (mNAPSI) score 
 
The following sentences have been deleted:  
 If 1 or 2 response items scored on the 0 to 1 scale are missing, the missing response(s) will be 
imputed by the average of the available responses. Otherwise, the total mNAPSI score will 
be set to missing. 
Change #72 
Section 8.3.2 IGA response 
 
 IGA response (Clear) is defined as an IGA score of zero (Table 8-1). Shift from Baseline in 
IGA score is defined at each Post-Baseline visit timepoint relative to Baseline. 
Has been updated to 
 IGA response (Clear with at least 2-category improvement from Baseline) is defined as an 
IGA score of zero (Table 8-1) with at least 2-category improvement from Baseline. Shift 
from Baseline in IGA score is defined at each Post-Baseline visit timepoint relative to 
Baseline. 
Change #73 
Section 8.3.2 IGA response 
 
A line plot of the IGA, scalp IGA responder rate over time, by treatment group will be produced.  
Has been updated to 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 104 of 122 
A line plot of the IGA (both clear or almost clear and clear) and scalp IGA responder rate over 
time, by treatment group will be produced.  
Change #74 
Patient Symptom Diary (PSD) 
 
The following text was deleted: 
Definitions and derivations of absolute change and percent change from Baseline in the Patient 
Symptom Diary responses, responder at Week 16 based on each PSD item have been outlined in 
Section 8.2.1.3.  
Change #75 
Patient Symptom Diary (PSD) 
 
For PSD response score of redness, burning, cracking, dryness, irritation, sensitivity, lesions, 
thickening, fatigue, embarrassment, choice of clothing, the responder criterions in terms of 
change from Baseline are set to 3.05, 1.99, 2.01, 3.04, 2.82, 2.60, 2.69, 2.68, 1.51, 2.43, and 2.14 
respectively. For PSD response scores and PSD responder data for each item, the analyses 
specified in Section 8.2.2 will be provided 
 
In addition, cumulative distribution plots will be provided for absolute and percent change from 
Baseline PSD at Week 16 for each item. 
 
Has been updated to  
 
For PSD response score of redness, burning, cracking, dryness, irritation, sensitivity, lesions, 
thickening, fatigue, embarrassment, choice of clothing, the responder criterions in terms of 
change from Baseline are set to 3.05, 1.99, 2.01, 3.04, 2.82, 2.60, 2.69, 2.68, 1.51, 2.43, and 2.14 
respectively. Number and percentage of subjects who are responders will be summarized based 
on each of these items.  
 
In addition, cumulative distribution plots will be provided for absolute and percent change from 
Baseline PSD at Week 16 for each item. 
 
Change #76 
Section 8.3.10 Short Form 36-item Health Survey (SF-36) 
 
The SF-36 will be used using QualityMetric’s Health Outcomes™ Scoring Software. The 
software uses updates 2009 U.S. population norms and applies a Full Missing Score Estimation 
(Full MSE) method as follows: 
Has been updated to 
 
The SF-36 will be used using QualityMetric’s Health Outcomes™ Scoring Software Version 5.1 
or later. The software uses updated 2009 U.S. population norms and applies a Full Missing Score 
Estimation (Full MSE) method as follows: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 105 of 122 
Change #77 
Section 8.3.11 Euro-Quality of Life 5-Dimensions, 3 levels (EQ-5D-3L) 
 
The following text was added: 
Responses to EQ-5D-3L will be summarized based on OC only as primary analysis. No 
imputation is applied to responses to EQ-5D-3L but is applied to EQ-5D-3L VAS scores. 
 
Change #78 
Section 8.3.12 Patient Health Questionnaire (PHQ)-9 Scores 
 
This section was deleted. 
 
Change #79 
New Section 8.4 Additional statistical analysis of other efficacy variables 
 
Change #80 
Section 9.1 Pharmacokinetics 
 
The following sentence has been deleted:  
 Additional PK analysis will be described in the separate data analysis plan (DAP). 
 
Change #81 
Section 9.1 Pharmacokinetics 
The following sentence has been added: 
 In addition, if the PK sampling date is >1 day after the dosing date, then the plasma 
concentration from that visit will be excluded from the PK summary. 
Change # 82 
Section 9.2 Immunogenicity  
 The analysis of immunogenicity will be performed on PK-PPS. 
Has been changed to: 
 The analysis of immunogenicity will be performed on SS. 
Change #83 
Section 9.2.2 Anti-bimekizumab antibodies 
 
Samples were taken at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 
36, Week 48, Week 56 and in subjects who do not enter into the OLE (PS0014) a sample at SFU 
(20 weeks after the last dose). 
 
Has been updated to 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 106 of 122 
Samples were taken at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 
36, Week 48, Week 56 and in subjects who do not enter into the open label extension study 
(PS0014) a sample at SFU (20 weeks after the last dose). For the interim analysis, the SFU visit 
(after Week 56) will be excluded in the analyses. 
 
Change #84 
Section 9.2.2. Anti-bimekizumab antibodies 
 
The following text was updated: 
Subject Classification: 
 For subjects who are negative at baseline, and antibody negative at all sampling points post 
initial treatment (including SFU) - pre ADAb negative - treatment emergent ADAb negative 
 For subjects who are negative at baseline, and antibody positive at any sampling point post 
initial treatment (including SFU) - pre ADAb negative - treatment emergent ADAb positive.  
If a subject has a missing pre-treatment sample (either missing or insufficient volume) at 
baseline with one or more ADAb positive post-initial treatment samples will be also 
classified as pre ADAb negative - treatment emergent ADAb positive 
 For subjects who are positive at baseline, and antibody negative at all sampling points post 
initial treatment (including SFU) - pre ADAb positive - treatment emergent reduced ADAb 
 For subjects who are positive at baseline, and are positive at any sampling point post initial 
treatment (including SFU) with titer values of the same magnitude as baseline (i.e. ≤ then a 
predefined 2.07 fold difference from the baseline value) - pre ADAb positive - treatment 
emergent unaffected ADAb positive 
 For subjects who are positive at baseline, and are positive at any sampling point post initial 
treatment (including SFU) with increased titer values compared to baseline (above a 
predefined 2.07 fold difference increase from baseline value which will be defined within the 
validation of the assay and will be included in the TFLs and/or SAP when available) - pre 
ADAb positive - treatment emergent ADAb boosted positive. 
 For Subjects who have a positive pre-treatment sample and some post- initial treatment 
samples are missing, while other post-initial treatment samples are ADAb negative, the 
subject will be classed as inconclusive. 
Derivation for above classification will be different for the interim analysis and the final 
analysis. For the interim analysis no SFU data will be considered. Only for the final 
analysis, when all SFU data will be available, data from the SFU visits will be considered. 
 
Change # 85 
Section 9.2.2 Anti-bimekizumab antibodies 
The following text has been deleted: 
In addition to the ADAb classifications, subjects will also receive an overall neutralizing 
(nADA) classification for each nADA assay separately, inclusive of baseline and post-
baseline results, on the nADA assay results: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 107 of 122 
 nADA negative: no nADA positive samples at baseline or post-baseline 
 nADA positive: one or more positive samples at baseline or post-baseline 
 Missing: relevant nADA samples are missing, e.g. if subject had samples selected for nADA 
testing based on their ADA levels, but there was insufficient sample left for nADA testing. 
 A summary table to present the incidence (%) of subjects classified as treatment emergent 
ADAb positive with incidence of IL-17A and IL-17F neutralizing ADAb, respectively over 
the 56 weeks. 
Change # 86 
Section 9.2.2 Anti-bimekizumab antibodies 
 
 The number and percentage of subject in each of the 6 categories will be tabulated and 
separated by treatment group, with an additional category combining subjects, who  are pre 
ADAb positive - treatment emergent reduced ADAb positive and - pre ADAb positive -
treatment emergent ADAb boosted positive, summarized as Total treatment emergent. 
Has been changed to: 
 The number and percentage of subject in each of the 6 categories will be tabulated and 
separated by treatment group, with an additional category combining subjects in categories 2 
and 5, summarized as total treatment emergent. In addition, the counts and percentage of 
subjects who are pre-anti-bimekizumab positive will be calculated (this is the sum of 
categories 3,4, and 5).  
Change # 87 
Section 9.2.2 Anti-bimekizumab antibodies 
 Individual plots of Bimekizumab Concentrations/ADAb titer and % Change from baseline 
(all Y-axes) versus time (x-axis) for the full treatment period including SFU, where a patient 
has not progressed into the OLE. Plots should be labeled and grouped into the 6 sub-
categories 
Has been changed to: 
 Individual plots of Bimekizumab Concentrations/ADAb titer and % Change from baseline 
(all Y-axes) versus time (x-axis) for the full treatment period (excluding SFU for interim 
analyses and including SFU for final analyses), where a subject has not progressed into the 
open label extension study (PS0014). Plots should be labeled and grouped into the 6 sub-
categories 
Change # 88 
Section 9.2.2 Anti-bimekizumab antibodies 
 
The following has been deleted: 
A summary table to present the incidence (%) of subjects classified as treatment emergent ADAb 
positive with incidence of IL-17A and IL-17F neutralizing ADAb, respectively over the 56 
weeks. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 108 of 122 
 
Change #89 
Section 10 Safety Analysis 
The following sentence has been added: 
 Selected summaries of safety during the Escape Period will also be presented and will be 
based on the ESS 
Change #90 
Section 10.1 Extent of exposure 
 >0 weeks 
 >=16 weeks 
 >=24 weeks 
 >=56 weeks 
Has been changed to:  
 >0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks; ≥ 16 weeks for Initial Treatment Period 
 >0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks; ≥ 16 weeks; ≥ 20 weeks; ≥ 40 weeks for 
Randomized-Withdrawal Period  
 >0 weeks; ≥ 4 weeks; ≥8 weeks; ≥ 12 weeks for Escape Period  
Change #91 
Section 10.1.1 Exposure during the Initial Treatment Period for SS 
 
The following text has been added: 
o The total number of days in the Initial Treatment Period (112 days). For AEs that 
emerged after 112 days but still within the 140 days window, those AEs 
would be classified as TEAE, but will be excluded from the output based on 
the Initial Treatment Period. However these AEs will be included in the AE 
summaries for Randomized-Withdrawal Period or Escape Period for 
subjects in the WK16ResS and ESS respectively. 
 
Change #92 
Section 10.1.2 Exposure during the Randomized Withdrawal Period for WK16ResS 
 
The following text has been added: 
Note: If date of last dose in the Randomized-Withdrawal Period + 28 days (or 56 days in the case 
of Q8W dosing) extends to a date beyond the date of the first dose in the 12-Week Escape 
Period, then this calculation reverts to:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 109 of 122 
Date of first dose in the 12-Week Escape Period – date of first dose in the Randomized-
Withdrawal Period + 1. 
Change #93 
Section 10.1.2 Exposure during the Randomized Withdrawal Period for WK16ResS 
 
The following has been added: 
 For all other subjects, use the minimum of the following:  
o Date of last dose in the Randomized-Withdrawal Period – date of first dose in the 
Randomized-Withdrawal Period + 140 days. 
o Date of first dose in the 12-Week Escape Period – date of first dose in the 
Randomized-Withdrawal Period + 1. 
o Date of last clinical contact – date of first dose in the Randomized-Withdrawal 
Period + 1.  
 
Change #94 
A new section, Section 10.1.3 Exposure during the Escape Period for ESS, has been added. 
Change #95 
Section 10.1.4 Exposure during the Initial and Randomized-Withdrawal for AMS 
The following text was updated: 
Definitions for study medication duration (days) and time at risk (days) entire study treatment 
period (the Initial and the Randomized-Withdrawal Period, and the Escape Period) are provided 
as follows: 
Change #96 
Section 10.1.14 Exposure during the Initial and Randomized-Withdrawal for AMS 
 
The following text was updated: 
For subjects who do not switch study treatments and do not enter the 12-Week Escape Period: 
 
Change #97 
Section 10.1.4 Exposure during the Initial and Randomized-Withdrawal and 12-Week Escape 
Period for AMS 
 
The following text has been deleted: 
 12-Week Escape Period (attributed to BKZ 320mg Q4W): 
o Date of last dose in the 12-Week Escape Period – date of first dose in the 12-
Week Escape Period + 28 days 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 110 of 122 
Note: If date of last dose in the 12-Week Escape Period + 28 days extends to a 
date beyond the final visit date of the 12-Week Escape Period (not including 
SFU), then this calculation reverts to: 
 Final visit date of the 12-Week Escape Period (not including SFU) – date 
of first dose in the 12-Week Escape Period + 1. 
Note: For subjects who die during the 12-Week Escape Period, then this 
calculation reverts to: 
 Date of death – date of first dose in the 12-Week Escape Period + 1. 
The followings have been deleted: 
 12-Week Escape Period (attributed to BKZ 320mg Q4W): 
o For subjects who complete the 12-Week Escape Period as planned and continue 
into an open-label study (and, therefore, do not have the SFU visit in the feeder 
study): Final visit date of the 12-Week Escape Period – date of first dose in the 
12-Week Escape Period + 1. 
o For subjects who die prior to the final visit of the 12-Week Escape Period: Date of 
death – date of first dose in the 12-Week Escape Period + 1. 
o For all other subjects, use the minimum of the following:  
 Date of last dose in the 12-Week Escape Period – date of first dose in the 
12-Week Escape Period + 140 days. 
 Date of last clinical contact – date of first dose in the 12-Week Escape 
Period + 1.  
Change #98  
Section 10.2 Adverse events 
 
 Events that fulfill the anaphylaxis criteria for acute events (refer to Appendix 1in 
“Bimekizumab Safety Topics of Interest.docx”) 
Has been updated to: 
 Events that fulfill the anaphylaxis criteria for acute events (refer to Appendix A in Section 
12.1) 
 
Change #99  
Section 10.2.1 Data considerations 
 
The following description has been added: 
 Selected summaries, as specified in Section 10.2.2, will include the risk difference between 
bimekizumab and placebo. The risk difference is calculated as: 𝑅𝐷= 𝐼𝑃𝐵𝐾𝑍−𝐼𝑃𝑃𝐵𝑂  where 
𝐼𝑃𝐵𝐾𝑍 is the incidence proportion for the bimekizumab-treated group and 𝐼𝑃𝑃𝐵𝑂 is the 
incidence proportion for the placebo group. Note that incidence proportion simply refers to 
the percentage of subjects within the specified treatment group that experienced a given 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 111 of 122 
adverse event. The standard error for the risk difference is calculated as follows: 𝑆𝐸𝑅𝐷=
√(𝐼𝑃𝐵𝐾𝑍× (
1−𝐼𝑃𝐵𝐾𝑍
𝑛𝐵𝐾𝑍)) + (𝐼𝑃𝑃𝐵𝑂× (
1−𝐼𝑃𝑃𝐵𝑂
𝑛𝑃𝐵𝑂))  
where 𝑛𝐵𝐾𝑍 is the number of subjects in the bimekizumab-treated group and 𝑛𝑃𝐵𝑂 is the 
number of subjects in the placebo group.  The corresponding confidence interval for the risk 
difference is as follows: 𝐶𝐼𝑅𝐷= 𝑅𝐷 ± 𝑍1−𝛼2
⁄ × (𝑆𝐸𝑅𝐷)  where 𝑍1−𝛼2
⁄  is the 𝑍 statistic for 
the corresponding level of alpha. For the risk difference confidence intervals calculated in 
this SAP, 1.96 will be used (corresponding to a two-sided alpha of 0.05 and 95% confidence 
interval). The risk difference and corresponding CI will be displayed as percentage. 
Change #100  
Section 10.2.1 Data considerations 
 
The following text was deleted: 
Adverse drug reactions (ADRs) are defined as a response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of disease or for modification of physiological function. Any AE that is considered 
“Related” to study treatment will be classed as an ADR. 
 
Change #101 
Section 10.2.2 AE Summaries 
 
The following has been added: 
Additional summaries for the ESS will include only the TEAE overview, TEAEs and SAEs per 
100 subject years, and TEAEs tables for safety topics of interest. For AEs that emerged after 112 
days but still within the 140 days window, those AEs would be classified as TEAE. These AEs 
will be excluded from the outputs based on the Initial Period but included in the AE summaries 
for Initial and Randomized-Withdrawal Period.  
 
Change #102 
Section 10.2.2 AE Summaries 
 
The following clarifications have been added;  
 Incidence of TEAEs Above Reporting Threshold of 5% with Risk Differences by SOC and 
PT 
 Incidence of Serious TEAEs and Risk Differences by SOC and PT  
The tables with risk differences will also be accompanied by figures (dot plots) which show the 
incidence of the adverse events and corresponding 95% risk difference confidence intervals. 
These will be ordered by descending order of risk difference (bimekizumab vs placebo). 
 
Change # 103 
Section 10.2.2 AE Summaries 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 112 of 122 
 Incidence of Serious Adverse Drug Reactions by SOC, HLT, and PT 
 Incidence of Non-Serious TEAEs by Relationship SOC, HLT, and PT 
 Incidence of Adverse Drug Reactions by SOC, HLT, and PT 
 Incidence of Adverse Drug Reactions Above Reporting Threshold of 5% by SOC and PT 
Have been update to 
 Incidence of Related Serious TEAE by SOC, HLT, and PT 
 Incidence of Non-Serious TEAEs by Maximum Relationship SOC, HLT, and PT 
 Incidence of Related TEAEs by SOC, HLT, and PT 
 Incidence of Related TEAEs Above Reporting Threshold of 5% by SOC and PT 
 
Change #105 
Section 10.2.3 Other Safety topics of interest  
 
The following sentence has been added: 
 Along with the tables described, there will be a table which displays the risk difference and 
95% confidence intervals for each of the topics of interest. A corresponding figure (with dot 
plots) will be prepared. 
Change #106 
Section 10.2.3.2 Infections (serious, opportunistic, fungal, and TB) 
The following text was deleted: 
The following steps are followed for identifying and reviewing opportunistic infections: 
Step 1: Refer to column B of the spreadsheet which identifies the Preferred Terms (PTs) to be 
classified as opportunistic infections using either a single ‘x’ or a double ‘xx’. 
 TEAEs which code to a PT flagged with a single ‘x’ need to also be serious to be 
considered an opportunistic infection. 
 All TEAEs which code to a PT flagged with a double ‘xx’ are considered to be an 
opportunistic infection, regardless of seriousness.  
All serious TEAEs in the study database which code to a PT flagged with a single ‘x’ and all 
TEAEs in the study database which code to a PT flagged with a double ‘xx’ will be summarized 
as an opportunistic infection in the stand-alone table. 
Step 2: Refer to column C of the spreadsheet which identifies the PTs that need to be evaluated 
on a case-by-case basis by the study physician to determine whether it is a true opportunistic 
infection or not. The process for physician review is as follows: 
 Study programming team creates a spreadsheet which lists all of the subjects with a 
TEAE present in the database which codes to a PT identified as case-by-case. 
Information from the AE dataset to be included in the spreadsheet: Subject ID, AE 
verbatim term, SOC, High Level Term (HLT), Lower Level Term (LLT), PT, AE start 
date, AE end date, seriousness, severity, relationship to study medication, action taken. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 113 of 122 
Additionally, a column will be included where the study physician can document their 
decision on the case. 
 Study physician reviews the cases in the spreadsheet and indicates in the additional 
column which AEs are confirmed to be opportunistic infections via a single ‘x’. 
 At quarterly Infectious Disease Committee (IDC) Meetings, outputs will be produced and 
reviewed by the study physician ahead of the IDC Meeting. The IDC will then agree on 
the final adjudication for each potential opportunistic infection. A final output for 
opportunistic infections will be produced and agreed upon between the study physician 
and the IDC prior to finalizing the database.  
 Study programming team incorporates these decisions into the AE dataset by merging the 
final decisions for individual subjects / PTs and flagging the confirmed opportunistic 
infections as such in the dataset. 
All subjects with a case-by-case PT reported that has been confirmed by the study physician to 
be an opportunistic infection in Step 2 will be summarized as such in the stand-alone table, along 
with all events identified in Step 1 of this process. 
The timing and frequency of Step 2 will be outlined and agreed to by the study team at the 
beginning of the study. It is suggested that this process be executed multiple times throughout the 
course of the study, more frequently in the weeks prior to the DMC meeting.  
Following the initial physician review of case-by-case events, subsequent reviews will be based 
on the cumulative set of case-by-case events present in the database at each time point of 
spreadsheet creation. Physician decisions from previous runs should be retained in each 
subsequent run. The final run of the spreadsheet, with all final study physician decisions (with 
IDC agreement) on the full set of case-by-case events, will be archived at the conclusion of the 
study. 
Change #107 
Section 10.2.3.2 Infections (serious, opportunistic, fungal, and TB) 
 
The following text was added: 
The following steps are followed for identifying and reviewing opportunistic infections: 
 
Identification Process 
 
The two steps below outline two ways in which opportunistic infections (or potential 
opportunistic infections) can be identified: 
 
Step 1: Refer to column B of the spreadsheet which identifies the Preferred Terms (PTs) to be 
classified as opportunistic infections using either a single ‘x’ or a double ‘xx’. 
 
TEAEs which code to a PT flagged with a single ‘x’ need to also be serious to be considered an 
opportunistic infection. 
All TEAEs which code to a PT flagged with a double ‘xx’ are considered to be an opportunistic 
infection, regardless of seriousness.  
Step 2: Refer to column C of the spreadsheet which identifies the PTs that need to be evaluated 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 114 of 122 
on a case-by-case basis by the study physician to determine whether or not it is an opportunistic 
infection. If Column C has a single ‘x’, then the corresponding preferred term should be flagged 
for case-by-case review by the study physician.  
 
Review Process 
 
Opportunistic infections for a given study will be reviewed on the following occasions: 
 
At quarterly Infectious Disease Committee (IDC) Meetings, listings will be produced for each 
study (see details below) and reviewed by the corresponding study physician ahead of the IDC 
Meeting. These listings will be posted as part of the broader SSD deliverable to a folder named 
for the given quarter (eg, 2018Q4) on the SharePoint. They should be based on the same data cut 
as the one used for SSD and should be delivered at the same time as the SSD outputs. The IDC 
will then agree on the final adjudication for each potential opportunistic infection. 
For each study, a final listing for opportunistic infections (in the format described below) will be 
produced and agreed upon between the study physician and the IDC prior to finalizing the 
database. 
In each of the circumstances described above, the study programming team will produce an 
Excel listing that will be provided to the project lead statistician, project lead programmer, and to 
the study physician (who will subsequently provide it to the IDC). The Excel listing will contain 
the following columns (using the descriptions below as the column headings in the Excel listing): 
 
Study ID 
Unique Subject ID 
AE Term (Verbatim) 
AE Preferred Term 
AE System Organ Class 
AE High Level Term 
AE Low Level Term 
Date of Onset 
Outcome of Adverse Event 
Date of Outcome 
TEAE Flag 
Serious Adverse Event? 
Relationship to Study Medication  
Intensity 
Action Taken with IMP 
Opportunistic Infection – Automatic 
Opportunistic Infection – Manual Review 
Flag 
Data Cut Date 
Opportunistic Infection – Final Adjudication 
Note the following about the final 5 variables in this listing: 
 
Opportunistic Infection – Automatic: This is flagged as “Y” if the criteria for automatic selection 
as described in “Step 1” of the identification process are met. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 115 of 122 
Opportunistic Infection – Manual Review: This is flagged as “Y” if the criteria for case-by-case 
selection as described in “Step 2” of the identification process are met. 
Flag – This has a value of either “NEW” or “OLD”. It is marked as “NEW” if the event is 
appearing for the first time in that run of the listing. Otherwise, if it has appeared previously, it is 
marked as “OLD”. Unique records are determined by USUBJID AESPID for purposes of 
identifying whether an event has been modified from a previous run. 
Date – Only for cases where Flag is “NEW”, this field will be populated with the data cut date 
for that particular run of the listing. 
Opportunistic Infection – Final Adjudication – For new events, this is always left blank by the 
programmers. It should be completed by the study physician/IDC for every event that appears in 
the listing. For events adjudicated as opportunistic, the field should be populated with a “Y”.  
Following each review by the study physician and IDC, the Opportunistic Infection – Final 
Adjudication column will be completed (as described above), and the spreadsheets for each study 
will be returned to the study programming team via e-mail (coordinated by the IDC secretary). 
Then, for subsequent runs of the listing, the study programming teams will incorporate 
adjudications from previous runs. 
 
Change #108 
Section 10.2.3.2 Malignancies, including lymphoma has been renamed Malignancies. 
 
Change #109 
Section 10.2.3.3 Adjudicated Major adverse cardiac event  
 
The following has been added:   
A separate table and listing will present the adjudicated cardiovascular events by type. For each 
cardiovascular event type (24 total), the individual PTs which fall within each event type will be 
summarized. 
Additionally, a listing of all events identified for potential review by the cardiovascular event 
adjudication committee will be produced. This listing will indicate whether each event was 
escalated to the committee for formal review/adjudication.   
 
Change #110 
Section 10.2.3.5 Neuropsychiatric events (in particular depression and suicide) 
 
The title has been changed to Suicidal Ideation and Behavior. 
 
The following has been deleted: 
 This table is based on SMQ of “Depression and suicide/self-injury” (all TEAE which code to 
a PT included in the Scope-Broad and/or Scope=Narrow). 
The following has been added: 
 . A table and a listing for SIB events as determined by the adjudication committee will be 
included Additionally, a listing of all events identified for potential review by the 
neuropsychiatric adjudication committee will be produced. This listing will indicate 
whether each event was escalated to the committee for formal review/adjudication.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 116 of 122 
Change #11 
Section 10.2.3.6 Inflammatory bowel disease 
 
The following has been deleted: 
The incidence and events rate will be presented by history of IBB at Baseline. 
 
The following has been added: 
The table will be stratified by subjects with or without a previous medical history of 
inflammatory bowel disease. Previous medical history of inflammatory bowel disease will be 
determined using the information recorded on the Extra-Articular Assessment at Screening 
CRF page ("Does subject have a history of IBD?”). 
 
Change #112 
Section 10.2.3.7 Hypersensitivity (including anaphylaxis) 
 
The title was updated to Hypersensitivity (including analphylaxis). 
 This table will be prepared based on the MedDRA anaphylaxis algorithm (refer to Appendix 
1 A in Bimekizumab Safety-Topics of Interest.docx section 12) for acute events (reported on 
the same day) and for treatment-emergent PTs including the term “hypersensitivity” reported 
at any time. 
Has been changed 
 A separate table will be prepared based on the MedDRA anaphylaxis algorithm (refer to 
Appendix A in Section 12) for acute anaphylactic events (reported on either the same day as 
when an injection was administered or one day after). A separate table will be prepared to 
summarize hypersensitivity events, identified using the SMQ “Hypersensitivity (SMQ)”. All 
TEAEs which code to a PT included in the Scope=Narrow search will be included in this 
table.  
 
Change #113 
Section 10.2.3.8 Hepatic events and DILI 
 Cases of Hy’s Law will be reported separately in a liver function test table (with adjudication 
for “potential DILI” confirmation). 
Has been changed to: 
 Cases of Hy’s Law will be reported separately in a liver function test table. 
Change #114 
10.3 Clinical laboratory evaluations 
Laboratory values, including markedly abnormal laboratory values and urinary values will be 
presented descriptively by treatment group for the SS, WK16ResS and AMS.  
Has been updated to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 117 of 122 
Laboratory values, including markedly abnormal laboratory values will be presented 
descriptively by treatment group for the SS, WK16ResS and AMS. In addition, the ESS will be 
summarized for only markedly abnormal laboratory values and Hy’s Law outputs. 
The markedly abnormal tables and those based on CTCAE grade will be produced only for 
selected laboratory variables. 
 
Change #115 
10.3 Clinical laboratory evaluations 
 A summary of the number and percentage of subjects experiencing markedly abnormal 
values by laboratory variable, treatment group and visit 
Has been changed to: 
 A summary of the number and percentage of subjects experiencing markedly abnormal 
values at any time while on treatment (assessment on or following the first dose of study 
treatment through the final dose of study treatment + 140 days) by laboratory variable and 
treatment group 
Change #116 
10.3 Clinical laboratory evaluations 
The following item has been added:  
 A summary of the number and percentage of subjects with a given CTCAE grade (0,1,2,3, or 
4) based on minimum/maximum post-baseline value by laboratory variable and treatment 
group 
Change #117 
10.3 Clinical laboratory evaluations 
 A shift table of the number and percentage of subjects experiencing low, normal or high 
values at Baseline to maximum post-Baseline value (i.e., low, normal, high), by laboratory 
variable and treatment group 
Has been changed to: 
 A shift table of the number and percentage of subjects experiencing CTCAE grade 0,1,2,3, or 
4 values (as applicable) at Baseline to maximum post-Baseline  CTCAE grade, by laboratory 
variable and treatment group 
Change #118 
10.3 Clinical laboratory evaluations 
The year in the following has been updated from 2010 to 2017: 
U.S. Department of Health and Human Services 2017 
Change #119 
10.3 Clinical laboratory evaluations 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 118 of 122 
The following items have been deleted:  
 A Shift table of the number and percentage of subjects experiencing low, normal or high 
values at Baseline to minimum post-Baseline value (i.e., low, normal, high), by laboratory 
variable and treatment group 
 A Shift table of the number and percentage of subjects experiencing low, normal or high 
values at Baseline to the End of Treatment1 value (i.e., low, normal, high), by laboratory 
variable and treatment group. 
 
1The End of Treatment value refers to the value from the last observed non-missing post 
Baseline visit prior to the end of treatment.  
 
Change #120 
10.3 Clinical laboratory evaluations 
 
The following text has been added: 
Tables summarizing markedly abnormal values should include a summary (counts and 
percentages) of markedly abnormal labs observed at any time while on treatment (ie, treatment-
emergent markedly abnormal [TEMA]). For this summary, Baseline values and values observed 
more than 140 days after the last administration of study medication are not considered. 
Change #121 
10.3 Clinical laboratory evaluations 
 AST: >2xULN, >3xULN, >5xULN, >10xULN, >20xULN 
 ALT: >2xULN, >3xULN, >5xULN, >10xULN, >20xULN 
 AST or ALT: >2xULN, >3xULN, >5xULN, >10xULN, >20xULN 
 Bilirubin: >1xULN, >1.5xULN 
 ALP: >2xULN 
In addition, a table will be produced to summarize potential Hy’s Law cases. The following two 
definitions will be used in that table: 
 [AST ≥3xULN or ALT ≥3xULN] and Total Bilirubin ≥2xULN 
 [AST ≥3xULN or ALT ≥3xULN] and Total Bilirubin ≥2xULN in the absence of ALP 
≥2xULN  
In order to meet either of the above criteria, a subject must experience the elevation in bilirubin 
and ALT or AST (and the absence of ALP elevation, if applicable) at the same visit. 
 
Has been updated to: 
 AST: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 119 of 122 
 ALT:   >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 AST or ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 Bilirubin: >1.5xULN, >2xULN 
In addition, a table will be produced to summarize potential Hy’s Law cases. The following two 
definitions will be used in that table: 
  [AST ≥3xULN or ALT ≥3xULN] and Total Bilirubin ≥2xULN in the absence of ALP 
≥2xULN  
In order to meet the above criteria, a subject must experience the elevation in bilirubin and ALT 
or AST (and the absence of ALP elevation, if applicable) at the same visit. 
Change #121 
10.3 Clinical laboratory evaluations 
The following clarifications have been added: 
 In addition, the ESS will be summarized for only markedly abnormal laboratory values and 
Hy’s Law outputs. 
 The markedly abnormal tables and those based on CTCAE grade will be produced only for 
selected laboratory variables. 
Change #122 
10.3 Clinical laboratory evaluations 
The following sentences have been deleted:  
A summary table highlighting the potential cases of Hy’s Law, within each treatment group will 
be presented. Hy’s Law is defined as:  
 AST >3xULN or ALT >3xULN and 
 Total Bilirubin >2xULN 
In order to meet the above criteria, a subject must experience the elevation in bilirubin and ALT 
or AST at the same visit. For example, a subject who experiences a >=2 x ULN elevation of 
bilirubin at one visit and a 3 x ULN elevation in ALT (or AST) at a subsequent visit has not 
fulfilled the Hy’s law criteria. 
 Change #123 
10.3 Clinical laboratory evaluations 
 AST: >2xULN, >5xULN, >10xULN, >20xULN 
 ALT: >2xULN, >5xULN, >10xULN, >20xULN 
 AST or ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 Bilirubin: >1xULN, >1.5xULN 
Have been updated to: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 120 of 122 
 AST: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 AST or ALT: >3xULN, >5xULN, >8xULN, >10xULN, >20xULN 
 Bilirubin: >1.5xULN, >2xULN 
Change #124 
10.3 Clinical laboratory evaluations 
The following item has been deleted.  
  [AST ≥3xULN or ALT ≥3xULN] and Total Bilirubin ≥2xULN 
 ALP>2xULN  
Change #125 
10.4.3 Electrocardiograms 
 A summary of the number and percentage of subjects with normal, abnormal not clinically 
significant and abnormal clinically significant ECG results at all applicable visits will be 
provided. 
Has been updated to: 
 A summary of the number and percentage of subjects with normal, abnormal ECG results, as 
determined by the central reader, will be presented for all applicable visits. 
Change #126 
Section 10.4.3 Electrocardiograms 
 
A by-subject listing of all 12-lead ECG data will be provided. 
Has been updated to: 
Two separate by-subject listing of all 12-lead ECG data will be provided based on interpretation 
from central reader and from site, respectively. 
Change #127 
Section 10.4.4.1 Assessment and management of TB and TB risk factors 
By-subject listing of the result of chest x-ray for tuberculosis will be provided by treatment 
group based on interpretation from central reader and from site. 
Has been updated to: 
By-subject listing of the result of chest x-ray for tuberculosis will be provided by treatment 
group. 
 
Change #128 
10.4.4.5 Patient Health Questionnaire (PHQ)-9 Score 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 121 of 122 
 
This section has been moved from section 8.3.12 
 
Change #130 
Section 11: References 
The following reference has been deleted:  
Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y., The Dermatology Life 
Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J 
Dermatol., 2008; 159, 997-1035. 
 
Change #131 
Section 11: References 
The following reference has been added: 
Ratitch, B., Lipkovich, I., O’Kelly, M. Combining Analysis Results from Mutiply Imputed 
Categorical Data, PharmaSUG, 2013, SP03. 
 
Change #132 
Section 11: References 
The version and year in the following have been updated from 4.0 to 5.0 and 2010 to 2017:  
 U.S. Department of Health and Human Services, Common Terminology Criteria for Adverse 
Events (CTCAE), Version 5.0, June 2017. 
Change #133 
Section 12.1 Appendix A: MedDRA algorithmic approach to anaphyalaxis 
 
Appendix A was updated according to program standards. 
 
Change #134 
Section 12.2 Appendix B: MedDRA algorithmic approach to anaphylaxis  
Appendix B was added. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


UCB 
 
16 Sep 2019 
Statistical Analysis Plan 
Bimekizumab 
PS0013 
 
 
 
Confidential 
Page 122 of 122 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE 
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 


Approval Signatures
Name:
PS0013-sap-amendment1
Version:
1. 0
Document Number:
CLIN-000138962
Title:
PS0013-sap-amendment1
Approved Date:
16 Sep 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 15-Sep-2019 20:35:26 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 16-Sep-2019 10:58:51 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof.